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Chemistry is all around us. Protons, neutrons and electrons make up elements, elements 
combine to molecules and monomeric molecules form the polymers of which our plastic bags, 
house insulation, or even our delicious French fries are made of. Life also equals chemistry. 
Other than that carbohydrate (starch) in potatoes, molecules combine to make peptides and 
lipids. Peptides, originating from information embedded in each species’ DNA code, assemble 
to bigger units: proteins. Proteins make up enzymes which regulate numerous critical 
processes such as digestion in the human body, providing it with the required energy we ingest 
from the food we consume. Phospholipids on the other hand make up the cell membrane, 
holding the cell and its constituents together.  
But what are these macromolecules chemically made of? Almost 99% of human body mass 
consists of six elements: carbon, hydrogen, oxygen, nitrogen, calcium and phosphorus. While 
water (H and O), proteins (C, H, O and N), carbohydrates and lipids (C, H, O) mainly consist 
of just four elements, other constituents of the human body contain calcium (mainly in 
hydroxyapatite, a mineral in the bone matrix) and phosphorus (again in hydroxyapatite, but 
also in DNA, RNA and phospholipids) atoms (Figure 1).1 
    
Figure 1: Elemental composition of the human body by mass (left),  
‘The Alchemist Discovering Phosphorus’ by Joseph Wright of Derby (right). 
Phosphorus was the unlucky 13th element to be discovered, more than a hundred years before 
oxygen, and first synthesized in 1669 by the German alchemist Brandt. In his unsurprisingly 
unsuccessful quest for the philosopher’s stone, a substance that would turn inexpensive 
metals such as copper or zinc into gold, Herr Doktor Brandt - as he wished to be called - found 
one night in Hamburg that upon intensively heating copious amounts of urine, a glow-in-the-
dark material was obtained (Figure 1). Unknowingly, he had prepared elemental phosphorus, 
from the phosphate excreted in urine. The glowing properties did not originate from 
phosphorescence, the phenomenon where certain materials emit light at a reduced intensity 
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after they have been charged with intense light, but from a chemiluminescent reaction. White 
phosphorus, one of the allotropes of elemental phosphorus, reacts with oxygen, 
simultaneously emitting light. Other researchers later correctly observed that phosphorus can 
be made from several other living – plant or animal – materials, such as mammals, fish, birds, 
plants and trees. The association of phosphorus with life had been demonstrated for the first 
time.2 
Phosphorus is indeed involved in important biological processes. Phosphorylation of sugars is 
the first step in their catabolism, eventually providing the cell with energy in the form of ATP.3 
ATP, adenosine triphosphate, is known as the energy carrier of the cell, as it is constantly 
being used and replenished in numerous transformations that require energy in living beings. 
The creation and scission of phosphorus-oxygen bonds in phosphates illustrates that the P-O 
bond is a highly energetic bond, which is easily hydrolysable. In organophosphorus 
compounds, at least one of those P-O bonds has been replaced by a bond between 
phosphorus and carbon, which is resistant to hydrolysis. This important feature has led to the 
development of several phosphonate-containing drugs. Twelve of the twenty-four FDA-
approved phosphorus-containing drugs belong to the family of phosphonates and phosphonic 
acids.4 
What makes organophosphorus compounds such interesting targets? First of all, 
organophosphorus natural products have been a rich source for agricultural and medicinal 
applications. Ciliatine 1, 2-aminoethyl phosphonic acid, was the first phosphonate natural 
product to be isolated (Figure 2). Between its discovery in 1959 and 2013, twenty-two more 
naturally occurring phosphonate (containing one P-C bond) and phosphinate (containing two 
P-C bonds) small molecules were isolated, every single one of them displaying biological 
activities. Bioassays showed that they inhibit bacterial and fungal growth or prevent seed 
germination. Three of those natural products – fosfomycin 2, bialaphos 3 and 
phosphinotricin 4 – have been commercialized as a drug or a biotechnological product. In 
addition to that, fosmidomycin 5 and its N-acetylated analogue FR900098 6 have been tested 
in clinical trials against Plasmodium, for the treatment of malaria.5 Very recently, an intensive 
genome mining program, allowed the isolation and identification of nineteen more 
phosphonate natural products.6 
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Figure 2: Examples of phosphonic and phosphinic acid natural products. 
Apart from phosphonate natural products, a great deal of synthetic phosphonates have been 
prepared. Because of their chelating properties, phosphonates are used as water-softening 
and anti-scaling agents in cooling water systems, preventing iron or steel corrosion.7, 8 These 
chelating properties also make them peroxide bleach stabilizers in the pulp and paper 
manufacturing industry, by complexing the metals that would otherwise inactivate the 
peroxide.9 These three features are the reason why they are widely used in detergents as 
well.10 One of the most simple phosphonates is dimethyl methylphosphonate 7 and is used 
commercially as a flame retardant (Figure 3).11 Bayer Crops Science’s ethephon 8 is the most 
widely used plant growth regulator and has greatly facilitated the production of cotton. It 
releases ethylene upon plant metabolism, which regulates plant growth and ripeness.12 
Importantly, phosphonates are characterized by low aquatic toxicities and are readily 
biodegraded, as certain soil bacteria have evolved to metabolize phosphonates, probably 
because of the presence of phosphonate natural products in the environment.13 
Another very small phosphonate is foscarnet 9, an antiviral medication approved in 1991 for 
the treatment of herpes (HSV-1 and HSV-2) and human cytomegalovirus (HCMV) retinitis and 
is particularly of interest in infections where resistance against other antiviral agents has 
developed.14-16 Bisphosphonates 10, developed in the 19th century and initially used to soften 
water in irrigation systems, were investigated in the 60s for the treatment of bone diseases 
such as osteoporosis.17 In the 90s, their mechanism of action was demonstrated, preventing 
osteoclasts from destroying bone, a process that inevitably occurs in the body upon aging. 
Currently, ten bisphosphonate drugs are marketed worldwide.18  
I. Introduction and Goals 
5 
 
Figure 3: Examples of marketed phosphonate and phosphonic acid compounds. 
Cidofovir 11, adefovir 12 and tenofovir 13 are three acyclic nucleoside phosphonates that have 
acquired a prominent position in the treatment of antiviral diseases (Figure 4). Cidofovir 11 has 
been licensed for the treatment of HCMV retinitis in AIDS patients by terminating viral DNA 
chain elongation. Adefovir 12 was eventually approved by the FDA as treatment for HBV 
infections (chronic hepatitis B). Since 2001, tenofovir 13 has been licensed for the treatment 
of HIV infections and is marketed as a single drug (Viread®) or in combinatorial therapies 
(Truvada® or Atripla™). These one pill daily drugs are considered a real breakthrough in the 
management of HIV infections, being much more effective than the twenty something pills, 
HIV-cocktails used to consist of.19 Tenofovir has also been approved for prophylactic use, 
effectively protecting individuals from contracting HIV.20 
 
Figure 4: Structures of nucleoside phosphonic acids marketed as antiviral drugs. 
Aminophosphonates are the phosphonic acid analogues of amino acids, although they differ 
in terms of acidity (more acidic than the corresponding amino acids), size (bigger steric 
hindrance) and shape (carboxylates are planar whereas phosphonates are tetrahedral). The 
phosphonate moiety successfully mimics the tetrahedral intermediate that is formed when the 
amide bond in peptides is being hydrolyzed. Aminophosphonates can thus act as inhibitors of 
these enzymes, a phenomenon that is well described for metalloproteases. This strategy has 
resulted in the development of fosinopril 14 (Figure 5), a phosphinate antihypertensive drug, 
which inhibits angiotensin I converting enzyme (ACE). The chelated complex samarium 
(153Sm) lexidronam 15 (trade name Quadramet) contains several phosphonate groups, which 
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effectively chelate a samarium radioisotope, used for pain relief when cancer has spread to 
the bone. It is preferentially absorbed where the bone has been invaded by cancer, killing 
nearby cells through emission of E-particles.21, 22 Glyphosate 16 (commercialized by Monsanto 
as Roundup in the 70s) also belongs to the class of aminophosphonates, and has been used 
on an enormous scale as a herbicide.23 Although glyphosate and its formulations have been 
approved by regulatory bodies all over the world, it is still met with criticism regarding toxicity 
to mammals and environmental risks.24 At present there is no consensus about its toxicity as 
the WHO concluded in 2015 that glyphosate is “probably carcinogenic in humans”,25 while the 
EFSA’s assessment in the same year said that “the substance is unlikely to be genotoxic (i.e. 
damaging DNA) or to pose a carcinogenic threat to humans.”26 June 2017, the EFSA and 
ECHA again came to the conclusion that “there is no reason to doubt the toxicity studies stating 
that glyphosate is not carcinogenic.”27 
 
Figure 5: Examples of marketed aminophosphinates and aminophosphonic acids. 
Aminophosphonates can also irreversibly bind enzymes, as has been showcased for 
proteases with a serine residue in the catalytic center. P-Terminal amino acids and peptide 
diaryl phosphonates can transesterify the serine residue, effectively preventing the enzyme to 
interact with its normal substrate through its covalent bonding mode. This approach has 
resulted in the synthesis of inhibitors of proteases, involved in several diseases such as 
hypertension, type 2 diabetes and cancer. Diaryl aminophosphonate 17, for instance, 
successfully inhibits uPa (Urokinase-type plasminogen activator), a key serine protease 
involved in tumor cell invasion and metastasis (Scheme 1).28  
 
Scheme 1: Inhibition of uPa (urokinase-type plasminogen activator) by irreversible enzyme inhibition. 
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For almost two decades, the development of new methodologies for the synthesis of 
phosphonylated azaheterocycles and aminophosphonates has been one of the major research 
topics of the SynBioC Research Group of the Department of Sustainable Organic Chemistry 
and Technology, Faculty of Bioscience Engineering at Ghent University.29-33 This has resulted 
in the synthesis of a variety of phosphonylated compounds, such as aziridines,34, 35 
pyrrolidines,36 benzazepines,37 phosphonopyrroles,38-40 bicyclic41 and tricyclic42 
aminophosphonates, benzazocines,43 oxazolidinones and imidazolidinones,44 E-lactams,45-47 
J-lactams,48 benzocarbacephems,49 isoindoles50 and tetrahydroquinolines.51  
Accordingly, the aim of this work was to synthesize an innovative type of highly functionalized 
building blocks, aminoallenylphosphonates, and to explore their potential as precursors to 
innovative aminophosphonates. Allenes are highly interesting building blocks, displaying a 
broad range of reactivities owing to their unique molecular structure of cumulated double 
bonds.52, 53 They are excellent substrates for transition-metal-catalyzed cycloisomerizations 
and readily participate in cycloadditions.54 They are, however, often underused because of 
their supposed low stability. Heteroatom substituents can bring about important changes in the 
electron density on the allene. Allenes bearing an O- or N-substituent are donor-substituted 
allenes, while allenes conjugated to a carbonyl group are classified as acceptor-substituted 
allenes. Moreover, heteroatoms such as N and P are present in important natural products and 
synthetic drugs. Hence, the synthesis of an allene, decorated with both a N and P substituent, 
would be highly interesting. Would this densily functionalized small molecule 25 (Scheme 4) 
behave as an acceptor- or donor-substited allene and what kind of reactivities would be 
possible? Amino-substituted allenes react with alcohols, thiols, and secondary amines to give 
1,2-adducts55 and react in [2 + 2] or [2 + 4] cycloadditions.56 Amidoallenes, being less electron-
rich, are hydroaminated through Lewis acid activation of the proximal double bond57 or undergo 
alkoxylation at the D- or J-position, but usually not at the E-position.58 On the other hand, 
nucleophilic addition to acceptor substituted allenes usually takes place at the E-position. This 
is the case if the well-documented allenylphosphonates are reacted with nucleophiles, while 
they cyclize upon addition of electrophiles.  
In a first chapter, cyclization of these allenylphosphonates – lacking a N-substituent – with 
electrophiles will be evaluated in the design of chiral spirocyclic oxaphospholenes 22. Although 
achiral versions of these compounds have been prepared in the past, chiral spirocyclic 
oxaphospholenes have never been reported. These compounds could be of interest as novel 
chiral inducers in asymmetric synthesis, given their resemblance to BINOL phosphate 
catalysts and the configurational rigidity, produced by the spirocyclic backbone. The designed 
approach passes through allenylphosphonates 21, which would be prepared from acetylide 
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addition to chiral pool ketoterpenes 19, followed by treatment with ClP(OEt)2 (Scheme 2). Upon 
addition of a Lewis acid, cyclization should occur, producing spirocycles 22. 
Scheme 2: Strategy towards chiral spirocyclic oxaphospholenes. 
Secondly, a one-pot procedure for the preparation of bisphosphonomethyl oxazol-2-ones 24 
will be investigated (Scheme 3). This transformation was discovered in preliminary research 
and was thought to pass through an aminoallenylbisphosphonate intermediate. The original 
procedure, however, suffered from low isolated yields. Nonetheless, these 
bisphosphonomethyl oxazol-2-ones 24 are of interest as they are unprecedented compounds 
that combine two interesting structural features. The hydrogenated counterparts, 
oxazolidin-2-ones, are known for their use as chiral auxiliaries and is also the pharmacophore 
in a variety of marketed drugs, while the bisphosphonomethyl motif is of huge importance in 
bisphosphonate drugs. 
  
Scheme 3: One-pot synthesis of 5-bisphosphonomethyl oxazol-2-ones. 
The third and fourth chapter of this research focuses on the preparation of 
3- aminoallenylphosphonates 25 (Scheme 4). As not a single synthesis of these compounds 
had been reported at the start of this research, it was to be investigated if they could be 
prepared at all. A first strategy relied on the Skattebøl rearrangement, in which 
dihalocyclopropanes are transformed into allenes upon treatment with an organolithium 
reagent. The required dihalocyclopropyl aminophosphonates 26 will be prepared through 
dihalocarbene addition to enaminophosphonates. These precursors will be obtained through 
a copper-catalyzed hydroamination of alkynylphosphonates 27.59 
  
Scheme 4: Retrosynthetic approach towards 3-aminoallenylphosphonates via the Skattebøl 
rearrangement. 
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A second synthetic approach targets 3-aminoallenylphosphonates 28 through isomerization of 
3-aminoprop-1-yn-1-yl phosphonates 29 or 3-aminoprop-2-yn-1-yl phosphonates 30 (Scheme 
5). 3-Aminoprop-2-yn-1-yl phosphonates 30 should be accessible through a copper-catalyzed 
cross coupling reaction of copper acetylide 31 with a nitrogen nucleophile.60 3-Aminoprop-1-
yn-1-yl phosphonates 29 will be prepared by phosphonylation of protected propargylamines 32 
with diethyl chlorophosphate. In case these aminoallenylphosphonates 28 could be prepared, 
their reactivity will be evaluated. Since allenylphosphonates are known to undergo nucleophilic 
addition at the central E-carbon, while non-phosphonylated N-containing allenes react as 
nucleophiles themselves, it is not straightforward to predict the reactivity of this densily 
functionalized small molecule. 
 
Scheme 5: Strategies towards 3-aminoallenylphosphonates starting from protected propargylamines or 
copper acetylides. 
In a last, more exploratory part of this work, the synthesis of fosmidomycin-inspired antimalarial 
analogues 33 will be investigated (Scheme 6). As the 3-carbon linker between the 
phosphonate and the amino functionalities in aminoallenylphosphonates 28 corresponds to 
the motif found in fosmidomycin 5, it was reasoned that aptly substituted 
aminoallenylphosphonates 34 could serve as a precursor to substituted fosmidomycin and 
FR900098 derivatives. This is of huge interest, given the developing resistance against 
currently available antimalarial drugs. In a retrosynthetic approach, it was anticipated that 
alkynylphosphonate precursor 35 could be prepared through phosphonylation of N-propargyl 
hydroxamate 36, which in turn should be accessible from O-benzyl hydroxamic acid 37 and 
propargylbromide. Isomerization of alkynylphosphonate precursor 35 should then yield 
aminoallenylphosphonate 34, which can ultimately be derivatized. 
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Scheme 6: Retrosynthetic approach towards new fosmidomycin analogues via an 
aminoallenylphosphonate intermediate. 
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Fifty years of 
(benz)oxaphospholene  
chemistry 
As delineated in the Introduction and Goals, this work focuses on the preparation and reactivity 
of allenylphosphonates and aminoallenylphosphonates. Since the synthesis of the latter is still 
in its infancy, a short overview of the available literature will be given at the beginning of 
chapter 3 in the Results and Discussion. Since the huge number of existing reports on 
allenylphosphonates in literature and since these allenylphosphonates will be used to produce 
oxaphospholenes in chapter 1 of the Results and Discussion, the part Literature Overview of 
this work will be devoted to the existing synthetic entries into benzoxaphospholenes and 
oxaphospholenes.  
1. Introduction 
Organophosphorus compounds have attracted since long the attention of chemists because 
of their interesting biological properties.61, 62 Aminophosphonates can serve as amino acid 
mimetics,63 several bisphosphonates are marketed for the treatment of bone diseases64 and 
phosphonate nucleoside analogues are important antiviral drugs. Tenofovir 13, for instance, is 
used in the treatment of Hepatitis B and HIV/AIDS (Figure 6).19 Phosphorus heterocycles, more 
specifically, are no longer laboratory oddities, but are of interest as ligands and as molecular 
components in electronic devices.65 Ifosfamide and cyclophosphamide 40, two phosphorus-
containing heterocycles, were introduced on the market more than thirty years ago and are still 
used to date in the treatment of cancer.4, 66 Oxaphospholenes 41-42, five-membered 
heterocycles containing one double bond, one oxygen and one phosphorus atom, could be 
useful precursors for furanose carbohydrate mimics,67 while the saturated 
oxaphospholanes 43 are bioisosteres of J-butyrolactones. D-Methylene-J-butyrolactones are 
structural motifs often found in natural products, which are associated with numerous biological 
activities.68 Parthenolide 44 is an example of an D-methylene-J-butyrolactone being evaluated 
as a potential anticancer treatment.69 On the other hand, bactericidal,70 insecticidal,70 
pesticidal,70 herbicidal71 and fungistatic72 properties have been attributed to several 
benzoxaphospholes and phospholene oxides. 
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Figure 6: Structures of tenofovir, cyclophosphamide, different (benz)oxaphospholene isomers,  
an oxaphospholane and parthenolide. 
This literature review will focus on oxaphospholenes with structures 41 and 42 and 
benzoxaphospholenes with structures 45 and 46. Publications in which 
(benz)oxaphospholenes are formed as an intermediate and were not isolated, are not 
considered within the scope of this review. References dealing with the corresponding 
oxaphospholenic acids are not included either. The focus of this review is on the synthetic 
routes towards these oxaphospholenes and benzoxaphospholenes. 
2. Synthetic routes towards oxaphospholenes and 
benzoxaphospholenes 
2.1. Transesterification reactions at P 
The first type of oxaphospholenes ever mentioned in literature were benzoxaphosphole 
oxides 48, reported exactly fifty years ago (Scheme 7).73-76 These were prepared from salicyl 
alcohol 47, or from the corresponding ether or amine.  
 
Scheme 7: Preparation of benzoxaphospholenes from salicyl alcohols and phosphites. 
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It was proposed that, under these harsh conditions, substitution of the poor leaving group by 
the phosphite took place, followed by cyclization/transesterification at the phosphorus atom of 
benzylphosphonate 50 (Scheme 8). According to the authors, in the case of salicyl alcohol, 
kinetic experiments and spectral data ruled out a mechanism involving the mixed phosphite 53. 
Later however, when the mixed phosphite 53 was prepared by ethanolysis from the cyclic 
chlorophosphite 52, the mixed phosphite 53 was found to contract spontaneously to the 
corresponding benzoxaphosphole oxide 51.77  
 
Scheme 8: Plausible mechanisms for the formation of benzoxaphospholenes from salicyl alcohol and 
P(OEt)3. 
The same authors were also able to couple Stavudine (d4T), a nucleoside derivative used in 
the treatment of HIV/AIDS, to a cyclic chlorophosphite, yielding a benzoxaphosphole oxide 54, 
carrying a nucleoside containing ester moiety at the phosphonate in 10% yield (Figure 7).77 
Later, Wakselman reported on the Arbuzov reaction of trimethyl phosphite with 
2-(bromomethyl)phenol 55, giving the acyclic phosphonate 56. Heating to 190 °C resulted in 
cyclization, yielding the benzoxaphosphole oxide 57 (Scheme 9).78 
 
Figure 7: Stavudine-containing benzoxaphosphole oxide. 
 
Scheme 9: Arbuzov reaction of trimethyl phosphite with 2-(bromomethyl)phenol. 
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Benzoxaphosphole oxides 60 were prepared through addition of an aryllithium reagent to 
aldehyde 58, followed by treatment with PBr3 and triethyl phosphite (Scheme 10).79 
Benzoxaphosphole oxides were next investigated for their reactivity towards oxygen: a low 
reactivity is an essential property of a potential antioxidant. This is usually not the case for 
C-centered radicals, although lactone HP-136 61 (Figure 8) has been patented and 
commercialized as an antioxidant.80, 81 Because of the structural resemblance, a similar kind 
of behavior was expected for benzoxaphosphole oxide 60. Transient absorption spectroscopy 
experiments, following excitation of the synthesized compounds in the presence of di-tert-butyl 
peroxide, did indeed show a low reactivity towards oxygen. In follow-up experiments, it was 
demonstrated that acyclic benzylphosphonates were not reactive towards hydrogen 
abstraction.82  
 
Scheme 10: Preparation of sterically hindered benzoxaphosphole oxides. 
 
Figure 8: Structure of lactone HP-136. 
During the 90’s, Gross prepared the phenolic bisphosphonate 65 from protected 
salicylaldehyde 62 and diethyl phosphite (Scheme 11).83 After reaction with thionyl bromide, 
an Arbuzov reaction and deprotection of the benzyl protective group, the phenolic 
bisphosphonate 65 was obtained. Upon heating, transesterification occurred to give the 
phosphonylated benzoxaphospholene 66 in good yield.  
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Scheme 11: Preparation of phosphono-substituted benzoxaphosphole oxides. 
Amongst the first oxaphospholenes to be reported were compounds 68 and 69, resulting from 
the hydrolysis of lactone 67 and subsequent transesterification at the phosphorus atom 
(Scheme 12).84 Two diastereomers, epimers at the phosphorus atom, were obtained through 
a probable epoxide intermediate 71, which allowed the Z/E interconversion of the alkene 
moiety. Butenolides 67 were obtained from biacetyl and trimethyl phosphite in a first step, 
followed by reaction with carbon suboxide (C3O2). 
 
Scheme 12: Synthesis of oxaphospholenes out of lactones. 
At the end of the seventies, Saito found that 1,2-oxaphosphole-3-ene-2-oxide 78 was 
spontaneously formed out of hydroxyphosphonate 77, during column chromatography or upon 
three days of standing at room temperature (Scheme 13).85 Hydroxyphosphonate 77 was 
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prepared through partial hydrogenation of alkynylphosphonate 75, which was obtained after 
Grignard addition of the terminal alkyne 73 to dibutyl chlorophosphate followed by THP 
deprotection. 1,2-Oxaphosphole-3-ene-2-oxide 78 spontaneously hydrolyzed to the 
corresponding phosphonic monoacid 79 upon two days of standing under air at room 
temperature. When stored under nitrogen however, no such conversion took place. 
Alternatively, oxaphospholene 78 could also be obtained by partial hydrogenation of 74, 
followed by THP deprotection and simultaneous cyclization with pTsOH. 
 
Scheme 13: Synthesis of oxaphospholene out of protected propagyl alcohols. 
Sturtz showed in 1987 that diol phosphonates, prepared through dihydroxylation of 
alkenylphosphonates 80, could perform an intramolecular cyclization (Scheme 14).86 
 
Scheme 14: Dihydroxylation of allylphosphonates producing unsubstituted oxaphospholenes. 
When studying the hydrotelluration of internal alkynes, Lee found in 2000 that the produced 
telluroalkenylphosphonate 82 yielded an oxaphospholene in low yield upon treatment with 
MeMgBr and benzaldehyde (Scheme 15).87 After transmetallation of the 
telluroalkenylphosphonate 82, the intermediate allylic alcohol 83 could not be isolated and 
spontaneously cyclized to the oxaphospholene 84.  
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Scheme 15: Preparation of disubstituted oxaphospholenes from telluroalkenylphosphonates. 
This was the incentive to investigate the synthesis of oxaphospholenes 89 with an electron 
withdrawing group in the 3-position, which could be of interest as precursors for 
1,2-oxaphospholane-2-oxides 90 (Scheme 16). To that end, an acyl group was installed in 
allylic phosphonates 85, which were subsequently treated with m-CPBA.67 The expected 
epoxide 87 could not be isolated and instead the oxaphospholene 89 was obtained, in a low 
25% yield. However, this product was only recovered if MgSO4 was used during work-up. The 
authors reasoned that the formed epoxide 87 was not stable enough to be isolated, but was 
stabilized through coordination by Mg2+ in the form of the allylic alcohol 88, which then rapidly 
cyclized at the phosphorus atom. Next, a series of substituted oxaphospholenes 89 were 
prepared in good yields, without a very pronounced diastereoselectivity. The isolated 
oxaphospholene diastereomers 89 finally underwent entirely stereoselective 1,4-addition with 
cuprates to yield 1,2-oxaphospholane-2-oxides 90, which are of interest as carboyhydrate 
mimics. 
 
Scheme 16: Synthesis of 1,2-oxaphospholane-2-oxides via epoxidation of allylphosphonates. 
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2.2. Addition of phosphorus nucleophiles to carbonyl 
compounds 
Activated alkenes have provided an entry to oxaphospholenes since the end of the 60s. In 
1967, Arbuzov reported on the Michael addition of diethyl phosphite to acetyl alkenoate 91, 
which after cyclization yielded a 3H-1,2-oxaphosphole 2-oxide 92 for the first time (Scheme 
17, method A).88 The isolated yield was not reported, but later on, this product was also isolated 
as the result of a competing cyclization reaction in the acetylation of 
hydroxyallylphosphonates.89 Later, 3-ethylidene acetylacetone 93 was found to react with 
dimethyl phosphorisocyanatidite 94 to give product 92 again (Scheme 17, method B).90, 91 
3-Ethylidene acetylacetone 93 also gave rise to oxaphospholenes after reaction of its enolate 
with diethyl chlorophosphite, followed by a cyclization step (Scheme 17, method C).92 In this 
way, oxaphospholenes with a fluorine-containing ester chain could be prepared as well when 
fluorinated dialkyl phosphite was used.93 
 
Scheme 17: Preparation of oxaphospholenes from acetyl alkenoates or acetyl enones. 
Simple enones94 95 or acryloyl chlorides95 98 were shown to produce respectively methyl 
substituted or chlorinated oxaphospholenes 97 or 99 when treated with dialkyl halophosphites 
(Scheme 18). In almost the same way, thiocarbonyl compounds gave rise to oxaphospholenes 
in a reaction with trimethylsilyl dimethyl phosphite.96  
 
Scheme 18: Synthesis of oxaphospholenes via reaction of unsaturated carbonyl compounds with halo 
dialkylphosphites. 
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Addition of phosphonite 100 to diethyl mesoxolate 101 yields dicarboxyl-substituted 
oxaphospholenes 10297 as does the addition of H-phosphinates 104 to D-ketoesters 10398 
(Scheme 19). Using dioxaphosphorinone 107 as a nucleophile allowed the synthesis of a 
3,5-disubstituted oxaphospholene 108 (Scheme 19).99 
 
Scheme 19: Preparation of oxaphospholenes through addition of alkynyl phosphites or phosphonites to 
carbonyl compounds. 
1,2-Addition of dialkyl phosphites to 2,6-dibenzylidene cyclohexanone 109 afforded the 
disubstituted hexahydrobenzoxaphosphole oxides 110 in good yields upon refluxing in toluene 
(Scheme 20).100  
 
Scheme 20: Addition of dialkyl phosphites to dibenzylidene cyclohexanone. 
Quite recently, an example of an oxaphospholene carrying a 4-pyrazolyl substituent was 
reported, resulting from the 1,4-addition of diethyl phosphite to enone 111 (Scheme 21).101  
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Scheme 21: Preparation of an oxaphospholene bearing a 4-pyrazolyl substituent. 
As part of a screening on antioxidant activity of S- and N-containing spirocycles, one tetracyclic 
structure 118 containing an oxaphospholene moiety was obtained in a three-step sequence 
(Scheme 22).102 Spirocyclic tricycle 116, which was obtained by condensation of indoline-2,3-
dione 113 with p-fluoro aniline 114 and 2-mercaptoacetic acid 115, was transformed into 
enone 117 via a Knoevenagel-type condensation. Treatment of 117 with diethyl phosphite and 
BF3·OEt2 eventually gave tetracycle 118 after 1,4-addition and subsequent 
transesterification/cyclization at the phosphorus center.  
 
Scheme 22: Preparation of tetracyclic oxaphospholenes. 
Only one example of an oxaphospholene substituted with long alkyl chains, is described. 
Fürmeier reported the addition of trimethyl phosphite to allenylketone halides under reflux 
conditions in toluene (Scheme 23).103 In the case of a chlorine substituent in the 4-position with 
respect to the ketone, addition of the phosphite to the central allene carbon atom results in the 
formation of a vinylogous enolate 121 according to the proposed mechanism. After elimination 
of the chloride, it dealkylates one of the methoxy groups, producing a phosphonylated enone. 
The corresponding enol 123 finally transesterifies at the phosphorus atom, yielding the 
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oxaphospholene 120. Alternatively, an SN2’ reaction can also account for the formation of 
intermediate 122. 
 
Scheme 23: Halo allenylketones as precursors for the synthesis of oxaphospholenes. 
2.3. Through cyclization of allenylphosphonates promoted by 
electrophiles 
When the cyclization of allenic carboxylic acid esters to halogenated lactones by addition of 
bromine was discovered in the mid-seventies,104, 105 it was demonstrated soon after that 
oxaphospholenes could be synthesized from the corresponding allenylphosphonates.106 
Thanks to the discovery by Mark and Boisselle in 1962 of the [2,3]-sigmatropic rearrangement 
which occurs after treatment of propargylic alcohols 124 with diethyl chlorophosphites,107, 108 a 
very convenient synthesis of allenylphosphonate precursors 125 was available. Indeed, 
allenylphosphonates cyclized just as easily as allenic carboxylic acid esters upon addition of 
electrophiles such as chlorine,109 sulfurylchloride,110-112 bromine,113, 114 iodine,115 iodine 
monohalogenides116 or KICl2117, 118 (Scheme 24). The distal, more electron-rich, double bond 
first forms a halonium intermediate, which is then attacked intramolecularly by the phosphoryl 
group. Dealkylation of one of the alkoxy groups by the corresponding halide yields the 
oxaphospholenes 126.113 When unsubstituted 1,2-propadienylphosphonates were treated with 
bromine, electrophilic addition of the dihalogen took place instead of cyclization, probably 
because of the lack of stabilization of the halonium intermediate. Under the same conditions, 
3-monosubstituted allenylphosphonates predominantly gave the oxaphospholene cyclization 
products.113 Vinyl, allyl, benzyl and propargyl substituents were well tolerated in this 
electrophilic addition/cyclization step,114, 119, 120 while allenylphosphonates carrying a cyclohexyl 
group produced spirocyclic oxaphospholenes.121 Soon, this two-step strategy became the 
method of choice to prepare oxaphospholenes 126.122-125 Later, when other synthetic entries 
to allenylphosphonates were found, the cyclization reaction of these allenylphosphonates with 
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dihalogens remained an attractive strategy to afford oxaphospholenes.126 Oxaphospholenes 
with a 3-phenylthio-,114 3-phenylseleno,114 3-hydroxymethyl,127 3-fluoromethyl,128 or an extra 
3-halo-substituent129 could be synthesized from the appropriately functionalized 
allenylphosphonates.  
 
Scheme 24: Traditional strategy for the synthesis of oxaphospholenes through preparation of 
allenylphosphonates and cyclization with an electrophile. 
In a competition experiment, 2-phosphoryl-2,3-alkadienoate 127a was treated with bromine 
and a mixture of two cyclization products was obtained (Scheme 25). Both the 
oxaphospholene 128, which was formed as the major product, and the lactone 129 were 
isolated.130 Competitive reactions also occurred when the phosphonyl group is in J-position 
with respect to the carboxyl function.131 Treatment of 1-phosphoryl-1-sulfinate-2,3-
butadiene 127b similarly yielded a mixture of two heterocycles, which could each be isolated 
separately.132 
 
Scheme 25: Competition experiment of substituted allenylphosphonates yielding oxaphospholenes, 
lactones and 5H-1,2-oxathiole 2-oxides. 
Alternatively, phosphono pentadienes can serve as precursors for the electrophile-induced 
synthesis of oxaphospholenes as well. The terminal alkene in the 2-phosphonopentadiene 132 
is activated by the electrophile, which is followed by ring closure through intramolecular attack 
of the phosphoryl group onto the internal double bond (Scheme 26).133, 134 
II. Literature Overview 
 
24 
 
Scheme 26: Phosphono pentadienes as precursors for the preparation of oxaphospholenes. 
Not only halogen sources could initiate cyclization of allenylphosphonates 125. Sulfenyl-,135-139 
selenyl-110, 140-145 or tellurylhalides146, 147 efficiently gave rise to 4-chalcogeno 
oxaphospholenes 134 (Scheme 27). In reaction with sulfenylhalides, 1,3,3-trisubstituted and 
1,3-disubstituted allenylphosphonates exclusively yielded the oxaphospholene cyclization 
products 134,138, 139 while 3,3-disubstitued allenylphosphonates also gave small amounts of 
1,2-adducts 135 of the sulfenylchloride in some cases.136, 137, 139, 142, 143 Unsubstituted 
allenylphosphonates did not produce oxaphospholenic cyclization products and only yielded 
1,2-adducts 135 or 2,3-adducts 136.138, 148-152 3-Monosubstituted allenylphosphonates gave 
mixtures of oxaphospholenes and 1,2- and 2,3-adducts 135 and 136.148-150 1-Vinylsubstituted 
and 3-vinylsubstituted allenylphosphonates gave mixtures of phosphonylated thiophenes 137 
and 4-thio oxaphospholenes 134.135, 153 With sulfur dichloride the produced oxaphospholenyl 
sulfenylchlorides could further be transformed into the corresponding thioethers when reacting 
these with alkenes.154, 155  
 
Scheme 27: Variety of electrophiles capable of inducing cyclization to oxaphospholenes. 
From a mechanistic point of view, a thiiranium intermediate 138 is first formed in these 
cyclization reactions, through the reaction of the sulfenylchloride with the distal double bond of 
allenylphosphonate 125 (Scheme 28). Intramolecular attack of the phosphoryl group yields a 
phosphonium intermediate 139, which usually undergoes dealkylation swiftly. When 
bis(methylthio)sulfonium hexachloroantimonate (MDTSAN) was used as the electrophile, the 
phosphonium intermediate could be isolated and converted to the oxaphospholene upon 
heating.156  
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Scheme 28: Mechanism of the sulfenylchloride-promoted cyclization of allenylphosphonates. 
Selenylhalides, in contrast to sulfenylchlorides, selectively yielded oxaphospholenes in some 
cases,140-145 but the formation of 1,2- and 2,3-adducts could not always be avoided in non-
extensively substituted allenylphosphonates.157, 158 Phosphonylated selenophenes and 
selenium-containing bicyclic oxaphospholenes were formed as well.153, 159 Alternatively, 
phenylselenylamides could also be used as electrophiles when activated with sulfur trioxide 
pyridine complex.160 Alternatively, oxaphospholenes with a thiophosphate substituent installed 
in the 4-position were prepared through reaction of allenylphosphonates with the phosphorus 
containing pseudohalogens of structure (RO)2(O)PSCl.161 Not only allenylphosphonates, but 
also 1,3-pentadienylphosphonates could lead to oxaphospholenes when reacted with 
phenylsulfenylchloride.162 
In 1980 Mikhailova reported on the acid-promoted cyclization of allenylphosphonates to 
produce oxaphospholenes withouth a substituent in the 4-position (Scheme 29).163 
Oxaphospholenes 141 were obtained selectively when the allenylphosphonate 125 contained 
a tertiary J-carbon and when the reaction was run in a polar solvent.  
 
Scheme 29: HCl-promoted cyclization of allenylphosphonates. 
In 1985 Trifonov found that allenylphosphonate 142 could be transformed into aminomethyl 
oxaphospholenes 144-145 through electrophilic addition of imine 143, activated by BF3·OEt2 
(Scheme 30).164 
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Scheme 30: Transformation of allenylphosphonates into oxaphospholenes carrying an aminomethyl 
substituent. 
In the search for new antiviral compounds, the preparation of nucleoside analogues carrying 
an oxaphospholene moiety 148 was envisioned, as the authors reasoned that the heterocyclic 
moiety may mimic the ribose unit of natural nucleosides.165, 166 Hence, 
4-chloroallenylphosphonates 146 were prepared and reacted with adenine in the presence of 
a base, to yield the alkylated adenine derivatives 147. These were subsequently cyclized with 
chlorine or bromine and eventually deprotected to give the oxaphospholenic acids 149 
(Scheme 31). 
 
Scheme 31: Preparation of an oxaphospholene with an adenine substituent. 
In 2009, the group of Ma published their findings on the halolactonization of monoesters of 
allenyl phosphonic acids with copper halides (Scheme 32).167 Reaction of the phosphonic acid 
monoesters 150, which were prepared by partial hydrolysis of the corresponding dialkyl 
phosphonates, smoothly yielded the 4-halo oxaphospholenes 151 upon addition of 
copper (II) chloride or copper (II) bromide. Not only are the copper salts easier to handle than 
the corresponding halogens, they also leave allylic substituents on the allenyl phosphonic acid 
unchanged. Fully substituted allenes all reacted in good yields, but in the case of R3 = H, the 
yield decreased considerably. When 1-monosubstituted and 3,3-disubstituted substrates were 
evaluated, no reaction occurred at all. 
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Scheme 32: Halolactonization of monoesters of allenylphosphonates. 
The obtained 4-halo oxaphospholenes could further be derivatized by means of a Suzuki 
coupling with organo boronic acids (Scheme 32).167 PdCl2(SPhos)2 proved to be the catalyst 
of choice, as other Pd catalysts produced the cross coupling products 152-153 only in low 
yields or not at all. Under optimized conditions, a set of 4-halo oxaphospholenes were coupled 
in moderate to near-quantitative yields. 4-Chloro oxaphospholenes reacted slower and 
required a larger excess of phenylboronic acid than their bromo counterparts to obtain the 
products in the same yields. Finally, both aryl boronic acids carrying EDGs and EWGs were 
successfully coupled, although a larger excess and longer reaction times were required and 
lower yields were obtained for electron poor aryl boronic acids. Alkenyl and alkyl boronic acids 
were also well tolerated. 
Two years later, Ma’s group reported on the same halocyclization reaction using dialkyl 
phosphonate ester substrates 154 instead of mono alkyl phosphonate esters 150, hence 
eliminating the need for an additional deprotection step in alkaline aqueous medium (Scheme 
33).168 Moreover, addition of 2.2 equivalents copperhalide - instead of 4 equivalents - was 
allowed and although the transformation worked well in a variety of solvents, the highest yields 
and fastest reaction were obtained in EtOH. Alkyl, allyl and phenyl substituents were all 
tolerated, producing the oxaphospholenes 151 in good to excellent yields. Next, reaction 
conditions were optimized as well for the CuCl2-mediated transformation. Again, a variety of 
solvents does the job, but running the reaction in toluene produced the highest yields. The 
substrate scope and yields were more or less the same as for the CuBr2-catalyzed reaction. 
One should note that for both catalytic systems, the less reactive 3,3-disubstituted, 
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1-monosubstituted or unsubstituted allenylphosphonates were not considered in the substrate 
scope. The CuCl2-mediated synthesis on the other hand, offers a good alternative access to 
4-chloro oxaphospholenes 151, as the reagent is significantly more easy to handle than 
chlorine. 
 
Scheme 33: CuBr2-mediated cyclization of allenylphosphonates. 
One example of a disubstituted allene 155 was synthesized and evaluated to check if chirality 
could be successfully transferred in the halolactonization reaction. With a larger excess of 
CuCl2 and a slightly longer reaction time, two diastereomers were obtained in excellent yield 
with a 50/50 diastereomeric ratio, efficiently transferring the axial chirality of the allene to 
central chirality in the oxaphospholenes 156-157 (Scheme 34). The second stereogenic center 
is created at the phosphorus atom at the moment dealkylation occurs. The obtained 
oxaphospholenes 156-157 could again be further derivatized by means of Suzuki cross-
coupling reactions. 
 
Scheme 34: CuCl2-mediated cyclization of allenylphosphonates. 
Very recently, the group of Virieux reported on the double cyclization of 
bisallenylphosphonates 161 (Scheme 35).169 These were prepared through a Glaser-Hay 
coupling reaction of the corresponding alkynes 158 and 159, followed by a [2,3]-sigmatropic 
rearrangement of the resulting (un)symmetrical dialkynes 160 with diethyl chlorophosphite. All 
derivatives reacted in good to excellent yields in this two-step sequence, except for the 
cyclopropyl-substituted propargyl alcohol. Although it was successfully engaged in the 
Glaser-Hay coupling reaction, the cyclopropyl group probably ring-opened during the 
sigmatropic rearrangement step and a complex mixture was obtained. The conjugated 
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bisallenes 161 could be finally cyclized upon addition of I2 to give two different products. 
Although more than one cyclization mode is possible, pathways b and c could be ruled out as 
deprotection of the ethyl phosphonic ester functions resulted in the detection of only one 
product. Before deprotection, the two singlets observed by 31P NMR spectroscopy indeed 
resulted from meso and C2-symmetric bisoxaphospholenes 163 and 164. When the 
phosphonic acid 165 is obtained, the phosphorus atom is no longer a stereogenic center and 
thus one achiral product is detected by 31P NMR spectroscopy. Moreover, the 
bisoxaphospholenic core was also confirmed by X-ray analysis.  
 
Scheme 35: Synthesis of bisoxaphospholenes from bisallenylphosphonates. 
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CuBr2 also promoted cyclization and, depending on the substrate, some dibromo-
bisoxaphospholenes 163-164 were obtained with high diastereoselectivities and in moderate 
to good yields. The dibenzosuberenyl-substituted derivative did not produce the corresponding 
bisoxaphospholene, as probably electrophilic addition preferentially took place at the double 
bond of the benzosuberenyl group. 
2.4. Through Ring-Closing Metathesis 
With the breakthrough reports of Grubbs on RCM (ring-closing metathesis) in 1992, the 
potential of this method to synthesize all kinds of cycles was soon being explored.170-172 A 
couple of years later, reports on the synthesis of oxaphospholenes through RCM were 
appearing.173, 174 Symmetrical phosphonates were cyclized with the first generation Grubbs 
catalyst, although in low yields, with high catalyst loadings, reflux conditions and long reaction 
times (Scheme 36, method A).173, 175 Moreover, the catalyst proved to be not very selective, 
resulting in the formation of mixtures of 5- and 7-membered cycles. In 2000, Timmer 
demonstrated the superiority of the second generation Grubbs catalyst, synthesizing 
oxaphospholenes 171 out of symmetrical or unsymmetrical vinyl phosphonates 170.175 These 
were easily, and often in excellent yields, accessible from bis(isopropyl)phosphine 166, which 
was treated successively with two different alcohols or with an excess of one alcohol, to yield 
unsymmetrical or symmetrical phosphonites 168. Oxidation with t-BuOOH afforded the desired 
vinyl phosphonates 169, which were subjected to RCM. Yields were increased from 25-65% 
to 92-100%, while reaction times were decreased from several days to 30 minutes, with a 
catalyst loading as low as 1% (Scheme 36, method B). Moreover, no seven-membered cycles 
were produced. 
 
Scheme 36: RCM of vinylphosphonates producing oxaphospholenes. 
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Timmer next expanded the scope of this method to construct bicylic oxaphospholene 
structures 173a-b through ene-yne metathesis.176 In the case of the symmetrical diallyl 
phosphonate 172a, the monocycle 174a was exclusively obtained (Scheme 37). Bicyclic 
oxaphospholenes 173b were only obtained if the five-membered ring was fused to a 
seven-membered ring and if the catalyst loading was increased to 5 mol%. Monocyclic six-
membered rings or bicyclic [4.4.0] ring products were not detected. 
 
Scheme 37: RCM of alkynylphosphonates producing monocyclic and bicyclic oxaphospholenes. 
2.5. Transition metal-catalyzed cyclization reactions 
2.5.1. Palladium-catalyzed coupling-cyclizations 
In 2007 Ma reported on the first Pd-catalyzed synthesis of oxaphospholenes.177 Monoesters 
of allenyl phosphonic acids 150 were found to react with allylic halides in the presence of 
5 mol% PdCl2(PhCN)2 and in the absence of a base to yield 4-allyl oxaphospholenes 176 in 
moderate to good yields (Scheme 38). Addition of a base seemed to be counterproductive, 
lowering the product yield or causing O-allylation to occur. Different alkyl substituents were 
tolerated as R1 and even a bulky t-Bu group only lowered the yield to some extent. When there 
was no substituent in the alpha position (R1 = H), the yield dropped more significantly. 
Substituents at the gamma position were well tolerated as well. Substituents at the allylic 
coupling partner were well tolerated as well since 3-chlorobut-1-ene and 2-methylallyl chloride 
were efficiently used in this coupling-cyclization reaction. The reaction time for the less reactive 
chloride coupling partners did increase however. 
 
Scheme 38: Coupling-cyclization of allenylphosphonates with allyl bromide. 
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Treatment of three derivatives 177, each carrying two allyl groups, with 5 mol% of Grubbs 
second generation catalyst swiftly yielded the corresponding tetrahydrobenzoxaphosphole 
oxides 178 through RCM (Scheme 39).177 These could be efficiently transformed into 
dihydrobenzoxaphosphole oxides 179 through DDQ-mediated oxidation.  
 
Scheme 39: Transformation of allyl-disubstituted oxaphospholenes into benzoxaphospholenes through 
RCM and oxidation. 
The same authors next investigated whether it was possible to use alkenes instead of allyl 
halides in the cyclization/coupling reactions with the monoester of allenylphosphonic 
acids 150.178 Evaluation of the PdCl2(PhCN)2 catalytic system with acrylonitrile as the coupling 
partner, CuCl2 as an oxidant and K2CO3 as the base, afforded one single isomer of the desired 
product 181, albeit in low yield, alongside some 4-chloro oxaphospholene 182 (Scheme 40). 
During optimization experiments, CuCl2 turned out not to be the best oxidant and reaction 
conditions were set as follows: a catalytic amount of NaI in air as the oxidant, no K2CO3 and 5 
mol% CaH2; yielding the desired alkenyl-substituted oxaphospholene 181 regio- and 
stereoselectively and in very good yields. A study of the scope of the reaction revealed that 
acrylates were excellent coupling partners. Less reactive alkenes, such as styrene, acrylamide 
and methyl methacrylate, proved to be more challenging substrates and the yields decreased 
significantly for those substrates. Using a stoichiometric amount of benzoquinone as the 
oxidant instead of NaI, yielded these derivatives in good yields nonetheless. On the other hand, 
different alkyl substituents on the allene were well tolerated, but yields dropped significantly 
when the allene was unsubstituted at one or multiple positions.  
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Scheme 40: Cyclization-coupling reaction of allenylphosphonate monoesters with alkenes. 
In 2013, Lee’s group found that benzylphosphonic acid monoethyl esters 183 (R2 = R3 = Me) 
could undergo C-H activation (Scheme 41).179-181 Optimization of reaction conditions showed 
that benzoxaphospholenes 184 were produced in the presence of Pd(OAc)2, NaOAc and 
PhI(OAc)2. A substrate scope study revealed that an ortho substituent was tolerated, which 
was not the case for the C-H activation of the related phenyl acetic acid.182 In the case of a 
meta substituent, the cyclization unsurprisingly took place at the less hindered ortho position. 
Benzylphosphonates with different EDGs or EWGs all reacted well under the optimized 
conditions. The Thorpe-Ingold effect was illustrated as well, as unsubstituted or mono methyl 
substituted derivatives at the benzylic position did not react. Increasing the steric bulk to two 
propyl groups at the benzylic position, afforded the benzoxaphospholenes in almost 
quantitative yield on the other hand. 
 
Scheme 41: C-H activation of benzylphosphonic acid monoethyl esters producing benzoxaphospholenes. 
Very recently, Zhao’s group found that phosphonylated propargyl alcohols 186 afforded 4-aryl 
oxaphospholenes 187 by means of a palladium-catalyzed domino addition, followed by a 
cyclization step (Scheme 42).183 The alkyne 186 first undergoes hydropalladation, after which 
a transmetallation and reductive elimination step yields a J-hydroxy alkenylphosphonate. This 
intermediate ultimately transesterifies to form the phosphonate. Under optimized conditions a 
multitude of arylboronic acids 185 was efficiently coupled in high to quantitative yields, 
tolerating various electron donating substituents on the aryl boronic acid 185. Although aryl 
boronic acids containing reactive functionalities such as a carbonyl or hydroxyl group afforded 
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the desired products in lower yields, they did not require protecting groups. That steric 
hindrance had an impact on the cyclization step was demonstrated by varying the size of the 
alkoxy group of the phosphonate: diisopropyl esters of the phosphonate reacted in a lower 
47% yield, while the dimethyl esters produced the reaction products in near-quantitative yields. 
Crowding the propargylic position with extra methyl groups, required an increase of the 
temperature and reaction time, but still afforded the products in excellent yields. 
 
Scheme 42: Palladium-catalyzed domino addition of propargyl alcohols with boronic acid,  
followed by cyclization. 
In 2015, Lee’s group published another report on Pd-catalyzed C-H activation/C-O bond 
formation of phosphonate monoesters 188 (Scheme 43).184 The important feature of this 
method is that unactivated alkenes could be engaged as substrates. Mixtures of 
phosphaisocoumarins 190 and benzoxaphospholenes 191 were initially obtained. By careful 
tuning of the reaction conditions, it was possible to shift the ratio of formed products in favor of 
the phosphaisocoumarins 190. Although the reaction was selective for most substrates, some 
benzoxaphospholenes 191 were still isolated in low yields (7-17%). 
 
Scheme 43: C-H activation of phosphonate monoesters with unactivated alkenes producing of 
phosphaisocoumarins and benzoxaphospholenes. 
2.5.2. Rhodium-catalyzed cyclization 
In 2013, the group of Lee reported on the C-H activation of o-tolylphosphonic acid monoethyl 
esters 192 (Scheme 44).185 They found that when these compounds reacted with electron 
deficient alkenes in the presence of a Rh-catalyst, an oxidant (AgOAc) and a base, producing 
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two products in an almost equimolar ratio: alkenyl product 193 and benzoxaphosphole 194. It 
is clear that benzoxaphosphole 194 results from intramolecular oxa-Michael addition of 193. 
Base and solvent screening led to optimized conditions in which only the desired 
benzoxaphospholene 194 was produced in 85% isolated yield. Substrate scope determination 
revealed that a variety of electron-deficient alkenes readily reacted to give the 
benzoxaphospholenes 194 in high yields. Alkenes lacking an EWG however (styrene, 
4-phenyl-1-butene, cyclohexene, vinyltriethoxysilane, vinyltrimethylsilane) did not engage in 
this reaction. Other substituents in ortho position of the phosphonate - such as halogens, 
alkoxy and phenyl groups - were well tolerated, as well as additional substituents on the 
aromatic ring. Adding a methyl substituent on the 5-position lowered the yield of the 
benzoxaphospholene considerably though, as it is probably generating too much steric 
hindrance for the C-H activation to occur efficiently.  
 
Scheme 44: Rh-catalyzed C-H activation of o-tolylphosphonic acid monoethyl esters producing 
benzoxaphospholenes. 
When phenylphosphonic acid monoethyl ester 195 was selected as a substrate for this 
reaction, dialkenylation of both ortho-positions occurred (Scheme 45). One of the two 
subsequently underwent an oxa-Michael addition, affording 3-alkenylated-7-alkylated 
benzoxaphospholenes 196. Again, a variety of electron withdrawing or electron donating 
substituents in para-position was tolerated. Meta-substituted (R1 = Me, Br) phenyl phosphonic 
acid monoethyl esters produced monoalkenylated benzoxaphospholenes, which did not 
undergo an oxa-Michael addition, seemingly illustrating that a subtle balance between the 
electronic and steric properties of the substituents on the aromatic ring is required for the 
tandem reaction. 
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Scheme 45: Rh-catalyzed dialkenylation of phenylphosphonic acid monoethyl ester. 
2.5.3. Au-catalyzed hydroarylation 
Just a couple of months later, Lee’s group reported on the hydroarylation of 
aryl alkynylphosphonates 197 (Scheme 46).186 Phosphacoumarins 199 were consistently 
produced in moderate to excellent yields via a 6-endo-dig cyclization. However, in the case of 
certain disubstituted aryl derivatives, a 5-exo-dig cyclization mode became the dominant or 
even exclusive pathway to yield benzoxaphospholenes 198 in decent yields. 
 
Scheme 46: Au-catalyzed hydroarylation of aryl alkynylphosphonates yielding benzoxaphospholenes and 
phosphacoumarins. 
2.6. Horner-Wadsworth-Emmons-type reactions 
In their quest for new pyridazine derivatives, Shaddy’s group explored additions of stabilized 
phosphonate carbanions to a densely functionalized pyridazine 200.187 Treatment of 
pyridazine 200 with a small excess of methylthio methylphosphonate 201, afforded the dihydro 
oxaphospholo pyridazine-2-oxide 202 under microwave irradiation in good yield (Scheme 47). 
In an antibacterial (versus B. tumefaciens, S. aureus and K. pneumonia) and antifungal (versus 
A. niger, A. flavus) screening, compound 202 was found to be 1.1 to 1.6 times as active as the 
standards Streptomycin and Mycostatin. 
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Scheme 47: Synthesis of dihydro oxaphospholo pyridazine-2-oxide 202 through addition of methylthio 
methylphosphonate to a pyridazinone. 
When alkylphosphonochloridates 203 are reacted with D-hydroxyesters, phosphonates 204 
are obtained in decent yields (Scheme 48).188 After deprotonation, ring closure leads to 
4-hydroxy oxaphospholenes 205 in poor yields. 
 
Scheme 48: Reaction of alkylphosphonochloridates with D-hydroxyesters. 
Quite recently, the Postel group synthesized a variety of saccharidic spirocyclic 4-amino 
oxaphospholenes 210 (Scheme 49).189 These compounds were prepared as precursors for 
P-TSAO-T 207, a family of spirocyclic, phosphorus-containing nucleoside analogues of 
TSAO-T 206 (Figure 9). TSAO-T and earlier described derivatives display significant activities 
against Reverse Transcriptase Human Immunodeficiency Virus type-1 (RT-HIV-1) and 
Hepatitis C Virus (HCV).190-192 As they only differ in the heteroatom in the unsaturated ring, 
phosphorus instead of sulfur, these derivatives were of interest as new potential lead 
compounds. The difference in polarity of the P=O bond, because of the lower electronegativity 
of phosphorus, in comparison to the S=O bond, might induce important changes in the 
formation of hydrogen bonds in the binding pockets.  
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Figure 9: Structures of TSAO-T and P-TSAO-T (RT-HIV-1 and HCV inhibitors). 
The key step in this synthesis consisted of the generation of a stabilized carbanion that would 
create the second ring upon attack of the nitrile function. A screening of reaction conditions 
revealed that an extra EWG, next to the phosphonate, was required to prevent degradation. 
Thus, ribo-cyanohydrin 209 was prepared from ketose 208, an oxidized derivative of D-xylose, 
under Strecker conditions (Scheme 49). A one-pot two-step reaction with NaH and 
phosphonochloridates 210 afforded the desired spirocyclic oxaphospholenes 211 in moderate 
yields. The 3-phenyl substituted oxaphospholene could not be prepared in a one-pot sequence 
and required treatment of the phosphonate intermediate 212 with LDA to afford the 
corresponding spirocyclic oxaphospholene. 
Scheme 49: Synthesis of P-TSAO-T precursors. 
2.7. Other methods 
In 1990, Abramovitch reported on the thermolysis of azirinylmethylphosphonates 217 (Scheme 
50).193 These were prepared through addition of tetramethylguanidinium azide 214 to 
allenylphosphonates 213 and trapping of the resulting azido vinylphosphonates 215 with 
triphenylphosphine. The obtained phosphinimines 216 could be transformed into the 
corresponding azirinylmethylphosphonates 217 through photolysis in excellent yields. 
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Finally, the 4-amino oxaphospholenes 218 were obtained in moderate yields by heating in 
toluene with catalytic amounts of PdCl2(PhCN)2.  
 
Scheme 50: Thermolysis of azirinylmethylphosphonates yielding oxaphospholenes. 
A simple one-step synthesis of oxaphospholenes consists of a nucleophilic substitution 
reaction of 1,2-dibromo-3-chloropropane 219 with diethyl phosphite, first yielding a dihaloalkyl 
phosphonate intermediate 220. Intramolecular displacement of the chloride by the 
phosphonate oxygen atom is then followed by dealkylation of the resulting phosphonium 
intermediate and elimination of HBr to yield the oxaphospholene 221 (Scheme 51).194 
 
Scheme 51: Preparation of unsubstituted oxaphospholenes from 1,2-dibromo-3-chloropropane and 
diethyl phosphite. 
In 1981, Miles published a synthesis starting from arylphosphonate 222 (Scheme 52).195 After 
bromination with NBS and intramolecular displacement of the bromide in aryl 
phosphonate 223, dealkylation of the resulting phosphonium intermediate yielded 
benzoxaphospholene 224 upon refluxing in o-dichlorobenzene.  
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Scheme 52: Synthesis of benzoxaphospholenes through intramolecular reaction of o-phosphonylated 
benzyl bromides. 
Benzoxaphosphole oxides could also be prepared from salicylaldehyde 225a or from 
1-(2-hydroxyphenyl)ethan-1-one 225b in a reaction with ClP(OEt)2 or with PCl3 followed by 
ethanolysis.196, 197 Depending on the substrate, benzoxaphospholene oxides 226 or 227 were 
obtained (Scheme 53).  
 
Scheme 53: Synthesis of benzoxaphospholenes through treatment of salicaldehydes with trivalent 
phosphorus compounds. 
On prolonged heating in xylene, dinaphthyl propadienylphosphonate 228 afforded the tricylic 
structure 229 in poor yield through an intramolecular Diels-Alder reaction (Scheme 54).198 Only 
one diastereomer is formed, presumably the one experiencing the least steric repulsion. 
Diphenyl propadienylphosphonate, nor dinaphthyl 3-methyl-1,2-propadienylphosphonate 
reacted in this intramolecular Diels-Alder reaction.  
 
Scheme 54: Diels-Alder reaction of diaryl allenylphosphonates yielding tricylic benzoxapholenes. 
Quite recently, Terada described a cyclization reaction of alkynyl D-ketoanilides 230. Addition 
of dialkyl phosphites to the ketone moiety gives 3,4-dihydro-2-quinolones 232 after a 
1,2-phospha-Brook rearrangement (Scheme 55).199 In the case where the alkyne bears a 
phenyl substituent (R3 = Ph), the vinylic anion attacks the phosphorus atom, eliminating one 
of the ethoxides and thus generating tricyclic structure 233. 
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Scheme 55: Preparation of tricyclic oxaphospholenes from cyclization of alkynyl D-ketoanilides. 
The group of Terada looked to extend this tandem [1,2]-phospha-Brook 
rearrangement/cyclization methodology to other derivatives. The addition of diethyl phosphites 
on 2-(2’-alkynylaryl)-benzoates 236 initially produced only limited amounts of the desired 
phenanthrene derivatives 237 until optimized conditions were found (Scheme 56).200 An 
important by-product was tetracyclic oxaphospholene 241, originating from an attack of the 
vinylic anion intermediate 240 on the phosphorus center, eliminating an ethoxide. 
Compound 241 was isolated, but the yield was not reported. This side reaction was 
suppressed by switching to diisopropyl phosphite as the nucleophile and the pathway to 
tetracyclic oxaphospholenes 241 was not further explored.  
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Scheme 56: [1,2]-Phospha-Brook rearrangement-cyclization yielding phenanthrenes and tetracyclic 
oxaphospholenes. 
During their work on phosphonylated carbohydrate derivatives, the group of Suarez reported 
an SN2’ substitution reaction on phospha-1-oxo-pentofuranoses 242 by glycine methyl ester 
producing oxaphospholene 243 (one diastereomer shown) (Scheme 57).201, 202 
 
Scheme 57: SN2’ substitution reaction on phospha-1-oxo-pentofuranoses by glycine methyl ester. 
Attempting to deprotect the PMB protecting group of aminoallenylphosphonates 244 using 
CAN, the group of Rabasso discovered that a rearrangement took place, yielding spirodienone 
lactams 249 in moderate to high yields, with concomitant expulsion of diethyl phosphite 
(Scheme 58).203 
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Scheme 58: Proposed mechanism for the synthesis of spirodienone lactams upon treatment of 
PMB-protected 1-aminoallenylphosphonates with CAN. 
In some cases the spirodienone lactams 249 were produced in reduced yields or not at all. In 
three of those cases, the authors were capable of isolating tricyclic structures 251 (Figure 10). 
In the case of the aminoallenylphosphonate derived from 4-chromanone, which did not 
produce the corresponding spirodiene lactam, spirocyclic oxaphospholene 254 was obtained 
in a high yield of 84%. A plausible mechanism was proposed in which intermediate 246 
underwent intramolecular cyclization instead of the hydrolysis and subsequent diethyl 
phosphite expulsion steps. Oxidation of the resulting phosphonium ion 250 with CAN would 
lead to tricyclic oxaphospholenes 251. The authors reasoned that without the addition of water, 
increased yields should be obtained as competitive formation of the spirodienone lactams 
would not be possible. However, this was true for only one example. Additionally, one substrate 
that did give a good conversion to the spirodienone lactam 249, could also produce the tricyclic 
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oxaphospholene 255 in a fair 30% yield, when the reaction was run in the absence of water. 
Other substrates could not be engaged in this transformation. 
 
Figure 10: Prepared spirocyclic oxaphospholenes through treatment of  
PMB-protected 1-aminoallenylphosphonates with CAN. 
3. Conclusions 
Benzoxaphospholenes and oxaphospholenes have been investigated for half a century now 
with new syntheses appearing frequently. The first synthetic routes were mainly focusing on 
benzoxaphospholenes and were conducted under harsh conditions. With allenylphosphonates 
becoming easily accessible precursors, the possible transformations towards 
oxaphospholenes really boomed. Initially, difficult to handle and toxic reagents such as 
halogens, alkylsulfenyl- and alkylselenylhalides were mainly employed. Later, safer 
alternatives such as copper halides made their entry. Transition-metal catalyzed reactions 
impressively opened up the structural variety of (benz)oxaphospholenes that could be 
prepared: cross coupling reactions afforded vinyl-substituted oxaphospholenes, 
C-H activitation yielded a multitude of substituted benzoxaphospholene derivatives while an 
alternative approach to (benz)oxaphospholenes was realized through RCM. The development 
of P-TSAO-T’s as potentially new antiviral agents illustrates possible applications. With the 
emergence of more sophisticated precursors, such as bisallenylphosphonates or 
PMB-protected 1-aminoallenylphosphonates, the structural complexity of novel 
oxaphospholenes has drastically increased in recent years. New exciting studies on the design 
of novel methodologies for the preparation of oxaphospholenes with even more structural 
variety are definitely to be expected in the future. 
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1. Three-step synthesis of chiral spirocyclic 
oxaphospholenes 
1.1. Introduction 
The importance of chiral BINOL phosphate catalysts in asymmetric transformations may hardly 
be overestimated. Although many chiral catalysts have been prepared and assessed for their 
enantioselective properties, only few have been applied on a broad scope of substrates. 
Together with, amongst others, Salen complexes, bis(oxazoline) ligands and cinchona 
alkaloids, BINOL and the derived BINOL phosphates belong to the class of 'privileged chiral 
inducers'. Since the pioneering reports of the groups of Akiyama and Terada in 2004 on 
asymmetric Mannich-type reactions,204, 205 BINOL phosphoric acid derivatives have been 
deployed in asymmetric versions of numerous and important organic transformations such as 
Friedel-Crafts,206 Pictet-Spengler,207 Strecker,208 reductive amination209 and 
hydrophosphonylation reactions,210 as well as transfer hydrogenations.211, 212 The outstanding 
characteristics of BINOL phosphates to control enantioselectivities originate from the 
phosphorus containing seven-membered ring and the chiral binaphthyl moiety, locking the 
conformation of the Brønsted acid function.213 Inspired by our expertise in oxaphospholene 
chemistry,174, 214 the synthesis of phosphorus containing allenes53, 215 and heterocycles40, 41, 216, 
we envisioned the synthesis of chiral spirocyclic oxaphospholenes 22, which may be of interest 
for the design of new chiral phosphonic acid catalysts. Even though the halocyclization of 
(3-cyclohexyl)allenylphosphonates to spirocyclic oxaphospholenes has been known for a few 
decades,121, 168 this is the first example of the design of such spirocyclic compounds that are 
chiral. The synthesis we envisioned is based on three successive transformations from readily 
available chiral starting materials. Addition of an organometallic acetylide to chiral pool 
ketoterpenes 19217 will be followed by treatment of the resulting propargylic alcohols 20 with 
diethyl chlorophosphite (Scheme 59).107, 108 Subsequently, the obtained chiral 
allenylphosphonates 21 will finally be subjected to a halocyclization to give the desired chiral 
spirocyclic oxaphospholenes 22.168  
 
Scheme 59: Approach to chiral spirocyclic oxaphospholenes. 
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1.2. Synthesis of chiral spirocylic oxaphospholenes 
1.2.1. With a varying alkyne substituent 
a. Synthesis of propargylic alcohol precursors 
The first objective was the synthesis of propargylic alcohols 257 from cheap and commercially 
available chiral pool ketoterpenes 256. (-)-Menthone was selected as a model substrate and 
was reacted with ethynylmagnesium bromide to swiftly yield the corresponding propargylic 
alcohols 256a and 257a. A good diastereoselectivity was obtained and the diastereomers were 
easily separated and isolated in 87% yield (Table 1, entry 1). 
Table 1: Optimized conditions for preparation of propargyl alcohol precursors. 
 
entry R equiv acetylide t (h) dra yield (%)b 
1 H 1.3c 2 80/20 87 
2 Ph 1.8c 16 75/25 79 
3 4-MeC6H4 1.5d 24 73/27 91 
4 2-MeC6H4 1.3d 16 76/24 89 
5 n-Bu 1.5d 3 81/19 95 
a determined by GC-MS b isolated yield of separated diastereomers combined  
c commercially available Grignard reagent was used d lithium acetylide was prepared in situ with 1.6 equiv n-BuLi 
 
A series of (-)-menthone derived propargylic alcohols was consecutively prepared, making use 
of different alkynes. In each reaction, conversions were complete and the diastereoselectivities 
of the acetylide addition were comparable (entries 2-5). The acetylides were prepared in situ 
by deprotonation of the corresponding alkynes with n-BuLi, unless a Grignard reagent was 
commercially available, as in the cases of acetylene and phenylacetylene. 
b. Synthesis of allenylphosphonates 
Allenylphosphonates are traditionally prepared by phosphonylation of progargylic alcohols with 
dialkyl chlorophosphite in diethyl ether, after which the resulting dialkyl propargyl phosphite 
spontaneously rearranges to produce a thermodynamically more stable, pentavalent 
allenylphosphonate.107, 108 Recently, catalytic transformations using non-toxic dialkyl 
phosphites, have been described by the groups of Stawinski, Han and Zhao. While the latter 
two methods either failed to produce or did not report on the transfer of central-to-axis 
III. Results and Discussion 
49 
chirality,218, 219 Stawinski conditions allowed a clear transfer of the chirality present in the 
propargylic starting materials.220, 221 However, the catalytic system required the propargylic 
alcohol precursors to be modified to contain a good leaving group. We considered this extra 
derivatization step as a drawback and opted to use dialkyl chlorophosphites for the direct [2,3]-
sigmatropic rearrangement using propargylic alcohols 257a-e, as it displays simultaneous 
center-to-axial chirality transfer owing to a concerted mechanism.168, 221, 222 
In a preliminary experiment, a mixture of diastereomers 257a and 258a (55/45) was treated 
with diethyl chlorophosphite and triethylamine (Table 2, one diastereomer shown). After one 
hour at room temperature, all of the 258a starting material had been consumed (entry 1). Only 
after addition of a second portion of diethyl chlorophosphite and overnight stirring at room 
temperature, phosphonylation of the sterically more demanding propargylic alcohol 257a 
started to take place. Refluxing 257a in diethyl ether with an excess of diethyl chlorophosphite 
gave a complete conversion, but only after 6 days (entry 2). The product was not purified, 
because more optimized reaction conditions were first searched for. Preforming the alkoxide 
by treatment of alcohol 257a with NaH prior to the addition of diethyl chlorophosphite, did not 
enhance the progress of the reaction at room temperature (entry 3).  
Table 2: Optimized conditions for preparation of allenylphosphonate precursors. 
 
entry t (h) T solvent 259a (%)a yield (%)b 
1c 1 
16 
0 °C to rt 
rt 
Et2O 55 
67 
- 
 
2 6 days ' Et2O 100 - 
3d 5 0 °C to rt Et2O 0 - 
4e 17 
2 
' THF 79 
98 
- 
43 
5f 24 ' THF 95 75 
a conversion determined by GC-MS b isolated yield c a 55/45 mixture of 257a/258a was used  
d NaH instead of NEt3 e 0.5 equiv ClP(OEt)2 was added after 17 h f 2 equiv ClP(OEt)2 
 
When refluxing propargyl alcohol 257a in THF in the presence of diethyl chlorophosphite and 
triethylamine, 79% conversion to the corresponding allenylphosphonate 259a was achieved 
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after 17 hours. Additionally adding half an equivalent of diethyl chlorophosphite, gave complete 
conversion with complete diastereoselectivity after heating for two more hours (entry 4).  
Although Stawinski reported that racemization of allenylphosphonates may occur upon 
prolonged heating when even weakly nucleophilic chloride species are present in the reaction 
mixture,221 no epimerization was observed in our case. With an excess of diethyl 
chlorophosphite (2 equivalents, added in one portion), the allenylphosphonate 259a was 
isolated in 75% yield (entry 5). Under these optimised conditions, all of the (-)-menthone 
derived propargylic alcohols 257a-e reacted smoothly to give the allenylphosphonates 259a-e 
in yields up to 78% (Figure 11). 
 
Figure 11: Allenylphosphonates based on the (-)-menthone backbone. 
c. Cyclization to oxaphospholene spirocycles 
Ma reported the copper-mediated cyclization of allenylphosphonates, using a twofold excess 
of CuX2, to give halogenated oxaphospholenes.168 Upon addition of 2.2 equivalents of CuBr2, 
starting material 259a was indeed entirely consumed and two epimers at the phosphorus atom 
were formed, along with three unidentified products and a monobrominated product 262a, 
resulting from bromine addition followed by HBr elimination (Scheme 60). Unsurprisingly, 
purification on silicagel was unsuccessful, as oxaphospholenes are known to hydrolyse during 
chromatography.85, 173  
 
 
Scheme 60: CuBr2-mediated synthesis of spirocyclic  
oxaphospholene 261a (conversion and dr determined via 31P NMR). 
Fortunately, when simply heating a solution of allenylphosphonate 259a with one equivalent 
of I2 in chloroform for half an hour, a mixture of only two oxaphospholene epimers 263a was 
obtained (Table 3, entry 1).115, 126, 169, 223, 224 In this transformation, two stereogenic centers were 
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simultaneously created and consequently four enantiopure diastereomers could be formed. 
Interestingly, only two diastereomers were obtained. Most probably, the control of chirality was 
highly efficient at the quaternary carbon, while dealkylation of the phosphonate was 
non-selective. The two stereoisomers are only epimers at the phosphorus atom. Unfortunately, 
the product was not crystalline and consequently, the absolute configuration could not be 
determined via X-ray diffraction. In previous research, however, it has been shown that the 
axial chirality was efficiently transferred to center chirality.169 Thus, the stereochemistry 
depicted in Table 3 is mechanism-based. According to 31P NMR, 8% of side-product 264a was 
detected, probably resulting from Brønsted acid induced cyclization (HI). In order to minimize 
the moisture content in the mixture, different combinations of solvent, temperature, inert 
atmosphere and glassware were screened (entries 1-5). Heating the mixture in cyclohexane 
under nitrogen atmosphere in a dried Schlenk flask were found to be the optimal conditions. 
Attempts were made to influence the diastereomeric ratio by varying the temperature or the 
solvent (entries 1-3, 5, 6). A slightly better diastereomeric ratio was obtained, than those 
observed by Ma's copper-mediated synthesis of non-spirocyclic oxaphospholenes.168 
Table 3: Optimization of spirocyclic oxaphospholene synthesis. 
 
entry t (h) T (°C) solvent 263a (%)a dr (%)a yield (%)b 
1 0.5 110 CHCl3c 87 39/61 - 
2 0.5 100 DCEc 93 39/61 - 
3 0.5 80 DCEc 95 38/62 - 
4 0.5 80 DCEc 92 39/61 - 
5d 0.5 80 cyclohexane 100 40/60 91 
6 3.5 35 n-pentaned 70 38/62 - 
a conversion determined by 31P NMR b combined isolated yield, no purification  
c anhydrous d Ar instead of N2 atmosphere 
 
These optimized conditions were then applied to substrates 259a-e to give a series of chiral 
spirocyclic oxaphospholenes while no purification step was needed (Figure 12). Cyclization 
was not hampered by the increased steric hindrance of a phenyl or p-tolyl substituent (87-94% 
yields). It was observed that an o-tolyl substituent was equally well tolerated and the 
oxaphospholene was isolated in excellent yield (91%). Thanks to rotation of the aromatic ring, 
the o-methyl group could be oriented away from the allene, allowing iodine also in this case to 
be attacked by the distal allenyl double bond. For such compounds, steric hindrance induces 
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slow rotation of the Co-tolyl-Coxaphospholene bond and rotamers were observed in both 1H NMR and 
13C NMR. An n-butyl substituent did not pose any problems either and the 
oxaphospholene 263e was isolated in almost quantitative yield. 
 
Figure 12: Spirocyclic oxaphospholenes based on the (-)-menthone backbone. 
1.2.2. With a varying ketoterpenic backbone 
a. Synthesis of propargylic alcohol precursors 
In a second series of propargylic alcohols, the alkyne part remained unchanged while the 
ketoterpenic moiety was varied. Although commercially available, (+)-menthone was 
quantitatively prepared from the much cheaper (+)-menthol by Dess-Martin oxidation and 
subsequently transformed into the propargylic alcohol 257f with ethynylmagnesium bromide 
(Figure 13, one diastereomer shown). (-)-Fenchone and (+)-camphor reacted sluggishly with 
the Grignard reagent and dimerization was observed when switching to less mild reaction 
conditions. Nevertheless, with the in situ generated lithium trimethylsilyl acetylide, the bicylic 
propargylic alcohols 257g and 257h were obtained in good yields after TMS-deprotection.225 
Moreover, thanks to the increased steric hindrance of the bicyclic backbone, one diastereomer 
was exclusively formed in both cases. 
 
a determined by GC-MS b yield over two steps 
Figure 13: Propargyl alcohol precursors with varying terpenic backbone. 
b. Synthesis of allenylphosphonates 
Next, allenylphosphonates 259f-h with a fenchone- or camphor-based structure were 
prepared, using the earlier optimized conditions (Figure 14). All allenylphosphonates were 
easily isolated in moderate to good yields (56-75%). 
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Figure 14: Allenylphosphonates with varying terpenic backbone. 
c. Cyclization to oxaphospholene spirocycles 
 (+)-Menthone derived allenylphosphonate 259f was easily cyclized to give spirocyclic 
oxaphospholene 263f in excellent yield (Figure 15). Oxaphospholene 263g, derived from 
(+)-fenchone, was not formed under standard conditions though. As the starting material was 
recovered unchanged, the reaction temperature was increased to 110 °C. Unfortunately, a 
mixture of starting material and unidentified rearrangement products was then obtained, while 
oxaphospholene 263g was not detected. The decreased reactivity at 80 °C was probably a 
result of the increased steric hindrance around the distal double bond of 
allenylphosphonate 259g, which prevented the electrophilic attack of iodine. When reacted at 
80 °C for three hours, a mixture of at least ten phosphonylated compounds with an important 
amount of starting material was obtained. In the case of (+)-camphor derived 
allenylphosphonate 259h, the starting material was rapidly consumed at 80 °C and a complex 
mixture of phosphonylated products was obtained, in which oxaphospholene 259h was not 
present. Running the reaction at 60 °C instead, did not improve selectivity, while the starting 
material 259h was not even entirely consumed. These results were not unsurprising though, 
as camphor is known to be prone to rearrangements in acidic media, of which fenchone is an 
intermediate.226, 227 Although a stable tertiary carbocation is initially formed, isomeric 
intermediates must be formed just as easily. 
 
Figure 15: Spirocylic oxaphospholenes with varying terpenic backbone. 
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1.3. Conclusion 
In conclusion, we have exemplified for the first time that chiral spirocyclic oxaphospholenes 
can be synthesized in a three-step sequence from chiral pool ketoterpenes. Addition of metal 
acetylides gives the corresponding propargylic alcohols in high yields with good to excellent 
diastereoselectivities, depending on the steric hindrance of the substrate. All of these propargyl 
alcohols were easily converted to the corresponding allenylphosphonates with diethyl 
chlorophosphite. Upon addition of a stoichiometric amount of iodine, bicyclic oxaphospholenes 
were swiftly obtained, without the need for purification. Bridged allenylphosphonates, derived 
from camphor and fenchone, either did not react due to steric hindrance or rearrangement, 
and did not yield the desired spirocyclic oxaphospholenes in both cases. The deprotection of 
the phosphonate moiety still needs to be addressed before the chirality inducing properties of 
the spirocyclic oxaphospholenic acids can be evaluated. 
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2. Synthesis of 5-bisphosphonomethyl oxazol-2-
ones and 5-phosphonomethylidene oxazolidin-2-ones 
2.1. Introduction 
Oxazolidin-2-ones have attracted a lot of attention as chiral auxiliaries (e.g. Evans 
oxazolidinones),228 as key structural components of natural products229 and as the 
pharmacophore of antibiotics used in the treatment of multi-drug resistant infections230-234 and 
blood thinners235. Linezolid 265, for instance, was found to have the best pharmacokinetic 
properties in a series of oxazolidin-2-one antibiotics and got approved by the FDA in 2000 
(Figure 16).236 Rivaroxaban 266 was approved in 2008 by the European Commission to 
prevent thromboembolism.235 Moreover, the oxazol-2-ones are interesting building blocks 
themselves,237, 238 often used in the synthesis of natural products and their analogues.239, 240 
Bisphosphonomethyl oxazol-2-ones have never been reported before, although the 
bisphosphonomethyl moiety is a crucial motif of bisphosphonate drugs (f.i. Alendronate 267), 
used in the treatment of osteoporosis. A facile entry into compounds containing both the 
oxazolone and bisphosphonomethyl motif would be of interest for the evaluation of their 
biological properties. 
 
Figure 16: Examples of oxazolidin-2-one (left and center) and bisphosphonate (right) drugs. 
2.2. One-pot synthesis of bisphosphonomethyl oxazol-2-ones 
2.2.1. Identification and plausible reaction mechanism of bisphosphonomethyl 
oxazol-2-one 24 
The synthesis of phosphonylated azaheterocycles on the one hand and gold-catalyzed 
cyclization reactions on the other hand, have attracted our group’s interest for quite some 
time.35, 40, 41, 50, 241-244 Looking to evaluate the gold-catalyzed cyclization reaction of 
phosphonylated propargylamines, we were interested in preparing the protected 
3-amino, 3-phosphono prop-1-yn-1-yl phosphonate 268.  
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N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate 23 was synthesized from propargylamine and 
di-tert-butyl dicarbonate in 83% yield.245 Subsequently, it was treated with 2.5 equivalents of 
both LDA and diethyl chlorophosphate (Scheme 61).  
 
Scheme 61: Failed attempt to synthesize 3-phosphonopropargylamino phosphonate 268  
in a one-pot procedure. 
To our surprise, 31P NMR indicated that the major product was no alkynylphosphonate (it 
lacked a characteristic shift around -7 ppm), but appeared in the region of phosphonates 
connected to an sp2 or sp3 carbon (around 15 ppm). LC-MS analysis, however, showed that 
the mass of the desired compound (minus isobutene) was present, so it was concluded that a 
rearrangement to an isomer had occurred. After purification, the major compound was isolated 
as a crystalline material. NMR data revealed that  
x a bisphosphonate unit was clearly present (triplet in 13C NMR at 37.5 ppm, 1JCP = 
133.3 Hz, one single peak in 31P NMR at 14.2 ppm) 
x the alkyne carbons were changed to alkene carbons 
x two carbamate-like carbons were present, although only one t-Bu group was present 
in 1H NMR 
x a proton on a heteroatom was present (broad singlet at 8.20 ppm in 1H NMR) 
This led to the conclusion that a cyclization reaction had taken place, with a N to C Boc-shift. 
X-ray diffraction confirmed the structure of the rearranged product to be the 
bisphosphonomethyl oxazol-2-one 24 (Figure 17).  
 
Figure 17: Structure of the bisphosphonomethyl oxazol-2-one 24 (left) formed in the attempted one-pot 
synthesis of 3-phosphonopropargylamino phosphonate and its X-ray structure (right). 
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The confirmation of the end product’s structure allowed us to propose a plausible reaction 
mechanism. The alkyne 23 was probably first phosphonylated at the most acidic position 
(Scheme 62). The excess of base then creates a 3-aminoallenylphosphonate 271 which gets 
phosphonylated again at the carbon already carrying a phosphonate group. For a 
[1,2]-Boc-shift to occur, one of the two Boc-groups needs to be attacked. Thus, it is anticipated 
that after another deprotonation step and isomerization, the Boc-group gets installed on the 
carbon atom in D-position of the nitrogen atom. Next, the aminoallenylbisphosphonate 275 is 
ready to be attacked in a 5-exo-dig fashion by the carbamate, yielding oxazole 277. Elimination 
of isobutene eventually yields the final product 24. In a control experiment, 1H NMR confirmed 
that the major product in the reaction mixture contained two t-Bu groups, while 31P NMR 
showed that it had a slightly different shift (15.5 ppm) than the product that was isolated after 
chromatography. This indicated that the product formed in the reaction mixture most probably 
was oxazole 277, which was converted to oxazol-2-one 24 when stirred with silica in ethyl 
acetate for 24 h. 
 
Scheme 62: Plausible mechanism for the formation of 5-bisphosphonomethyl oxazol-2-one 24. 
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2.2.2. Optimization of reaction conditions for the one-pot reaction 
Although compound 24 was the major product in the initial experiment (Table 4, entry 1), 
conditions were screened to increase the selectivity towards the desired compound and to 
simplify the procedure. The reaction was run at 0 °C to speed up the conversion, but 
unfortunately, the desired product was not formed and a complex mixture was obtained 
(entry 2). When n-BuLi was used instead of LDA, it attacked the Boc-group after which the 
propargylamine was phosphonylated at the N-atom, yielding the phosphoramidate 278 as the 
major product (entry 3). When repeating the original procedure, it was observed that some of 
the phosphorus-containing side-products could be evaporated at 60 °C and 2 mbar, affording 
a mixture of 83% purity (entry 4). Besides the bisphosphonomethyl oxazol-2-one 24, 
phosphoramidate 278 was detected along with phosphonomethyl oxazol-2-one 279. This 
monophosphonylated heterocycle probably results from LDA-induced dealkylation of the 
Boc-group of alkyne 269, followed by cyclization. Although the isolated yield could be improved 
to 17%, purification remained troublesome as the product partly eluted together with side-
products such as the monophosphonylated oxazol-2-one 279. 
Table 4: Screened reaction conditions for the one-pot synthesis of  
5-bisphosphonomethyl oxazol-2-one 24. 
 
entry base T (°C) t (h) 24 (%)b,c 278 (%)b 279 (%)b 
1 LDA - 78 
- 42 
rt 
1 
3 
on 
- 
- 
67 
- 
- 
0 
- 
- 
0 
2 LDA 0 
rt 
1 
3 
- 
0 
- 
5 
- 
0 
3d n-BuLi - 78 
- 42 
rt 
1 
3 
on 
- 
- 
8 
- 
- 
32 
- 
- 
0 
4 LDA - 78 
- 42 
rt 
1 
3 
on 
- 
- 
83 (17) 
- 
- 
1 
- 
- 
  2 
a no anhydrous solvent b conversion based on 31P NMR c isolated yield between brackets 
 d temperature was kept at - 78 °C for 1 h during deprotonation step 
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2.3. Stepwise synthesis of bisphosphonomethyl oxazol-2-
ones 
2.3.1. Synthesis of 3-amino prop-1-yn-1-yl phosphonate 269 
a. Via organolithium bases 
As the one-pot synthesis suffered from a low isolated yield, it was investigated whether a more 
selective reaction could be obtained through a stepwise approach.  
Table 5: Phosphonylation of N,N-di-tert-butylprop-2-ynylimidodicarbonate 23 with diethyl 
chlorophosphate. 
 
entry base T (°C) t (min) 269 (%)b,c 278 (%)b  280 (%)b 
1 n-BuLi - 78 30 54 9  10 
2 n-BuLi - 95 30 58 5  9 
3a n-BuLi - 95 10 42 1  2 
4 LDA - 95 30 41(3) 0  0 
5 LDA - 95 60 43 6  4 
6 LiHMDS - 95 30 1 28  0 
a 0.5 equiv n-BuLi, 0.5 equiv ClP(O)(OEt)2  
b conversion based on 1H NMR c isolated yield between brackets 
When N,N-di-tert-butylprop-2-ynylimidodicarbonate 23 was treated with a slight excess of both 
n-BuLi and diethyl chlorophosphate, about half of the starting material was converted to the 
phosphonylated propargylamine 269 (Table 5, entry 1). Products 278 and 280 result 
from n-BuLi-induced loss of a Boc-group, followed by N-phosphonylation. Lowering the 
temperature to - 95 °C did not result in a more selective reaction (entry 2). When only half an 
equivalent of reactants were used, selectivity did improve and a proportionally higher 
conversion was achieved (entry 3). The side-products 278 and 280 were still detected, 
indicating that these did not result from the excess n-BuLi initially used. Isolation of the desired 
alkyne 269 proved to be impossible as it eluted together with the phosphoramidate 280. When 
LDA was employed, the desired product was formed as the major product, and the side-
products 278 and 280 were not detected (entry 4). Other unseparable and unidentifiable side-
products troubled the purification again, resulting in a low isolated yield of phosphonylated 
propargylamine 269 of 3%. An important part of the starting material (55%) had not been 
consumed in the reaction with LDA, so the reaction time was increased. The resulting 
III. Results and Discussion 
 
60 
conversion did not increase significantly though, and the side-products 278 and 280 were 
detected again (entry 5). Although all of the starting material was consumed with LiHMDS as 
base, only trace amounts of phosphonylated alkyne 269 were detected, along with, amongst 
others, phosphoramidate 278 (entry 6).  
b. Via a transition metal-catalyzed cross coupling reaction 
As it proved to be difficult to obtain the phosphonylated alkyne 269, an alternative approach 
was considered. A copper-catalyzed cross coupling reaction of alkynes with dialkyl phosphites 
under a dry air atmosphere had been reported in literature.246 N-Tosyl propargylamine was 
oxidatively coupled to diethyl phosphite in the presence of 0.1 equivalent Cu(OAc)2 and 0.2 
equivalent NEt3 in 83% yield on a scale of 0.5 mmol. A big advantage of this method is that 
diethyl phosphite is a cheap reactant and much more easy to handle than the toxic and 
moisture-sensitive diethyl chlorophosphate. 
Table 6: Copper-catalyzed oxidative phosphonylation of  
N,N-di-tert-butylprop-2-ynylimidodicarbonate 23 with diethyl phosphite. 
 
entry scale (mmol) equiv DEP equiv Cu(OAc)2 atmosphere t (h) 269 (%)c,d 281 (%)c 282 (%)c 
1a 1.8 0.83 0.083 air 16 21 9 21 
2a,b 1.8 0.83 0.083 air 16 27 4 19 
3a,b 1.8 1 0.1 air 16 47 2 3 
4 1.8 1.2 0.1 air 16 52 2 6 
5 1.8 2 0.1 air 16 74 1 1 
6 1.8 4 0.1 air 16 83 12 5 
7 10 2 0.1 air 16 3 3 0 
8 1 2 0.3 O2 (1 atm) 4 44 1 0 
9 5 3 0.1 + 0.2 O2 (1 atm) 5 87 1 0 
10 5 2 + 1 0.1 + 0.2 O2 (1 atm) 5 98 (72) 2 0 
11 10 2 + 1 0.1 + 0.2 O2 (1 atm) 5 98 (73) 2 0 
a 0.17 equiv NEt3 was used b 80 °C c conversion according to 1H NMR d isolated yield between brackets 
When these conditions were applied on substrate 23 on a slightly bigger scale, a poor and 
non-selective conversion was obtained (Table 6, entry 1). Increasing the temperature from 
55 °C to 80 °C hardly improved the conversion, nor the selectivity (entry 2). 
Vinylphosphonate 281 resulted from hydrophosphonylation of the alkyne, which occurs when 
the oxidation step is inhibited.246 Dialkyne 282 results from a Glaser-Hay coupling because the 
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dialkyl phosphite was present in a lower than equimolar amount. A clear effect was observed 
however, when the amount of diethyl phosphite was increased. A conversion of up to 83% was 
then obtained (entries 1 vs 3-6). Part of the diethyl phosphite is inevitably converted to 
hypophosphate 283, particularly when it is used in equimolar or excess amounts.247 As the 
alkyne starting material was considered to be the more valuable substrate, it was decided to 
minimize the formation of Glaser-Hay coupling product 282, and sacrifice the dialkyl phosphite 
by adding it in excess amounts. Unfortunately, when the reaction was scaled up, the 
conversion dropped significantly, indicative of a poor oxygen transfer into the medium (entry 
7). To increase the oxygen concentration in solution, oxygen gas was bubbled through the 
mixture and after merely 4 hours, almost half of the starting material was selectively converted 
(entry 8). Only trace amounts of hydrophosphonylation product 281 were formed, while the 
Glaser-Hay coupling product was not detected at all. Further optimization showed that within 
5 hours, all of the starting material was efficiently phosphonylated when three equivalents of 
diethyl phosphite and 0.3 equivalent of Cu(OAc)2 were applied, irrespective of the scale of the 
reaction (up to 10 mmol, entries 9-11). It also proved to be advantageous to add the copper 
catalyst and the diethyl phosphite in two portions (entries 10, 11). In a control experiment, 
without alkyne substrate 23, it was confirmed that under oxidative conditions in the presence 
of Cu(OAc)2 and NEt3, diethyl phosphite underwent homocoupling to yield the 
hypophosphate 283. Adding the diethyl phosphite in portions avoided it from being consumed 
all at once in this side-reaction. After purification, the phosphonylated alkyne 269 was obtained 
in 73% isolated yield, using cheap and safe reagents. 
2.3.2. Attempted synthesis of the aminoallenyl bisphosphonate 272 
Next, it was attempted to generate a second intermediate, the aminoallenyl 
bisphosphonate 272, which was thought to be involved in the formation of the 
bisphosphonomethyl oxazol-2-one 24 (Scheme 63). Thus, alkynylphosphonate 269 was 
consecutively treated with one equivalent of both LDA and diethyl chlorophosphate. After one 
hour, 48% of the starting material was converted to phosphoramidate 280, after which 
conversion changed no more overnight. The aminoallenyl bisphosphonate 272 was not 
detected. As the Boc-group was attacked again, no further attempts were made to generate 
this intermediate. 
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Scheme 63: Attempted synthesis of aminoallenyl bisphosphonate 272. 
 
2.3.3. Transition metal-catalyzed 5-exo-dig cyclization of 3-amino 
prop-1-yn-1-yl phosphonate 269 yielding 5-phosphonomethylidene 
oxazolidin-2-one 284 
Transition metal-catalyzed cyclization of N-Boc protected propargylamines has been reported 
to efficiently yield the corresponding oxazolidin-2-ones in excellent yields, short reaction times 
and low catalyst loadings.248-250 It was envisioned that a similar cyclization reaction of 
alkyne 269 would lead to 5-phosphonomethylidene oxazolidin-2-ones 284. The 
5-bisphosphonomethyl oxazolidin-2-ones 285, which would obviously be bearing the 
Boc-group at the 3-position instead of at the 4-position as in 24, would consequently be 
obtained after treatment of oxazolidin-2-one 284 with a base and diethyl chlorophosphate 
(Scheme 64). To that end, several catalysts were screened to provide 5-
phosphonomethylidene oxazolidin-2-ones 284.  
 
 Scheme 64: Strategy towards 5-bisphosphonomethyl oxazol-2-one 284  
via 5-phosphonomethylidene oxazolidin-2-one 283. 
Copper catalysts were first screened but did not produce any 5-phosphonomethylidene 
oxazolidin-2-one 284 (Table 7, entries 1-3). Palladium catalysts did afford the desired product 
with a mediocre conversion in some cases (entries 4-6). NiCl2, ZnCl2, RuCl3, InCl3 and RhCl3 
all proved to be ineffective as only the starting material 269 was recovered (entries 7-11). Gold 
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catalysts, on the other hand, afforded the oxazolidin-2-one 284 smoothly, with AuCl giving a 
faster conversion than AuCl3 (entries 12, 13). According to the Baldwin rules, both 5-exo-dig 
cyclization and 6-endo-dig cyclization modes are possible. The 6-endo-dig cyclization product 
was never observed. 
Table 7: Transition metal-catalyzed synthesis of 5-phosphonomethylidene oxazolidin-2-one 284. 
 
entry catalyst t (h) 284 (%)a,b 286 (%) 
1 CuCl 18 0 0 
2 Cu(OAc)2 24 0 0 
3 Cu(OTf)2 24 0 0 
4 Pd(dba)2 24 0 0 
5 PdCl2 18 38 2 
6 Pd(OAc)2 24 29 0 
7 NiCl2 18 0 0 
8 ZnCl2 24 0 0 
9 RuCl3 24 0 0 
10 InCl3 24 0 0 
11 RhCl3 24 0 0 
12 AuCl 1 93 (56) 7 
13 AuCl3 3 87 13 
14 AgOAc 24 0 0 
15 AgOTf 24 0 0 
16 Au(PPh3)Cl 5d 2 0 
17 AuOTf 20 min 76 0 
18 Au(PPh3)OTf 10 min 90 0 
19 Au(PPh3)NTf2 10 min 89 0 
20 Au(OTf)3 20 min 14 0 
21 HCl 24 0 0 
22 pTsOH 24 0 0 
a conversion based on 1H NMR b isolated yield between brackets 
Although silver salts and chloro(triphenylphosphine)gold(I) did not produce the desired product 
in more than trace amounts (entries 14-16), other cationic gold complexes consumed the 
starting material very quickly (entries 17-20). Several unidentifiable impurities were formed 
though. Control experiments with HCl and pTsOH on the other hand demonstrated that the 
cyclization reaction was not simply an acid-catalyzed process, as these Brønsted acids did not 
result in conversion to the oxazolidin-2-one 284 (entries 21, 22).  
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Partial Boc-deprotection of the alkyne starting material 269 occurred when HCl or Cu(OTf)2 
was used (entries 3, 21). In the AuCl and AuCl3-catalyzed cyclizations, the 
oxazolidin-2-one 284 was partially deprotected as well. Oxazolidin-2-one 284 could be 
separated from the Boc-deprotected oxazolidin-2-one 286 in 56% yield. Literature data show 
that the coupling constant for the allylic carbon atom of E-vinylphosphonates is significantly 
bigger than for Z-vinylphosphonates (3JCP, E = 18-30 Hz vs 3JCP, Z = 5-13 Hz).251-256 The 
observed 3JCP coupling constant for the allylic carbon atom was 18 Hz and thus, the 
stereochemistry around the double bond was concluded to be E. 
Next, a solvent screening was performed for the Au(I)Cl-catalyzed cyclization reaction. It was 
observed that Boc-deprotection did not occur when dichloromethane or THF was used 
(Table 8). As only one product was formed, the purification step could be eliminated and the 
oxazolidin-2-one 284 was isolated in 98% yield. Moreover, the catalyst loading was easily 
lowered down to 2 mol%, still achieving fast and complete conversion to the 
oxazolidin-2-one 284 (entries 2, 3). With a catalyst loading of 1 mol% however, the reaction 
rate dropped significantly (entry 4).  
Table 8: Solvent screening for the synthesis of 5-phosphonomethylidene oxazolidin-2-one 284. 
entry catalyst (mol%) t (h) CH2Cl2 (%)a THF (%)a,b CH3CN (%)a,c 
1 15 1 ND ND 100 
2 5 1 100 100 (98) 27d 
3 2 1 
3 
100 
- 
54 
100 
ND 
- 
4 1 6 
18 
80 
100 
59 
100 
ND 
- 
a conversion based on 1H NMR b isolated yield between brackets c anhydrous d 5 days 
 
2.3.4. Attempted introduction of the second phosphonate group to 
5-phosphonomethylidene oxazolidin-2-one 284 
Oxazolidin-2-one 284 was treated with one equivalent of LDA and diethyl chlorophosphate in 
order to obtain bisphosphonomethyl oxazol-2-one 285. The starting material 284 was entirely 
consumed after one hour at - 78 °C, but unfortunately the bisphosphonomethyl 
oxazol-2-one 285 was not detected (Table 9, entry 1). Instead, a complex mixture was 
obtained. E-Ketophosphonate 287 was identified as one of the products and results from 
hydrolysis of the starting material with consecutive loss of CO2 upon quenching with water. 
With NaH and KOtBu, the starting material was entirely recovered, while the diethyl 
chlorophosphate was slowly converted to tetraethyl pyrophosphate (entries 2, 3). To evaluate 
how the oxazolidin-2-one 284 behaved when treated with strong bases, the reaction was run 
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without diethyl chlorophosphate. Phosphonomethylidene oxazolidin-2-one 284 effectively 
rearranged to oxazol-2-one 279, as it was detected in low amounts upon treatment with an 
equimolar amount of n-BuLi (entry 4). Most of the product hydrolyzed to 
E-ketophosphonate 287 however. When oxazolidin-2-one 284 was treated with LDA and 
quenched with MeOH-d4, it was entirely converted into oxazol-2-one 279 (entry 5). It was not 
possible however to isolate this product as it hydrolyzed upon filtration of the lithium salts over 
celite. The E-ketophosphonate 287 could be isolated and spectral data were consistent with 
literature values.257, 258 No further attempts were undertaken to synthesize the 
bisphosphonomethyl oxazol-2-one 285. 
Table 9: Screened conditions for the phosphonylation of  
5-phosphonomethylidene oxazolidin-2-one 284 with diethyl chlorophosphate. 
 
entry base solvent T1 (°C) t1 (min) T2 (°C) t2 (h)  285 (%)b 287 (%)b 279 (%)b 288 (%)b 
1 LDA THF - 78 to 0 60 - 78 1 0 6 0 1 
2 NaH THF rt 1 rt 48 0 0 0 0 
3 KOtBu THF rt 0 rt 24 0 0 0 0 
4a n-BuLi Et2O - 78 5 - - 0 95 3 2 
5a LDA Et2O - 78 5 - - 0 0 100 0 
a no ClP(O)(OEt)2 added b conversion based on 31P NMR 
2.4. Conclusion 
During the synthesis of 3-amino, 3-phosphono prop-1-yn-1-yl phosphonate 268 from 
N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate 23 and an excess diethyl chlorophosphate, a 
rearrangement reaction, yielding bisphosphonomethyl oxazol-2-one 24, was observed. 
Unfortunately, in this one-pot procedure, several side-products were formed, which elute 
together with bisphosphonomethyl oxazol-2-one 24, decreasing the isolated yield to 17%. In a 
stepwise approach, 3-amino prop-1-yn-1-yl phosphonate 269 was first prepared separately. A 
copper-catalyzed cross coupling procedure of terminal alkynes with dialkyl phosphites, which 
had been recently described in literature, was improved, affording alkynyl phosphonate 269 in 
short reaction times and good yields on a 10 mmol scale. Gold-catalyzed 5-exo-dig cyclization 
smoothly yielded 5-phosphonomethylidene oxazolidin-2-one 284 in quantitative yield. The 
second phosphonate moiety however, could not be introduced at the stage of 
alkynylphosphonate 269, nor at the stage of 5-phosphonomethylidene oxazolidin-2-one 284. 
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Remarkably, 5-phosphonomethylidene oxazolidin-2-one 284 and phosphonomethyl oxazol-2-
one 279 are much more sensitive to hydrolysis than bisphosphonomethyl oxazol-2-one 24. 
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3. Attempted syntheses of 1-N,N-dialkyl 
aminoallenylphosphonates and 3-N,N-dialkyl 
aminoallenylphosphonates 
3.1. Introduction 
In the following four chapters, we explored the synthesis and unique reactivity pattern of 
allenylphosphonates bearing a nitrogen substituent. Although allenylphosphonates have been 
reported decades ago,107, 108 the first synthesis of an aminoallenylphosphonate was published 
only recently. In 2012 Rabasso found that the same [2,3]-sigmatropic rearrangement that has 
been used for the synthesis of allenylphosphonates (vide supra), produces 
1-aminoallenylphosphonates when ynamidols 290 are used instead of propargyl alcohols 
(Scheme 65).259 A copper-catalyzed coupling reaction of amines with bromopropargyl 
alcohols 289 afforded the ynamides 290 in variable yields. 1-Aminoallenylphosphonates 291 
were obtained after reaction with diethyl chlorophosphite in good yields.  
 
Scheme 65: The first synthesis of an aminoallenylphosphonate and its transformations. 
Just like their allenylphosphonate counterparts, these 1-aminoallenylphosphonates could be 
selectively hydrogenated to produce D-aminovinylphosphonates 292,260 which could be further 
converted to 2-phosphono-2-pyrrolines through RCM, after the appropriate alkenyl group was 
introduced by a Mitsunobu reaction.261 The group of Rabasso also discovered that 
PMB-protected 1-aminoallenylphosphonates 291 generated a spirodienone lactam 293 upon 
treatment with CAN. Consequently, they were able to generate a library of these spirocycles 
with an impressive structural complexity as pentacyclic structures with two spirocyclic 
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connections could be obtained (Figure 18, compound 254).203 Cao and coworkers found that 
acceptor-substituted aminoallenes, such as 1-aminoallenylphosphonates 291, reacted well 
with a series of primary amines to yield persubstituted imidazoles 294. Acceptor-substituted 
imidazoles are an important class of compounds as the imidazole motif is present in a lot of 
natural products and pharmaceutical compounds,262-264 such as Olmesartan 295, which is an 
angiotensin II receptor antagonist.265  
 
Figure 18: Example of a spirodienone lactam and structure of Olmesartan (angetionsin II receptor 
antagonist). 
It is thus clear that aminoallenylphosphonates are useful building blocks for the synthesis of a 
variety of (heterocyclic) aminophosphonates. Since the first synthesis of 
aminoallenylphosphonates was reported only a couple of years ago, it is to be expected that 
the exploration of their potential is only starting. Moreover, only one isomer of 
aminoallenylphosphonates, the 1-aminoallenylphosphonates, was described. In our quest for 
alternative strategies to synthesize aminoallenylphosphonates, we mainly focused on 
preparing 3-aminoallenylphosphonates. 
3.2. Preparation of 3-amino allenylphosphonates employing 
the Skattebøl rearrangement 
A first strategy relied on the Skattebøl rearrangement, which transforms geminal dihalo 
cyclopropanes via a cyclopropylcarbene intermediate to the corresponding allene in the 
presence of an organolithium base.266 In order to obtain 3-aminoallenylphosphonates, the 
dihalo cyclopropane had to be functionalized with a phosphorus and an amino substituent. It 
was envisioned that these dihalocyclopropyl aminophosphonates 26 were accessible through 
dihalocarbene addition to E-enaminophosphonates (Scheme 66). E-Enaminophosphonates 
would be obtained by copper-catalyzed hydroamination of alkynylphosphonates 27,59 which in 
turn could be prepared through the copper-catalyzed oxidative coupling of commercially 
available alkynes and dialkyl phosphites.215  
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Scheme 66: Retrosynthetic approach to 3-aminoallenylphosphonates using the Skattebøl rearrangement. 
 
3.2.1. Preparation of enaminophosphonate 297 
Phenylacetylene was readily phosphonylated with diethyl phosphite to afford the phenylethynyl 
phosphonate 296 in 82% yield. Phenylethynyl phosphonate 296 was next evaluated in the 
copper-catalyzed hydroamination reaction with diethylamine.59 One day of reflux in dry THF 
only yielded trace amounts of the enaminophosphonate 297 (Table 10, entry 1). An almost 
complete conversion was reached however, when the mixture was heated during three days 
in dry methanol (entry 2). Under microwave heating to 70 °C during 16 hours, a slightly lower 
conversion was observed (entry 3). However, when the mixture was heated to 100 °C in the 
microwave, phenylethynyl phosphonate 296 was entirely converted to the 
enaminophosphonate 297 which was isolated in 75% yield (entry 4). Reaction time could be 
shortened to nine hours when the temperature was increased to 130 °C while conversion 
remained complete (entry 5). 
Table 10: Optimization of conditions for the hydroamination of alkynylphosphonate 296. 
 
entry solvent T (°C) t (h) 297 (%)b,c 
1 THF ' 24 traces 
2 MeOHa ' 72 90 
3d MeOHa 70 16 70 
4d MeOHa 100 16 100 (75) 
5d MeOHa 130 9 100 
a anhydrous b conversion based on 31P NMR c isolated yield between brackets d microwave irradiation 
 
3.2.2. Attempted synthesis of dihalocyclopropyl aminophosphonate 298 
It has been shown that geminal dihalocyclopropanes can be prepared from alkenes through 
the addition of dihalocarbenes.267-269 Thus, in a next step, enaminophosphonate 297 was 
reacted with a variety of species that can generate dihalocarbenes (Table 11). 
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Table 11: Screened conditions for the dihalocyclopropanation of enaminophosphonate 297. 
 
entry dihalocarbene source base solvent T (°C) t (d) reaction products 
1a 25 equiv CHCl3 40 equiv NaOH(aq.) heptane rt 5 SM + 299 
2a 25 equiv CHBr3 40 equiv NaOH(aq.) heptane rt 7 SM + 299 + 300 + 301 + 298 
3 25 equiv CHBr3 5 equiv KOt-Bu - rt 2 SM + 301 
4  1 equiv Cl3CCO2Na - DME ' 2 SM + 299 
5b - - CHBr3 ' 1 SM 
6 2 equiv PhHgCCl3 - toluene 80 1.25 SM + 302 
a 0.04 equiv PTC (TEBAC) b 8 equiv Mg turnings 
Under phase-transfer conditions in chloroform, no conversion to the dihalocyclopropane took 
place, not even after five days (entry 1). Also Michael-type addition of the CCl3 anion, which 
was reported to take place sometimes, was not observed.267 A compound with the mass of 
diethyl (1-phenylethyl) amine 299 was found in minor amounts but was not isolated (Figure 19). 
With bromoform, the same compound 299 was present, together with trace amounts of the 
bromo alkyne 300, the bromo enamino phosphonate 301 and the desired product 298 
(entry 2). Again, Michael-type addition of the CBr3 anion did not take place270 and a longer 
reaction time (up to seven days) only resulted in a complex mixture in which the starting 
material was still the major compound. When KOt-Bu was added to a solution of the starting 
material in bromoform, an exothermic reaction took place, but disappointingly no conversion 
of the starting material was observed, not even after two days (entry 3). Only some trace 
amounts of bromo enaminophosphonate 301 were found. The base, used to generate the 
dihalocarbene, possibly competes with the olefin for reaction with the dihalocarbene.271 
Sodium trichloroacetate has been shown to be able to convert vinylphosphonates to the 
corresponding geminal dihalocyclopropyl phosphonates in the absence of a base.267 When it 
was refluxed in DME with substrate 297, a complex mixture was obtained in which only 
amine 299 could be identified (entry 4). In the case of poorly nucleophilic olefins, this method 
has been reported not to work well, as the generated dihalocarbenes rather react with the 
sodium trichloroacetate than with the alkene.272  
 
Figure 19: Structure of detected products in the dihalocyclopropanation of enaminophosphonate 297. 
However, recently it was shown that electrodeficient olefins were transformed in good yields 
to dibromocyclopropanes when treated with magnesium turnings in THF with a large excess 
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of bromoform.270 When applied to substrate 297, only starting material was recovered after 16 
hours of reaction (entry 5). The use of the Seyferth reagent (PhHgCCl3) has also been reported 
to be a source of dibromocarbenes which efficiently reacts with weakly nucleophilic olefins.269, 
271, 273, 274 When PhHgCCl3 was heated with enamino phosphonate 297 to 80 °C in toluene, 
about half of the starting material was converted to three phosphorus-containing products 
(entry 6). One of them apparently underwent a CO insertion and is proposed to have 
structure 302, the second one seems to result from the first one after dehydration. The third 
product could not be identified. Unfortunately, none of those products could be isolated, but 
NMR data – the characteristic CHP fragment was found in both 1H and 13C NMR spectra - 
supported the MS data found for structure 302. Moreover, 2D NMR data showed a quaternary 
carbonyl signal that couples to the CHP fragment, suggesting that the carbonyl group has 
indeed been introduced next to phosphonate moiety. As the options to prepare 
dihalocyclopropanes seemed to be depleted, the Skattebøl strategy was not further 
investigated.  
 
3.3. Attempted synthesis of phosphonylated (hetero)cycles 
through cycloaddition reactions with diazomethane 
3.3.1. Attempted cyclopropanation of enaminophosphonates 297 with 
diazomethane 
Since the search for new methods to synthesize aminophosphonates has been a research line 
of the research group for quite a while now,29, 32, 36, 275 it was investigated whether the earlier 
prepared enaminophosphonates of type 297 could serve as precursors to aminocyclopropyl 
phosphonates 303. Previous research in the group has focused on getting access to 
cyclopropylamines via a Simmons-Smith reaction of enamines.276 Synthetic routes towards 
molecules carrying the aminocyclopropane phosphonate motif, however, are only scarcely 
reported in literature.277-281 Although cyclopropanation of E-enaminophosphonates 297 has 
never been investigated, one example of a reaction of an D-enaminophosphonate with 
diazomethane has recently been reported.282 Aminocyclopropanephosphonic acid has shown 
to be a potent inhibitor of aminocyclopropanecarboxylate (ACC) deaminase from 
Pseudomonas sp. and alanine racemase from Bacillus stearothermophilus.283 The 
aminocyclopropanephosphonic moiety is also present in oligopeptides that are potent 
Hepatitis C virus (HCV) NS3 protease inhibitors.284, 285  
 
When enaminophosphonate 297 was reacted with a five-fold excess of diazomethane, trace 
amounts of aminocyclopropyl phosphonate 303 were found after one hour at room temperature 
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(Table 12, entry 1). Reaction progress was monitored for two days, but unfortunately 
conversion did not increase. Pyrazoline intermediates were not observed either. It had been 
reported that when a catalyic amount of Pd(OAc)2 was added to a solution of an alkene and 
diazomethane, cyclopropanes could be obtained.286 In our case however, no cyclopropanation 
products were detected (entry 2). The only observed product, E-ketophosphonate 304, results 
from hydrolysis of the starting material upon quenching of the reaction mixture with acetic acid. 
 
Table 12: Screened conditions for the cyclopropanation of enaminophosphonate 297 with diazomethane. 
 
entry equiv CH2N2 equiv Pd(OAc)2 T (°C) t (h) conversion (%) 
1 5 - rt 48 traces 
2 1 0.02 0 1 0 
3a 20 
10 
0.01 rt 1 
2.5 + 1 
10 
4a 20 0.10 ' 2 0 
a diazomethane is mixed with catalyst prior to addition of substrate 
On the other hand, it is decribed in literature that Pd(OAc)2 is reduced in situ by an excess of 
diazomethane, producing palladium nanoparticles which are more active than Pd(0) 
complexes, preformed nanoparticles or commercial palladium powder.287 The authors stated 
that the reactant addition sequence is of utmost importance: Pd(0) formation and high 
conversions were only obtained when the diazomethane is added to a solution already 
containing the catalyst and the olefin. Although an immediate evolution of nitrogen gas, 
indicative of Pd(OAc)2 reduction, was indeed observed when these conditions were applied, 
only 10% conversion of the starting material to unidentified reaction products was detected 
(entry 3). Increasing the amount of the catalyst did not alter the outcome (entry 4). 
 
3.3.2. Synthesis of phosphonylated pyrazoles from alkynylphosphonates and 
diazomethane 
Since the strategies to cyclopropanated products 303 were met with failure, this route was 
abandoned. However, with the easy acces to alkynylphosphonates 296 in mind, one last 
attempt was made to gain acces to phosphonylated heterocycles. One example of the reaction 
of diazomethane with an acceptor-substituted alkynylphosphonate was reported, yielding a 
mixture of phosphonylated pyrazoles regioisomers.288 Pyrazoles are known as anticancer 
agents,289 non-nucleoside HIV-1 reverse transcriptase inhibitors290 and CNS depressants291 
and the motif occurs in many drugs such as Viagra, Celebrex and Acomplia. Most of the 
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reported syntheses rely on cyclocondensation strategies of hydrazines with 1,3-difunctional 
compounds.292, 293 Only a small number of phosphonylated pyrazoles are prepared by 
cycloadditions of diazoalkanes.282, 288, 294-298 
 
Two alkynylphosphonates were screened for their reactivity with an excess of diazomethane. 
Alkyne 296 gave the 1H-pyrazole 306a and the N-methylated pyrazole 307a, next to an 
important amount of starting material (Table 13, entry 1). N-phthaloyl-protected 
propargylamine 305 gave almost complete conversions, again yielding pyrazoles 306b and 
307b which could both be isolated (entry 2). Values for the C-P coupling constants were 
consistent with literature values for 5-phosphonylated pyrazoles,299 confirming that the 
C-terminus of diazomethane had attacked the carbon atom in E-position of the phosphonate. 
 
Table 13: Tested conditions for the synthesis of phosphonylated pyrazoles 306 and 307. 
 
entry R equiv CH2N2 t (h) SM (%) 306 (%)a 307 (%)b 
1 Ph 5 4 66 26 5 
2c  CH2NPhth 5 3 0 37 (2) 44 (67) 
3 Ph 1 3.5 85 11 0 
4  CH2NPhth 1 16 100 0 0 
5 Ph 2 72 86 14 0 
6 CH2NPhth 2 72 100 0 0 
7 CH2NPhth 3 72 86 6 0 
8 CH2NPhth 5 72 15 28 11 
a isolated yield after 2 consecutive pTLC steps b isolated yield after pTLC c THF instead of Et2O 
Trying to get a more selective conversion to one of the products, several conditions were 
screened. To be able to dose exactly one equivalent of diazomethane, the diazomethane 
ethereal solution was titrated.300 However, no or very poor conversions were obtained 
(entries 3, 4), even when the amount of diazomethane was doubled or if reaction times were 
increased (entries 5, 6). When larger excesses of diazomethane were used, conversions 
increased again (entries 7, 8), but as the reaction outcome was hard to reproduce and mixtures 
of at least three different products were obtained, this route was finally abandoned as well. 
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3.4. Preparation of 3-aminoallenylphosphonates through 
prototropic rearrangement 
3.4.1. Through isomerization of 3-(dibenzylamino)prop-1-yn-1-yl phosphonate 
310 
In an alternative strategy, it was attempted to get access to 3-amino allenylphosphonate 311 
via isomerization of 3-(dibenzylamino)prop-1-yn-1-yl phosphonate 310 (Scheme 67). 
Dibenzylpropargylamine 309 was prepared by treating dibenzylamine with sodium hydride and 
propargyl bromide. Oxidative cross coupling with diethyl phosphite afforded 
3-(dibenzylamino)prop-1-yn-1-yl phosphonate 310 in 57% yield. 
Scheme 67: Preparation of 3-(dibenzylamino)prop-1-yn-1-yl phosphonate 310. 
Next, isomerization of 3-(dibenzylamino)prop-1-yn-1-yl phosphonate 310 was evaluated with 
a variety of bases (Table 14). Isomerization of trifluoromethyl alkynes with an excess sodium 
hydroxide in a mixture of THF and water was reported in literature to yield the corresponding 
allenes.301 When substrate 310 was subjected to these conditions, no conversion initially took 
place. Using longer reaction times, monodealkylation of the phosphonate ester, producing 
compound 312, and dephosphonylation of the alkynylphosphonate, producing alkyne 309 and 
diethylphosphate, were observed (entry 1). Treatment with NaH resulted in complete 
recuperation of the starting material (entry 2). With one equivalent of LiHMDS, the starting 
material was entirely converted to a complex mixture of at least ten products within one hour 
at - 78 °C (entry 3). The only product that could be identified was dibenzylamine. n-BuLi also 
gave a complex mixture of at least twenty products after merely thirty seconds (entry 4). Both 
N,N-dibenzyl propargylamine 309 and n-butyl phosphonate 313 were detected, indicating that 
n-BuLi rather acted as a nucleophile. In a last attempt, the use of t-BuLi was evaluated as it 
was reasoned that the increased steric hindrance might lower the nucleophilic behaviour. 
Unfortunately, these conditions immediately resulted in a complex mixture as well (entry 5). 
Dibenzylamine was detected once more.  
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Table 14: Screened conditions for the isomerization of 3-(dibenzylamino)prop-1-yn-1-yl phosphonate 310. 
 
entry base solvent T (°C) t (h) SM (%)a 311 (%)a 312 (%)a 309 (%)a 
1b NaOH 2:1 THFc/H2O rt 19 
68 
100 
0 
0 
0 
0 
81 
0 
19 
2  NaH THF 0 to rt 3 100 0 0 0 
3 LiHMDS THF - 78 1 0 CM 
4 n-BuLi THF - 78 30 sec 0 CM 
5 t-BuLi THF - 78 60 sec 0 CM 
a based on 1H NMR b not anhydrous c 3.0 equiv base were used  
 
3.4.2. Through isomerization of 3-amino-3-phenylprop-1-yn-1-yl phosphonate 
317 
Since the isomerization of 3-(dibenzylamino)prop-1-yn-1-yl phosphonate 310 with strong 
bases was not fruitful, it was investigated if the presence of a phenyl substituent in the 
propargylic position would be favourable. Alkynes are known to isomerize more easily to the 
corresponding allenes if a phenyl group is conjugated to the newly formed double bond.52 
Consequently the isomerization of 3-amino-3-phenylprop-1-yn-1-yl phosphonate 317 would be 
evaluated (Table 15).  
 
Table 15: Conditions for the A3 coupling of substituted propargylamine 316. 
 
entry equiv 
acetylene 
equiv 
amine 
equiv 
aldehyde 
catalyst 
(mol%) 
T 
(°C) 
t 
(h) 
solvent 316 
(%)a,b 
1c 1 1 1.5 CuBr (0.05) 120 48 THF 92 
2d 1 1.3 1.6 CuI (0.15) 100 0.5 neat 100 (5) 
a conversion to 316a based on 1H NMR b isolated yield of 316b between brackets c pressure vial d microwave heating 
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A³ coupling reactions are particularly suited to provide substituted propargylamines and 
consequently, benzaldehyde, dibenzylamine and trimethylsilyl acetylene were engaged in a 
copper-catalyzed A³ coupling reaction.302-305 Almost full conversion was obtained after two 
days at 120 °C in a pressure vial (entry 1). Although the authors of the original procedure were 
able to isolate the substituted propargylamines in 15-30% yield, in our case, the product could 
unfortunately not be separated from the impurities. Under microwave conditions, the starting 
material was entirely converted after 30 minutes at 100 °C under neat conditions, and 
deprotected from the TMS-moiety with K2CO3 in MeOH (entry 2). Purification of this very apolar 
compound proved to be difficult once more and the substituted propargylamine was isolated 
in a poor 5% yield. It was next decided to repeat the reaction under those conditions and use 
the crude mixture as such in the cross coupling reaction with diethyl phosphite. The 
phosphonylated propargylamine 317 was obtained after five hours under the earlier developed 
conditions. Disappointingly, phosphonylated propargylamine 317 could not be isolated after 
meticulous purification and only a fraction of 90% purity was separated in 23% yield (yield over 
two steps). Given the difficulties encountered during the purification at both stages, further 
efforts were aborted and the isomerization reaction to the 3-phenyl-3-amino 
allenylphosphonate 318 was not evaluated.  
 
 
3.4.3. Through isomerization of 3-(dibenzylamino)prop-2-yn-1-yl phosphonate 
319 
Since the syntheses of 3-amino allenylphosphonates 311 from phosphonylated 
propargylamines 310 or 317 were problematic, the preparation of 3-(dibenzylamino)prop-2-yn-
1-yl phosphonate 319 as a precursor to 3-amino allenylphosphonate 320 was envisaged 
(Scheme 68). A literature protocol described the efficient synthesis of ynamides from copper 
acetylides and N-nucleophiles carrying an electron withdrawing group.60 Thus, the coupling of 
copper acetylide 31 with dibenzylamine was envisioned. Since copper acetylides are reported 
to be conveniently generated from the corresponding alkynes and a copper source,306, 307 the 
propargyl phosphonate would be prepared from a propargylbromide 321 with a phosphite. 
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Scheme 68: Retrosynthetic approach to 3-(dibenzylamino)propa-1,2-dienylphosphonate 320. 
Thus, propargylbromide 321a was engaged in an Arbuzov reaction with triethylphosphite 
(Table 16, entry 1). Propargyl phosphonate 322a seemed to be present in a complex mixture 
with at least six other phosphorus-containing products, probably as a result of SN’ reactions. 
When lowering the temperature to 40 °C, propargyl phosphonate 322a could no longer be 
detected (entry 2). Michaelis-Becker reaction on trimethylsilyl propargylbromide 321b did 
however yield the desired TMS-protected propargylphosphonate 322b in 41% yield after 
purification (entry 3).308  
 
Table 16: Arbuzov and Michaelis-Becker reaction on substrate 321. 
 
entry R nucleophile equiv NaHMDS solvent T (°C) t (h) 322 (%)a,b 
1 H 1.1 equiv P(OEt)3 - neat 110 20 ND 
2 H 1.1 equiv P(OEt)3 - neat 40 2 0 
3 TMS 1.0 equiv HP(O)(OEt)2 1.1 THF rt 1 90 (41) 
a conversion based on 1H NMR b isolated yield between brackets 
 
Upon deprotection of the TMS-group, instantaneous and complete rearrangement took place 
to internal alkynyl phosphonate 323 (Table 16). Trapping the acetylide anion at 0 °C with 
copper iodide in a mixture of ethanol and aqueous ammonia or in the presence of potassium 
carbonate in DMF, was unsuccessful. Once more, our efforts had to be prematurely 
discontinued. 
 
3.5. Preparation of 1-aminoallenylphosphonates through 
spontaneous prototropic rearrangement 
It was next anticipated, however, that due to the observed spontaneous rearrangement, a 
trimethylsilyl alkynylaminophosphonate 325 could provide a facile entry into 1-amino 
allenylphosphonate 324. Upon deprotection of the TMS group, the rearrangement 
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would spontaneously yield 1-aminoallenylphosphonate 324, provided that 
1-amino-3-trimethylsilylprop-2-yn-1-yl phosphonate 325 could be prepared (Scheme 69). 
 
Scheme 69: Retrosynthetic approach to 1-aminoallenylphosphonates. 
At first sight, an A3 coupling reaction seemed an attractive approach to construct the alkynyl 
aminophosphonate 325,309 yet this route was not explored. The aldehyde part would in this 
case be the hydrate of formylphosphonate, which requires a three-step synthesis involving 
azides, diazo compounds and dimethyldioxirane.310 A quicker, cheaper and slightly less 
explosive alternative consists of a LiClO4-catalyzed three component Kabachnik-Fields 
reaction. In such a reaction, aminophosphonates are obtained from the corresponding 
aldehyde, an amine and a dialkyl phosphite, often in excellent yields and very short reaction 
times.311 The precursors in this case are 3-(trimethylsilyl)propiolaldehyde 326, 
diethylamine 327 and dimethyl phosphite 328a. 
 
However, upon addition of diethylamine to ynaldehyde 326 the amine reacts violently, while 
31P NMR indicated that no phosphorus-containing products other than the dimethyl phosphite 
starting material were present 8 minutes after the addition of the phosphorus nucleophile 
(Table 17, entry 1). 
 
Table 17: Screened conditions for the Kabachnik-Fields reaction of propargylaminophosphonate 325. 
 
entry order of addition R tamine (min) tphosphite (min) result 
 2 3     
1 amine 327 phosphite 328a H 2 8 333 
2 phosphite 328a amine 327 H 5 1 mixture + 329aa 
3 phosphite 328b amine 327 TMS 5 1 82% 329a + 18% 329b 
a isolated in 33% yield 
 
LC-MS analysis showed that the major compound had a mass corresponding to the 
corresponding amidinium compound 333 (Scheme 70). It is reported that in an ethereal 
solution of lithium perchlorate, iminium intermediates are easily generated and could even be 
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detected by 1H NMR.312 Presumably, a fast addition of a second molecule of diethylamine takes 
place, yielding aminal 331, resulting in the amidinium 333 after prototropic rearrangement and 
protonation. Given the immediate violent reaction between the aldehyde and the amine, it is 
not surprising that the phosphorus nucleophile did not participate in the reaction. NMR data 
confirm the presence of the double bond (doublets at 5.48 and 7.79 ppm, J = 12.6 Hz) in 
amidinium 333.  
 
Scheme 70: Plausible mechanism for the formation of amidinium 333. 
To avoid that the phosphorus nucleophile is outcompeted and to make sure it can immediately 
attack the iminium intermediate, dimethyl phosphite was mixed with ynaldehyde 326 in LPDE. 
Adding the amine to this mixture, both the phosphorus nucleophile 328a and the aldehyde 326 
are effectively consumed within five minutes, giving rise to three phosphonylated products 
(20.7 ppm, 20.2 ppm, 19.3 ppm in a 2:1:2 ratio). The amidinium product 333 is not detected in 
1H NMR (entry 2). LC-MS analysis confirmed that two isomers of product 325 were present. 
Although alkynyl aminophosphonate 325 could not be recovered after purification, alkynyl 
hydroxyphosphonate 329a was isolated in 33% yield. When diethylamine was added to a 
mixture of trimethylsilyl dimethyl phosphite 328b and ynaldehyde 326 in LPDE, all of the 
DMTMSP, which is a stronger nucleophile than DMP, had reacted with the aldehyde 326 
before the amine had the chance. A mixture of hydroxyphosphonate 329a and O-trimethylsilyl 
hydroxyphosphonate 329b was obtained (entry 3). It was thus concluded that this one-pot 
three-component reaction was not a feasible approach for the direct synthesis of 
precursor 325.  
 
Given the ease of formation of hydroxyphosphonate 329a, it was investigated if the 
mesylate 334 could be prepared (Scheme 71). By means of a substitution reaction with an 
appropriate nitrogen nucleophile, alkynyl aminophosphonate 325 could then be obtained. 
When ynaldehyde 326 was phosphonylated with DMTMSP 328b in LPDE, the starting material 
was entirely converted to an 80/20 mixture of hydroxyphosphonates 329a and 329b after 
merely one minute. Within half an hour, the TMS group had entirely hydrolyzed to give the 
hydroxyphosphonate 329a along with a small amount of DMP 328a. As the Rf value of DMP 
was almost equal to that of the product, it was evaluated whether hydroxyphosphonate could 
be purified after mesylation. One hour after the addition of mesylchloride, about 31% of the 
starting material 329a was converted to O-mesylated alkynylphosphonate 334. However, 16% 
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allene 335 was detected as well. The expelled chloride anion is able to entirely deprotect the 
TMS group within four hours. Eventually, it was decided to abandon this strategy. 
 
Scheme 71: Attempted synthesis of mesylated propargyl hydroxyphosphonate 334. 
3.6. Conclusion 
In this chapter, various approaches were explored to access 3-aminoallenylphosphonates. 
First, it was tried to prepare dihalocyclopropyl aminophosphonates as substrates for the 
Skattebøl rearrangement. Oxidative cross coupling of terminal alkynes with dialkyl phosphites 
readily provided alkynylphosphonates which were hydroaminated in good yields. The resulting 
enaminophosphonates did not give dihalocyclopropyl aminophosphonates with in situ formed 
dihalocarbenes. The enaminophosphonates were successfully used to prepare 
phosphonylated pyrazoles with diazomethane, but the reaction proved to be hard to reproduce. 
Isomerization of phosphonylated propargylamines under alkaline conditions was unsuccessful. 
Preparation of copper acetylides from prop-2-yn-1-yl phosphonate, which was envisioned to 
react with amines to produce 3-amino-prop-2-yn-1-yl phosphonate precursors was not 
successful either. Finally, it was attempted to prepare 1-amino-3-trimethylsilylprop-2-yn-1-yl 
phosphonates through a Kabachnik-Fields reaction, as these substrates would probably 
rearrange to the corresponding 1-amino allenylphosphonates upon removal of the TMS group. 
Unfortunately, the 1-amino-3-trimethylsilylprop-2-yn-1-yl phosphonates were not obtained as 
the aldehyde immediately reacted with either the nitrogen or the phosphorus nucleophile to 
give amidinium or hydroxyphosphonate products. 
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4. In situ formation and E-derivatization of 
3-imidoallenylphosphonates 
4.1. Introduction 
 
In the previous chapter, the syntheses of dialkylamino allenylphosphonates were 
unsuccessful. When looking closer to the non-phosphonylated counterparts, amino-substituted 
allenes are sometimes reported to be difficult to handle. They tend to polymerize even at low 
temperatures, and are sensitive to moisture.313 Amido-allenes, being less electron-rich, are 
more stable and display enamide reactivity. Dialkylamino allenylphosphonates are possibly too 
electron rich to be synthesized, so it was reasoned that the introduction of an electron 
withdrawing group on the nitrogen atom would be advantageous. Next, the isomerization 
reaction to the corresponding 3-amino allenylphosphonates would be evaluated again in order 
to study their reactivity towards nucleophiles. 
 
4.2. Towards 3-imidoallenylphosphonates 
To this end, di-Boc-protected propargylamine 23 and the commercially available N-propargyl 
phthalimide 336 were phosphonylated according to the earlier developed copper-catalyzed 
oxidative cross coupling with diethyl phosphite (Scheme 72). Although the phosphonylated 
alkynes were easily prepared on a 10 mmol scale, it was noticed that the DMSO solvent was 
oxidized under the oxidative conditions. Considerable amounts of dimethyl sulphone were 
produced and this complicated purification. Fortunately, running the reaction in DMF afforded 
the alkynylphosphonates 269 and 305 with comparable ease and in equally good yields. 
 
Scheme 72: Approach towards 3-imidoallenylphosphonates 337 and 338. 
In preliminary experiments, phosphonylated N,N-di-Boc-propargylamine 269 was used as 
starting material. At first, stoichiometric isomerization was evaluated with organolithium bases 
(n-BuLi, LDA) in aprotic media.314, 315 However, the isomeric allenic products 337 could not be 
detected (Table 18, entries 1-2). With n-BuLi the alkyne 269 was dephosphonylated, while 
LDA attacked the t-Bu group producing the carbamic acid, which cyclized to produce the 
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corresponding oxazolidinone. Accordingly, phthaloyl protected alkyne 305 was then used 
exclusively, as the Boc-groups of alkyne 269 were not stable under the previously applied 
conditions. Next, the isomerization using a milder NaH or KOtBu aprotic system was 
investigated. Using a stoichiometric amount of NaH, the 3-imidoallenylphosphonate 338 was 
detected for the first time as 32% conversion was observed within one hour,316 after which 
degradation quickly occurred (entry 3). Using a catalytic amount of NaH led to a lower 
conversion, while secondary reactions still occurred (entry 4). When performing the reaction in 
DMSO with KOtBu as the base,317 7% conversion to an addition product 339 was observed 
(entry 5). Although allene 338 was not detected, this addition product caught our interest given 
the position of the double bond. Switching the solvent to THF, and employing a stoichiometric 
amount of base318 gave the allene intermediate 338 and the addition product 339 together for 
the first time (entry 6). Providing a proton source by adding one equivalent of t-BuOH markedly 
increased the conversion of the starting material, giving approximately 50% of the allene in 
only two minutes at 0 °C (entry 7). Longer reaction times gave complex mixtures.  
 
Table 18: Optimization of isomerization and nucleophilic addition conditions. 
 
entry SM equiv base base solvent T (°C) t (min) 337/338 (%)a 339/340 (%)a 
1 269 1 BuLi Et2O - 78 60 0 0 
2 269 1 LDA Et2O 0 180 0 0 
3 305 1 NaH THF rt 60 32 0 
4 305 0.2 NaH THF ' 30 24 0 
5 305 0.2 KOtBu DMSO rt 5 0 7 
6 305 1 KOtBu THF rt 1 19 4 
7b 305 0.2 KOtBu THF 0 2 47 0 
8 305 1 KOtBu t-BuOH 40 5 34 25 
9 305 2 KOtBu t-BuOH 40 1 0 100 
10c 305 1 K2CO3 THFd rt 8 days 0 100 
11c 305 1 Cs2CO3 THFd rt 40 0 100 
a conversion based on 31P NMR b 1 equivalent of t-BuOH added c 1 equivalent EtOH added d not anhydrous 
 
Screening of different solvents in the KOtBu/t-BuOH system revealed that conversion to 
allene 338 was rapid but a conversion higher than 50% could not be achieved (Table 19), as 
alkyne 305 and allene 338 were most likely in equilibrium. We then decided to scavenge the 
intermediate allene 338 in order to get full conversion to the addition product 339. 
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Table 19: Solvent screening for the isomerization to imidoallenylphosphonate 338. 
 
entry solventa t (min)b 338 (%)c 339 (%)c 
1 THF 5  34 0 
2 Et2O 2  43 13 
3 CDCl3 5  10 0 
4 CH3CN 2  34 15 
5 dioxane 2 34 10 
6 toluene 2  14 15 
7 CH2Cl2 2  24 26 
a not anhydrous b reaction time indicates maximal conversion before degradation started to occur  
c conversion based on 31P NMR 
 
Performing the addition in t-BuOH instead of adding just one equivalent of t-BuOH as a proton 
source319 clearly drives addition of the nucleophile to the allene intermediate 338 (entry 8). 
Increasing the amount of KOtBu to two equivalents gave complete reaction in no more than 
60 seconds (entry 9). We next investigated whether other - and eventually non-volatile - 
nucleophiles could be added. To that end, a non-nucleophilic base, an aprotic solvent, and the 
use of a stoichiometric amount of the nucleophile were required. Hence, K2CO3 and THF were 
selected, using one equivalent of EtOH as nucleophile. The addition product 340 was obtained 
as the single product, but full conversion required eight days (entry 10). We reasoned that the 
limited solubility of the base hampered reaction progress. Thus, replacing K2CO3 with Cs2CO3 
gave a completed reaction in only 40 minutes (entry 11) and purification was superfluous. It 
was noted that when a catalytic amount of Cs2CO3 was used, full conversion could not be 
obtained. NMR disclosed a Z-configuration of the olefin based on a 2.5% NOE-enhancement 
of the vinylic proton when irradiating CH2P. No NOE-effects were observed between OCH2 
and the vinylic proton. 
 
4.3. E-alkoxylation of 3-imidoallenylphosphonates 
4.3.1. Addition of O-nucleophiles 
Next, we prepared a small library of derivatives. The addition of primary, secondary, and 
tertiary alcohols was first evaluated (Scheme 73, compounds 339-351). As steric hindrance of 
the introduced nucleophile increased, the transformation proceeded more slowly, and in the 
case of t-BuOH, a complex mixture was obtained. With i-PrOH, the addition product was still 
the major product, along with some remaining alkyne and allene starting material and a 
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multitude of minor impurities. For volatile nucleophiles, the nucleophile could be applied as the 
solvent (conditions B). With EtOH, addition was rapid (60 seconds), and the addition product 
340 was isolated in 97% yield.  
Scheme 73: Substrate scope of formation of E-functionalized aminophosphonates. Isolated yield and 
reaction time are indicated. 
The i-PrOH derivative 341 could similarly be obtained in 94% yield. Upon conducting the 
reaction in t-BuOH as a solvent, 82% conversion to 339 was achieved after three hours at 
40 °C. Longer reaction times gave secondary reactions that prevented isolation of 339. Other 
primary alcohols such as n-BuOH and BnOH smoothly gave the desired compounds 342 and 
344 in yields around 90% (conditions A), again without the need for purification. Phenol reacted 
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rapidly to give a mixture of two addition products 343a and 343b in a 6:1 ratio and 90% yield. 
With the sterically demanding (-)-borneol as a nucleophile, the intermediacy of the allene was 
illustrated once again, but a conversion higher than 20% to the addition product 345 could not 
be achieved, nor could 345 be isolated. The presence of an electrophilic group in the substrate, 
such as the aldehyde in 5-HMF (5-hydroxymethylfurfural), did not complicate matters giving 
full conversion to 346 in 90% crude yield in one hour. When preparing an analytical sample, 
the removal of some minor impurities required reversed phase flash chromatography causing 
partial degradation, which has been previously observed in the isolation of related HMF 
derivatives.320 The coupling of two allene moieties with ethylene glycol also proved to be easily 
achievable as all of the starting material was converted into an easily separable 91:9 mixture 
of bis-adduct 347a and mono-adduct 347b. When water was evaluated as a nucleophile, the 
formation of the corresponding ketone was expected, but we instead observed formation of a 
complex reaction mixture, probably due to aldol-type reactions. 
 
Finally, the addition of more complex and biologically relevant molecules was investigated. 
Addition of DL-D-palmitin gave rise to phospholipid-type product 348. Full conversion was 
obtained in thirty minutes, resulting in four addition products (ratio 9:34:50:7 in 96% crude 
yield), which could not be separately isolated. Competition between the primary and secondary 
alcohol and E/Z isomerism accounts for the different products formed. Running the reaction at 
0 °C resulted in a slower conversion, but not in a higher selectivity. One fraction could be 
enriched in the major isomer that was formed, giving rise to spectral data that allowed clear 
assignment of all relevant signals. Moreover, HMBC data indicated that the major isomer is 
the one resulting from addition of the primary alcohol. HaHb and HdHe have a different chemical 
shift and as HdHe couples with the ester carbon in HMBC, the shift of HaHb is known. As the 
phthalimidoyl carbonyl carbon for all other derivatives couples to HaHb (and not to Hc) in their 
HMBC spectrum, it is assumed that this is the case here as well. Thus, the major isomer is the 
addition of the primary alcohol.  
 
Addition of protected amino acids resulted in side-chain O-derivatized amino acids 349 and 
350. Amino acid derivatives containing a phosphorus moiety often display important biological 
activities. Bialaphos for instance is an antibacterial metabolite, which also possesses strong 
herbicidal properties.321 Adduct 349 was isolated in 63% yield as a 9/1 Z/E mixture. Partial 
elimination of the addition product 349, giving 352 and 353 was unavoidable, even when 
running the reaction at 0 °C, and accounts for the slightly lowered yield in comparison to less 
complex nucleophiles (Scheme 74). Spectral data for elimination products 352 and 353 were 
in accordance with literature values.322 
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Scheme 74: Elimination of the N-Z-L-serine methyl ester addition product. 
N-Z-L-tyrosine methyl ester was prepared following a literature procedure.323 Addition of this 
protected amino acid did not suffer from this elimination reaction, since no appropriately 
positioned leaving group is present in the tyrosine methyl ester. As was the case with the 
addition of phenol, allylphosphonate 350a and vinylphosphonate 350b were swiftly formed in 
a 6:1 ratio in 97% crude yield, after which the regioisomers were separated from each other. 
The conformation of 350b was confirmed to be Z since a 2% NOE-effect was found on the 
vinylic proton when irradiating NCH2. Ultimately, the addition of protected uridine was 
evaluated, since phosphononucleosides like tenofovir and adefovir are used in the treatment 
of HIV. We were pleased to find that the uridine addition product 351 could be isolated in 64% 
yield. For all of the synthesized derivatives, addition selectively occurs at the central carbon 
atom. This illustrates that 3-imidoallenylphosphonates behave as acceptor substituted allenes.  
 
4.3.2. Mechanistic considerations 
Next, we investigated the mechanism of this alkoxylation reaction. Michael addition to 
alkyne 305324 would initially produce vinylphosphonate 358 which can isomerize to yield the 
allylphosphonate 357. Although vinylphosphonate 358 was never detected in NMR 
experiments, only alkoxylation of isolated allene 338 can unambiguously rule out Michael 
addition. To this end, alkyne 305 was isomerized to the allene 338 with one equivalent of 
Cs2CO3 resulting in the first ever isolation of the 3-imidoallenylphosphonate 338 in 16% yield. 
First of all, it was found to be stable for at least several days, thus countering arguments that 
these allenes display low stability. Secondly, allene 338 was indeed in equilibrium with 
alkyne 305, since 16% isomerization to 305 was found under the same conditions. 
 
Most importantly, full conversion of allene 338 to allylphosphonate 357 in the presence of 
Cs2CO3 and EtOH is smoking gun evidence for the allene being the key intermediate in this 
one-pot, two-step reaction. However, it is clear that product 358 can also be produced from 
the addition to allene 338 (Scheme 75). Whether the nucleophile adds across the CD-CE or the 
CE-CJ double bond of the allene, it always results in the formation of a non-conjugated allyl 
anion - 354 or 356 - owing to the unique orbital structure of allenes. These non-conjugated 
anions can either be immediately protonated to give 357 or 358 respectively or they can rotate 
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around their single bond, and form the conjugated allyl anion 355. After protonation this can 
either lead again to the formation of the allylphosphonate 357 or the vinylphosphonate 358.  
 
Scheme 75. Proposed mechanism. 
During our syntheses we exclusively observed the formation of allylphosphonates 357, except 
for phenolic nucleophiles. In the case of phenol addition at room temperature, a 6:1 357:358 
ratio was found. When this addition was repeated at 0 °C we found a 12:1 357:358 ratio. This 
indicates that the addition reaction is either under kinetic control or that Michael addition to 
alkyne 305 occurs (305 to 358) and is suppressed at this lower temperature. Under the applied 
conditions (room temperature, Cs2CO3) 358 did not isomerize to 357. Furthermore, 357 was 
shown to be the thermodynamically more stable product, as 358 was entirely converted to 357 
upon eighteen hours of reflux. Moreover, it was shown that the addition was irreversible under 
the applied conditions. No exchange of the alkoxide moiety was observed upon reacting 340 
with BnOH and Cs2CO3.Thus, the formation of 358 is not a part of the major reaction pathway. 
This is in accordance with literature data as addition of NaN3 to 3-phenylpropa-1,2-
dienylphosphonate also gives the allylphosphonate, preserving the double bond conjugated to 
the aromatic group.325  
 
4.3.3. Attempted reduction and alkoxide exchange of addition product 340 
 
A peculiar reactivity was observed when reduction of the enimide 340 to J-
aminophosphonate 359a was attempted. First, hydrogenation with palladium and platinum 
catalysts was evaluated and led only to recovery of the starting material 340 after prolonged 
reaction times (Table 20, entries 1, 2).326 Also upon reduction with NaBH(OAc)3 at reflux 
temperature in THF, the starting material 340 was exclusively recovered (entry 3). When 
NaBH4 was used, 19% conversion to the J-aminophosphonate 359b was observed as the 
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enimido intermediate 360a was probably overreduced (entry 4). Repeating the reaction in 
methanol at room temperature, did not result in any conversion initially (entry 5). When the 
mixture was refluxed overnight however, complete conversion to the E-methoxy-E-
enimidophosphonate 360b had taken place. Strikingly, full and clean conversion was also 
observed when E-ethoxy-E-enimidophosphonate 340 was refluxed for two hours with one 
equivalent of Cs2CO3 in methanol (entry 6). Unlike under the conditions of entry 4, the 
intermediacy of enamine 360a was not possible in this case. Presumably, an addition-
elimination reaction via intermediate 361 was responsible for this reactivity. Unfortunately, this 
strategy could not be further exploited for the synthesis of E-amino-
E-enimidophosphonates 360c. Prolonged heating in diethylamine did not result in any 
conversion of the starting material 340, indicating that the amine is not sufficiently nucleophilic 
to react with enimide 340 (entry 7). 
Table 20: Reduction and alkoxide exchange of addition product 340. 
 
entry reducing agent catalyst base T t (h) solventa outcome 
1 5 bar H2 10 wt% Pd/C - rt 48 MeOH SM 
2 5 bar H2 10 wt% PtO2 - rt 40 MeOH SM 
3b 1.0 equiv NaBH(OAc)3 - - rt 
' 
2.5 
11 
THF SM 
SM 
4 1.0 equiv NaBH4 - - rtc on THF 19% 359b 
5 1.0 equiv NaBH4 
1.0 equiv NaBH4 
- - rtc 
' 
0.75 
on 
MeOH SM 
100% 360b 
6 - - 1 equiv Cs2CO3 ' 2 MeOH 100% 360b 
(61%)d 
7 - - 1 equiv Cs2CO3 ' 16 HNEt2 SM 
a not anhydrous b 1 equiv AcOH was added c NaBH4 added at 0 °C d isolated yield 
 
4.3.4. Attempted deprotection of the phthalimidoyl group 
It was found that phosphonylated alkynes, bearing a phthalimidoyl group, were excellent 
substrates for the preparation and E-alkoxylation of 3-aminoallenylphosphonates. Next, it was 
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briefly investigated if this phthalimidoyl protective group could be easily removed. Given the 
enimide function present in allylphosphonate 340, it was anticipated that, upon complete 
removal of the phthalimidoyl moiety with hydrazine, the generated enamine would immediately 
hydrolyze and complicate matters. On the other hand, substituted phthalimides were reported 
to undergo ring opening to afford phthalamides upon treatment with primary amines at room 
temperature.327 However, no conversion took place when allylphosphonate 340 was mixed 
with n-BuNH2 or BnNH2 (Table 21, entries 1, 2). Treatment with isopropylamine did not alter 
the outcome, not even after heating at reflux temperature. When LDA is used instead, 
formation of small amounts of an unidentified compound is observed. The desired product 362 
is not detected however. The base is possibly too sterically hindered to perform nucleophilic 
attack or is consumed when deprotonating the D-position of the phosphonate 340. Further 
attempts were not undertaken to deprotect the phthalimidoyl moiety.  
Table 21: Attempted deprotection of the phthalimidoyl group in allylphosphonate 340. 
 
entry nucleophile R1 R2 T (°C) t (h) solvent conversion (%) 
1 n-BuNH2 n-Bu H rt 27 neat 0 
2 BnNH2 Bn H rt 40 neat 0 
3 i-PrNH2 i-Pr H rt 
' 
17 
7 
neat 0 
0 
4 LDA 
(1.0 equiv) 
i-Pr i-Pr - 40 
rt 
1.5 
1 
THF 15 
7 
 
4.4. Towards 1-enimido-2-phosphonylated tetrahydrofurans 
Next, it was investigated if cyclic structures of type 364 could be prepared by reaction of 
imidoallenylphosphonates with haloalcohols (Table 22). Half an hour after 2-chloro ethanol 
was added, 97% conversion to addition product 363a was obtained. After another hour, 
conversion was complete and an extra equivalent of cesium carbonate was added to promote 
cyclization to tetrahydrofuran 364a. After 16 hours, no conversion to tetrahydrofuran 364a was 
observed and the addition product 363a was isolated in 80% yield (entry 1). A similar result 
with 3-chloropropanol, bearing a longer linker, was obtained (entry 2). 
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Table 22: Screened conditions for the one-pot cyclization  
to substituted tetrahydrofurans and tetrahydropyrans. 
 
 
entry substrate n X additive T t (h) 363 (%)b,c 364 (%)b 
1 305 2 Cl 1 equiv Cs2CO3  
1 equiv Cs2CO3 
rt 0.5 
16 
97  
100 (80) 
0 
0 
2 305 3 Cl 1 equiv Cs2CO3 rt 2 100 (84) 0 
3 305 3 Br 
I 
I 
I 
1 equiv Cs2CO3 
1 equiv NaI 
6 equiv NaI  
- 
rt 
rt 
rt 
' 
5 
16 
6 
16 
100 (21) 
traces 
100 
100 (55) 
0 
0 
0 
0 
4 363b 3 Cl 1 equiv Cs2CO3 
1 equiv AgNO3 
 
rt 
 
16 
 
- 
 
0 
5 363a 2 Cl 1 equiv KOtBu  rt 7 - d 0 
6 363a 2 Cl 1 equiv KOtBu ' 48 - 0 
7 363c 3 Br 1 equiv KOtBu  ' 48 - traces 
a not anhydrous b conversion based on 31P NMR c isolated yield between brackets d 72% deuteration upon quench with D2O 
 
The use of a nucleophile carrying a better leaving group, 3-bromopropanol, did not provide the 
tetrahydrofuran product 364c either (entry 3). However, after five hours, a complete conversion 
to addition product 363c was obtained. About one third of the mixture was isolated to yield 
compound 363c in 21% yield. To the remainder of the mixture, one equivalent of NaI was 
added in order to install an even better leaving group. After reacting overnight, traces of the 
iodoalkoxylated product 363d were detected. Complete conversion to iodoalkoxylated 
product 363d was obtained after six hours of reaction with an excess of NaI. Refluxing this 
mixture overnight did not yield the cyclized product 364d either. 
 
Treatment of isolated haloalkoxylated product 363b in the presence of AgNO3 and Cs2CO3 did 
not change the outcome (entry 4). The use of a stronger base, KOtBu, did not result in 
conversion of the starting material either (entry 5). Around 75% of the starting material 363a 
was deuterated upon quench with D2O, indicating that the substrate was effectively 
deprotonated in D-position of the phosphonate function. Refluxing the same substrate in THF 
with one equivalent of KOtBu for two days did not yield any conversion either (entry 6). 
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Although some traces of the tetrahydrofuran product 364c were found after refluxing the bromo 
derivative 363c for two days, it was concluded that cyclisation was not favourable (entry 7). 
 
4.5. Towards phosphonylated chromenes 
Given the ease with which alcohols reacted with the imidoallenylphosphonate 338, the addition 
of salicylaldehyde was evaluated in order to obtain phosphonylated chromenes. Chromenes 
display interesting biological activities, e.g. they inhibit tubulin polymerization which is an 
important process in apoptosis.328 At the same time they are important precursors in medicinal 
chemistry, for instance in the synthesis of the antihypertensive agent levcromakalim.329 In THF 
at room temperature, starting material 305 was entirely consumed after half an hour, giving a 
mixture of cyclized products 366-369, along with some unidentified minor compounds 
(Table 23, entry 1). Intermediate 365 was not detected. Phosphonylated chromenes 367-369 
all originate from attack of an allylic anion to the aldehyde carbonyl group, followed by 
aromatization and concomittant elimination of water. It is not surprising that both 
3-phosphonylated and 3-imidochromenes are formed, as it was illustrated earlier on that 
phenolic nucleophiles give a mixture of allyl and vinylphosphonate addition products 
(Scheme 73). Dephosphonylated chromene 366 is a result from a Horner-Wadsworth-
Emmons reaction, in which a phosphate is eliminated instead of water during aromatization. 
This dephosphonylation had previously been observed as well when salicaldehyde was 
reacted with allenylphosphonates.330, 331 Chromenes 366, 368 and 369 were all isolated, albeit 
in low yields. Chromene 367 was characterized by a singlet at 19.57 ppm in 31P NMR, a doublet 
of doublets at 5.60 ppm (J = 6.5 Hz and J = 3.5 Hz) in 1H NMR and a doublet at 101.6 ppm in 
13C NMR (1JCP = 192 Hz), but could not be isolated separately. It was observed earlier that 
allylphosphonate 357 is more selectively produced when lowering the temperature to 0 °C in 
the case of phenolic nucleophiles (vide supra). However, when keeping the temperature at 
0 °C for 7 hours, it did not result in an increased selectivity, but only in a slower reaction 
progress (entry 2). It had also been observed that vinylphosphonate addition products 358 
could be converted to allylphosphonate addition products 357 upon reflux in THF. When 
alkynylphosphonate 305 was refluxed in THF with salicylaldehyde, the starting material and 
the allene intermediate were consumed within half an hour (entry 3). The major product was 
indeed no longer the 3-imido chromene 367, but the 3-phosphonochromene 368. Moreover, 
3-imidochromene 367 proved to be interconvertible to 3-phosphonochromene 368 and a high 
61% conversion to the 3-phosphonochromene 368 was obtained after 2 hours of reflux. Further 
heating resulted in degradation and a complex mixture was obtained. Alternatively, the mixture 
was refluxed in toluene to further increase the selectivity. However, a complex mixture was 
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obtained quite fast and at no point a high conversion to one specific product was obtained 
(entry 4).  
Table 23: Screened conditions for the one-pot synthesis of phosphonylated chromenes. 
 
entry solvent T (°C) t (h) 366 (%)b,c 367 (%)b 368 (%)b,c 369 (%)b,c other (%)d 
1 THF rt 0.5 
1 
4 
6 (3) 
40 
39 
15 
26 (6) 
4 
8 (1) 
37 
22 
2 THF 0 
 
rt 
1.5 
7 
16 
0 
5 
5 
5 
26 
42 
0 
14 
21 
0 
2 
7 
0 
19 
26 
3 THF ' 0.5 
2 
3 
19 
9 
11 
10 
 
29 
14 
9 
 
42 
61 
51 
CM 
10 
11 
15 
 
9 
3 
14 
 
4 toluene ' 0.5 
6 
20 
9 
11 
 
26 
19 
 
21 
33 
CM 
5 
8 
 
40 
31 
 
5 CH3CN 65 0.5 
6 
ND 
ND 
27 
22 
12 
28 
28 
37 
10 
13 
6 dioxane 65 0.17 
6 
27 
ND 
ND 
5 
49 
26 
16 
7 
14 
11 
30 
60 
56 
13 
0 
6 
7 H2O 65 3 
6 
 0 
0 
0 
0 
0 
0 
100 
0 
8 CH2Cl2 ' 0.5 
6 
27 
 31 
4 
5 
7 
18 
16 
23 
62 
60 
39 
17 
10 
a not anhydrous b conversion calculated based on 1H and 31P NMR integrations c isolated yield after purification  
d unidentified products, other than alkyn starting material 305 or allene intermediate 338 
 
Since the most selective reaction occurred at 65 °C in THF, solvent screening was performed 
at this temperature. In all cases, the starting material was consumed within half an hour. When 
the reaction was run in CH3CN, no pronounced selectivity was observed (entry 5), while a 
decent selectivity was obtained in dioxane (entry 6). Remarkably, the other isomer was 
predominantly formed as compared to the reaction in THF (entry 3). When water was used as 
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the solvent, the mass of the intermediate 365 was detected for the first time, while 
characteristic signals in 1H NMR and 31P NMR were found (entry 7). Unfortunately, the product 
degraded upon further heating. Refluxing in CH2Cl2 gave the same result as compared to 
dioxane (entry 8). It was concluded that the selectivity to one specific isomer was not sufficient 
and thus the synthesis of phosphonylated chromenes was not further investigated. 
 
4.6. Addition of N-nucleophiles 
In a later stage, it was investigated whether nucleophiles other than alcohols could be used in 
the one-pot synthesis and E-derivatization of 3-imidoallenylphosphonates. First, the addition of 
secondary amines was evaluated. Under the same conditions as for the E-alkoxylation, 
E-amino vinylphosphonate 370a was obtained after one hour in 72% yield (Table 24, entry 1). 
Given the encountered difficulties with iso-propylalcohol (vide supra), conversion 
unsurprisingly proceeded sluggishly with the more sterically hindered diisopropylamine 
(entry 2). Although the addition product 370b was detected, a complex mixture was obtained 
which consisted of several dimeric products of the starting material 305. Addition of 
dibenzylamine resulted in complete consumption of the starting material 305 after 6 hours 
(entry 3). Along with two minor phosphorus-containing compounds, possibly the 
allylphosphonate 371c and a dimer of the starting material 305, vinylphosphonate 370c was 
produced. Moreover, only 40% of the dibenzylamine seemed to be consumed, which is logical 
if a dimer of the starting material is effectively formed. After purification, the product was 
isolated together with E-ketophosphonate 353, indicating that the desired product was not 
stable on silica gel. When the reaction was repeated and purified via reversed phase 
chromatography, the vinylphosphonate 370c was obtained as a white crystalline material in 
28% yield (entry 4). With pyrrolidine, the starting material was entirely consumed within one 
hour, giving rise to a 4/1 mixture of the vinylphosphonate 370d and the allylphosphonate 371d, 
which were not separated (entry 5). In the case of N-methyl phenylamine, addition of the 
nucleophile proved to be slow again, probably due to a high steric hindrance (entry 6). Although 
24% of the starting material 305 was converted to the allene intermediate within 15 minutes, 
subsequent addition was hampered, after which secondary reactions started to occur. 
Eventually, a complex mixture was obtained after 6 hours, in which vinylphosphonate 370e 
was one of the many products. It was clear that secondary amines did not react as easily as 
the corresponding alcohols. Remarkably, for the amines that did react, the stereoselectivity 
was opposite to the one observed during the alkoxylation of 3-imidoallenylphosphonates. 
III. Results and Discussion 
 
94 
Table 24: Hydroamination of in situ prepared 3-imidoallenylphosphonates.
 
entry R1 R2 t (h) 370 (%)b 371 (%)b 
1 Et  Et 1.5 100 (72)c 0 
2 iPr iPr 8 CM 
3 Bn Bn 6 84 9 
4 Bn Bn 7 80 (28)d 7 
5 (CH2)4 1 80 20 
6 Ph  Me 6 CM 
a not anhydrous b conversion based on 31P NMR c isolated yield after normal phase column chromatography 
d isolated yield after reversed phase column chromatography 
 
4.7. Addition of P-nucleophiles 
Phosphorus nucleophiles could also be added to the allene intermediate. With one equivalent 
of diethyl phosphite in THF at room temperature, a mixture of four phosphonylated products 
was obtained (Table 25, entry 1). As in the case of addition of phenol and certain amines, the 
addition of diethyl phosphite is not stereoselective. Initially, the product 372, with the double 
bond conjugated to the phthalimide moiety, is primarily formed. Overnight, compound 372 
isomerizes to the E/Z stereoisomers 373 and 374 with the double bond between the two 
phosphonate groups. Ratios do not change significantly upon longer reaction times. A fourth 
product was detected, in which two equivalents of diethyl phosphite had been incorporated. 
The compound, now containing three phosphorus atoms, is characterized by two doublets in 
31P NMR (at 16.9 ppm and -1.3 ppm with a coupling constant of 35 Hz) and one singlet (at 
21.6 ppm). Determination of its structure was not possible however, since the small amount of 
isolated product did not allow to record 13C NMR spectra. In order to shift the reaction towards 
this triple phosphonylated product 375, one equivalent of diethyl phosphite was added in 
excess (entry 2). Initially, more or less equal amounts of products 372-374 were obtained. 
Strikingly, after 7 hours, product 372 was no longer detected, while stereoisomers 373 and 374 
now accounted for almost 90% of the reaction products. Continued stirring at room temperature 
did not alter the composition of the reaction mixture. Refluxing the mixture in THF with an 
equimolar amount of diethyl phosphite, also resulted in a more stereoselective reaction, as 
compound 372 was not detected (entry 3). Adding the phosphorus nucleophile at 0 °C, it was 
attempted to avoid the formation of the triple phosphonylated product (entry 4). Unfortunately, 
this was not successful. An intermediate temperature of 12 °C did not prove to be a fruitful 
compromise either, as the reaction was slowed down too drastically while selectivity was still 
not increased (entry 5). Changing the solvent to dioxane did not alter the outcome either (entry 
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6). Remarkably, when the reaction was run at 100 °C in acetonitrile with microwave heating, 
the triple phosphonylated product is predominantly produced (entry 7). While stereoisomers 
373 and 374 seem to be convertible to compound 375, full conversion could not be achieved 
and a fifth unidentified procuct was formed. An excess diethyl phosphite or heating to 130 °C 
did not enhance the formation of compound 375 (entry 8). Further attempts were not 
undertaken, as it was too difficult to obtain one of the products selectively.  
Table 25: Hydrophosphonylation of in situ prepared 3-imidoallenylphosphonates. 
 
entry equiv HP(O)(OEt)2 solventa T (°C) t (h) 372 (%)b,c 373 (%)b,c 374 (%)b,c 375 (%)b,c 
1 1 THF  rt 0.5 
on 
48 
47 
22 
18d 
18 
45 
49 (12) 
12 
19 
20d 
13 
13 
13 (1) 
2 2 THF rt 0.5 
1.5 
7 
72 
42 
12 
0 
0 
27 
49 
65 
63 
19 
25 
24 
24 
12 
14 
11 
13 
3 1 THF ' 10 min 
9 
0 
0 
56 
67 
20 
11 
24 
22 
4 1 (dropwise) THF 0 1 11 3 6 2 
5 1 (dropwise) THF 12 2 6 2 2 1 
6 1 (dropwise) 1,4-dioxane 12 2 5 1 1 0 
7e 1 CH3CN 100 0.5 
5.5 
on 
0 
0 
0 
38 
8 
7 
8 
0 
0 
42 
65 
59 
8e 2 CH3CN 100 
 
130 
0.5 
5.5 
1 
0 
0 
0 
35 
32 
28 
16 
7 
5 
42 
52 
47 
a not anhydrous b conversion based on 31P NMR c isolated yield between brackets  
d compounds 372 and 374 could not be separated e microwave irradiation was applied 
 
4.8. Addition of C-nucleophiles 
To conclude, the addition of carbon nucleophiles was evaluated. With equimolar amounts of 
KCN and Cs2CO3, 13% of the starting material 305 was converted to addition product 376 
(Table 26, entry 1). Upon longer reaction times, the remaining starting material was consumed, 
but a complex mixture was obtained. The experiment was repeated with a catalytic amount of 
base so that the starting material 305 can reprotonate the addition product 376. This resulted 
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in a slow conversion of the starting material, but the desired product 376 was not detected 
(entry 2).  
Table 26: Addition of cyanide to in situ prepared 3-imidoallenylphosphonates. 
 
entry Nu t (h) 376 (%)b 
1 KCN  4 
22 
13 
CM 
2c KCN 72 0 
a not anhydrous b conversion based on 31P NMR c 0.1 equiv Cs2CO3 was used  
 
Next, diethyl malonate, a protic carbon nucleophile with a low pKa, was selected. The starting 
material 305 and the allene intermediate were consumed within 90 minutes, but afforded a 
mixture of regioisomers (Table 27, entry 1). The enimidophosphonate 377 seemed to be the 
initial addition product since it isomerizes to product 378 with the double bond conjugated to 
the malonate. After two hours, the vinylphosphonate 379 becomes the major product. On 
repetition of this reaction, vinylphosphonate 379 does not turn out to be the more stable 
product, as conversion in favour of compound 378 took place (entry 2). Enimidophosphonate 
377 is detected in important amounts at the beginning of the reaction again. As 
stereoselectivity was increased upon heating in the case of phenol addition (vide supra), this 
parameter was varied in this case again. Within ten minutes, all of the starting material was 
consumed and the major compound was indeed altered. Vinylphosphonate 379 accounted for 
half of the phosphonylated compounds detected (entry 3). Addition of malononitrile resulted in 
22% conversion to product 378 after one hour at room temperature (entry 4). Upon longer 
reaction times, at least ten other phosphonylated compounds were detected, while the starting 
material was still present. In all of the discussed cases with carbon nucleophiles, an important 
amount of unidentifiable products were detected as well and thus no further attempts were 
performed to optimise the selectivity of the addition of these nucleophiles. 
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Table 27: Addition of malonate-type nucleophiles to in situ prepared 3-imidoallenylphosphonates. 
 
entry R t (h) 377 (%)b 378 (%)b,c 379 (%)b 
1 CO2Et 10 min 
1.5 
2.25 
17 
9 
4 
4 
65 
23 
1 
17 
50 
2 CO2Et 1 
3 
on 
22 
6 
8 
12 
16 
45 (10) 
30 
45 
5 
3d CO2Et 10 min 
0.5 
1.25 
8 
5 
4 
28 
13 
17 
48 
53 
44 
4 CN 1 
31 
0 
 
22 
CM 
0 
a not anhydrous b conversion based on 31P NMR c isolated yield between brackets  
d reflux instead of rt 
 
4.9. Conclusion 
In conclusion, the first synthesis of 3-imidoallenylphosphonates was demonstrated. This 
transformation proceeds via a prototropic rearrangement under very mild conditions and the 
imidoallenylphosphonate was isolated and characterized. Moreover, it can be alkoxylated in a 
one-pot procedure in very short reaction times in excellent chemical yields. The method is 
applicable to an array of highly functionalized biologically relevant O-nucleophiles, furnishing 
these adducts in moderate to good yields. Purification on column was needed only in the case 
of the more complex nucleophiles. Treatment with haloalcohols did not afford substituted 
tetrahydrofurans, while an exchange of the alkoxide moiety was observed when the ethanol 
addition product was mixed with cesium carbonate in methanol. Addition of salicyl aldehyde 
afforded the envisioned phosphonylated chromenes, but a mixture of isomers was obtained. 
Diethylamine was easily added to the allene intermediate as well, but other N-nucleophiles 
were more challenging to add selectively. Phosphorus nucleophiles could also engage in this 
addition reaction, affording a mixture of four phosphonylated products. Carbon nucleophiles, 
such as the cyanide anion or diethylmalonate, could be introduced as well, but an incomplete 
reaction or a mixture of isomers was obtained. 
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5. Aminoallenylphosphonates as a key intermediate 
in the synthesis of new antiviral agents 
5.1. Introduction 
The interest in new antiviral compounds is huge. Yellow fever for instance is a viral disease for 
which an effective vaccin exists, but nonetheless resulted in 127 000 severe infections and 
45 000 deaths in 2013.332 As known antivirals were shown not to be successful, no cure is 
available once a person is infected. Influenza, on the other hand, is reported to result in about 
250 000 to 500 000 deaths a year,333 while in 2015 around 37 million people were living with 
HIV and 1.2 million people succumbed to AIDS-related illnesses.334, 335 Between its discovery 
in 1981 and 2014, AIDS is estimated to have been responsible for no less than 39 million 
deaths worldwide.336 In 1986, azidothymidine was approved by the FDA as the first drug for 
the treatment of HIV.337 At the same time, acyclic nucleoside phosphonic acids turned out to 
be a class of very potent antiviral compounds. In 1986 and 1987, adefovir 12 and cidofovir 11 
were discovered respectively (Figure 20).338, 339 While the former has been approved for the 
treatment of HBV infections (Hepatitis B Virus), the latter is used to treat HCMV retinitis (human 
cytomegalovirus) in AIDS patients.19 In 1993, the anti-HIV properties of tenofovir 13 were first 
described.340 In 2001 tenofovir disoproxil fumarate (TDF) was licensed by the FDA for the 
treatment of HIV infections. Since 2008 it is also approved to treat HBV infections. Moreover, 
tenofovir might also be used prophylactically in order to prevent HIV infections.19 
 
 
Figure 20: Examples of antiviral acyclic nucleoside phosphonates. 
As the straightforward addition of O-nucleophiles to 3-imidoallenylphosphonate 338 was 
demonstrated earlier, it was decided to create a set of nucleoside addition products which 
would then be tested in a broad spectrum antiviral test. Four protected nucleosides were 
selected, which were commercially available in their acetonide protected form: uridine 
acetonide 380, adenosine acetonide 381, guanosine acetonide 382 and inosine acetonide 383, 
the latter being the nucleoside which is formed when hypoxanthine is attached to ribofuranose 
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(Figure 21). Cytidine and thymidine compounds were not selected, as derivatives with easily 
removable protecting groups, such as the acetonide, were not commercially available. 
 
 
Figure 21: Commercially available nucleosides acetonides. 
The screening for antiviral activity would be assessed on two levels: virus-infected cell cultures 
– including herpes, HIV, influenza and yellow fever viruses – were to be used to test the 
nucleoside phosphonates. The deprotected phosphonic acid derivatives however are 
necessary to measure specific enzyme inhibition in enzyme assays. It was reasoned that a 
dibenzyl phosphonate precursor 384 would be a better choice than a diethyl phosphonate 
precursor 305. Benzyl phosphonates are lipophilic, which means a better uptake in the cell, 
and are known to liberate the phosphonic acids upon cytochrome P450 oxidation, a process 
which ethyl phosphonates cannot undergo.341 Also, benzylphosphonates can give the free 
phosphonic acids upon hydrogenation, which is interesting as the TMSBr deprotection method 
of dialkyl phosphonates is known to be troublesome in some cases.342 
 
5.2. Synthesis of nucleoside phosphonates 
5.2.1. Preparation of dibenzyl alkynylphosphonate 384 
In view of the synthesis of nucleoside phosphonates, N-propargyl phthalimide 336 was 
phosphonylated with dibenzyl phosphite according to the earlier developed procedure. 
However, under standard conditions and after two consecutive purification steps, the isolated 
product 384 was still contaminated with N-((benzyloxy)methyl)-N-methylacetamide 385 
(Table 28, entry 1). Probably an N-acetyl iminium intermediate was formed under the applied 
oxidative conditions, which was attacked by traces of free benzyl alcohol. An alternative solvent 
which is stable under the oxidative conditions was searched for. In sulfolane, a poor conversion 
of 37% was obtained after three hours (entry 2). In N-formyl morpholine, a better conversion 
was obtained after six hours (entry 3). A complete conversion was obtained when an equimolar 
amount of copper was used (entry 4). Adding three equivalents of the dibenzylphosphite at the 
beginning of the reaction, allowed the reaction to be completed within two hours (entry 5). 
Scaling up the reaction to a 10 mmol scale, required a slightly bigger excess of dibenzyl 
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phosphite to achieve complete conversion (entry 6). After extensive washing with brine and 
aqueous LiCl solution, followed by column chromatography, dibenzyl alkynylphosphonate 384 
was isolated in 81% yield.  
 
Table 28: Optimization of conditions for the preparation of dibenzyl alkynylphosphonate 384. 
 
 
entry solvent t (h) equiv Cu(OAc)2 equiv HP(O)(OBn)2 384 (%)a,b 
1 DMF 0 
1 
2 
0.1 
0.2 
1 
2 
 
- 
21 
77 (23) 
2 sulfolane  0 
1 
2 
3 
0.1 
 
0.2 
2 
 
1 
- 
4 
6 
37 
3 NFM 0 
1 
2 
2.5 
3.5 
4.5 
6 
0.1 
 
 
0.2 
2 
 
 
 
 
1 
- 
15 
17 
- 
63 
- 
78 
4 NFM 0 
1 
3 
4 
1 2 
 
1 
 
- 
70 
70 
100 
5 NFM 0 
2 
1 3 - 
97 
6c NFM 0 
3 
3.75 
4.5 
1 3 
 
0.5 
- 
89 
 
100 (81) 
a conversion based on 1H NMR b isolated yield between brackets c 10 mmol scale 
 
5.2.2. Addition of nucleobases to dibenzyl alkynylphosphonate 384 
Next, the addition of uridine acetonide 380 was evaluated. When an equimolar amount of 
nucleophile was used, the alkynylphosphonate 384 was entirely consumed after 6 hours, 
although the mixture contained 37% non-incorporated uridine acetonide starting material 380 
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(Table 29, entry 1). Moreover, separation on column was not successful. Although the 
transformation previously never required the use of dried solvent, the reaction was now run in 
dry THF. According to 31P NMR, the reaction was finished within 4 hours but 1H NMR showed 
that even more uridine acetonide starting material 380 remained (entry 2). Even an excess of 
alkynylphosphate 384 was consumed within three hours, while the nucleoside starting material 
was still present (entry 3). A change of solvent resulted only in a small improvement (entry 4). 
Possibly, an addition-elimination step of hydroxide (as was observed when ethanol addition 
product 340 was mixed with Cs2CO3 in methanol, vide supra), yielded the starting material 380 
and E-ketophosphonate 387 (Scheme 76). Elimination product 388 (the analogue of compound 
352, which was produced when serine was added to imidoallenylphosphonate 338, vide supra) 
was not observed. The most successful conditions were repeated before the mixture was 
purified via reversed phase column chromatography (entry 4). Unfortunately, also in this way 
no analytically pure material could be obtained.  
 
Table 29: Screened conditions for the synthesis of uridine acetonide addition product 386. 
 
entry equiv alkyne 384 t (h) solvent 386 (%)a remaining SM 380 (%)b 
1 1 6 THFc  77 37 
2 1 4 THF 62 45 
3 1.5 3 THF 48 32 
4 1 2 CH3CNd 70 18 
5 1 2 CH3CNd 70 30 
a conversion based on 31P NMR b conversion based on 1H NMR c not anhydrous d anhydrous 
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Scheme 76: Possible formation of E-ketophosphonate 387. 
5.2.3. Debenzylation of the dibenzyl phosphonate addition product 386 
It was then decided to deprotect the nucleoside phosphonate esters first and purify the mixture 
at the phosphonic acid stage. Treatment of nucleoside phosphonate 386 with 10 wt% Pd/C 
resulted in complete deprotection but three unidentified impurities were also formed (Table 
30). Purification by means of preparative TLC (mobile phase: 8:2 iPrOH/water) did not result 
in a cleaner product. Moreover, most of the product could not be recovered. Also reversed 
phase chromatography proved to be unsuccessful as the product did not show any affinity for 
the stationary phase, eluting immediately with 100% water (entry 2).  
 
Table 30: Deprotection and conditions for the attempted purification of  
uridine acetonide phosphonic acid aduct 389. 
 
entry purification result 
1 pTLC (8/2 iPrOH/H2O) unsuccessful 
2 RP chromatography (100% H2O) unsuccessful 
3 Wash n-hexane 
Wash ethyl acetate 
one apolar impurity removed 
loss of material in organic phase 
4 Recrystallization MeOH unsuccessful 
 
One of the three major impurities could be removed by dissolving the product in water and 
extracting the impurity with hexane (entry 3). Washing with ethyl acetate resulted in loss of the 
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product 389 in the organic phase, while the remaining product 389 in the aqueous phase was 
still contaminated with the other two impurities. Recrystallization from MeOH was also 
unsuccessful (entry 4). When the crude reaction mixture was refluxed in THF/HCl(aq.), the 
entirely deprotected target structure 390, was easily obtained (Scheme 77). An analytically 
pure sample could once again not be obtained as recrystallization in water, adding acetone as 
an antisolvent, was unsuccessful.  
 
 
a not anhydrous 
Scheme 77: Deprotection of the acetonide and phosphonate moieties. 
 
5.2.4. Deprotection of the diethyl phosphonate addition product 351 with TMSBr 
Although the uridine phosphonic acid 389 was predominantly obtained from the dibenzyl 
phosphonate 386, purification was shown to be troublesome. Consequently, the deprotection 
of diethyl nucleoside phosphonate 351 (vide supra), with TMSBr was considered nonetheless 
(Table 31). Earlier on, diethyl nucleoside phosphonate 351 had been obtained from uridine 
acetonide addition to 3-imidoallenylphosphonate 338 and was easily purified via normal phase 
chromatography. Thus, diethyl nucleoside phosphonate 351 was selected as a model 
substrate for the deprotection of the diethyl phosphonate ester moiety. Treatment of nucleoside 
phosphonate 351 with two equivalents of TMSBr resulted both in phosphonate ester and 
acetonide deprotection (entry 1). After 4 hours, 80% of the starting material 351 was 
monodeprotected at the phosphorus center, producing compounds 392 and 393. 
Unfortunately, after the addition of 1 extra equivalent TMSBr, no phosphonic acid product 394 
could be detected. When analytically pure 2’,3’-deprotected nucleoside phosphonate 391 
(preparation, vide infra) was treated with four equivalents of TMSBr, small amounts of the 
phosphonic acid nucleoside 394 were detected (entry 2). The major product was still the mono 
ethyl phosphonic acid 393. As the target phosphonic acids were hardly obtained, purification 
was not pursued. 
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Table 31: Deprotection of the phosphonate moiety in adducts 351 and 391 with TMSBr. 
 
entry equiv TMSBr t (h) starting material SMa 391 (%)a 392 + 393 (%) a,b 394 (%)a 
1 2c 
1 
 
2 
4 
5 
351 10 
10 
0 
55 
10 
30 
35 
80 
70 
0 
0 
0 
2 4c 20 391 25 - 70d 5 
a determined through LC-MS b compounds 392 and 393 co-elute c added at start of reaction d only 393 
 
5.2.5. Acetonide deprotection of dibenzyl phosphonate prodrugs 
Since no easy entry into nucleoside phosphonic acid 394 was found, it was decided to refocus 
on the preparation of dibenzyl phosphonate prodrugs 395 with a 2’,3’-deprotected ribose 
moiety (Table 32). Treatment of dibenzyl nucleoside phosphonate 386 with pTsOH in THF 
resulted in almost complete consumption of the starting material, but next to 
dibenzylphosphonate 395, monobenzyl phosphonate 396 was also detected (entry 1). The 
acetonide deprotection was as good as completed after 4.5 hours (entry 2). Deprotection of 
the phosphonate moiety only seemed to take place upon longer reaction times. Unfortunately, 
the product 395 could again not be separated from the impurities. Running the reaction at room 
temperature did not improve the selectivity and resulted in a poor conversion of the starting 
material 386 (entry 3). 
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Table 32: Deprotection of the acetonide moiety of dibenzyl phosphonate adduct 386. 
 
entry T t (h) 386b 395b 396b 397b 
1 ' 24 5 50 40 0 
2 ' 4.5 9 87 4 0 
3 rt 6 days 72 25 3 0 
a not anhydrous b determined through LC-MS 
 
5.2.6. Acetonide deprotection of diethyl phosphonate prodrugs 
Ultimately, it was attempted to prepare acetonide-deprotected diethyl nucleoside phosphonate 
prodrugs. Diethyl 2′,3′-O-isopropylideneuridine phosphonate 351, which had been prepared 
earlier (vide supra), did undergo selective deprotection of the acetonide moiety upon treatment 
with pTsOH.343 After one day of reflux in THF, uridine phosphonate 401 was isolated in 50% 
yield after extractive work-up (Table 33, entry 1). Deprotection of the phosphonate ester was 
not observed. Encouraged by this result, the addition of three other nucleosides and the 
subsequent deprotection step were evaluated. Reaction with 2′,3′-O-isopropylideneadenosine 
swiftly afforded the 2′,3′-O-isopropylideneadenosine phosphonate 398 after normal phase 
chromatography (entry 2). After deprotection of the 2′,3′-O-isopropylidene group, the 
adenosine phosphonate 402 was isolated, without the need for purification at this stage, in 
80% yield. When 2′,3′-O-isopropylideneinosine 382 was used, a complex mixture was 
obtained, in which the aliphatic alkoxylated addition product 399 was observed along with the 
phenolic hydroxypurinyl double addition product 405 (entry 3 and Figure 22). Double alkylation 
was observed as well when 2′,3′-O-isopropylideneguanosine 383 was used as a substrate. In 
this case, only products 400 and 407 and no other impurities were formed and consequently, 
both addition products could be isolated in low yields via preparative reversed phase 
chromatography (entry 4). Ultimately, the acetonide protecting group of both alkoxylated 
products 400 and 407 was readily deprotected. 
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Table 33: Synthesis of acetonide-deprotected diethyl phosphonate prodrugs 401-404. 
 
entry NuH 
Protected nucleoside 
phosphonates 
351, 398-400 
Deprotected nucleoside 
phosphonates 
401-404 
1 
   
2 
   
3 
   
4 
   
a not anhydrous b isolated yield 
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Figure 22: Double addition products 405 and 407 and the deprotected derivative 408. 
5.3. Biological evaluation of nucleoside phosphonates 
The antiviral properties of diethyl nucleoside phosphonates 401, 402, 404 and 408 were 
assessed at the Rega institute for Medical Research (KU Leuven) against several viruses in 
four different cell cultures (Figure 23).344 HEL cell cultures (Human Embryonic Lung fibroblast 
cells) were used to test the activity against herpes simplex virus type 1 (HSV-1), an aciclovir 
resistant strain of thymidine kinase-deficient HSV-1, herpes simplex virus type 2 (HSV-2), 
vaccinia virus, human adeno virus type 2 (Ad2) and human coronavirus (Table 34). No activity 
was observed at the highest concentrations tested for any of the viruses. 
 
Figure 23: Prepared diethylnucleoside phosphonates, used in the broad-spectrum antiviral screening. 
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Table 34: Cytotoxicity and antiviral activity in HEL cell cultures. 
compound Minimum  
cytotoxic  
concentrationa,b  
EC50a,c 
HSV-
1 
HSV-1 TK- 
ACVr 
HSV-
2 
Vaccinia 
virus 
Ad2 Human 
coronavirus 
401 
402 
404 
408 
Brivudin 
Cidofovir 
Aciclovir 
Ganciclovir 
Zalcitabine 
Alovudine 
UDAd 
Ribavirin 
>100 
>100 
>100 
>100 
>250 
>250 
>250 
>100 
>250 
>250 
>100 
>250 
>100 
>100 
>100 
>100 
0.04 
2 
0.9 
0.07 
- 
- 
- 
- 
>100 
>100 
>100 
>100 
14 
5 
100 
0.8 
- 
- 
- 
- 
>100 
>100 
>100 
>100 
>250 
5.8 
3.4 
0.4 
- 
- 
- 
- 
>100 
>100 
>100 
>100 
22 
19 
>250 
>100 
- 
- 
- 
- 
>100 
>100 
>100 
>100 
- 
10 
- 
- 
29 
22 
- 
- 
>100 
>100 
>100 
>100 
- 
- 
- 
- 
- 
- 
1.8 
146 
a concentrations expressed in μM, except for UDA: μg/mL b required to cause a microscopically detectable alteration of normal 
cell morphology c required to reduce virus-induced cytopathogenicity by 50% d Urtica dioica agglutinin 
 
Next, the antiviral activity against vesicular stomatitis virus, coxsackie virus B4 and respiratory 
syncytial virus was tested in HeLa cell cultures. Unfortunately, no activity was observed at the 
highest concentrations tested (Table 35).  
 
Table 35: Cytotoxicity and antiviral activity in HeLa cell cultures. 
compound Minimum  
cytotoxic  
concentrationa,b  
EC50a,c 
Vesicular  
stomatitis virus 
Coxsackie virus B4 Respiratory  
syncytial virus 
401 
402 
404 
408 
DS-10.000 
Ribavirin 
>100 
>100 
>100 
>100 
>100 
>250 
>100 
>100 
>100 
>100 
>100 
8.9 
>100 
>100 
>100 
>100 
34 
45 
>100 
>100 
>100 
>100 
0.4 
1.5 
a concentrations expressed in μM, except for DS-10.000: μg/mL b required to cause a microscopically detectable alteration of 
normal cell morphology c required to reduce virus-induced cytopathogenicity by 50% 
 
Antiviral activity of compounds 401, 402, 404 and 408 was investigated against para-influenza-
3-virus, reovirus-1, sindbis virus, Coxsackie virus B4, punta toro virus and yellow fever virus in 
Vero cell cultures. Again, at the highest concentrations tested, no activity was observed (Table 
36).  
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Table 36: Cytotoxicity and antiviral activity in Vero cell cultures. 
compound Minimum  
cytotoxic  
concentrationa,b  
EC50a,c 
Para- 
influenza- 
3-virus 
Reovirus-
1 
Sindbis 
virus 
Coxsackie 
virus B4 
Punta 
Toro 
virus 
Yellow 
Fever 
virus 
401 
402 
404 
408 
DS-10.000 
Ribavirin 
Mycophenolic 
acid 
>100 
>100 
>100 
>100 
>100 
>250 
>100 
>100 
>100 
>100 
>100 
100 
50 
0.5 
>100 
>100 
>100 
>100 
>100 
>250 
6 
>100 
>100 
>100 
>100 
45 
>250 
45 
>100 
>100 
>100 
>100 
20 
>250 
>100 
 
>100 
>100 
>100 
>100 
>100 
45 
2.3 
>100 
>100 
>100 
>100 
12 
>250 
2 
a concentrations expressed in μM, except for DS-10.000: μg/mL b required to cause a microscopically detectable alteration of 
normal cell morphology c required to reduce virus-induced cytopathogenicity by 50% 
 
Next, the antiviral properties of nucleoside phosphonates 401, 402, 404 and 408 were tested 
against three types of influenza in MDCK (Madin Darby canine kidney cells) cell cultures. No 
activity was observed either (Table 37).  
 
Table 37: Cytotoxicity and antiviral activity in MDCK cell cultures. 
compound Cytotoxicity EC50b 
Influenza A/H1N1 Influenza A/H3N2 Influenza B 
CC50a Minimum  
cytotoxic  
concentrationb,c 
visual CPE 
score 
MTS visual CPE 
score 
MTS visual CPE 
score 
MTS 
401 
402 
404 
408 
Zanamivir 
Ribavirin 
Amandatine 
Rimandatine 
>100 
>100 
>100 
>100 
>100 
>100 
>100 
>200 
>100 
>100 
>100 
>100 
>100 
>100 
>100 
>200 
>100 
>100 
>100 
>100 
0.1 
8.9 
20 
>200 
>100 
>100 
>100 
>100 
0.3 
18.2 
22.6 
>200 
>100 
>100 
>100 
>100 
0.4 
2.3 
0.2 
0.01 
>100 
>100 
>100 
>100 
0.01 
1.4 
0.03 
0.01 
>100 
>100 
>100 
>100 
0.4 
5.6 
>100 
>200 
>100 
>100 
>100 
>100 
0.4 
4.6 
>100 
>200 
a 50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay b 
concentrations expressed in μM c Minimum compound concentration that causes a microscopically detectable alteration of normal 
cell morphology c 50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as 
determined by visual scoring of the CPE, or by measuring the cell viability with the colorimetric formazan-based MTS assay 
 
Finally, the anti-HIV properties of nucleoside phosphonates 401, 402, 404 and 408 were 
evaluated against the HIV-1 NL4.3 and HIV-1 BaL strains in TZM-bl cells and against the HIV-
1 NL4.3 and HIV-2 ROD strains in MT-4 cells. Disappointingly, no antiviral activity was 
observed against any of these strains in the TZM-bl or MT-4 cells (Table 38). 
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Table 38: Cytotoxicity and antiviral activity in TZM-bl cells and MT-4 cells. 
compound CC50a and EC50b in TZM-bl cells CC50a and EC50b in MT-4 cells 
 CC50a EC50b,c 
HIV-1 
NL4.3 
EC50 b,c 
HIV-1 
BaL 
CC50a EC50 b,c 
HIV-1 
NL4.3 
EC50 b,c 
HIV-2 
ROD 
401 
402 
404 
408 
AMD3100 
AMD14031 
>100 
>100 
>100 
>100 
>1000 
>1000 
>100 
>100 
>100 
>100 
1.3 
- 
>100 
>100 
>100 
>100 
- 
3.0 
>100 
>100 
>100 
>100 
>1000 
>100d 
>100 
>100 
>100 
>100 
17 
8.5d 
>100 
>100 
>100 
>100 
16 
1.5d 
a 50% cytotoxic concentration of the compound in this cell line b concentrations expressed in μM, except for AMD3100: ng/mL 
c 50% effective concentration or compound concentration producing 50% inhibtion of HIV-induced cytopathic effect 
d PMPA was used as a reference instead of AMD14031 
 
In all of the cytotoxicity tests, none of the nucleoside phosphonates were found to be cytotoxic. 
The four nucleoside phosphonates were also tested in an enzymatic assay with influenza 
PA-Nter endonuclease.345 Even at the highest concentrations tested, no inhibition of the 
influenza polymerase was observed (Table 39). 
 
Table 39: Activity in enzymatic assay with influenza PA-Nter endonuclease. 
compound IC50a,b  
401 
402 
404 
408 
DPBAc 
>500 
>500 
>500 
>500 
1.6 
a compound concentration producing 50% inhibition of PA-Nter mediated cleavage of the DNA substrate  
b concentrations expressed in μM c 2,4-dioxo-4-phenylbutanoic acid 
 
5.4. Conclusion 
In this chapter, it was investigated whether the earlier developed 3-imidoallenylphosphonate 
building block could be exploited for the synthesis of nucleoside phosphonate prodrugs and 
nucleoside phosphonic acids. Antiviral activity would be assessed in an enzymatic essay with 
influenza PA endonuclease, which required the preparation of the nucleoside phosphonic 
acids. Secondly, the nucleoside phosphonates would be tested as prodrugs in cell culture 
against a broad spectrum of viruses. To that end, a dibenzyl alkynylphosphonate precursor 
was prepared, as benzyl phosphonates can yield the corresponding phosphonic acids upon 
hydrogenation. Addition of the nucleoside occurred smoothly, but isolation of the pure 
compound proved to be cumbersome. Although the phosphonate ester and 2’,3’-O-
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isopropylidene protecting groups were both readily removed, purification at either of these 
stages was not successful. Disappointingly, the diethyl nucleoside phosphonate could not yield 
the nucleoside phosphonic acid either. However, four diethyl nucleoside phosphonate 
prodrugs could be prepared, originating from the addition of either 
2’,3’-O-isopropylideneuridine, 2’,3’-O-isopropylideneadenosine or 
2’,3’-O-isopropylideneguanosine to diethyl 3-imidoallenylphosphonate, followed by acetonide 
deprotection with pTsOH. The synthesized compounds showed no activity in a broad-spectrum 
antiviral screening in cell cultures or enzyme assays. 
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6. Applying the aminoallenylphosphonate strategy to 
the production of new fosmidomycin-based 
antimalarials 
6.1. Introduction 
Malaria is a tropical disease, spread most commonly by the female Anopheles mosquito. It 
was reported that in 2015, there were 296 million cases of malaria worldwide, probably causing 
around 731 000 deaths.334, 335 With 90% of those deaths and infections occuring in Africa, the 
disease has a huge impact on these societies and their economic development.346 Although 
several antimalarial medications exist, treatment becomes increasingly problematic because 
the parasite has developed resistance against all antimalarial drugs apart from artemisinins. 
Since treatment of malaria infections, caused by resistant strains, increasingly relied on the 
use of those last resort drugs, artemisinin resistance is developing as well.347 It is universally 
acknowledged that new antimalarial drugs are urgently needed, but the resources for the 
development of a treatment of this poverty disease are sadly enough still limited. 
Fosmidomycin 5 is a natural product, first isolated from Streptomyces lavendulae, and was 
first investigated for its antibacterial activity.348, 349 Later it was found that fosmidomycin 5 and 
its N-acetyl derivative FR900098 6, which is about twice as potent, display important activities 
against the parasite Plasmodium falciparum.350, 351 Fosmidomycin inhibits DXP 
reductoisomerase, a key enzyme in the non-mevalonate pathway. Some organisms, such as 
the malaria parasite, rely on this pathway for their isoprenoid biosynthesis. Human beings use 
the mevalonate pathway for their isoprenoid biosynthesis, rendering this approach particularly 
attractive. Although quite some D- and J-substituted fosmidomycin derivatives have been 
prepared,352-354 only 14 examples of E-substituted fosmidomycin and FR 900098 derivatives 
have been reported in literature.348, 355-364 In previous chapters, it has been demonstrated that 
3-imidoallenylphosphonate 305 is an intermediate that can be easily prepared from 
phosphonylated N-propargyl phthalimide 336 and that it is easily derivatized at the central 
carbon atom. Oxygen nucleophiles react particularly well, in high yields, short reaction times 
and displaying good stereoselectivity. Although a decreased stereoselectivity was often 
observed, nitrogen, phosphorus and carbon nucleophiles could be introduced as well in some 
cases. Aptly substituted 3-aminoallenylphosphonate 34 could consequently serve as the 
precursor to make a small library of unsaturated E-substituted fosmidomycin derivatives 39 
(Scheme 78). To effectively use the previously developed methodology, the phthalimidoyl 
group in precursor 338 had to be replaced by a masked hydroxamic acid functional group while 
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the free phosphonic acids instead of the phosphonate esters are desired in the target 
molecules. As the deprotection of diethyl phosphonates to the free phosphonic acids with 
TMSBr is often cumbersome, both ethyl and benzyl phosphonates would be prepared. The 
latter have the advantage that they can be be deprotected upon hydrogenation and ideally, the 
O-benzyl protected hydroxamic acid function would be deprotected at the same time. So, 
alkynylphosphonate precursors 35 would be prepared from successive alkylation of O-benzyl 
hydroxamic acid 37 and copper-catalyzed phosphonylation of the resulting alkyne 36 with 
dialkylphosphite. 
 
Scheme 78: Retrosynthetic approach to E-substituted analogues of FR900098 and structures of 
fosmidomycin and its N-acetyl analogue FR900098. 
6.2. Synthesis of E-substituted FR900098 derivatives 
6.2.1. Preparation of N-alkylated hydroxamic acid 410 
O-benzyl hydroxamic acid 37 is not commercially available but was conveniently prepared from 
O-benzyl hydroxylamine hydrochloride 409 with acetyl chloride (Scheme 79).365 O-benzyl 
hydroxamic acid 37 was isolated as a mixture of rotamers with an isolated yield of 85%.  
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Scheme 79: Preparation of O-benzyl hydroxamic acid 37. 
Alkylation with propargyl bromide predominantly gave the desired N-alkylated product 410, 
next to two O-alkylated isomers 411a and 411b (Table 40).366 Initially, N-alkylated hydroxamic 
acid 410 was isolated in 66% yield, although purification was not straightforward given the 
comparable Rf values of the products (entry 1).  
 
Table 40: Propargylation of O-benzyl hydroxamic acid 37. 
 
entry base T t (h) 410 (%)a,b 411a (%)a 411b (%)a,b 
1 K2CO3  ' 15 86 (66) 3 11 (5) 
2 Cs2CO3 ' 0.5 89 (42) 2 8 
3 Cs2CO3 rt 4 91 (66) 2 8 
4 K2CO3 ' 15 ND (88)c ND ND 
a conversion based on 1H NMR b isolated yield between brackets c work-up limited to solvent evaporation 
 
To facilitate this purification step, conditions were screened in order to minimize the formation 
of the O-alkylated products 411a and 411b. Since O-allylated hydroxamic acids are known to 
undergo thermal [3,3]-rearrangement to their N-allylated counterparts,367 one of the two O-
propargyl, O’-benzyl hydroxamic acid isomers 411a or 411b was refluxed in DMF. 
E/Z isomerization was observed upon reflux in DMF for one day, but unfortunately no 
conversion to the N-propargyl hydroxamic acid 410 was observed (Scheme 80).  
 
Scheme 80: Attempted N to O thermal rearrangement. 
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With Cs2CO3 instead of K2CO3 as the base in the alkylation step, the selectivity for the desired 
isomer 410 was only marginally improved (entry 2). Because of the higher solubility of Cs2CO3, 
the reaction sped up drastically. It was consequently investigated whether regioselectivity 
would be increased when running the reaction at a lower temperature. However, at room 
temperature, O-propargylation still occurred in small amounts (entry 3). Because of the higher 
price of Cs2CO3, it was decided to use K2CO3 from then on since comparable yields were 
obtained. It was also observed that a considerable amount of product was lost during aqueous 
work-up (entries 2 and 3). Hence, work-up was limited to evaporation of the solvent prior to 
purification of the crude mixture on column. This resulted in a high 88% isolated yield of 
N-propargyl hydroxamic acid 410 (entry 4). 
 
6.2.2. Synthesis of phosphonylated hydroxamic acid precursors 412a-b 
Next, N-alkylated hydroxamic acid 410 was successfully phosphonylated with dialkyl 
phosphites, using the earlier developed procedure (Table 41). The diethyl phosphonate 
precursor 412a could be isolated in 66% yield (entry 1). Similarly, the dibenzyl 
phosphonate 412b was prepared from reaction with dibenzyl phosphite in NFM, to avoid 
reaction with the solvent (vide supra). In the latter case, an equimolar amount of catalyst was 
used in order to obtain a complete conversion on a reasonable time scale (entry 2). Dibenzyl 
phosphonate 412b was eventually isolated in 20% yield. Part of the product was probably lost 
during the extensive washing with aqueous LiCl solution, while another part eluted together 
with tetrabenzyl hypophosphate 413.  
 
Table 41: Preparation of dialkyl phosphonate precursors 412a-b. 
 
 
entry R equiv Cu(OAc)2 equiv DAP t (h) solvent 412 (%)a,b 
1c Et 0.4  2 1 DMF 97 (66) 
2 Bn 1 3 3.5 NFM 96 (20) 
a conversion based on 31P NMR b isolated yield c 0.3 equiv NEt3 was used  
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6.2.3. Attempted addition of nucleophiles to phosphonylated hydroxamic acid 
precursors 414a-b 
With the alkynylphosphonate precursor 412a-b in hand, the addition of O-nucleophiles was 
evaluated at room temperature (Table 42, entry 1). Twenty minutes after the addition of one 
equivalent ethanol, the starting material was entirely consumed, giving a complex mixture. 
After three hours, three major products were detected by 31P NMR, while signals of the 
intermediates had disappeared. 
 
Table 42: Attempted synthesis of E-alkoxylated FR900098 derivatives. 
 
entry SM equiv EtOH t (h) solvent 415 (%)a 416 (%)a,b 417 (%)a 
1 412a 1  3 THF 20 54 (11) 26 
2 412b 2 1 min neat 47 37 16 
3 412b - 5 min EtOH 75 15 10 
4 412b 0 3 THF 0 60 40 
a conversion based on 31P NMR b isolated yield between brackets 
 
Minor amounts of the addition product 414a were detected, which could not be recovered after 
purification. However, oxazole 416a, which was the major product, was isolated in 11% yield. 
Spectral data were in accordance with literature values for comparable compounds.368 When 
substrate 412b was allowed to react with two equivalents of EtOH, the starting material was 
entirely consumed within one minute yielding a mixture of oxazoles 415-417 (entry 2). When 
ethanol was added in excess, the benzyl alcohol addition product still accounts for 15% 
conversion (entry 3).  
 
A plausible mechanism is suggested for the formation of oxazoles 415-417, in which an 
apparent [1,2]-shift of the alkoxy group has occurred (Scheme 81). In alkaline medium, the 
highly conjugated N-acetyl ynimine 418 is presumably produced with concomittant expulsion 
of benzyloxide (path a). The N-acetyl ynimine 418 can then yield hemiaminal 419 after an 
attack of an alkoxide. A 5-exo-dig Michael-type cyclization followed by an isomerization step 
possibly yields the oxazoles 415 or 416 (path c). Alternatively, isomerization of the 
hemiaminal 419 occurs, giving the amino allenylphosphonate 421, which yields the 
oxazoles 415 or 416 upon 5-exo-dig cyclization (path d). The intermediacy of the N-acetyl 
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ynimine 418 explains the presence of ethanol cross-over product 415. Moreover, after 20 
minutes the N-acetyl ynimine 418 is observed in 1H NMR (doublet at 7.83 ppm (JHP = 1.1 Hz)) 
and at -7.41 ppm in 31P NMR. After three hours, these signals have disappeared, indicating 
that this intermediate is further converted. In addition to that, 31P NMR data showed that P-
C(sp2) fragments were also present at the beginning of the reaction, possibly originating from 
the allene 421. The presence of the reduced oxazole 417 can be explained by cyclization of 
secondary amide 422, which could result from homolytic scission of the N-O bond (path b). 
 
Scheme 81: Plausible mechanism for the formation of oxazoles 415-417. 
In an aprotic medium, the N-acetyl ynimine 418 was observed again and evidently no ethanol 
cross-over product was observed (entry 4). Further reaction to the benzyloxy substituted 
oxazole 416 and the reduced oxazole 417 could not be prevented. 
 
6.2.4. Understanding the proposed mechanism through synthesizing 
intermediates and derivatives 
In order to eventually prevent the formation of oxazoles 415-417, proof for this pathway was 
sought for. The N-(benzyloxy)-N-(but-2-yn-1-yl)acetamide 423 was prepared to assess if the 
hemiaminal 419 is an intermediate indeed (Table 43). As the triple bond in the hemiaminal 425 
is probably not sufficiently polarized to initiate 5-exo-dig cyclization, it was anticipated that 
hemiaminal 425 would be observed. When N-(benzyloxy)-N-(but-2-yn-1-yl)acetamide 423 was 
reacted with one equivalent of Cs2CO3, the starting material was recovered, even after a long 
reaction time (entry 1). The N-acetyl ynimine intermediate 424 was not observed in 1H NMR. 
This is not surprising, as the propargylic protons in N-(benzyloxy)-N-
(but-2-yn-1-yl)acetamide 423 are probably significantly less acidic as compared to those in that 
position in the phosphonate-containing hydroxamic acid 412. When the reaction is repeated in 
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ethanol, 23% conversion to the N-(1-alkoxybut-2-yn-1-yl)acetamide 425 was detected after 
four days (entry 2). Moreover, the mass of the N-acetyl ynimine intermediate 424 was detected 
in trace amounts in LC-MS analysis. These two observations show that the hemiaminal 425 
can indeed be formed under these mild conditions, even though the propargylic protons are 
not as acidic as in the phosphonylated substrate 412. Cyclization of hemiaminal 425 did not 
occur indeed. 
 
Table 43: Preparation of the non-phosphonylated analogue 425. 
 
entry equiv Cs2CO3 t (d) solvent 423 (%)a 424 (%)a 425 (%)a 
1 1  14 THF 100 0 0 
2 2 4 EtOH 77 0 23 
a conversion based on 1H NMR 
 
Next, phosphonylated amide 422 was prepared to assess whether this proposed intermediate 
would cyclize in the presence of a mild base. Boc-protected propargylamine 23 was 
phosphonylated with diethyl phosphite, deprotected with HCl and then acetylated.245 (Scheme 
82).  
 
 
Scheme 82: Preparation and cyclization of the amide 422. 
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Upon treatment with one equivalent Cs2CO3 and one equivalent ethanol at room temperature, 
95% of the amide 422 was converted to oxazole 417a after 6 days. Spectral data are similar 
to literature values for comparable compounds.368 Allenic intermediates were not observed and 
thus it is reasonable to assume that hemiaminal 419, once formed, reacts in much the same 
way (pathway c). Given the difference in reaction rate however, the intermediacy of amino 
allenylphosphonate 421 cannot be excluded in the case of hemiaminal 419. 
 
6.2.5. Nucleophilic addition to tert-butyl (benzyloxy)(3-
(diethoxyphosphoryl)prop-2-yn-1-yl)carbamate 428 
Next, it was anticipated that the acidity of the propargylic protons in precursor 412 could be 
downregulated by replacing the acetyl group by a Boc group. O-benzyl hydroxylamine 
hydrochloride 409 was N-Boc protected and next propargylated in good yield (Scheme 83). 
Oxidative cross coupling with diethyl phosphite then yielded precursor 428. Unfortunately, 
upon treatment of precursor 428 with one equivalent of Cs2CO3, loss of the OBn and Boc 
signals was observed in 1H NMR. It was concluded that the present approach was too 
challenging and the E-alkoxylation strategy was abandoned. 
 
 
Scheme 83: Preparation and E-alkoxylation of O-benzyl-N-Boc protected hydroxylamine 428. 
6.2.6. Copper-catalyzed hydroamination of alkynylphosphonate 412 
As the introduction of an oxygen nucleophile in alkaline medium proved to be problematic, 
another approach for the introduction of nucleophiles was considered. In literature, the copper-
catalyzed addition of secondary amines to alkynylphosphonates has been described.59 This 
method was evaluated on substrate 412 in order to get access to E-enamino fosmidomycin 
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derivatives 430 (Table 44). Applying the conditions of the original procedure afforded a 
complex mixture, in which oxazole 416a accounted for one third of the phosphorus-containing 
products (entry 1). When the reaction was run in HNEt2 as a solvent, the starting material was 
consumed after one hour (entry 2). One isomer of the addition product 430 and one isomer of 
a double addition product 431 were detected.  
 
Table 44: Screened conditions for the hydroamination of phosphonylated O-benzyl hydroxamic acid 412. 
 
entry equiv HNEt2 T (°C) t (h) solvent 430a (%)a 430b (%)a 431 (%)a 416a (%)a 
1 1  100 16 MeOH 0 0 0 33 
2 - 100 1 HNEt2 0 6 39 0 
3 - rt 20 HNEt2 7 13 39 0 
4 1 rt 8 d MeOH 0 0 32 0 
5 - - 41 4 HNEt2 15 2 47 0 
a conversion based on 1H NMR 
The latter can be explained by the intermediacy of ynamide 418, which can then undergo two 
consecutive Michael addition steps, one in the direction of the phosphonate and another in the 
direction of the imine (Scheme 84). At room temperature, a slightly more encouraging result 
was obtained as both isomers 430a-b were detected, along with the double addition 
product 431 (entry 3). At room temperature in methanol, the reaction slowed down 
dramatically, without detecting any addition product 430a-b after eight days (entry 4). In 
diethylamine at even lower temperatures, selectivity towards addition products 430a-b did not 
increase (entry 5). Eventually, this strategy was abandoned as well, as the abundancy of 
functional groups seemed to be too high for the introduction of an extra nucleophile. 
 
Scheme 84: Plausible mechanism for the formation of double addition product 431. 
 
  
III. Results and Discussion 
 
122 
6.3. Conclusion 
In our efforts to develop new fosmidomycin-inspired antimalarials, the hydroxamate-containing 
alkynylphosphonate precursors were successfully prepared through simple acylation and 
alkylation of O-benzyl hydroxylamine, followed by oxidative phosphonylation with dialkyl 
phosphites. When the one pot isomerization to the corresponding allene and subsequent 
introduction of an O-nucleophile was attempted, oxazoles were primarily obtained. 
Presumably, an elimination-addition reaction takes place yielding an amide that is prone to 
cyclization. Moreover, the N-O bond of the hydroxamic acid moiety seems to be a sensitive 
part of the molecule as well, as a reduced oxazole was observed. Copper-catalyzed 
hydroamination of the hydroxamate-containing alkynylphosphonate precursor was not 
successful either. 
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A very efficient strategy has been developed to prepare chiral, spirocyclic oxaphospholenes in 
a three-step synthesis from ketoterpenes. To evaluate the chiral inducing properties, the 
phosphonic acid 433 is required. Treatment of phosphonate esters with LiBr is a known method 
to prepare monodealkylated phosphonate esters.369 Alternatively, treatment with silica could 
yield the phosphonic acid too, since the spontaneous hydrolysis of oxaphospholenes upon 
purification on silica has been described (Scheme 85).  
 
Scheme 85: Proposed preparation of oxaphospholenic acids  
by deprotection of the corresponding phosphonate esters. 
Although both the alkyne substituent and the ketoterpenic moiety were varied, more variation 
is still possible. Iodine was selected because it is an easy to add dihalogen. Other halogenated 
derivatives, particularly the brominated ones, would be interesting to prepare, as vinylbromides 
are widely used in cross coupling reactions (Scheme 86). Via a Suzuki coupling, additional 
structural variety can be introduced if, for instance, steric or electronic properties need to be 
altered. 
  
Scheme 86: Further exploration of the structural variety in the oxaphospholenic skeleton. 
Since the stepwise synthesis of 5-bisphosphonomethyl oxazol-2-ones suffered from the use 
of strong bases, the second phosphonate group could not introduced. This attractive class of 
compounds could possibly be accessed even so through an alternative approach. The gold-
catalyzed 5-exo-dig cyclization of Boc-protected propargylamines 437 has been described in 
literature.249 Endowing substrate 438 with this vinyl halide handle, the second phosphonate 
moiety could then be installed via a cross coupling reaction with diethyl phosphite 
(Scheme 87).370 
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Scheme 87: Alternative strategy to access 5-bisphosphonomethyl oxazol-2-ones 440 and 
5-bisphosphonomethyl oxazolidin-2-ones 441. 
In our approach to prepare 3-aminoallenylphosphonates through cross coupling of 
phosphorus-containing copper acetylides with amines, isomerization of the 
propargylphosphonate to the internal alkyne immediately occurred upon removal of the 
TMS-group. However, a direct alkynyl group transfer from silicon to copper is described in 
literature.371 If the copper acetylide can be prepared in this way, the coupling reaction with 
N-nucleophiles and ultimately the isomerization to the allene can be evaluated (Scheme 88).  
 
Scheme 88: Preparation of copper acetylide 31 through direct alkynyl group transfer from silicon  
to copper and its evaluation in the synthesis of 3-aminoallenylphosphonates. 
3-Imidoallenylphosphonates have been shown to react very efficiently with a variety of 
O-nucleophiles. N, P and C-nucleophiles have also been employed, although less successfully 
because of selectivity issues. If suitable follow-up reactions can be found that convert two or 
more isomers to one product, these transformations could still prove to be useful. 
Hydrogenation, for instance, would respectively yield aminophosphonates, bisphosphonates 
and J-phosphonomalonates.  
In the case of C-nucleophiles, substrates with a low pKa were selected, given the mild 
conditions the transformation uses. Hydroarylation with aryl boronic acids and cross coupling 
with aryl halides could be interesting opportunities to further expand the scope of introducible 
C-substituents (Scheme 89). Examples of both hydroarylation372, 373 and cross coupling373 
reactions have been reported in literature for allenylphosphonate substrates. A comparison of 
IV. Perspectives 
 
126 
the behaviour of aminoallenylphosphonates under these conditions would definitely be of 
interest. 
 
Scheme 89: Proposed hydroarylation of 3-imidoallenylphosphonates with aryl boronic acids and cross 
coupling with aryl halides. 
The influence of different substituents on the N-atom – with the possibility for their deprotection 
at a later stage in mind – on the preparation and reactivity of 3-aminoallenylphosphonates 
remains to be explored. So far, the phthalimidoyl group of the addition products could not be 
removed, although treatment with hydrazine and a reducing agent or with NaBH4 in acidic 
medium should be evaluated (Scheme 90).374 Aminoallenylphosphonates bearing alternative 
protective groups – like tosyl, Boc and benzyl groups – should definitely be looked into since 
the preparation of their alkynylphosphonate precursors has been realized already. 
  
Scheme 90: Possible reduction methods for the deprotection of the phthalimidoyl moiety. 
The antiviral evaluation of the first set of nucleoside phosphonates was not very promising. 
Some major issues need to be addressed. First of all, the conventional purification techniques 
were not successful for the isolation of the nucleoside phosphonic acids. Other 
chromatographic techniques, like the use of a cellulose stationary phase, need to be evaluated 
since the deprotection conditions for both the acetonide deprotection and debenzylation of the 
phosphonate, have been shown to be feasible. Secondly, the phthalimidoyl protecting group 
might prove to be too big and too apolar to fit in the active site of viral enzymes. If an easily 
removable protecting group can be found – for instance a Cbz group that can be 
simultaneously deprotected with the benzyl groups of the phosphonate – a primary enamine 
would be obtained that can be reduced to the amine and, if desired, further derivatized 
(Scheme 91). The antiviral potential of this new series of derivatives can then be assessed 
again. The synthetic potential of the aminoallenylphosphonate building block and its 
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applications has definitely not been maximally explored and will be of interest in future 
research. 
 
Scheme 91: Suggested deprotection strategies for the synthesis of nucleoside phosphonic acids. 
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1. General methods 
Commercially available reagents were not purified and used as such, unless otherwise stated. 
Reactions were run in non-flame dried glassware and open to air, unless otherwise noted. Inert 
atmosphere refers to a N2 atmosphere, if not indicated otherwise. 
1.1. Solvents 
Unless otherwise noted, anhydrous THF, Et2O, CH2Cl2, n-pentane and toluene were used, 
either collected in a Schlenk tube (THF, Et2O, CH2Cl2, n-pentane and toluene) from an 
MBRAUN Solvent Purification System or either freshly distilled from sodium 
benzophenone/ketyl (THF, Et2O) or by distillation over calcium hydride (CH2Cl2).  
Other solvents like CH3CN, MeOH, EtOH, t-BuOH, dioxane, CHCl3, CHBr3, DMSO, DMF, 
DME, sulfolane, NFM and acetone were not dried before use, unless otherwise noted. 
Anhydrous methanol was obtained by heating methanol with dried magnesium turnings and 
iodine for two hours, before distillation. The distillate was stored on 4Å molecular sieves and 
under argon atmosphere. Anhydrous CHCl3 was collected in a Schlenk tube from an MBRAUN 
Solvent Purification System. Anhydrous CH3CN was distilled and stored over 4Å molecular 
sieves. 
1.2. Pressure reactions 
Hydrogenation reactions up to 5 bar H2-pressure, were executed in a Parr-flask on a stirring 
plate, shielded by an iron cage in case of explosion.  
1.3. Column chromatography 
Purification on column was performed on silica gel (particle size 70-200 μm, pore diameter 
60Å) in a glass column using appropriate mixtures of solvents, as determined by TLC. Spots 
were visualized by UV irradiation or by staining with KMnO4 or phosphomolybdic acid solution. 
Reversed phase column chromatography was performed on a Reveleris® X2 Flash 
Chromatography System with a Reveleris® C18 RP cartridge. 
1.4. Preparative TLC 
Preparative TLC was run on 2000 μm 20 x 20 cm TLC plates in an elution chamber using an 
appropriate eluent. Visualization was done by means of UV irradiation or by staining a small 
part of the plate with a KMnO4 solution. 
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1.5. Gas chromatography 
GC analyses were performed on an Agilent 6890 Series  Gas Chromatograph connected to a 
FID, using an Alltech EC-5 capillary column (30 m x 0.25 mm) having a film thickness of 0.25 
μm and using He as the carrier gas. GC-MS analyses were run on a Shimadzu QP2010 SE 
gas chromatograph-mass spectrometer (Electron Impact), using an Phenomenex ZB 5ms 
capillary column (20 m x 0.18 mm) with a film thickness of 0.18 μm and He as the carrier gas. 
1.6. Liquid chromatography 
Routine follow-up analyses were run on an Agilent 1200 Series liquid chromatograph using a 
reversed phase column (Eclipse plus C18, 50 x 46 mm, particle size 3.5 μm) connected to a 
UV-VIS detector and an Agilent 1100 Series LC/MSD type SL mass spectrometer (ESI, 70 eV) 
using a mass selective single quadrupole detector. A mixture of water (5mM NH4OAc) and 
CH3CN was used as the mobile phase, employing a gradient starting from 30% CH3CN to 
100% CH3CN. 
1.7. Preparative HPLC 
An Agilent 1100 Series liquid chromatograph with a reversed phase column (Zorbax Eclipse 
XDB-C18 column, 150 x 21.2 mm, particle size 5 μm), connected to a UV-VIS Variable 
Wavelength Detector, was used. A mixture of water and CH3CN was used as the mobile phase. 
1.8. Mass spectrometry 
Low-resolution MS analyses were run on an Agilent 1100 Series LC/MSD type SL mass 
spectrometer (ESI, 70 eC) using a mass selective single quadrupole detector. High-resolution 
mass spectra were obtained with an Agilent Technologies 6210 Time-Of-Flight mass 
spectrometer (ESI or APCI). 
1.9. NMR spectroscopy 
High-resolution 1H (400 MHz), 13C (100 MHz), 19F (376 MHz) and 31P (162 MHz) NMR spectra 
were recorded on a Bruker Avance III Nanobay 400 MHz spectrometer at room temperature, 
unless otherwise noted. DEPT, APT, COSY, HSQC, HMBC, H2BC and NOESY techniques 
were used to assign peaks. Deuterated solvents with TMS as an internal standard were used 
to dissolve samples. Chemical shifts are expressed as parts per million (ppm). 
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1.10. Infrared spectroscopy 
IR-spectra were recorded on a Perkin-Elmer Spectrum One BX FT-IR spectrophotometer with 
an ATR accessory. Samples were analyzed in neat form and selected peaks are listed. 
1.11. Melting points 
The melting point of crystalline compounds was determined on a Wagner & Munz WME 
Heizbank Kofler bench. 
1.12. Microwave irradiation 
Reactions were performed in a 10 mL thick-walled Pyrex reaction vessel in a CEM Discover 
Benchmate with a continuous power output (0 to 300 W). The vessel was closed with a snap-
cap and equipped with a stirring bar, while stirring was performed using a rotating magnetic 
plate, located at the bottom of microwave cavity. The desired temperature was reached by 
increasing the temperature within a maximum ramp time of 5 minutes and was maintained 
during the course of the reaction. An external infrared sensor was used to measure the 
temperature at the bottom of the reaction vessel and was communicated to the on-board 
computer to adjust the power output (1 W increments). When the reaction was finished, the 
vessel was cooled down using a stream of air onto the vial to cool down the vial down to 40 °C 
in approximately 2 minutes.  
1.13. Optical rotation 
Optical rotation was determined by means of a Jasco P-2000 polarimeter. 
1.14. X-ray analysis 
X-ray diffraction was performed using an Agilent Supernova Dual Source (Cu at zero) 
diffractometer, equipped with an Atlas CCD detector using CuKD radiation (l = 1.54178 Å) and 
Z scans. The images were interpreted and integrated with the program CrysAlisPro (Agilent 
Technologies). Using Olex2, the structure was solved by direct methods using the ShelXL 
program package. Non-hydrogen atoms were anisotropically refined and the hydrogen atoms 
in the riding mode and isotropic temperature factors fixed at 1.2 times U (eq) of the parent 
atoms. The amide and amine hydrogen atoms were located from a difference electron density 
map and were unrestrainedly refined. All X-ray diffraction analyses were performed in 
collaboration with Prof. dr. Kristof Van Hecke, XStruct, Department of Inorganic and Physical 
Chemistry, Ghent University, Belgium.   
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2. Safety 
2.1. General safety aspects 
The practical work in this thesis was performed according to the SynBioC Research Group 
Internal Guidelines and with the aid of the internal safety document “Safety Instructions: How 
to work with chemicals”. Wherever possible, hazardous or toxic reagents were avoided and/or 
substituted by safer or greener alternatives.  
2.2. Specific safety aspects  
A list of the risks associated with each chemical is available in the corresponding safety data 
sheet (SDS), which can be found on the website of the supplier. Therein, a classification of the 
hazards was made according to the European Regulation (EC) No 1272/2008 [EU-GHS/CLP], 
which combines the Globally Harmonized System of Classification and Labeling of Chemicals 
(GHS) and Classification, Labelling and Packaging regulations (CLP). A brief overview of the 
chemicals employed in this work classified as category 1, the most severe category, of the 
respective hazard class will be given below, along with the GHS hazards and precautions.  
Alkyllithium reagents: pyrophoric liquids, substances and mixtures which in contact with 
water emit flammable gases, acute toxicity after inhalation, acute and chronic hazards to the 
aquatic environment. Keep away from heat, fire, hot surfaces, sparks and ignition sources. 
Avoid contact with air or water and work under an inert atmosphere. In case of fire use dry 
sand, dry chemical- or alcohol-resistant foam to extinguish.  
Bromoform: specific target organ toxicity. Avoid inhalation. Acute oral toxicity. 
Chloroform: specific target organ toxicity following repeated exposure. Avoid inhalation.  
Diazomethane: extremely explosive gas. Preparation and manipulation should take place 
behind a blast shield. Use rounded glassware for distillation and check for sharp edges or 
scratches on any glassware that comes into contact with the substance. Explodes when 
heating above 100 °C, when exposed to intense light or in the presence of alkali metals. Toxic 
by inhalation and through skin contact. Deaths from diazomethane poisoning have been 
reported (fulminating pneumonia). Alkylating compound, so carcinogenic. Wear gloves and 
protective clothing. 
Diethyl chlorophosphate: highly toxic through dermal absorption. Acts as a cholinesterase 
inhibitor. Wear gloves, protective clothes and respiratory protection. Wash hands immediately 
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after use. In case of contact with the skin, wash carefully with plenty of water and soap. In case 
of swallowing, immediately call a poison center. 
Diethyl chlorophosphite: specific target organ toxicity. Wear protective gloves and clothing. 
H2-gas: flammable gas, especially when compressed. Keep away from heat, fire, hot surfaces, 
sparks and ignition sources.  
Inorganic acids (HCl, H2SO4): skin corrosion, corrosive to metals. Wear protective gloves and 
clothing.  
Inorganic bases (NaOH, NaH): skin corrosion, corrosive to metals. Wear protective gloves 
and clothing. NaH releases flammable gases upon contact with water, which might ignite 
spontaneously. 
Iodine (I2): acute toxicity, skin corrosion. Avoid inhalation, wear protective gloves and clothing, 
avoid release in the environment.  
Organic acids (acetic acid, para-toluenesulfonic acid): skin corrosion. Wear protective 
gloves and clothing.  
Organic bases (NEt3, KOtBu, LDA, LiHMDS): skin corrosion. Keep away from heat, fire, hot 
surfaces, sparks and ignition sources. Avoid inhalation and wear protective gloves and 
clothing.  
Phenyl trichloromethyl mercury (PhHgCCl3): is a carcinogenic material and should be 
handled accordingly. Wear appropriate gloves, protective clothing and respiratory protection. 
Palladium-based catalysts: highly flammable solids. Keep away from heat, sparks, open 
flames or hot surfaces. 
Propargyl bromide: acute toxicity after inhalation. Avoid inhalation. 
Solvents in general: acute toxicity after inhalation, specific target organ toxicity following 
single or repeated exposure. Keep away from heat, fire, hot surfaces, sparks and ignition 
sources. Avoid inhalation and wear protective gloves and clothing. A useful tool for solvent 
selection is the “GSK solvent selection guide” which lists a wide variety of hazards associated 
with specific solvent classes as well as more benign alternatives for commonly used solvents.  
Transition metal salts: acute and chronic aquatic toxicity. Avoid release in the environment.  
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3. Biological evaluation 
3.1. Broad spectrum antiviral evaluation in cell cultures 
The antiviral activity of the compound in cell culture was assessed via cytopathic effect (CPE) 
reduction assays, using a diverse panel of viruses.344 On human embryonic lung fibroblast 
cells, the following viruses were used: herpes simplex virus type 1 (HSV-1) strain KOS, a 
thymidine kinase-deficient (TK-) HSV-1 KOS strain resistant to acyclovir, herpes simplex virus 
type 2 (HSV-2) strain G, vaccinia virus (Lederle strain), a clinical isolate of human adenovirus 
type 2 (Ad2), and human coronavirus (strain 229E). To study the antiviral effect on vesicular 
stomatitis virus (VSV), Coxsackie B4 virus and respiratory syncytial virus (RSV), human cervix 
carcinoma HeLa cells were used. African Green Monkey Vero cells were used to investigate 
the antiviral activity on para-influenza-3 virus; reovirus-1, Sindbis virus, Coxsackie B4 virus 
and Punta Toro virus. The activity against human influenza A/H1N1, A/H3N2 and B viruses 
was assessed on Madin-Darby canine kidney (MDCK) cells. Finally, human immunodeficiency 
virus type 1 and type 2 were examined on human MT-4 lymphoblast cells. At a multiplicity of 
infection of 100 CCID50 (50% cell culture infective dose) or 20 PFU (plaque forming units) per 
well, semiconfluent cell cultures were inoculated with the virus in 96-well plates. Serial dilutions 
of the test or reference compounds were added simultaneously with the virus. The plates were 
next incubated at 37°C (or 35°C in the case of influenza virus) until clear CPE was reached, 
i.e. during 3 to 6 days. Ad2 required 10 days incubation. To determine the antiviral activity 
[expressed as 50% effective concentration (EC50)] and cytotoxicity [expressed as minimum 
cytotoxic concentration (MCC)], microscopic scoring was performed. The viral effects on cell 
viability were confirmed by the colorimetric formazan-based MTS cell viability assay for a 
selection of viruses.  
 
3.2. Enzymatic assay with influenza PA-Nter endonuclease 
The pET28a(+) plasmid was used to clone the coding sequence for PA-Nter (i.e. residues 
1-217 from the PA protein of influenza virus strain A/X-31).345 The protein was obtained after 
expression in E. coli BL21-CodonPlus cells and purification by 6xHis-Ni-NTA chromatography 
followed by buffer exchange. In the enzyme assay, 1 μg of recombinant PA-Nter was incubated 
with 1 μg (16.7 nM) of single-stranded circular DNA plasmid M13mp18 (Bayou Biolabs, 
Metairie, Louisiana) in the presence of the test compounds or the reference compound 
2,4-dioxo-4-phenylbutanoic acid (DPBA), at a final volume of 25 μL. The buffer used in the 
assay, contained 50 mM Tris-HCl pH 8, 100 mM NaCl, 10 mM β-mercaptoethanol and 1 mM 
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MnCl2. After incubation at 37 °C for 2 hours, the reaction was stopped by heat inactivation 
(80 °C, 20 min). Using gel electrophoresis on a 1% agarose gel with ethidium bromide staining, 
the endonucleolytic digestion of the plasmid was visualized. ImageQuant TL software 
(GE Healthcare) was used to quantify the amount of remaining intact plasmid. GraphPad Prism 
software (GraphPad Software, La Jolla, CA) was used to plot the percentage inhibition of PA 
endonuclease activity against the compound concentration on a semi-logarithmic plot. 
Nonlinear least-squares regression analysis afforded the 50% inhibitory concentrations (IC50). 
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4. Synthetic procedures and spectral data 
4.1. Synthesis of protected propargylamines 
N,N-dibenzylprop-2-yn-1-amine 309 
N,N-dibenzylprop-2-yn-1-amine 309 was prepared according to a literature procedure and 
spectral data were in accordance with literature values.375 
1. 1H NMR (400 MHz, CDCl3) G: 2.28 (1H, t, J = 2.3 Hz, CH), 3.26 (2H, d, J = 2.3 
Hz, NCH2Cq) 3.69 (4H, s, N(CH2Cq,ar)2) Yield: 80% (1214 mg), white crystals. 
N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate 23 
N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate 23 was prepared according to a literature 
procedure and spectral data were in accordance with literature values.376 
1H NMR (400 MHz, CDCl3) G: 1.53 (18H, s, Cq(CH3)3), 2.18 (1H, t, J = 2.4 Hz, CH), 
4.36 (2H, d, J = 2.4 Hz, NCH2) Yield: 83%, yellow oil. 
4.2. Synthesis of phosphonylated alkynes through oxidative 
cross coupling with dialkylphosphites 
4.2.1. Procedure for the preparation of diethyl alkynyl phosphonates 
Representative example 305: A round-bottom 100 mL flask was charged with 181 mg (1 mmol) 
Cu(OAc)2, 40 mL DMF, 2.760 g (20 mmol) diethyl phosphite and 202 mg (2 mmol) 
triethylamine. An oxygen flow was allowed to bubble through the reaction mixture. Next, 1.850 
g (10 mmol) of the alkyne was added and the mixture was magnetically stirred, while keeping 
a steady oxygen flow bubbling through the mixture. After one hour, a second portion of 
Cu(OAc)2 (362 mg, 2 mmol) and diethyl phosphite (1.38 g, 10 mmol) were added. Reaction 
progress was followed by NMR. After another half an hour, the reaction was completed and 
the mixture was concentrated in vacuo, diluted in ethyl acetate and washed twice with a 1M 
aqueous solution of LiCl. The crude mixture was purified via column chromatography (1/1 
PE/EtOAc) or crystallized from ethyl acetate to give white crystals. Spectral data were in 
accordance with literature data. 
diethyl (phenylethynyl)phosphonate 296246 
1H NMR (400 MHz, CDCl3) G: 1.41 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 4.16-
4.31 (4H, m, P(OCH2CH3)2), 4.49 (2H, d, 4JHP = 3.7 Hz, NCH2), 7.33-7.42 
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(2H, m, CHar), 7.43-7.49 (1H, m, CHar), 7.54-7.61 (2H, m, CHar) 31P NMR (161 MHz, CDCl3) G: 
-5.98 MS (ESI, pos): m/z 239.1/240.2 (M + H+, 100/12). Rf: 0.20 (7/3 PE/EtOAc). Yield: 82% 
(1.961 mg), yellow oil. 
diethyl (3-(dibenzylamino)prop-1-yn-1-yl)phosphonate 310 
1H NMR (400 MHz, CDCl3) G: 1.421 (3H, t, J = 7.1 Hz, P(OCH2CH3)), 
1.422 (3H, t, J = 7.1 Hz, P(OCH2CH3)), 3.39 (2H, d, 4JHP = 3.7 Hz, 
NCH2Cq), 3.71 (4H, s, NCH2Cq,ar), 4.21 (2H, q, J = 7.1 Hz, P(OCH2CH3)), 
4.23 (2H, q, J = 7.2 Hz, P(OCH2CH3)), 7.24-7.42 (10H, m, CHar) 13C NMR (100 MHz, CDCl3) 
G: 16.2 (d, 3JCP = 7 Hz, P(OCH2CH3)2), 41.5 (d, 3JCP = 4 Hz, NCH2Cq), 57.7 (s, N(CH2Cq,ar)2), 
63.2 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 75.9 (d, 1JCP = 296 Hz, PCq), 96.8 (d, 2JCP = 50 Hz, PCqCq), 
127.4 (CarH), 128.5 (CarH), 128.9 (CarH), 138.3 (Cq,ar) 31P NMR (161 MHz, CDCl3) G: -6.91. MS 
(ESI, pos): m/z 372.2/373.3 (M + H+, 100/16). Rf: 0.18 (7/3 PE/EtOAc). Yield: 57% (4.229 g), 
white crystals. mp: 91-92 °C. 
 
N,N-di-tert-butyl-3-(diethoxyphosphoryl)prop-2-yn-1-ylimidodicarbonate 269 
1H NMR (400 MHz, CDCl3) G: 1.36 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 1.53 
(18H, s, Cq(CH3)3), 4.11-4.19 (4H, m, P(OCH2CH3)2), 4.49 (2H, d, 4JHP = 
3.7 Hz, NCH2) 13C NMR (100 MHz, C6D6) G: 16.0 (d, 3JCP = 7 Hz, P(OCH2CH3)2), 28.0 
(Cq(CH3)3), 36.0 (d, 3JCP = 5 Hz, NCH2), 63.2 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 72.5 (d, 1JCP = 
293 Hz, PCq), 83.7 (Cq(CH3)3), 96.6 (d, 2JCP = 51 Hz, PCqCq), 151.1 (NC(O)) 31P NMR (161 
MHz, CDCl3) G: -7.24. MS (ESI, pos): m/z 236.1/237.2 (M + H+ - Boc - C4H9), 100/16). IR (cm-
1) νmax: 1698 (C=O), 1226 (P=O), 1017 (P-O). Rf: 0.24 (65/35 PE/EtOAc). Yield: 73%, pale 
yellow oil. 
 
diethyl (3-(1,3-dioxoisoindolin-2-yl)prop-1-yn-1-yl)phosphonate 305 
1H NMR (400 MHz, CDCl3) G: 1.36 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
4.11-4.29 (4H, m, P(OCH2CH3)2), 4.58 (2H, d, 4JHP = 3.9 Hz, NCH2), 
7.78 (2H, dd, J = 5.5 Hz, J = 3.0 Hz, CHar), 7.90 (2H, dd, J = 5.5 Hz, 
J = 3.0 Hz, CHar) 13C NMR (100 MHz, CDCl3) G: 16.0 (d, 3JCP = 7 Hz, 
P(OCH2CH3)2), 27.3 (d, 3JCP = 5 Hz, NCH2), 63.4 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 73.4 (d, 1JCP 
= 293 Hz, PCq), 93.5 (d, 2JCP = 51 Hz, PCqCq), 123.7 (2 x CarH), 131.7 (2 x CarH), 134.5 (2 x 
CarH), 166.5 (2 x NC(O)Cq) 31P NMR (161 MHz, CDCl3) G: -7.87. MS (ESI, pos): m/z 
322.1/323.2 (M + H+, 100/16). HRMS: m/z calcd for C15H17NO5P (M + H)+ 322.0839, found 
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322.0836. IR (cm-1) νmax: 2223 (C≡C), 1714 (C=O), 1260 (P=O), 1015 (P-O). Rf: 0.17 (1/1 
PE/EtOAc). Yield: 72% (2311 mg), white crystals. mp: 86-87 °C. 
diethyl (3-(N-(benzyloxy)acetamido)prop-1-yn-1-yl)phosphonate 412a 
1H NMR (400 MHz, CDCl3) G: 1.35 (6H, t, J = 7.1, 
(CH3CH2O)2P), 2.11 (3H, s, CH3C(O)), 4.10-4.20 (4H, m, 
(CH3CH2O)2P), 4.47 (2H, m, JHP = 3.9 Hz, NCH2), 4.97 (2H, s, 
Cq,arCH2), 7.34-7.45 (5H, m, CHar) 13C NMR (100 MHz, CDCl3) 
G: 16.1 (d, JCP = 7 Hz, CH3CH2OP), 20.5 (C(O)CH3), 37.1 (d, JCP = 4 Hz, NCH2), 63.3 (d, JCP = 
5 Hz, CH3CH2OP), 74.1 (d, JCP = 295 Hz, CqCqP), 77.9 (CH2ON ), 94.8 (d, JCP = 51 Hz, CqCqP), 
128.8 (Car), 129.2 (Car), 129.4 (Car), 134.1 (Cq,ar), 173.6 (C(O)) 31P NMR (121 MHz, CDCl3) G: 
-7.66. MS (ESI, pos): m/z 340.1/341.2 (M + H+, 100/20). IR (cm-1) νmax: 1022 (P-O), 1263 
(P=O), 1678 (C=O), 2212 (C≡C) Rf: 0.22 (2/8 PE/EtOAc) Yield: 66%, yellow oil. 
tert-butyl (benzyloxy)(3-(diethoxyphosphoryl)prop-2-yn-1-yl)carbamate 428 
1H NMR (400 MHz, CDCl3) G: 1.35 (6H, t, J = 7.1 Hz, (CH3CH2O)2P), 
1.51 (9H, s, Cq(CH3)3), 4.09-4.20 (4H, m, (CH3CH2O)2P), 4.24 (2H, 
d, JHP = 3.8 Hz, NCH2), 4.93 (2H, s, CH2Cq,ar), 7.30-7.47 (5H, m, 
CHar) 13C NMR (100 MHz, CDCl3) G: 16.0 (d, JCP = 7 Hz, 
(CH3CH2O)2P), 28.1 (Cq(CH3)3), 40.8 (d, JCP = 4 Hz, NCH2), 63.3 (d, 
JCP = 6 Hz, (CH3CH2O)2P), 73.9 (d, JCP = 296 Hz , CqCqP), 78.0 (CH2Cq,ar), 82.9 (Cq(CH3)3), 
95.5 (d, JCP = 51 Hz, CqCqP), 128.5 (CHar), 128.7 (CHar), 129.5 (CHar), 135.2 (Cq,ar), 156.3 
(C(O)OCq(CH3)3) 31P NMR (121 MHz, CDCl3) G: -7.47 MS (ESI, neg): m/z 294.1/295.1 (M + 
H+, 100/15) IR (cm-1) νmax: 1171 (P=O), 1258 (br., P-O), 1711 (C=O) Rf: 0.35 (5/5 PE/EtOAc) 
Rendement: 57%, yellowish oil. 
4.2.2. Procedure for the preparation of dibenzyl alkynyl phosphonates 
Representative example 384: A round-bottom 100 mL flask was charged with 1.81 g (10 mmol) 
Cu(OAc)2, 40 mL NFM, 7860 g (30 mmol) dibenzyl phosphite and 202 mg (2 mmol) 
triethylamine. An oxygen flow was allowed to bubble through the reaction mixture. Next, 1.850 
g (10 mmol) of the alkyne was added and the mixture was magnetically stirred, while keeping 
a steady oxygen flow bubbling through the mixture. Reaction progress was monitored by NMR 
spectroscopy and if necessary, a second partion of dibenzyl phosphite (1.31 g, 5 mmol) was 
added. After 4.5 hours, the reaction was completed and the mixture was diluted in 300 mL 
ethyl acetate and washed twenty times with a 1M aqueous solution of LiCl. The crude mixture 
was purified via column chromatography. 
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dibenzyl (3-(1,3-dioxoisoindolin-2-yl)prop-1-yn-1-yl)phosphonate 384 
1H NMR (400 MHz, CDCl3) G: 4.54 (2H, d, 4JHP = 4.0 Hz, NCH2), 
5.08 (d, 2JCP = 8.7 Hz, P(OCH2)2), 7.26-7.71 (10H, m, 
P(OCH2Cq,arCHar)2), 7.74-7.82 (2H, m, CHar), 7.85-7.94 (2H, m, 
CHar) 13C NMR (100 MHz, CDCl3) G: 27.3 (d, 3JCP = 5 Hz, NCH2), 
68.7 (d, 2JCP = 5 Hz, P(OCH2Cq,ar)2), 73.2 (d, 1JCP = 299 Hz, PCq), 94.4 (d, 2JCP = 51 Hz, PCqCq), 
123.7 (2 x CarH), 128.1 (4 x CarH), 128.56 (2 x CarH), 128.59 (4 x CarH), 131.8 (2 x Cq,ar), 134.5 
(2 x CarH), 135.2 (d, 3JCP = 7 Hz, 2 x Cq,ar), 166.4 (2 x NC(O)Cq). 31P NMR (161 MHz, CDCl3) 
G: -7.43. MS (ESI, pos): m/z 446.1/44.72 (M + H+, 100/27). Rf: 0.19 (65/35 PE/EtOAc). Yield: 
81% (2311 mg), white solid.  
dibenzyl (3-(N-(benzyloxy)acetamido)prop-1-yn-1-yl)phosphonate 412b 
1H NMR (400 MHz, CDCl3) G: 2.09 (3H, s, CH3), 4.43 (2H, d, 
JHP = 3.9 Hz, NCH2), 4.91 (2H, s, CH2ON), 5.06 (2H, s, POCH2), 
5.09 (2H, s, POCH2), 7.28-7.34 (10H, m, CHarCH2OP), 7.34-
7.43 (5H, m, CHarCH2ON).13C NMR (100 MHz, CDCl3) G: 20.5 
(CH3), 37.1 (d, JCP = 3 Hz, NCH2), 68.6 (d, JCP = 5 Hz, POCH2), 73.7 (d, JCP = 300 Hz, CqP), 
77.9 (CH2ON), 95.9 (d, JCP = 51 Hz, CqCqP), 128.0 (CHar), 128.61 (CHar), 128.62 (CHar), 128.8 
(CHar), 129.2 (CHar), 129.4 (CHar), 134.1 (CHar), 135.3 (Cq,ar), 135.4 (Cq,ar), 137.6 (Cq,ar), 173.6 
(C(O)) 31P NMR (121 MHz, CDCl3) G: -7.18. MS (ESI, pos): m/z 464.2/465.3 (M + H+, 100/30) 
IR (cm-1) νmax: 1263 (P=O), 1674 (C=O), 2210-2349 (C≡C) Rf: 0.20 (4/6 PE/EtOAc) Yield: 
20%, yellow oil. 
4.3. Synthesis of 5-bisphosphonomethyl oxazol-2-ones and 5-
phosphonomethylidene oxazolidin-2-ones 
4.3.1. Procedure for the one-pot synthesis of 5-bisphosphonomethyl oxazol-2-
ones 24 
A 100 mL round-bottom flask, equipped with a Claisen piece is flame dried under inert 
atmosphere. Next, the flask is charged with 1.87 mL distilled diisopropylamine (12.5 mmol) 
and 5 mL ether. After the mixture is cooled down to – 78 °C, 12.5 mmol n-butyllithium is added. 
The mixture is allowed to warm to 0 °C and is cooled down to – 78 °C again after one hour. 
Next, a solution of 1.278 g (5.0 mmol) N,N-di-tert-butylprop-2-ynylimidodicarbonate in 15 mL 
ether, is added and mixed for one hour at 0 °C. Subsequently, 1.82 mL (12.5 mmol) diethyl 
chlorophosphate is added at – 78 °C. After one hour at – 78 °C and three hours at – 42 °C, the 
mixture is left to stir at room temperature for another 24 hours. After addition of 30 mL of a 
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saturated NaHCO3 solution, the organic phase is washed with 5 mL of water, dried over 
MgSO4. After filtration and removal of the solvent in vacuo, volatile side-products can be 
removed by additional heating for one hour at 60 °C at 1 mbar. A dark viscous oil is obtained, 
which is redissolved in diethyl ether and stirred overnight with 300 mg silica. After column 
chromatography, orange crystals are obtained. Recrystallization in diethyl ether, the 
bisphosphonomethyl oxazol-2-one is finally obtained in 17% yield as white crystals (385 mg). 
tert-butyl 5-(bis(diethoxyphosphoryl)methyl)oxazolon-4-carboxylate 24 
1H NMR (400 MHz, CDCl3) G: 1.35 (12H, t, J = 6.8 Hz, P(OCH2CH3)2), 
1.55 (9H, s, Cq(CH3)3), 4.20-4.30 (8H, m, P(OCH2CH3)2), 4.80 (1H, t, 
PCHP, 2JHP = 24.8 Hz), 8.77 (1H, br. s, NH). 13C NMR (100 MHz, CDCl3) 
G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 28.1 (Cq(CH3)3), 37.5 (t, 1JCP = 
133 Hz, PCHP), 63.7 (d, 2JCP = 6 Hz, P(OCH2CH3)), 63.8 (d, 2JCP = 7 Hz, 
P(OCH2CH3)), 84.3 (OCq(CH3)3), 117.5 (t, 3JCP = 10 Hz, CqNH), 138.4 (t, 2JCP = 14 Hz, OCqCH), 
152.8 (OC(O)N), 157.3 (t, 4JCP = 3 Hz, (O)COCq(CH3)3). 31P NMR (161 MHz, CDCl3) G: 14.15. 
MS (ESI, pos): m/z 416.1 (M + H+ - C4H9), 472.2 (M + H+). IR (cm-1) νmax: 1780 (C=O), 1716 
(C=O), 1257 (P=O), 1022 (P-O). Rf: 0.12 (40/60 PE/EtOAc). Yield: 17%, white crystals. 
 
4.3.2. Procedure for the gold-catalyzed cyclization towards 5-
phosphonomethylidene oxazolidin-2-ones 283 
A 25 mL round-bottom flask, equipped with a Claisen piece is flame dried under inert 
atmosphere. Next, 30 mg (0.125 mmol) Au(I)Cl, 10 mL THF and 978 mg (2.5 mmol) N,N-di-
tert-butyl-3-(diethoxyphosphoryl)prop-2-ynylimidodicarbonate 269 were added. After stirring 
the mixture for one hour at room temperature, it is filtered twice over a pasteur pipette, filled 
with silica. After concentration of the filtrate in vacuo, a yellow viscous oil is obtained with an 
isolated yield of 98% (802 mg).  
tert-butyl (Z)-5-((diethoxyphosphoryl)methylene)-2-oxooxazolidine-3-carboxylate 283 
1H NMR (400 MHz, CDCl3) G: 1.353 (3H, t, J = 7.1 Hz, P(OCH2CH3)), 
1.354 (3H, t, J = 7.1 Hz, P(OCH2CH3)), 1.55 (9H, s, Cq(CH3)3), 4.14 (2H, 
q, J = 7.0 Hz, P(OCH2CH3)), 4.16 (2H, q, J = 7.0 Hz, P(OCH2CH3)), 4.58 
(2H, dd, 4JHP = 4.8 Hz, 4JHH = 2.1 Hz, NCH2), 4.97 (1H, dt, 2JHP = 5.8 Hz, 
4JHH = 2.1 Hz, CHP). 13C NMR (100 MHz, C6D6) G: 16.7 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 28.0 
(Cq(CH3)3), 47.9 (d, 3JCP = 18 Hz, NCH2), 62.1 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 84.0 (Cq(CH3)3), 
90.9 (d, 1JCP = 197 Hz, CHP), 147.8 (CHPCqOC(O)N or (CH3)3CqOC(O)N), 148.5 
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(CHPCqOC(O)N or (CH3)3CqOC(O)N), 154.4 (d, 2JCP = 4 Hz, (OCqCH2). 31P NMR (161 MHz, 
CDCl3) G: 12.07. IR (cm-1) νmax: 1022 (P-O), 1272 (P=O), 1678 (C=O), 1834 (C=O). MS m/z 
(%): (ESI, pos) 336 (M + H+). Yield: 98%. 
 
4.3.3. Procedure for the synthesis of E-ketophosphonate 287 
A 10 mL round-bottom flask, equipped with a Claisen piece, is flame dried under inert 
atmosphere. After addition of 0.073 ml (0.50 mmol) distilled diisopropylamine, dissolved in 5 
mL ether, 0.50 mmol n-butyllithium is added at – 78 °C. After stirring for one hour at 0 °C, 168 
mg (0.50 mmol) tert-butyl (Z)-5-((diethoxyphosphoryl)methylene)-2-oxooxazolidine-3-
carboxylate 283 was added at – 78 °C. After 10 minutes at – 78 °C, the mixture is quenched 
with two drops of water, filtered over silica and concentrated in vacuo. A slightly yellow oil is 
obtained with an isolated yield of 38% (120 mg).  
tert-butyl (3-(diethoxyphosphoryl)-2-oxopropyl)carbamate 287 
1H NMR (400 MHz, CDCl3) G: 1.34 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
1.45 (9H, s, Cq(CH3)3), 3.12 (2H, d, 2JHP = 22.9 Hz, PCH2), 4.05-4.28 
(6H, m, NCH2, P(OCH2CH3)2), 5.30 (1H, br. s, NH). 13C NMR (100 
MHz, CDCl3) G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 28.3 (Cq(CH3)3), 39.8 (d, 1JCP = 128 Hz, 
CHP), 51.3 ppm (CH2N), 62.9 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 80.0 (Cq(CH3)3), 155.6 
((O)CqOCq(CH3)3), 198.1 (d, 2JCP = 6 Hz, C(O)CH2). 31P NMR (161 MHz, CDCl3) G: 18.75. IR 
(cm-1) νmax: 3304 (NH), 1711 (C=O), 1246 (P=O), 1022 (P-O). MS m/z (%): (ESI, pos) 254 (M 
+ H+ - C4H9). Yield: 38%.  
 
4.4. Synthetic entry into N,N-dialkylamino 
allenylphosphonates 
4.4.1. Procedure for the synthesis of E-enaminophosphonate 297 
E-Enaminophosphonate 297 was prepared according to a literature procedure and spectral 
data were in accordance with those literature values that were available.59 The compound had 
not entirely been characterized however, and is hence described. 
  
V. Experimental procedures 
 
143 
diethyl (Z)-(2-(diethylamino)-2-phenylvinyl)phosphonate 297 
1H NMR (400 MHz, CDCl3) G: 1.08 (6H, t, J = 7.0 Hz, N(CH2CH3)2), 1.10 (6H, 
t, J = 7.1 Hz, P(OCH2CH3)2), 3.00-3.21 (4H, m, N(CH2CH3)2), 3.62-3.88 (4H, 
m, P(OCH2CH3)2), 4.21 (2H, d, 4JHP = 5.2 Hz, CHP), 7.28-7.42 (5H, m, CHar) 
13C NMR (100 MHz, CDCl3) G: 12.7 (N(CH2CH3)2), 16.1 (d, 3JCP = 7 Hz, P(OCH2CH3)2), 43.6 
(N(CH2CH3)2), 41.5 (d, 3JCP = 4 Hz, NCH2Cq), 60.4 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 77.1 (d, 1JCP 
= 218 Hz, PCH), 127.6 (CarH), 128.5 (CarH), 129.0 (CarH), 136.0 (d, 3JCP = 5 Hz, Cq,ar), 162.2 
(d, 2JCP = 19 Hz, PCHCq) 31P NMR (161 MHz, CDCl3) G: 25.08 MS (ESI, pos): m/z 312.2/313.3 
(M + H+, 100/16). Yield: 75% (971 mg), yellowish oil. 
 
4.4.2. Synthesis of phosphonylated pyrazoles 
An excess of a freshly distilled ethereal solution of diazomethane (+/-2.5 mmol) is added to a 
solution of diethyl (3-(13-dioxoisoindolin-2-yl)prop-1-yn-1-yl)phosphonate 305 (0.5 mmol) in 5 
mL THF and allowed to stir at room temperature. Reaction progress was monitored by NMR 
spectroscopy and LC-MS analysis and the mixture was quenched with acetic acid after 4 hours 
until the yellow color of diazomethane had disappeared. Next, 20 mL ethyl acetate was added 
and the organic phase was washed with 5 mL of a saturated NaHCO3 solution. The aqueous 
phase was extracted once with 5 mL ethyl acetate and the combined organic layers were dried 
over MgSO4 and concentrated in vacuo. Purified via pTLC (98/2 EtOAc/MeOH). After a first 
purification via pTLC (3/7 PE/EtOAc) pyrazole 307b could be obtained. Pyrazole 306b was 
isolated together with some impurities, but could be obtained as a pure compound after a 
second purification via pTLC (98/2 EtOAc/MeOH).  
diethyl (4-((1,3-dioxoisoindolin-2-yl)methyl)-1H-pyrazol-5-yl)phosphonate 306b 
1H NMR (400 MHz,CDCl3): G 1.33 (6H, t, J = 7.0 Hz, P(OCH2CH3)2), 4.01-
4.26 (4H, m, P(OCH2CH3)2), 5.08 (2H, s, NCH2), 7.37 (1H, d, J = 2.0 Hz, 
NCHar), 7.70-7.77 (2H, m, CHar), 7.82-7.99 (2H, m, CHar), 7.91 (1H, d, 3JCP = 
1.9 Hz, NCHar), 11.14 (1H, br. s, NH) 13C NMR (100 MHz,CDCl3): G: 16.3 (d, 
3JCP = 7 Hz, P(OCH2CH3)2), 34.1 (NCH2), 62.2 (d, 2JCP = 5 Hz, P(OCH2CH3)2), 
105.1 (d, 1JCP = 219 Hz, PCq), 123.5 (CarH), 132.1 (CqC(O)), 134.1 (CarH), 
138.6 (d, 3JCP = 22 Hz, NCarH), 147.7 (d, 2JCP = 16 Hz, PCqCq), 168.0 (N(C(O))2) 31P NMR (161 
MHz, CDCl3) G: 13.55 MS (ESI, pos): m/z 364.1/365.2 (M + H+, 100/15). Yield: 2% (4 mg), 
yellowish oil. 
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Both 3-phosphonopyrazoles and 5-phosphonopyrazoles can arise from cycloaddition. 
However, the observed coupling constants in 13C NMR are a perfect match with literature 
values for 5-phosphonopyrazoles.299  
diethyl (4-((1,3-dioxoisoindolin-2-yl)methyl)-1-methyl-1H-pyrazol-5-yl)phosphonate 
307b 
1H NMR (400 MHz,CDCl3): G 1.38 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 4.05 
(3H, s, NCH3), 4.11-4.35 (4H, m, P(OCH2CH3)2), 5.06 (2H, s, NCH2), 7.37 
(1H, d, J = 2.0 Hz, NCHar), 7.68-7.77 (2H, m, CHar), 7.82-7.90 (2H, m, CHar) 
13C NMR (100 MHz,CDCl3): G: 16.2 (d, 3JCP = 7 Hz, P(OCH2CH3)2), 32.4 
(NCH2), 39.5 (NCH3), 62.8 (d, 2JCP = 5 Hz, P(OCH2CH3)2), 123.3 (CarH), 126.1 
(d, 2JCP = 20 Hz, PCqCq), 127.7 (d, 1JCP = 212 Hz, PCq), 132.1 (CqC(O)), 134.0 
(CarH), 138.0 (d, 3JCP = 17 Hz, NCarH), 167.9 (N(C(O))2) 31P NMR (161 MHz, CDCl3) G: 5.64 
MS (ESI, pos): m/z 378.1/379.2 (M + H+, 100/16). Yield: 67% (126 mg), yellowish oil. 
 
4.4.3. Procedure of the A³ coupling affording N,N-dibenzyl-1-phenylprop-2-yn-
1-amine 316b 
N,N-dibenzyl-1-phenylprop-2-yn-1-amine 316b was prepared according to a literature 
procedure.377 Full conversion was obtained and the crude mixture was purified via flash 
chromatography (100/0 PE/EtOAc to 98/2 PE/EtOAc). 
N,N-dibenzyl-1-phenylprop-2-yn-1-amine 316b 
1H NMR (400 MHz, CDCl3) G: 2.65 (1H, d, J = 2.3 Hz, CHCq), 3.44 (2H, d, JAB = 
13.5 Hz, N(CHaHb)2), 3.73 (2H, d, JAB = 13.5 Hz, N(CHaHb)2), 4.72 (1H, d, J = 2.0 
Hz), 7.18-7.46 (13H, m, CHar), 7.60-7.73 (2H, m, CHar) MS m/z (%): (ESI, pos) 
312.2/313.3 (M + H+ 100/24). Yield: 5%.  
 
4.4.4. Procedure for the synthesis of diethyl (3-(trimethylsilyl)prop-2-yn-1-
yl)phosphonate 322b 
Diethyl (3-(trimethylsilyl)prop-2-yn-1-yl)phosphonate 322b was prepared according to a 
literature procedure.308 Spectral data were in accordance with literature values. 
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diethyl (3-(trimethylsilyl)prop-2-yn-1-yl)phosphonate 322b 
1H NMR (400 MHz, CDCl3) G: 0.15 (9H, s, Si(CH3)3), 1.36 (6H, t, J = 7.1 
Hz, P(OCH2CH3)2), 2.81 (2H, d, 2JHP = 22.2 Hz, PCH2), 4.12-4.32 (4H, 
m, P(OCH2CH3)2) 31P NMR (161 MHz, CDCl3) G: 20.97 MS (ESI, pos): 
m/z 249.1/250.2 (M + H+, 100/11). Rf: 0.19 (6/4 PE/EtOAc). Yield: 41% (673 mg), transparent 
oil. 
4.5. Synthesis of E-functionalized J-aminophosphonates 
4.5.1. Synthesis of E-alkoxylated derivatives 
Method A 
In a typical experiment, 250 mg (0.78 mmol) alkyne 305 was dissolved in 3 mL THF in a 10 
mL flask. 254 mg (0.78 mmol) Cs2CO3 and one equivalent (0.78 mmol) of the alcohol were 
added. The reaction progress was monitored via TLC or NMR. After completion of the reaction, 
the mixture was quenched with water, concentrated in vacuo, three times extracted with ethyl 
acetate, dried over MgSO4 and concentrated to give the desired product. Adducts 339-351 
were purified via chromatography. 
Method B 
In a typical experiment, 250 mg (0.78 mmol) alkyne 305 was dissolved in 3 mL of the alcohol 
in a 10 mL flask. 254 mg (0.78 mmol) Cs2CO3 was added and the reaction progress was 
monitored via TLC. After completion of the reaction, the mixture was quenched with water, 
concentrated in vacuo, three times extracted with ethyl acetate, dried over MgSO4 and 
concentrated to give the desired product.  
diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-ethoxyallyl)phosphonate 340 
1H NMR (400 MHz, CDCl3) G: 1.28 (3H, t, J = 7.2 Hz, CqOCH2CH3), 
1.32 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 3.29 (2H, d, 2JHP = 20.9 Hz, 
PCH2), 4.09-4.20 (4H, m, P(OCH2CH3)2), 4.33 (2H, q, J = 7.1 Hz, 
CqOCH2CH3), 7.10 (1H, d, 4JHP = 3.7 Hz, NCH), 7.51 (1H, td, J = 7.5 
Hz, J = 1.3 Hz, CHar), 7.56 (1H, td, J = 7.6 Hz, J = 1.6 Hz, CHar), 7.72 (1H, dd, J = 7.5 Hz, J = 
1.4 Hz, CHar), 7.85 (1H, dd, J = 7.4 Hz, J = 1.3 Hz, CHar). 13C NMR (100 MHz, CDCl3) G: 14.0 
(CqOCH2CH3), 16.4 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.4 (d, 1JCP = 145 Hz, PCH2), 61.6 
(CqOCH2CH3), 62.6 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 126.4 (d, 3JCP = 7 Hz, NCH, Cq,ar), 129.1 
(CarH), 129.2 (CarH), 130.0 (CarH), 130.8 (CarH), 132.2 (Cq,ar), 143.8 (d, 2JCP = 8 Hz, OCq), 160.2 
(d, 5JCP = 2 Hz, NC(O)Cq), 168.1 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.54. MS (ESI, 
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pos): m/z 367.9/368.9 (M + H+, 100/19). HRMS: m/z calcd for C17H23NO6P (M + H)+ 368.1258, 
found 368.1269. IR (cm-1) νmax: 1721 (C=O), 1256 (P=O), 1019 (P-O). Yield: 92%, orange oil. 
 
diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-isopropoxyallyl)phosphonate 341 
1H NMR (400 MHz, CDCl3) G: 1.28 (6H, d, J = 6.3 Hz, OCH(CH3)2), 
1.32 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 3.29 (2H, d, 2JHP = 21.0 Hz, 
PCH2), 4.09-4.19 (4H, m, P(OCH2CH3)2), 5.21 (1H, sept, J = 6.2 Hz, 
OCH(CH3)2), 7.10 (1H, d, 4JHP = 3.6 Hz, NCH), 7.48-7.58 (2H, m, 
CHar), 7.69-7.74 (1H, m, CHar), 7.80-7.85 (1H, m, CHar). 13C NMR (100 MHz, CDCl3) G: 16.4 
(d, 3JCP = 6 Hz, P(OCH2CH3)2), 21.7 (OCH(CH3)2), 24.5 (d, 1JCP = 145 Hz, PCH2), 62.6 (d, 2JCP 
= 7 Hz, P(OCH2CH3)2), 69.1 (OCH(CH3)2), 126.4 (d, 3JCP = 7 Hz, NCH, Cq,ar), 129.1 (CarH), 
129.2 (CarH), 130.0 (CarH), 130.7 (CarH), 132.6 (Cq,ar), 143.8 (d, 2JCP = 8 Hz, OCq), 160.3 (d, 
5JCP = 2 Hz, NC(O)Cq), 167.6 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.56 MS (ESI, pos): 
m/z 381.9/382.9 (M + H+, 100/19). HRMS: m/z calcd for C18H25NO6P (M + H)+ 382.1414, found 
382.1412. IR (cm-1) νmax: 1720 (C=O), 1257 (P=O), 1019 (P-O). Yield: 94%, orange oil. 
 
diethyl (Z)-(2-butoxy-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 342 
1H NMR (400 MHz, CDCl3) G: 0.92 (3H, t, J = 7.4 Hz, CH2CH2CH3), 
1.32 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 1.37 (2H, sext., J = 7.6 Hz, 
CH2CH2CH3), 1.58-1.68 (2H, m, CH2CH2CH3), 3.29 (2H, d, 2JHP = 
20.9 Hz, PCH2), 4.09-4.19 (4H, m, P(OCH2CH3)2), 4.28 (2H, t, J = 6.7 
Hz, OCH2CH2), 7.09 (1H, d, 4JHP = 3.6 Hz, NCH), 7.48-7.59 (2H, m, CHar), 7.68-7.74 (1H, m, 
CHar), 7.83-7.88 (1H, m, CHar). 13C NMR (100 MHz, CDCl3) G: 13.6 (CH2CH2CH3), 16.3 (d, 3JCP 
= 6 Hz, P(OCH2CH3)2), 19.0 (CH2CH2CH3), 24.4 (d, 1JCP = 145 Hz, PCH2), 30.4 (CH2CH2CH3), 
62.5 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 65.4 (OCH2CH2), 126.3 (Cq,ar), 126.4 (d, 3JCP = 7 Hz, NCH) 
128.9 (CarH), 129.1 (CarH), 130.0 (CarH), 130.7 (CarH), 132.1 (Cq,ar), 143.8 (d, 2JCP = 8 Hz, OCq), 
160.1 (d, 5JCP = 2 Hz, NC(O)Cq), 168.2 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.53. MS 
(ESI, pos): m/z 395.9/396.9 (M + H+, 100/22). HRMS: m/z calcd for C19H27NO6P (M + H)+ 
396.1571, found 396.1553. IR (cm-1) νmax: 1723 (C=O), 1256 (P=O), 1020 (P-O). Yield: 83%, 
orange oil. 
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diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-phenoxyallyl)phosphonate 343a 
1H NMR (400 MHz, CDCl3) G: 1.28 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
3.28 (2H, d, 2JHP = 20.9 Hz, PCH2), 4.05-4.15 (4H, m, P(OCH2CH3)2), 
7.13 (1H, d, 4JHP = 3.6 Hz, NCH), 7.21-7.30 (3H, m, CHar), 7.41 (2H, 
t, J = 7.9 Hz, CHar), 7.58 (1H, ~t, CHar), 7.64 (1H, ~t, CHar), 7.87 (1H, 
d, J = 7.4 Hz, CHar), 7.94 (1H, d, J = 7.3 Hz, CHar). 13C NMR (100 MHz, CDCl3) G: 16.3 (d, 3JCP 
= 6 Hz, P(OCH2CH3)2), 24.4 (d, 1JCP = 145 Hz, PCH2), 62.6 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 
121.3 (2 x CarH), 125.9 (CarH), 126.5 (Car,q), 126.6 (d, 3JCP = 7 Hz, NCH), 129.1 (CarH), 129.4 
(3 x CarH), 130.1 (CarH), 131.2 (Cq,ar), 131.4 (CarH), 144.2 (d, 2JCP = 8 Hz, OCq), 150.9 (OCq,ar), 
159.8 (d, 5JCP = 2 Hz, NC(O)Cq), 166.6 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.47. MS 
(ESI, pos): m/z 415.8/416.8 (M + H+, 100/23). HRMS: m/z calcd for C21H23NO6P (M + H)+ 
416.1258, found 416.1253. IR (cm-1) νmax: 1743 (C=O), 1244 (P=O), 1020 (P-O). Rf: 0.17 (1/9 
PE/EtOAc). Yield: 47%, orange oil. 
 
diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-phenoxyprop-1-en-1-yl)phosphonate 343b 
1H NMR (400 MHz, CDCl3) G: 1.34 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
4.09-4.19 (4H, m, P(OCH2CH3)2), 4.49 (1H, d, 2JHP = 4.3 Hz, PCH), 
5.17 (2H, d, 4JHP = 1.5 Hz, NCH2), 6.95 (2H, d, J = 7.7 Hz, CHar), 7.19 
(1H, t, J = 7.4 Hz, CHar), 7.34 (2H, t, J = 7.4 Hz, CHar), 7.70-7.76 (2H, 
m, CHar), 7.85-7.91 (2H, m, CHar) 13C NMR (100 MHz, CDCl3) G: 16.3 (d, 3JCP = 7 Hz, 
P(OCH2CH3)2), 37.9 (d, 3JCP = 2 Hz, NCH2), 61.7 (d, 2JCP = 5 Hz, P(OCH2CH3)2), 89.9 (d, 2JCP 
= 201 Hz, PCH), 121.7 (2 x CarH), 123.4 (2 x CarH), 126.0 (CarH), 130.0 (2 x CarH), 132.1 (Car,q), 
134.1 (2 x CarH), 152.9 (Car,q), 167.7 (d, 2JCP = 24 Hz, OCq), 167.9 (2 x NC(O)Cq). 31P NMR 
(161 MHz, CDCl3) G: 19.35. MS (ESI, pos): m/z 415.9/416.8 (M + H+, 100/23). IR (cm-1) νmax: 
1716 (C=O), 1209 (P=O), 1021 (P-O). Rf: 0.26 (1/9 PE/EtOAc). Yield: 4%, orange oil. 
 
diethyl (Z)-(2-(benzyloxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 344 
1H NMR (400 MHz, CDCl3) G: 1.30 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
1.37 (2H, sext., J = 7.6 Hz, CH2CH2CH3), 3.15 (2H, d, 2JHP = 20.8 Hz, 
PCH2), 4.06-4.16 (4H, m, P(OCH2CH3)2), 5.32 (2H, s, OCH2Cq), 7.04 
(1H, d, 4JHP = 3.7 Hz, NCH), 7.34 (5H, br. s, CHar), 7.51(1H, t, J = 7.4 
Hz, CHar), 7.56 (1H, t, J =7.3 Hz, CHar), 7.73 (1H, d, J = 7.4 Hz, CHar), 7.86 (1H, d, J = 7.6 Hz, 
CHar). 13C NMR (100 MHz, CDCl3) G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.2 (d, 1JCP = 145 
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Hz, PCH2), 62.5 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 67.3 (OCH2Cq), 126.4 (d, 3JCP = 8 Hz, NCH) 
128.2 (CarH), 128.3 (2 x CarH), 128.5 (2 x CarH), 129.1 (CarH), 129.1 (CarH), 130.0 (CarH), 131.0 
(CarH), 131.7 (2 x Cq,ar), 135.5 (Cq,ar), 144.0 (d, 2JCP = 8 Hz, OCq), 160.0 (d, 5JCP = 2 Hz, 
NC(O)Cq), 167.9 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.58. MS (ESI, pos): m/z 
429.8/430.8 (M + H+, 100/23). HRMS: m/z calcd for C22H25NO6P (M + H)+ 430.1414, found 
430.1413. IR (cm-1) νmax: 1725 (C=O), 1255 (P=O), 1020 (P-O). Yield: 89%, orange oil. 
 
diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-((5-formylfuran-2-yl)methoxy)allyl) 
phosphonate 346 
1H NMR (400 MHz, CDCl3) G: 1.32 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
3.30 (2H, d, 2JHP = 20.9 Hz, PCH2), 4.08-4.21 (4H, m, P(OCH2CH3)2), 
5.35 (2H, s, CqCH2O), 6.63 (1H, d, J = 3.5 Hz, CHarCq,arCH2), 7.05 
(1H, d, J = 3.8 Hz, CHarCq,arCHO), 7.21 (1H, d, J = 3.6 Hz, NCH), 7.51 
(1H, td, J = 7.6 Hz, J = 1.2 Hz, CHar), 7.58 (1H, td, J = 7.6 Hz, J = 1.2 
Hz, CHar), 7.71 (1H, dd, J = 7.7 Hz, 0.9 Hz, CHar), 7.87 (1H, d, J = 7.5 
Hz, CHar), 9.63 (1H, s, CHO) 13C NMR (100 MHz, CDCl3) G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 
24.4 (d, 1JCP = 145 Hz, PCH2), 58.9 (OCH2Cq,ar), 62.6 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 112.9 
(CHCqCH2O), 121.8 (br. s, CarHCq,arCHO), 126.3 (Cq,arC(O)N), 126.5 (d, 3JCP = 8 Hz, NCH), 
129.0 (CarH), 129.1 (CarH), 130.0 (CarH), 130.8 (Car,qC(O)N), 131.2 (CarH), 144.1 (d, 2JCP = 9 
Hz, OCqCH2P), 152.8 (CqCHO), 155 (CqCH2), 160 (d, 5JCP = 1 Hz, NC(O)Cq), 167.5 (NC(O)Cq), 
177.7 (CHO). 31P NMR (161 MHz, CDCl3) G: 21.55. MS (ESI, pos): m/z 448.2/449.3 (M + H+, 
100/22). HRMS: m/z calcd for C21H23NO8P (M + H)+ 448.1156, found 448.1156. Yield: 33%, 
yellow oil. 
The product was obtained after purification by reversed phase chromatography (5 CVs 5/95 
CH3CN/H2O, over 9 CVs to 12% CH3CN, over 6 CVs to 30% CH3CN, 4 CVs 30% CH3CN, over 
3 CVs to 50% CH3CN, 6 CVs 50% CH3CN). 
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diethyl ((Z)-2-(2-(((Z)-3-(diethoxyphosphoryl)-1-(1,3-dioxoisoindolin-2-yl)prop-1-en-2-
yl)oxy)ethoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 347a 
1H NMR (400 MHz, CDCl3) G: 1.30 (12H, t, J = 7.1 Hz, 2 x 
P(OCH2CH3)2), 3.22 (4H, dd, 1JHP = 20.9 Hz, 3JHH = 0.8 Hz, 2 x 
PCH2), 4.10 (4H, q, 3JHP = 7.1 Hz, 2 x P(OCHaHbCH3)2), 4.12 (4H, 
q, 3JHP = 7.1 Hz, 2 x P(OCHaHbCH3)2), 4.53 (4H, s, OCH2CH2O), 
6.99 (2H, d, 4JHP = 3.8 Hz, 2 x NCH), 7.50 (2H, td, 3JHH = 7.6 Hz, 
4JHH = 1.3 Hz, CHar), 7.56 (2H, td, 3JHH = 7.6 Hz, 4JHH = 1.4 Hz, 
CHar), 7.65 (2H, dd, 3JHH = 7.6 Hz, 4JHH = 1.2 Hz, CHar), 7.86 (2H, d, 3JHH = 7.8 Hz, 4JHH = 1.0 
Hz, CHar) 13C NMR (100 MHz, CDCl3) G: 16.3 (d, 3JCP = 6 Hz, 2 x P(OCH2CH3)2), 24.2 (d, 1JCP 
= 144 Hz, 2 x PCH2), 62.5 (d, 2JCP = 7 Hz, 2 x P(OCH2CH3)2), 63.0 (2 x OCH2), 126.1 (2 x Car,q), 
126.4 (d, 3JCP = 8 Hz, 2 x NCH), 128.8 (2 x CarH), 128.9 (2 x CarH), 129.9 (2 x CarH), 130.9 (2 
x CH), 131.4 (2 x Car,q), 143.9 (d, 2JCP = 9 Hz, OCq), 159.7 (2 x NC(O)Cq), 167.8 (2 x 
NC(O)Cq31P NMR (161 MHz, CDCl3) G: 21.50. MS (ESI, pos): m/z 705.3/706.3/707.3 (M + H+, 
100/33/9). HRMS: m/z calcd for C32H39N2O12P2 (M + H)+ 705.1973, found 705.1990. Yield: 
74%, yellow oil. 
The product was obtained after purification by reversed phase chromatography (2 CVs 30/70 
CH3CN/H2O, over 20 CVs to 100% CH3CN, 2 CVs 100% CH3CN). 
diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-(2-hydroxyethoxy)allyl)phosphonate 347b 
1H NMR (400 MHz, CDCl3) G: 1.34 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
3.33 (2H, dd, 2JHP = 21.0 Hz, 4JHP = 0.8 Hz, PCH2), 3.82-3.91 (2H, m, 
CH2OH), 4.10-4.21 (4H, m, P(OCH2CH3)2), 4.46-4.53 (2H, m, CH2O), 
7.08 (1H, d, J = 3.8 Hz, NCH), 7.50-7.60 (2H, m, CHar), 7.64-7.69 (1H, 
m, CHar), 7.90-7.95 (1H, m, CHar) 13C NMR (100 MHz, CDCl3) G: 16.4 (d, 3JCP = 6 Hz, 2 x 
P(OCH2CH3)2), 24.5 (d, 1JCP = 145 Hz, 2 x PCH2), 60.7 (CH2O), 62.8 (d, 2JCP = 7 Hz, 2 x 
P(OCH2CH3)2), 67.3 (CH2OH), 125.1 (Car,q), 126.3 (d, 3JCP = 8 Hz, NCH), 128.7 (CarH), 128.8 
(CarH), 130.3 (CarH), 130.7 (CarH), 132.1 (Car,q), 144.1 (d, 2JCP = 2 Hz, OCq), 159.9 (d, 5JCP = 2 
Hz, NC(O)Cq), 168.8 (NC(O)Cq31P NMR (161 MHz, CDCl3) G: 21.44. MS (ESI, pos): m/z 
384.2/385.2 (M + H+, 100/19). HRMS: m/z calcd for C17H23NO7P (M + H)+ 384.1207, found 
384.1217. Yield: 13%, yellow oil. 
The product was obtained after purification by reversed phase chromatography (2 CVs 30/70 
CH3CN/H2O, over 20 CVs to 100% CH3CN, 2 CVs 100% CH3CN). 
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(Z)-3-((3-(diethoxyphosphoryl)-1-(1,3-dioxoisoindolin-2-yl)prop-1-en-2-yl)oxy)-2-
hydroxypropyl palmitate 348 (major isomer) 
1H NMR (400 MHz, CDCl3) G: 0.83-0.92 (3H, m, CH3), 1.18-1.38 
(30H, m, (CH2)12, P(OCH2CH3)2), 1.52-1.70 (2H, m, CH2), 2.23-
2.41 (2H, m, CH2), 3.30 (2H, d, 2JHP = 20.9 Hz, 3JHH = 2.7 Hz, 
PCH2), 4.04-4.29 (7H, m, P(OCH2CH3)2, Hc, Hd, He), 4.30-4.44 
(1H, m, Ha), 4.45-4.52 (1H, m, Hb), 4.57 (1H, br. s, OH), 7.03-
7.12 (1H, m, NCH), 7.46-7.71 (3H, m, CHar), 7.83-7.98 (1H, m, CHar) 13C NMR (100 MHz, 
CDCl3) G: 14.1 (CH3), 16.4 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 22.7 (CH2), 24.4 (d, 1JCP = 145 Hz, 
PCH2), 24.9 (CH2), 29.1 (CH2), 29.3 (CH2), 29.3 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6-26.7 (m, 
5 x CH2), 31.9 (CH2), 34.1 (CH2), 62.8 (d, 2JCP = 7 Hz, P(OCH2CH3)), 62.8 (d, 2JCP = 7 Hz, 
P(OCH2CH3)), 64.8 (OCHdHe), 66.8 (OCHaHb), 67.7 (OCHc), 125.0 (Cq,ar), 126.4 (d, 3JCP = 8 
Hz, NCH), 128.7 (CarH), 128.7 (CarH), 130.3 (CarH), 130.7 (CarH), 130.8 (Car,qC(O)N), 131.8 
(Cq,ar), 144.1 (d, 2JCP = 10 Hz, OCqCH2P), 152.8 (CqCHO), 159.8 (d, 5JCP = 3 Hz, NC(O)Cq), 
168.6 (NC(O)Cq), 173.7 (C(O)O). 31P NMR (161 MHz, CDCl3) G: 21.34. MS (ESI, pos): m/z 
652.5/653.5/654.5 (M + H+, 100/42/9). HRMS: m/z calcd for C34H55NO9P (M + H)+ 652.3609, 
found 652.3608. Crude yield: 92%, orange oil. 
 
methyl (Z)-N-((benzyloxy)carbonyl)-O-(3-(diethoxyphosphoryl)-1-(1,3-dioxoisoindolin-
2-yl)prop-1-en-2-yl)serinate 349 
1H NMR (400 MHz, CDCl3) G: 1.29 (3H, t, J = 7.0 Hz, P(OCH2CH3)), 
1.29 (3H, t, J = 7.0 Hz, P(OCH2CH3)), 1.37 (2H, sext., J = 7.6 Hz, 
CH2CH2CH3), 3.17 (2H, d, 2JHP = 20.9 Hz, PCH2), 3.72 (3H, s, OCH3), 
4.04-4.18 (4H, m, P(OCH2CH3)2), 4.61 (1H, dd, 2JHH = 11.2 Hz, 3JHH = 
3.9 Hz, OCH2), 4.69 (1H, td, 3JNH =8.4 Hz, 3JHH = 3.9 Hz, OCH), 4.90 
(1H, dd, 2JHH = 11.2 Hz, 3JHH = 3.9 Hz, OCH2), 5.14 (2H, s, OCH2Cq), 6.71 (1H, d, J = 8.6 Hz, 
NH), 6.97 (1H, d, 4JHP = 3.8 Hz, NCH), 7.29-7.40 (5H, m, CHar), 7.45-7.59(3H, m, CHar), 7.86-
7.96 (1H, m, CHar) 13C NMR (100 MHz, CDCl3) G: 16.4 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.3 (d, 
1JCP = 145 Hz, PCH2), 52.7 (OCH3), 53.7 (OCH), 62.6 (d, 2JCP = 6 Hz, P(OCH2CH3)), 62.6 (d, 
2JCP = 7 Hz, P(OCH2CH3)), 64.8 (OCH2), 67.1 (OCH2Cq), 125.1 (Cq), 126.7 (d, 3JCP = 8 Hz, 
NCH) 128.2 (CarH), 128.3 (2 x CarH), 128.5 (3 x CarH), 128.6 (CarH), 130.1 (CarH), 130.8 (CarH), 
131.4 (Cq,ar), 136.2 (Cq,ar), 143.9 (d, 2JCP = 10 Hz, OCq), 156.2 (NC(O)O), 159.4 (d, 5JCP = 2 Hz, 
NC(O)Cq), 168.2 (NC(O)Cq), 170.0 (C(O)O). 31P NMR (161 MHz, CDCl3) G: 21.30. MS (ESI, 
pos): m/z 575.3/576.3/577.3 (M + H+, 100/30/6). HRMS: m/z calcd for C27H32N2O10P (M + H)+ 
V. Experimental procedures 
 
151 
575.1789, found 575.1773. Rf: 0.19 (2/8 PE/EtOAc). Yield: 63%, yellow oil. [D]D = -5.4° (c 0.4, 
acetone) 
 
methyl (Z)-2-(((benzyloxy)carbonyl)amino)-3-(4-((3-(diethoxyphosphoryl)-1-(1,3-
dioxoisoindolin-2-yl)prop-1-en-2-yl)oxy)phenyl)propanoate 350a 
1H NMR (400 MHz, CDCl3) G: 1.28 (6H, t, J = 7.1 Hz, 
P(OCH2CH3)2), 3.05 (2H, m, CHCH2Cq), 3.26 (2H, d, 2JHP = 20.9 
Hz, PCH2), 3.73 (3H, s, OCH3), 4.04-4.20 (4H, m, 
P(OCH2CH3)2), 4.66 (1H, m, CHNH), 5.11 (2H, s, OCH2Cq), 5.29 
(1H, d, J = 8.0 Hz, NH), 7.08-7.22 (5H, m, NCH, CHar), 7.28-7.41 (5H, m, CHar), 7.58 (1H, td, 
J = 7.5 Hz, J = 1.4 Hz, CHar), 7.58 (1H, td, J = 7.6 Hz, J = 1.5 Hz, CHar), 7.84 (1H, dd, J = 7.6 
Hz, J = 1.3 Hz, CHar), 7.93 (1H, dd, J = 7.5 Hz, J = 1.1 Hz, CHar). 13C NMR (100 MHz, CDCl3) 
G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.4 (d, 1JCP = 144 Hz, PCH2), 37.4 (CHCH2Cq), 52.5 
(OCH3), 54.9 (CHNH), 62.6 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 66.8 (OCH2Cq), 121.4 (CarH), 126.4 
(Cq,ar), 126.6 (d, 3JCP = 7 Hz, NCH), 128.0 (CarH), 128.1 (CarH), 128.5 (2 x CarH), 129.1 (CarH), 
129.4 (CarH), 130.1 (CarH), 130.2 (2 x CarH), 131.2 (Cq,ar), 131.4 (CarH), 133.8 (Cq,ar), 136.3 
(Cq,ar), 144.2 (br. s, OCq), 150.0 (OCq,ar), 155.1 (NC(O)O), 159.8 (br. s, NC(O)Cq), 166.5 
(NC(O)Cq), 171.9 (C(O)O). 31P NMR (161 MHz, CDCl3) G: 21.43. MS (ESI, pos): m/z 
651.3/652.3/653.3 (M + H+, 100/37/9). HRMS: m/z calcd for C19H27NO6P (M + H)+ 396.1571, 
found 396.1553. Rf: 0.19 (4/6 PE/EtOAc). Yield: 52%, dark yellow oil. [D]D = 0.0° (c 0.3, 
acetone) 
 
methyl (Z)-2-(((benzyloxy)carbonyl)amino)-3-(4-((1-(diethoxyphosphoryl)-3-(1,3-
dioxoisoindolin-2-yl)prop-1-en-2-yl)oxy)phenyl)propanoate 350b 
1H NMR (400 MHz, CDCl3) G: 1.33 (6H, t, J = 7.1 Hz, 
P(OCH2CH3)2), 3.02 (1H, dd, J = 13.7 Hz, J = 6.1 Hz, 
CHaHbCHN), 3.11 (1H, dd, J = 14.0 Hz, J = 5.7 Hz, CHaHbCHN), 
3.69 (3H, s, OCH3), 4.08-4.19 (4H, m, P(OCH2CH3)2), 4.46 (1H, 
d, 2JHP = 5 Hz, PCH), 4.56-4.67 (1H, m, CHNH), 5.06 (2H, s, 
OCH2Cq), 5.15 (2H, d, J = 1.5 Hz, CHNH), 5.21 (1H, d, J = 8.2 Hz, NH), 6.85 (2H, d, J = 8.5 
Hz, CHar), 7.06 (2H, d, J = 8.4 Hz, CHar), 7.27-7.38 (5H, m, CHar), 7.72 (2H, dd, J = 5.5 Hz, J 
= 3.1 Hz, CHar), 7.87 (2H, dd, J = 5.5 Hz, J = 3.0 Hz, CHar). 13C NMR (100 MHz, CDCl3) G: 16.3 
(d, 3JCP = 7 Hz, P(OCH2CH3)2), 37.6 (CHCH2Cq), 37.8 (d, 3JCP = 2 Hz, NCH2), 52.4 (OCH3), 
54.8 (CHNH), 61.7 (d, 2JCP = 5 Hz, P(OCH2CH3)2), 67.0 (OCH2Cq), 90.0 (d, 3JCP = 201 Hz, 
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CHP), 121.8 (2 x CarH), 123.4 (2 x CarH), 128.1 (2 x CarH), 128.2 (CarH), 128.5 (2 x CarH), 130.1 
(2 x CarH), 132.1 (2 x Cq,ar), 133.7 (Cq,ar), 134.1 (2 x CarH), 136.1 (Cq,ar), 151.9 (OCq,ar), 155.5 
(NC(O)O), 167.6 (d, 2JCP = 24 Hz, OCq), 167.9 (2 x NC(O)Cq), 171.7 (C(O)O). 31P NMR (161 
MHz, CDCl3) G: 19.24. MS (ESI, pos): m/z 651.3/652.3/653.3 (M + H+, 100/37/9). Rf: 0.19 (4/6 
PE/EtOAc). Yield: 9%, dark yellow oil. [D]D = 0.0° (c 0.2, acetone) 
 
diethyl ((Z)-2-(((3aS,4S,6S,6aS)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-3-(1,3-dioxoisoindolin-2-
yl)allyl)phosphonate 351 
1H NMR (400 MHz, CDCl3) G: 1.33 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
1.33 (3H, s, CqCH3), 1.55 (3H, s, CqCH3), 3.29 (1H, dd, 2JHP = 20.7, 
Hz, 3Jab = 16.5 Hz, PCHaHb), 3.36 (1H, dd, 2JHP = 21.1 Hz, 3Jab = 16.5 
Hz, PCHaHb), 4.10-4.22 (4H, m, P(OCH2CH3)2), 4.40-4.49 (1H, m, 
OCHCH2), 4.49-4.63 (2H, m, OCH2CH), 4.76 (1H, dd, J = 6.4 Hz, J = 
3.4 Hz, NCHCHO or OCH2CHCHO), 4.79 (1H, dd, J = 6.4 Hz, J = 2.1 
Hz, NCHCHO or OCH2CHCHO), 5.44 (1H, dd, 3JHH = 8.0 Hz, 4JNH = 1.1 Hz, CHC(O)), 5.71 
(1H, d, J = 2.1 Hz, NCHO), 7.07 (1H, d, 4JHP = 3.6 Hz, NCH), 7.20 (1H, d, 3JHH = 8.1 Hz, 
CHCHC(O)), 7.48-7.67 (3H, m, CHar), 7.91 (1H, td, J =7.8 Hz, J = 0.9 Hz, CHar), 8.89 (1H, br. 
s, NH). 13C NMR (100 MHz, CDCl3) G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.3 (d, 1JCP = 145 
Hz, PCH2), 25.2 (CqCH3), 27.1 (CqCH3), 62.7 (d, 2JCP = 6 Hz, P(OCH2CH3)2), 65.2 (OCH2CH), 
81.0 (OCH2CHCHO), 84.5 (NCHCHO), 84.8 (OCHCH2), 93.8 (NCHO), 102.3 (CHC(O)), 114.2 
(Cq(CH3)2), 123.4 (Cq,ar), 126.4 (d, 3JCP = 7 Hz, NCH), 128.7 (CarH), 128.9 (CarH), 130.2 (CarH), 
131.1 (CarH), 131.3 (Cq,ar), 141.6 (CHCHC(O)), 144.3 (d, 2JCP = 8 Hz, OCq), 150.2 (NCONH), 
160.0 (d, 5JCP = 2 Hz, NC(O)Cq), 163.6 (CHC(O)), 167.8 (NC(O)Cq). 31P NMR (161 MHz, 
CDCl3) G: 21.60. MS (ESI, pos): m/z 606.3/607.3/608.3 (M + H+, 100/30/7). Rf: 0.16 (99/1 
EtOAc/MeOH). Yield: 64%, white foam.  
 
4.5.2. Synthesis of 3-imidoallenylphosphonate 338 
64 mg (0.20 mmol) phosphonylated alkyne was dissolved in 3 mL of the THF in a 10 mL flask. 
65 mg (0.20 mmol) Cs2CO3 was added and the reaction progress was monitored via NMR. 
After 3 hours the mixture was quenched with water, concentrated in vacuo, three times 
extracted with ethyl acetate, dried over MgSO4 and concentrated. The 3-
aminoallenylphosphonate was isolated in 16% yield after preparative TLC. 
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diethyl (3-(1,3-dioxoisoindolin-2-yl)propa-1,2-dien-1-yl)phosphonate 338 
1H NMR (400 MHz, CDCl3) G: 1.36 (3H, t, J = 6.8 Hz, P(OCH2CH3)), 1.38 (3H, t, 
J = 6.8 Hz, P(OCH2CH3)), 4.15-4.28 (4H, m, P(OCH2CH3)2), 6.08 (1H, dd, 3JHH = 
6.4 Hz, 2JHP = 1.7 Hz, PCH), 7.21 (1H, dd, 4JHP = 12.8 Hz, 3JHH = 6.4 Hz, NCH), 7.76 (2H, dd, 
J = 5.5 Hz, J = 3.0 Hz, CHar), 7.89 (2H, dd, J = 5.5 Hz, J = 3.1 Hz, CHar) 13C NMR (100 MHz, 
CDCl3) G: 16.3 (d, 3JCP = 7 Hz, P(OCH2CH3)), 16.4 (d, 3JCP = 7 Hz, P(OCH2CH3)), 62.7 (d, 2JCP 
= 6 Hz, P(OCH2CH3)), 62.9 (d, 2JCP = 6 Hz, P(OCH2CH3)), 89.9 (d, 3JCP = 17 Hz, NCH), 90.8 
(d, 1JCP = 194 Hz, PCH), 123.8 (CarH), 131.9 (CarH), 134.6 (CarH), 164.9 (NC(O)Cq), 209.6 
(CHCqCH) 31P NMR (161 MHz, CDCl3) G: 11.47. MS (ESI, pos): m/z 322.1/323.2 (M + H+, 
100/14). Rf: 0.33 (2/8 PE/EtOAc). Yield: 16%, orange oil. 
 
4.5.3 Procedure for the alkoxide exchange reaction 
Phosphonate 340 (101 mg, 0.28 mmol) was dissolved in 4 mL MeOH. After addition of 90 mg 
(0.28 mmol) Cs2CO3, the mixture was refluxed and reaction progress was monitored via 1H 
NMR. After 2 hours, the mixture was quenched with 1 mL water. The solvent was evaporated 
under reduced pressure and 1 mL water and 10 mL EtOAc were added. The organic layer was 
separated and dried over MgSO4. After evaporation of the solvent in vacuo, the desired product 
was obtained in 61% yield. 
diethyl (Z)-(3-(1,3-dioxoisoindolin-2-yl)-2-methoxyallyl)phosphonate 360b 
1H NMR (400 MHz, CDCl3) G: 1.32 (6H, t, J = 7.0 Hz, P(OCH2CH3)2), 
3.30 (2H, dd, 2JHP = 21.1 Hz, 4JHH = 0.9 Hz, PCH2), 3.69 (3H, s, 
CqOCH3), 4.08-4.20 (4H, m, P(OCH2CH3)2), 7.09 (1H, d, 4JHP = 3.6 
Hz, 4JHH = 1.0 Hz, NCH), 7.51 (1H, td, J = 7.4 Hz, J = 1.3 Hz, CHar), 
7.56 (1H, td, J = 7.5 Hz, J = 1.4 Hz, CHar), 7.68-7.72 (1H, m, CHar), 7.85-7.90 (1H, m, CHar). 
31P NMR (161 MHz, CDCl3) G: 21.54. MS (ESI, pos): m/z 354.1/355.2 (M + H+, 100/17). Yield: 
61%, orange oil. 
 
4.5.4. Procedure for the addition of haloalcohols 
In a typical experiment, 160 mg (0.50 mmol) alkyne 305 was dissolved in 1.5 mL THF in a 10 
mL flask. 163 mg (0.50 mmol) Cs2CO3 and 33 μL (0.50 mmol) of the haloalcohol were added 
at room temperature. Reaction progress was monitored via NMR spectroscopy. After 
completion of the reaction, the mixture was quenched with water, concentrated in vacuo, three 
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times extracted with ethyl acetate, dried over MgSO4 and concentrated to give the desired 
product. 
diethyl (Z)-(2-(2-chloroethoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 363a 
1H NMR (400 MHz, CDCl3) G: 1.32 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
3.30 (2H, d, 2JHP = 20.9 Hz, PCH2), 3.73 (3H, t, J = 5.8 Hz, 
OCH2CH2Cl), 4.06-4.22 (4H, m, P(OCH2CH3)2), 4.54 (2H, t, J = 5.8 
Hz, OCH2CH2Cl), 7.09 (1H, d, 4JHP = 3.7 Hz, NCH), 7.52 (1H, td, J = 
7.5 Hz, J = 1.3 Hz, CHar), 7.58 (1H, td, J = 7.4 Hz, J = 1.4 Hz, CHar), 7.73 (1H, dd, J = 7.56Hz, 
J = 1.2 Hz, CHar), 7.87 (1H, dd, J = 7.5 Hz, J = 1.1 Hz, CHar). 13C NMR (100 MHz, CDCl3) G: 
16.4 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.5 (d, 1JCP = 145 Hz, PCH2), 41.2 (OCH2CH2Cl), 62.6 
(d, 2JCP = 7 Hz, P(OCH2CH3)2), 65.1 (OCH2CH2Cl), 126.4 (Cq,ar ), 126.5 (d, 3JCP = 8 Hz, NCH), 
129.07 (CarH), 129.13 (CarH), 130.1 (CarH), 131.1 (CarH), 131.3 (Cq,ar), 144.0 (d, 2JCP = 8 Hz, 
OCq), 159.9 (d, 5JCP = 2 Hz, NC(O)Cq), 167.8 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.49. 
MS (ESI, pos): m/z 402.1/404.1 (M + H+, 100/32). Yield: 80%, yellow oil. 
 
diethyl (Z)-(2-(3-chloropropoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 363b 
1H NMR (400 MHz, CDCl3) G: 1.32 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
2.12 (2H, quint, J = 6.1 Hz, CH2CH2Cl), 3.31 (2H, d, 2JHP = 21.0 Hz, 
PCH2), 3.55 (t, J = 6.5 Hz, CH2Cl), 4.06-4.21 (4H, m, P(OCH2CH3)2), 
4.43 (2H, t, J = 6.0 Hz, CqOCH2), 7.10 (1H, d, 4JHP = 3.7 Hz, NCH), 
7.52 (1H, td, J = 7.7 Hz, J = 1.4 Hz, CHar), 7.57 (1H, td, J = 7.8 Hz, J = 1.4 Hz, CHar), 7.69 (1H, 
dd, J = 7.4 Hz, J = 1.3 Hz, CHar), 7.86 (1H, dd, J = 7.6 Hz, J = 1.1 Hz, CHar). 13C NMR (100 
MHz, CDCl3) G: 16.3 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.3 (d, 1JCP = 145 Hz, PCH2), 31.4 
(CH2CH2Cl), 41.2 (CH2Cl), 62.2 (CqOCH2), 62.5 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 126.0 (Cq,ar), 
126.4 (d, 3JCP = 7 Hz, NCH) 128.87 (CarH), 128.89 (CarH), 130.0 (CarH), 130.8 (CarH), 132.2 
(Cq,ar), 144.0 (d, 2JCP = 9 Hz, OCq), 159.9 (d, 5JCP = 2 Hz, NC(O)Cq), 168.0 (NC(O)Cq). 31P NMR 
(161 MHz, CDCl3) G: 21.41. MS (ESI, pos): m/z 416.1/418.1 (M + H+, 100/33). Yield: 84%, 
yellow oil. 
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diethyl (Z)-(2-(3-bromopropoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 363c 
1H NMR (400 MHz, CDCl3) G: 1.33 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
2.12 (2H, quint, J = 6.3 Hz, CH2CH2Br), 3.31 (2H, dd, 2JHP = 21.0 Hz, 
3JHH = 0.8 Hz, PCH2), 3.41 (t, J = 6.6 Hz, CH2Br), 4.14 (2H, q, J = 7.2 
Hz, P(OCH2CH3)), 4.16 (2H, q, J = 7.2 Hz, P(OCH2CH3)), 4.35 (2H, t, 
J = 5.9 Hz, CqOCH2), 7.11 (1H, d, 4JHP = 3.8 Hz, NCH), 7.52 (1H, td, J = 7.4 Hz, J = 1.3 Hz, 
CHar), 7.57 (1H, td, J = 7.4 Hz, J = 1.3 Hz, CHar), 7.69 (1H, dd, J = 7.4 Hz, J = 1.5 Hz, CHar), 
7.86 (1H, dd, J = 7.3 Hz, J = 1.5 Hz, CHar). 13C NMR (100 MHz, CDCl3) G: 16.4 (d, 3JCP = 6 Hz, 
P(OCH2CH3)2), 24.5 (d, 1JCP = 145 Hz, PCH2), 29.6 (CH2CH2Br), 31.7 (CH2Br), 62.6 (d, 2JCP = 
7 Hz, P(OCH2CH3)2), 63.3 (CqOCH2), 126.2 (Cq,ar), 126.6 (d, 3JCP = 8 Hz, NCH) 128.98 (CarH), 
129.01 (CarH), 130.1 (CarH), 130.9 (CarH), 131.8 (Cq,ar), 144.0 (d, 2JCP = 8 Hz, OCq), 160.0 (d, 
5JCP = 2 Hz, NC(O)Cq), 168.2 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.47. MS (ESI, pos): 
m/z 460.1/462.1 (M + H+, 100/97). Yield: 22%, yellow oil. 
 
4.5.5.  Procedure for the synthesis of iodopropoxy derivative 363d 
302 mg (1.98 mmol) NaI was added to a mixture of diethyl (Z)-(2-(3-bromopropoxy)-3-(1,3-
dioxoisoindolin-2-yl)allyl)phosphonate 363c in THF at room temperature. Reaction progress 
was monitored via NMR spectroscopy. After completion of the reaction, the mixture was 
quenched with water, concentrated in vacuo, three times extracted with ethyl acetate, dried 
over MgSO4 and concentrated to give the desired product. 
diethyl (Z)-(2-(3-iodopropoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 363d 
1H NMR (400 MHz, CDCl3) G: 1.33 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
2.18 (2H, quint, J = 6.4 Hz, CH2CH2I), 3.18 (t, J = 6.9 Hz, CH2I), 3.32 
(2H, dd, 2JHP = 21.0 Hz, 3JHH = 0.6 Hz, PCH2), 4.13 (2H, q, J = 7.1 Hz, 
P(OCH2CH3)), 4.15 (2H, q, J = 7.1 Hz, P(OCH2CH3)), 4.42 (2H, t, J = 
6.0 Hz, CqOCH2), 7.10 (1H, d, 4JHP = 3.8 Hz, NCH), 7.52 (1H, td, J = 7.5 Hz, J = 1.3 Hz, CHar), 
7.57 (1H, td, J = 7.5 Hz, J = 1.3 Hz, CHar), 7.69 (1H, dd, J = 7.5 Hz, J = 1.4 Hz, CHar), 7.86 
(1H, dd, J = 7.5 Hz, J = 1.4 Hz, CHar). 13C NMR (100 MHz, CDCl3) G: 1.33 (CH2I), 16.4 (d, 3JCP 
= 7 Hz, P(OCH2CH3)2), 24.6 (d, 1JCP = 145 Hz, PCH2), 32.4 (CH2CH2I), 62.6 (d, 2JCP = 7 Hz, 
P(OCH2CH3)2), 65.2 (CqOCH2), 126.2 (Cq,ar), 126.6 (d, 3JCP = 7 Hz, NCH) 128.97 (CarH), 128.99 
(CarH), 130.0 (CarH), 130.9 (CarH), 131.8 (Cq,ar), 144.0 (d, 2JCP = 9 Hz, OCq), 160.0 (d, 5JCP = 3 
Hz, NC(O)Cq), 168.1 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 21.46. MS (ESI, pos): m/z 
508.0/509.0 (M + H+, 100/20). Yield: 55%, yellow oil. 
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4.5.6. Procedure for the preparation of phosphonylated chromenes 
In a typical experiment, 160 mg (0.50 mmol) alkyne 305 was dissolved in 1.5 mL THF in a 10 
mL flask. 163 mg (0.50 mmol) Cs2CO3 and 61 mg (0.50 mmol) salicylaldehyde were added at 
room temperature. Reaction progress was monitored via NMR spectroscopy. After completion 
of the reaction, the mixture was quenched with water, concentrated in vacuo, three times 
extracted with ethyl acetate and dried over MgSO4. Chromenes 366 and 368-369 were purified 
via pTLC (3/7 PE/EtOAc). 
2-((2H-chromen-2-ylidene)methyl)isoindoline-1,3-dione 366 
1H NMR (400 MHz, CDCl3) G: 5.47 (1H, s, mi), 5.81 (1H, d, J = 1.3 Hz, 
Ma), 6.14 (1H, d, J = 10.0 Hz, Ma), 6.33 (1H, d, J = 9.8 Hz, mi), 6.61 (1H, 
d, J = 9.8 Hz, Ma), 6.83 (1H, d, J = 8.1 Hz, mi), 6.90-7.01 (2H, m, Ma), 
7.04-7.10 (2H, m, mi), 7.14 (1H, td, J = 7.8 Hz, J = 1.3 Hz, mi), 7.23 (1H, td, J = 7.8 Hz, J = 1.3 
Hz, Ma), 7.71-7.80 (3H, m), 7.85-7.94 (3H, m) MS (ESI, pos): m/z 290.1/291.2 (M + H+, 
100/21). Yield: 3%, transparent liquid. 
A mixture of E/Z isomers was obtained. The predominant stereoisomer is described as Ma 
(Major), the other one as mi (minor). The stereoisomers were isolated in a 78/22 ratio. 
Assignment of the stereoisomerism was not possible. Given the low amount of isolated 
product, no complete characterization could be done.  
 
diethyl (2-((1,3-dioxoisoindolin-2-yl)methylene)-2H-chromen-3-yl)phosphonate 368 and 
369 
1H NMR (400 MHz, CDCl3) G: 1.17 (6H, t, J = 7.2 Hz, P(OCH2CH3)2), 
3.83-4.01 (4H, m, P(OCH2CH3)2), 5.93 (1H, t, 4JHP = 1.5 Hz, C10H), 
6.97 (1H, d, J = 8.2 Hz, C8H), 7.03 (1H, td, J = 7.5 Hz, J = 1.0 Hz, 
C6H), 7.22 (1H, dd, J = 7.6 Hz, J = 1.4 Hz, C5H), 7.36 (1H, td, J = 7.9 
Hz, J = 1.4 Hz, C7H), 7.71 (1H, d, J = 19.5 Hz, C3H), 7.70-7.80 (2H, m, C13H), 7.83-7.94 (2H,m, 
C14H). 13C NMR (100 MHz, CDCl3) G: 15.9 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 63.0 (d, 2JCP = 5 Hz, 
P(OCH2CH3)2), 98.9 (C10), 115.2 (C8), 118.9 (d, 1JCP = 189 Hz, C2), 119.0 (d, 3JCP = 15 Hz, C4), 
123.0 (C6), 123.2 (2 x C13), 128.7 (C5), 132.9 (2 x C12), 133.3 (C7), 133.9 (C14), 140.3 (d, 2JCP= 
7 Hz, C3), 144.1 (d, 2JCP = 6 Hz, C1), 153.9 (d, 4JCP = 2 Hz, C9), 168.3 (2 x C11). 31P NMR (161 
MHz, CDCl3) G: 13.99. MS (ESI, pos): m/z 426.1/427.2 (M + H+, 100/24). Yield: 1%, 
transparent liquid. 
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1H NMR (400 MHz, CDCl3) G: 1.44 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 4.17-
4.32 (4H, m, P(OCH2CH3)2), 6.05 (1H, s, C10H), 6.82 (1H, d, J = 8.2 Hz, 
C8H), 7.00 (1H, t, J = 7.4 Hz, C6H), 7.19 (1H, dd, J = 7.7 Hz, J = 1.3 Hz, 
C5H), 7.27 (1H, td, J = 11.7 Hz, J = 1.4 Hz, C7H), 7.56 (1H, d, J = 18.9 
Hz, C3H), 7.70-7.81 (2H, m, C13H), 7.84-7.98 (2H,m, C14H). 13C NMR (100 
MHz, CDCl3) G: 16.3 (d, 3JCP = 7 Hz, P(OCH2CH3)2), 62.8 (d, 2JCP = 4 Hz, 
P(OCH2CH3)2), 96.6 (C10), 115.5 (C8), 118.9 (d, 1JCP = 187 Hz, C2), 119.1 (d, 3JCP = 15 Hz, C4), 
123.3 (C6), 123.4 (2 x C13), 128.5 (C5), 132.5 (2 x C12), 132.6 (C7), 134.1 (C14), 140.3 (d, 2JCP= 
6 Hz, C3), 145.6 (d, 2JCP = 19 Hz, C1), 153.4 (d, 4JCP = 1 Hz, C9), 166.4 (2 x C11). 31P NMR (161 
MHz, CDCl3) G: 13.46. MS (ESI, pos): m/z 426.1/427.2 (M + H+, 100/24). Yield: 6%, 
transparent liquid. 
Both stereoisomers are described, but the stereochemistry of the double bond was not 
determined. 
 
4.5.7.  Procedure for the synthesis of E-hydroaminated products 
In a typical experiment, 250 mg (0.78 mmol) alkyne 305 was dissolved in 3 mL THF in a 10 
mL flask. 254 mg (0.78 mmol) Cs2CO3 and 57 mg (0.78 mmol) diethylamine were added at 
room temperature. Reaction progress was monitored via NMR spectroscopy. After completion 
of the reaction, the mixture was quenched with water, concentrated in vacuo, three times 
extracted with ethyl acetate, dried over MgSO4 and concentrated to give 283 mg (0.56 mmol) 
of the desired product. Dibenzylamine addition product 370c required purification. As 
hydrolysis occurred during normal phase column chromatography, the mixture was purified via 
reversed phase column chromatography (5 CV 90/10 H2O/CH3CN, 20 CV 90/10 to 70/30 
H2O/CH3CN, 10 CV 70/30 H2O/CH3CN). Only small amounts of product were obtained, which 
did not allow a full characterization. 
diethyl (Z)-(2-(diethylamino)-3-(1,3-dioxoisoindolin-2-yl)prop-1-en-1-yl)phosphonate 
370a 
1H NMR (400 MHz, CDCl3) G: 0.99 (3H, t, J = 7.0 Hz, N(CH2CH3)2), 
1.33 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 3.14 (4H, q, J = 7.0 Hz, 
N(CH2CH3)2), 4.03-4.21 (5H, m, P(OCH2CH3)2, PCH), 5.10 (2H, s, 
NCH2), 7.68-7.73 (2H, m, CHar), 7.79-7.87 (2H, m, CHar). 13C NMR 
(100 MHz, CDCl3) G: 12.0 (N(CH2CH3)2), 16.3 (d, 3JCP = 7 Hz, P(OCH2CH3)2), 36.9 (d, 2JCP = 4 
Hz, NCH2), 43.2 (N(CH2CH3)2), 60.8 (d, 2JCP = 4 Hz, P(OCH2CH3)2), 80.2 (d, 1JCP = 211 Hz), 
123.1 (2 x CarH), 134.0 (2 x CarH), 131.7 (2 x Cq,ar), 156.7 (d, 2JCP = 19 Hz, NCq), 167.4 (2 x 
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NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 24.96. MS (ESI, pos): m/z 395.2/396.3 (M + H+, 
100/18). Yield: 72%, transparent liquid. 
 
diethyl (Z)-(2-(dibenzylamino)-3-(1,3-dioxoisoindolin-2-yl)prop-1-en-1-yl)phosphonate 
370c. 
1H NMR (400 MHz, CDCl3) G: 1.26 (6H, t, J = 7.1 Hz, P(OCH2CH3)2), 
4.48 (4H, s, J = 7.0 Hz, N(CH2Cq,ar)2), 3.96-4.12 (4H, m, 
P(OCH2CH3)2), 4.25 (1H, d, J = 5 Hz, PCH), 5.33 (2H, d, J = 1.0 Hz, 
NCH2), 6.96-7.07 (6H, CHar), 7.07-7.17 (4H, CHar), 7.53-7.63 (4H, m, 
CHar). 31P NMR (161 MHz, CDCl3) G: 23.68. MS (ESI, pos): m/z 519.2/520.3 (M + H+, 100/31). 
Yield: 28%, white crystals. 
 
4.5.8.  Procedure for the synthesis of hydrophosphonylated products 
In a typical experiment, 80 mg (0.25 mmol) alkyne 305 was dissolved in 1.0 mL THF in a 10 
mL flask. 81 mg (0.25 mmol) Cs2CO3 and 35 mg (0.25 mmol) diethyl phosphite were added at 
room temperature. Reaction progress was monitored via NMR spectroscopy. After completion 
of the reaction, the mixture was quenched with water, concentrated in vacuo, three times 
extracted with ethyl acetate and dried over MgSO4. The mixture was purified via pTLC (4/6 
PE/EtOAc). Compounds 372 and 374 were obtained as a 38/62 mixture in a combined 18% 
yield and spectral data were easily extracted from the NMR spectra of the mixture of the two 
regioisomers. 
diethyl (Z)-(3-diethylphosphoryl-1-(1,3-dioxoisoindolin-2-yl) prop-1-en-2-
yl)phosphonate 372 
1H NMR (400 MHz, CDCl3) G: 1.08-1.34 (12H, m, 2 x P(OCH2CH3)2), 
2.75 (2H, ddd, 2JHP = 21.1 Hz, 3JHP = 3.7, Hz, 4JHH = 1.2 Hz, PCH2), 
3.87-4.25 (8H, m, 2 x P(OCH2CH3)2), 6.38 (1H, ddd, 3JHP = 2.6 Hz, 
4JHP = 1.4 Hz, 4JHH = 1.4 Hz, NCH), 7.53-7.68 (2H, m, CHar), 7.75-
7.90 (2H, m CHar). 13C NMR (100 MHz, CDCl3) G: 16.1-16.8 (m, 2 x P(OCH2CH3)2), 25.0 (d, 
1JCP = 145 Hz, PCH2), 62.5 (d, 2JCP = 4 Hz, P(OCH2CH3)), 62.6 (d, 2JCP = 4 Hz, P(OCH2CH3)), 
64.7 (d, 2JCP = 7 Hz, P(OCH2CH3)), 64.9 (d, 2JCP = 4 Hz, P(OCH2CH3)), 99.8 (d, 1JCP = 208 Hz, 
PCq), 107.8 (d, JCP = 9 Hz, NCH), 125.3 (2 x CarH), 132.7 (d, JCP = 3 Hz, 2 x Cq,ar), 133.8 
(CarH),165.0 (d, JCP = 6 Hz, NC(O)Cq), 166.6 (d, JCP = 2 Hz, NC(O)Cq). 31P NMR (161 MHz, 
CDCl3) G: 11.06, 21.32. MS (ESI, pos): m/z 460.1/461.1 (M + H+, 100/20).  
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tetraethyl (3-(1,3-dioxoisoindolin-2-yl)prop-1-ene-1,2-diyl)bis(phosphonate) 374 
1H NMR (400 MHz, CDCl3) G: 1.08-1.34 (12H, m, 2 x P(OCH2CH3)2), 
3.87-4.25 (8H, m, 2 x P(OCH2CH3)2), 4.28 (1H, ddd, 2JHH = 15.9 Hz, 
3JHP = 4.2, Hz, J = 1.4 Hz, NCHaHb), 4.58 (1H, ddd, 2JHP = 7.5 Hz, J = 
1.4 Hz, CHP), 4.65 (1H, ddd, 2JHH = 15.7 Hz, 3JHP = 3.0 Hz, 4JHH = 1.0 
Hz, NCHaHb), 7.53-7.68 (2H, m, CHar), 7.75-7.90 (2H, m CHar). 13C NMR (100 MHz, CDCl3) G: 
16.1-16.8 (m, 2 x P(OCH2CH3)2), 48.1 (d, 2JCP = 17 Hz, NCHaHb), 61.6 (d, 2JCP = 6 Hz, 
P(OCH2CH3)), 61.7 (d, 2JCP = 6 Hz, P(OCH2CH3)), 64.4 (d, 2JCP = 2 Hz, P(OCH2CH3)), 64.5 (d, 
2JCP = 2 Hz, P(OCH2CH3)), 84.4 (d, 1JCP = 196 Hz, CHP), 125.0 (CarH), 125.4 (CarH), 131.8 
(CarH), 131.7 (d, 4JCP = 4 Hz, Cq,ar), 133.6 (CarH), 140.7 (d, 4JCP = 9 Hz, Cq,ar), 144.0 (dd, 1JCP = 
254 Hz, 2JCP = 9 Hz, PCq), 166.4 (d, JCP = 2 Hz, NC(O)Cq). 172.9 (d, JCP = 10 Hz, NC(O)Cq). 
31P NMR (161 MHz, CDCl3) G: 11.66, 14.97. MS (ESI, pos): m/z 460.1/461.1 (M + H+, 100/20).  
diethyl (Z)-(2-(diethylamino)-3-(1,3-dioxoisoindolin-2-yl)prop-1-en-1-yl)phosphonate 
373. 
1H NMR (400 MHz, CDCl3) G: 1.23 (3H, t, J = 7.1 Hz, P(OCH2CH3)), 1.28 
(3H, t, J = 7.1 Hz, P(OCH2CH3)), 1.30 (3H, t, J = 7.1 Hz, P(OCH2CH3)), 1.33 
(3H, t, J = 7.0 Hz, P(OCH2CH3)), 3.93-4.30 (8H, m, 2 x P(OCH2CH3)2), 4.44 
(1H, dt, 2JHH = 16.9 Hz, J = 2.6 Hz, NCHaHb), 5.00 (1H, dt, J = 7.5 Hz, J = 
1.8 Hz, CHP), 5.18 (1H, ddd, 2JHH = 17.0 Hz, J = 2.8 Hz, J = 1.6 Hz, NCHaHb), 7.62-7.74 (2H, 
m, CHar), 7.84-7.90 (1H, m, CHar), 7.92-7.99 (1H, m, CHar). 13C NMR (100 MHz, CDCl3) G: 
16.2-16.5 (m, 2x P(OCH2CH3)2), 47.5 (NCH2), 43.2 (N(CH2CH3)2), 61.6 (d, JCP = 5 Hz, 
P(OCH2CH3)), 61.7 (d, JCP = 5 Hz, P(OCH2CH3)), 64.5 (d, 2JCP = 3 Hz, P(OCH2CH3)), 64.6 (d, 
2JCP = 3 Hz, P(OCH2CH3)), 84.7 (d, 1JCP = 204 Hz), 98.0 (d, 1JCP = 208 Hz), 125.0 (CarH), 125.4 
(CarH), 131.9 (CarH), 132.0 (d, 4JCP = 3 Hz, Cq,ar), 133.7 (CarH), 140.5 (d, 4JCP = 10 Hz, Cq,ar), 
170.3 (d, 2JCP = 25 Hz, NC(O)Cq), 172.8 (NC(O)Cq). 31P NMR (161 MHz, CDCl3) G: 12.25, 
18.51. MS (ESI, pos): m/z 460.1/461.1 (M + H+, 100/20). Yield: 12%, transparent liquid. 
 
4.5.9 Procedure for the synthesis of malonate addition products 
In a typical experiment, 160 mg (0.50 mmol) alkyne 305 was dissolved in 1.5 mL THF in a 10 
mL flask. 163 mg (0.50 mmol) Cs2CO3 and 80 mg (0.50 mmol) diethyl malonate were added 
at room temperature. Reaction progress was monitored via NMR spectroscopy. After 
completion of the reaction, the mixture was quenched with water, concentrated in vacuo, three 
times extracted with ethyl acetate and dried over MgSO4. The mixture was purified via pTLC 
(3/7 PE/EtOAc). 
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diethyl 2-(1-diethoxyphosphoryl)-3-(1,3-dioxoisoindolin-2-yl) propan-2-
ylidene)malonate 378 
1H NMR (400 MHz, CDCl3) G: 1.23-1.40 (12H, m, 2 x C(O)OCH2CH3, 
P(OCH2CH3)2), 3.39 (2H, d, 2JHP = 24.6 Hz, PCH2), 4.01-4.19 (4H, m, 
P(OCH2CH3)2), 4.25 (2H, q, J = 7.1 Hz, C(O)OCH2CH3), 4.31 (2H, q, J = 
7.1 Hz, C(O)OCH2CH3), 4.77 (2H, d, 4JHP = 2.5 Hz, NCH2), 7.68-7.79 (2H, 
m, CHar), 7.81-7.92 (2H, m, CHar). 13C NMR (100 MHz, CDCl3) G: 13.94 
(C(O)OCH2CH3), 13.97 (C(O)OCH2CH3), 16.3 (d, 3JCP = 6 Hz, 
P(OCH2CH3)2), 29.5 (d, 2JCP = 133 Hz, PCH2), 39.9 (d, 3JCP = 1 Hz, NCH2), 61.4 
(C(O)OCH2CH3), 61.7 (C(O)OCH2CH3), 62.4 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 123.6 (2 x CarH), 
130.3 (d, 3JCP = 12 Hz, Cq(C(O))2), 132.0 (Cq,ar), 134.3 (CarH), 143.2 (d, 2JCP = 12 Hz, PCH2Cq), 
164.2 (d, 4JCP = 4 Hz, C(O)), 164.9 (d, 4JCP = 4 Hz, C(O)), 167.9 (2 x NC(O)Cq). 31P NMR (161 
MHz, CDCl3) G: 23.36. MS (ESI, pos): m/z 482.3/4.83.3 (M + H+, 100/23). Yield: 10%, 
transparent liquid. 
 
4.6. Synthesis of diethyl nucleosides phosphonate prodrugs 
4.6.1. Preparation of acetonide-protected nucleoside phosphonates 
In a typical experiment, 321 mg (1.00 mmol) alkyne 305 was dissolved in 8 mL THF in a 25 
mL flask. 326 mg (1.00 mmol) Cs2CO3 and 323 mg (1.00 mmol) acetonide-protected 
nucleoside were added. The reaction progress was monitored via NMR spectroscopy. After 
completion of the reaction, the mixture was quenched with water, concentrated in vacuo, three 
times extracted with ethyl acetate, dried over MgSO4 and concentrated. Adenosine derivative 
398 was purified via normal phase column chromatography. Guanosine derivatives 400 and 
407 were purified via preparative LC. 
diethyl ((Z)-2-(((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-3-(1,3-dioxoisoindolin-2-
yl)allyl)phosphonate 398 
1H NMR (400 MHz, CD3OD) G: 1.32 (6H, t, J = 7.1 Hz, 
P(OCH2CH3)2), 1.40 (3H, s, CqCH3), 1.60 (3H, s, CqCH3), 3.46 (2H, 
d, 2JHP = 20.9 Hz, PCH2), 4.08-4.23 (4H, m, P(OCH2CH3)2), 4.40-
4.62 (3H, m, OCHCH2, OCH2CH), 4.99 (1H, dd, J = 6.2 Hz, J = 2.6 
Hz, NCHCHO or OCH2CHCHO), 5.45 (1H, dd, J = 6.2 Hz, J = 2.1 
Hz, NCHCHO or OCH2CHCHO), 6.15 (1H, d, J = 2.1 Hz, NCHO), 
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7.08 (1H, d, 4JHP = 4.0 Hz, NCH), 7.54-7.69 (3H, m, CHar), 7.77-7.82 (1H, m, CHar), 8.12 (1H, 
s, CHar), 8.13 (1H, s, CHar). 13C NMR (100 MHz, CD3OD) G: 16.7 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 
24.3 (d, 1JCP = 144 Hz, PCH2), 25.6 (CqCH3), 27.4 (CqCH3), 64.2 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 
66.4 (OCH2CH), 83.0 (NCHCHO or OCH2CHCHO), 85.4 (NCHCHO or OCH2CHCHO), 86.0 
(OCHCH2), 92.5 (NCHO),115.3 (Cq(CH3)2), 120.5 (Cq,ar), 127.20 (Cq,ar), 127.22 (d, 3JCP = 9 Hz, 
NCH), 130.25 (CarH), 130.34 (CarH), 131.6 (CarH), 132.4 (Cq,ar), 132.6 (CarH), 141.2 
((N)CHNCHO), 146.2 (d, 2JCP = 10 Hz, OCq), 150.1 (Cq,ar), 153.9 (NCHNCq,arN), 157.2 (Cq,ar), 
161.8 (d, 5JCP = 3 Hz, NC(O)Cq), 168.7 (NC(O)Cq). 31P NMR (161 MHz, CD3OD) G: 26.67. MS 
(ESI, pos): m/z 629.2/630.3 (M + H+, 100/30). Rf: 0.18 (9/1 EtOAc/MeOH). Yield: 35%, white 
foam.  
 
diethyl ((Z)-2-(((3aR,4R,6R,6aR)-6-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-3-(1,3-dioxoisoindolin-2-
yl)allyl)phosphonate 400 
Due to low amounts of product, not all signals could be observed and assigned. 
1H NMR (400 MHz, CD3OD) G: 1.30 (3H, t, J = 7.0 Hz, 
P(OCH2CH3)), 1.31 (3H, t, J = 7.0 Hz, P(OCH2CH3)), 1.37 (3H, 
s, CqCH3), 1.56 (3H, s, CqCH3), 3.44 (2H, d, 2JHP = 20.9 Hz, 
PCH2), 4.07-4.20 (4H, m, P(OCH2CH3)2), 4.35-4.48 (2H, m), 
4.55-4.64 (1H, m), 5.00 (1H, dd, J = 6.1 Hz, J = 3.0 Hz), 5.33 
(1H, dd, J = 6.1 Hz, J = 1.4 Hz), 5.98 (1H, d, J = 1.4 Hz, NCHO), 
7.08 (1H, d, 4JHP = 4.0 Hz, NCH), 7.53-7.69 (3H, m, CHar), 7.74 (1H, s, CHar), 7.77-7.84 (1H, 
m, CHar). 13C NMR (100 MHz, CD3OD) G: 16.7 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.3 (d, 1JCP = 
144 Hz, PCH2), 25.7 (CqCH3), 27.5 (CqCH3), 64.2 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 66.6 
(OCH2CH), 83.1 (NCHCHO or OCH2CHCHO), 85.5 (NCHCHO or OCH2CHCHO), 86.2 
(OCHCH2), 92.1 (NCHO), 115.1 (Cq(CH3)2), 118.2 (Cq,ar), 127.15 (NCH), 127.23 (Cq,ar), 130.3 
(CarH), 130.5 (CarH), 131.7 (CarH), 132.4 (Cq,ar), 132.6 (CarH), 146.2 (d, 2JCP = 10 Hz, OCq), 
152.2 (Cq,ar), 155.3 (Cq,ar), 159.5 (Cq), 161.2 (d, 5JCP = 3 Hz, NC(O)Cq), 168.8 (NC(O)Cq). 31P 
NMR (161 MHz, CD3OD) G: 22.80. MS (ESI, pos): m/z 645.2/646.3 (M + H+, 100/29). Yield: 
5%, white foam.  
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diethyl ((Z)-2-(((3aR,4R,6R,6aR)-6-(2-amino-6-(((Z)-3-(diethoxyphosphoryl)-1-(1,3-
dioxoisoindolin-2-yl)prop-1-en-2-yl)oxy)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 407 
Due to low amounts of product, no 13C NMR data could be collected. 
1H NMR (400 MHz, CD3OD) G: 1.24-1.34 (12H, m, 2 x 
P(OCH2CH3)2), 1.36 (3H, s, CqCH3), 1.56 (3H, s, CqCH3), 
3.46 (2H, d, 2JHP = 20.9 Hz, PCH2), 3.47 (2H, d, 2JHP = 
20.9 Hz, PCH2), 4.01-4.24 (8H, m, P(OCH2CH3)2), 4.30-
4.41 (1H, m), 4.46.-4.62 (2H, m), 4.91-4.99 (1H, m), 5.37 
(1H, d, J = 6.1 Hz), 5.98 (1H, br. s, NCHO), 7.09 (1H, d, 
4JHP = 3.9 Hz, NCH), 7.13 (1H, d, 4JHP = 4.0 Hz, NCH), 
7.54-7.81 (7H, m, CHar), 8.00 (1H, s, CHar), 8.03-8.11 (1H, 
m, CHar). 31P NMR (161 MHz, CD3OD) G: 22.64. MS (ESI, pos): m/z 966.3/967.4 (M + H+, 
100/45). Yield: 2%, white foam.  
 
4.6.2. Preparation of acetonide-deprotected nucleoside phosphonates 
In a typical experiment, 36 mg (0.06 mmol) addition product 351 was dissolved in 3 mL of a 
1/1 THF/H2O mixture in a 10 mL flask. 14 mg (0.07 mmol) pTsOH∙H2O was added before the 
mixture was refluxed. The reaction progress was monitored via NMR spectroscopy. After 
completion of the reaction, the mixture was washed with 2 mL of a saturated NaHCO3 solution. 
The aqueous phase was extracted three times with 5 mL CH2Cl2, dried over MgSO4 and 
concentrated under reduced pressure to afford 17 mg (0.03 mmol) of the deprotected 
nucleoside phosphonate.  
diethyl ((Z)-2-(((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 
401 
1H NMR (400 MHz, CDCl3) G: 1.21 (3H, t, J = 7.1 Hz, P(OCH2CH3)2), 
1.22 (3H, t, J = 7.1 Hz, P(OCH2CH3)2), 3.41 (2H, d, 2JHP = 20.9 Hz, 
PCH2), 3.88-3.98 (2H, m, OCH2CHCHO, NCHCHO), 3.98-4.11 (5H, 
m, P(OCH2CH3)2, OCHCH2), 4.41-4.52 (2H, m, OCH2CH), 5.18 (1H, 
dd, 3JHH = 8.1 Hz, CHC(O)), 5.70 (1H, d, J = 3.6 Hz, NCHO), 7.03 
(1H, d, 4JHP = 4.0 Hz, NCH), 7.39 (1H, d, 3JHH = 8.1 Hz, CHCHC(O)), 
7.52-7.65 (2H, m, CHar), 7.66-7.77 (1H, m, CHar), 7.91 (1H, m, CHar). 13C NMR (100 MHz, 
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CDCl3) G: 16.7 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.3 (d, 1JCP = 145 Hz, PCH2), 64.3 (d, 2JCP = 7 
Hz, P(OCH2CH3)2), 65.7 (OCH2CH), 71.2 (OCH2CHCHO), 75.3 (NCHCHO), 82.8 (OCHCH2), 
91.6 (NCHO), 102.5 (CHC(O)) 127.3 (Cq,ar), 127.4 (d, 3JCP = 8 Hz, NCH), 130.32 (CarH), 130.34 
(CarH), 131.9 (CarH), 132.7 (CarH), 132.9 (Cq,ar), 141.9 (CHCHC(O)), 146.4 (d, 2JCP = 10 Hz, 
OCq), 150.1 (NCONH), 161.6 (d, 5JCP = 3 Hz, NC(O)Cq), 165.9 (CHC(O)), 169.0 (NC(O)Cq). 
31P NMR (161 MHz, CDCl3) G: 22.83. MS (ESI, pos): m/z 566.1/567.2 (M + H+, 100/25). Yield: 
50%, white foam.  
 
diethyl ((Z)-2-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 402 
1H NMR (400 MHz, CD3OD) G: 1.20-1.36 (6H, m, P(OCH2CH3)2), 
3.43 (2H, d, 2JHP = 20.9 Hz, PCH2), 4.04-4.19 (4H, m, 
P(OCH2CH3)2), 4.25-4.32 (1H, m, OCHCH2 or NCHCHO or 
OCH2CHCHO), 4.39 (1H, t, J = 5.2 Hz, OCHCH2 or NCHCHO or 
OCH2CHCHO), 4.45 (1H, dd, JAB = 12.2 Hz, J = 3.8 Hz, 
OCHAHBCH), 4.63 (1H, dd, JAB = 12.2 Hz, J = 3.8 Hz, OCHAHBCH), 
4.67 (1H, t, J = 4.8 Hz, OCHCH2 or NCHCHO or OCH2CHCHO), 6.00 (1H, d, J = 4.2 Hz, 
NCHO), 7.07 (1H, d, 4JHP = 3.9 Hz, NCH), 7.54-7.75 (3H, m, CHar), 7.80-7.89 (1H, m, CHar), 
8.08 (1H, s, CHar), 8.12 (1H, s, CHar). 13C NMR (100 MHz, CD3OD) G: 16.6 (d, 3JCP = 6 Hz, 
P(OCH2CH3)2), 24.3 (d, 1JCP = 144 Hz, PCH2), 64.2 (d, 2JCP = 7 Hz, P(OCH2CH3)2), 66.0 
(OCHAHBCH), 71.8 (OCHCH2 or NCHCHO or OCH2CHCHO), 75.2 (OCHCH2 or NCHCHO or 
OCH2CHCHO), 83.3 (OCHCH2 or NCHCHO or OCH2CHCHO), 90.4 (NCHO), 120.4 (Cq,ar), 
127.2 (d, 3JCP = 8 Hz, NCH), 127.4 (Cq,ar), 130.38 (CarH), 130.40 (CarH), 131.7 (CarH), 132.7 
(CarH), 132.7 (Cq,ar), 140.3 ((N)CHNCHO), 146.1 (d, 2JCP = 10 Hz, OCq), 150.5 (Cq,ar), 153.9 
(NCHNCq,arN), 157.2 (Cq,ar), 161.7 (d, 5JCP = 2 Hz, NC(O)Cq), 169.0 (NC(O)Cq). 31P NMR (161 
MHz, CD3OD) G: 22.83. MS (ESI, pos): m/z 589.2/590.3 (M + H+, 100/26). Yield: 80%, white 
foam.  
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diethyl ((Z)-2-(((2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 
404 
1H NMR (400 MHz, CD3OD) G: 1.30 (3H, t, J = 7.1 Hz, 
P(OCH2CH3)), 1.31 (3H, t, J = 7.2 Hz, P(OCH2CH3)), 3.44 (2H, 
d, 2JHP = 20.9 Hz, PCH2), 4.07-4.18 (4H, m, P(OCH2CH3)2), 
4.18-4.25 (1H, m, OCHCH2), 4.37 (1H, t, J = 5.4 Hz, 
OCH2CHCHO or NCHCHO), 4.47-4.69 (3H, m, OCH2CH + 
OCH2CHCHO or NCHCHO), 5.82 (1H, d, J = 4.4 Hz, NCHO), 
7.08 (1H, d, 4JHP = 4.0 Hz, NCH), 7.56-7.76 (4H, m, CHar), 7.81-7.87 (1H, m, CHar). 13C NMR 
(100 MHz, CD3OD) G: 16.7 (d, 3JCP = 6 Hz, P(OCH2CH3)2), 24.3 (d, 1JCP = 144 Hz, PCH2), 64.3 
(d, 2JCP = 7 Hz, P(OCH2CH3)2), 66.3 (OCH2CH), 72.0 (NCHCHO or OCH2CHCHO), 75.1 
(NCHCHO or OCH2CHCHO), 83.2 (OCHCH2), 90.2 (NCHO), 118.1 (Cq,ar), 127.2 (NCH), 127.3 
(Cq,ar), 130.46 (CarH), 130.48 (CarH), 131.8 (CarH), 132.72 (CarH), 132.74 (Cq,ar), 138.0 (CarH), 
146.2 (d, 2JCP = 10 Hz, OCq), 152.9 (Cq,ar), 155.2 (Cq,ar), 159.3 (NCq(O)), 161.8 (d, 5JCP = 3 Hz, 
NC(O)Cq), 169.1 (NC(O)Cq). 31P NMR (161 MHz, CD3OD) G: 22.88. MS (ESI, pos): m/z 
605.2/606.3 (M + H+, 100/27). Yield: 87%, white foam.  
 
diethyl ((Z)-2-(((2R,3S,4R,5R)-5-(2-amino-6-(((Z)-3-(diethoxyphosphoryl)-1-(1,3-
dioxoisoindolin-2-yl)prop-1-en-2-yl)oxy)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)-3-(1,3-dioxoisoindolin-2-yl)allyl)phosphonate 408 
Due to low amounts of product, no 13C NMR data could be collected. 
1H NMR (400 MHz, CD3OD) G: 1.22-1.35 (12H, m, 2 x 
P(OCH2CH3)2), 3.43 (2H, d, 2JHP = 20.9 Hz, PCH2), 3.45 
(2H, d, 2JHP = 21.1, Hz, PCH2), 4.02-4.16 (8H, m, 
P(OCH2CH3)2), 4.17-4.23 (1H, m), 4.30-4.35 (1H, m), 
4.44-4.61 (3H, m), 5.89 (1H, d, J = 4.4 Hz, NCHO), 7.04 
(1H, d, 4JHP = 4.2 Hz, NCH), 7.10 (1H, d, 4JHP = 4.2 Hz, 
NCH), 7.56-7.74 (6H, m, CHar), 7.78-7.88 (2H, m, CHar), 
7.96 (1H, s, CHar), 8.02-8.09 (1H, m, CHar). 31P NMR (161 
MHz, CD3OD) G: 22.69, 22.82. MS (ESI, pos): m/z 926.3/927.4 (M + H+, 100/42). Yield: 70%, 
white foam.  
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4.7. Synthetic entry into fosmidomycin-inspired antimalarial 
analogues 
4.7.1. Procedure for the synthesis of N-(benzyloxy)acetamide 37 
N-(benzyloxy)acetamide was prepared according to a literature procedure.365 The desired 
compound was obtained as a mixture of rotamers (major rotamer depicted as M, minor rotamer 
depicted as m). Spectral data were in accordance with literature values. 
N-(benzyloxy)acetamide 37 
1H NMR (400 MHz, CDCl3) G: 1.72-1.97 (3H, br. s, CH3, M), 1.97-2.22 (3H, 
br. s, CH3, m), 4.63-4.87 (2H, br. s, CH2, m), 4.87-5.02 (2H, s, CH2, M), 7.30-
7.48 (5H, br. s, CHar), 7.65-7.91 (1H, br. s, NH, m), 7.91-8.14 (1H, br. s, NH, 
M) MS (ESI, pos): m/z 166.1/167.2 (M + H+, 100/9). Rf: 0.25 (1/1 PE/EtOAc) 
Yield: 82%, yellow oil. 
 
4.7.2.  Procedure for the alkylation of N-(benzyloxy)acetamide N-(benzyloxy)-N-
(prop-2-yn-1-yl)acetamide 37 
In a typical experiment, 2.607 g N-benzyloxyacetamide 37 (15.8 mmol) is dissolved in 25 ml 
acetone in a 50 ml round-bottom flask. To this solution, 2.184 g K2CO3 (15.8 mmol, 1.0 equiv) 
and 2.1 mL (18.9 mmol) of a 80% propargyl bromide solution in toluene was added. The 
mixture is refluxed until the starting material disappears according to TLC analysis. The solvent 
is removed in vacuo and the crude mixture is purified on column. N-(benzyloxy)-N-(prop-2-yn-
1-yl)acetamide is isolated in 75% yield. 
N-(benzyloxy)acetamide N-(benzyloxy)-N-(prop-2-yn-1-yl)acetamide 410 
1H NMR (400 MHz, CDCl3) G: 2.10 (3H, s, CH3), 2.27 (1H, t, J = 2.5 Hz, 
CqCH), 4.38 (2H, d, J = 2.4 Hz, NCH2), 5.00 (2H, s, CH2O), 7.35-7.51 (5H, 
m, CHar). 13C NMR (100 MHz, CDCl3) G: 20.6 (CH3), 36.7 (NCH2), 72.1 
(CqCH), 77.6 (Cq,arCH2O), 78.2 (CqCH), 128.7 (CHar), 129.1 (CHar), 129.4 
(CHar), 134.4 (Cq,ar), 173.4 (C(O)) MS (ESI, pos): m/z 204.1/205.2 (M + H+, 100/15) HRMS: 
m/z calcd for C12H13NO2 (M + H)+ 204.0946, found 204.1026. IR (cm-1) νmax: 1666 (C=O) Rf: 
0.18 (9/1 PE/EtOAc) Yield: 75%, yellow oil. 
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N-(benzyloxy)-N-(but-2-yn-1-yl)acetamide 423. 
The desired compound was obtained as a mixture of rotamers (major rotamer depicted as M, 
minor rotamer depicted as m). 
1H NMR (400 MHz, CDCl3) G: 1.83 (3H, t, J = 2.4 Hz, CqCH3, M), 1.86 
(3H, t, J = 2.4 Hz, CqCH3, m), 1.97 (3H, s, C(O)CH3, m), 2.08 (3H, s, 
C(O)CH3, M), 4.34 (2H, m, NCH2, M), 4.56 (2H, q, J = 2.4 Hz, NCH2, m), 
4.94 (2H, s, Cq,arCH2, m), 4.98 (2H, s, Cq,arCH2, M), 7.29-7.48 (5H, m, 
CHar). 13C NMR (100 MHz, CDCl3) G: 0.02 (CqCqCH3, m), 3.7 (CqCqCH3, M), 13.6 (C(O)CH3, 
m), 20.6 (C(O)CH3, M), 37.0 (NCH2, M), 55.0 (NCH2, m), 73.3 (CqCqCH3 of CqCqCH3), 75.8 
(Cq,arCH2O, m), 77.5 (Cq,arCH2O, M), 79.7 (CqCqCH3 of CqCqCH3), 127.7 (CHar, m), 128.26 
(CHar, m), 128.35 (CHar, m), 128.7 (CHar, M), 129.0 (CHar, M), 129.4 (CHar, M), 134.5 (Cq,ar), 
173.2 (C(O)) MS (ESI, pos): m/z 218.1/219.2 (M + H+, 100/15) IR (cm-1) νmax: 1672 (C=O) 
2000-2300 (C≡C) Rf: 0.16 (9/1 PE/EtOAc) Yield: 27%, white solid. 
 
4.7.2. Procedure for the preparation of oxazole 416a 
A 10 mL round-bottom flask was flame dried under inert atmosphere and shielded from 
moisture, using a CaCl2-tube. After dissolving 339 mg (1.0 mmol) dibenzyl (3-(N-
(benzyloxy)acetamido)prop-1-yn-1-yl)phosphonate 412a in 5 mL THF, 326 mg Cs2CO3 (1.0 
mmol) was added and stirred at room temperature. Reaction progress was followed by NMR 
spectroscopy and after complete consumption of the starting material, the mixture was 
quenched with 2 mL H2O. The mixture is diluted in 30 mL EtOAc en washed three times with 
5 mL H2O. After drying over MgSO4 and filtration, the filtrate is concentrated under reduced 
pressure. Purification on column finally yields the desired product. 
diethyl ((4-(benzyloxy)-2-methyloxazol-5-yl)methyl)phosphonate 416a 
1H NMR (400 MHz, CDCl3) G: 1.28 (6H, t, J = 7.1 Hz, (CH3CH2O)2P), 2.38 
(3H, d, J = 2.1 Hz, CqCH3), 3.10 (2H, d, JHP = 19.6 Hz, CH2P), 4.08 (4H, 
m, J = 7.3 Hz, (CH3CH2O)2P), 5.17 (2H, s, CH2Cq,ar), 7.26-7.43 (5H, m, 
CHar) 13C NMR (100 MHz, CDCl3) G: 14.5 (d, JCP = 1 Hz, CqCH3), 16.3 (d, JCP = 6 Hz, CH3CH2O), 
22.4 (d, JCP = 146 Hz, CH2P), 62.3 (d, JCP=7 Hz, CH2OP), 72.2 (CH2Car), 122.9 (d, JCP = 14 Hz, 
PCH2Cq ), 127.9 (CHar), 128.1 (CHar), 128.4 (CHar), 136.9 (Cq,ar), 150.4 (d, JCP = 10 Hz, 
OCq,arCq,arN), 157.4 (d, JCP = 3.6 Hz , OCar,q(CH3)N) 31P NMR (121 MHz, CDCl3) G: 22.48. MS 
(ESI, pos): m/z 340.1/341.2 (M + H+, 100/18) HRMS: m/z calcd for C16H22NO5P (M + H)+ 
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340.1236, found 340.1298. IR (cm-1) νmax: 966 (P-O), 1022 (P=O) Rf: 0.10 (2/8 PE/EtOAc) 
Yield: 22%, brownish oil. 
4.7.3. Preparation of amide intermediate 422 
Diethyl (3-aminoprop-1-yn-1-yl)phosphonate hydrochloride was prepared according to a 
literature procedure. Spectral data were in accordance with literature values.376 A 10 mL round-
bottom flask, equipped with a Claisen piece, is flame dried under inert atmosphere. Next, 455 
mg (2.0 mmol) of the diethyl (3-aminoprop-1-yn-1-yl)phosphonate hydrochloride and 0.56 mL 
(4.0 mmol) NEt3 are dissolved in 10 mL CH2Cl2 at room temperature. After 15 minutes, the 
mixture is cooled to 0 °C and 0.14 mL (2.0 mmol) AcCl is added dropwise. The mixture is 
allowed to warm to room temperature and reaction progress is followed by TLC analysis. After 
complete consumption of the starting material, 1 mL H2O is added and the mixture is diluted in 
25 mL EtOAc. The organic layer is washed five times with 3 mL of a saturated NaHCO3 
solution, dried over MgSO4 and concentrated under reduced pressure. Purification on column 
finally yielded the desired product. 
diethyl (3-acetamidoprop-1-yn-1-yl)phosphonate 422 
1H NMR (400 MHz, CDCl3) G: 1.37 (6H, t, J = 7.1 Hz, (CH3CH2O)2P), 
2.02 (3H, s, CH3), 4.09-4.29 (6H, m, NCH2 and (CH3CH2O)2P), 7.02-
7.26 (1H, br. s, NH) 13C NMR (100 MHz, CDCl3) G: 16.0 (d, JCP=7 Hz, 
CH3CH2OP), 22.8 (CH3), 29.2 (d, JCP = 4 Hz, NCH2), 63.5 (d, JCP = 6 
Hz, CH3CH2OP), 72.1 (d, JCP = 297 Hz, CqCqP), 97.7 (d, JCP=51 Hz, CqCqP), 170.2 (C(O)) 31P 
NMR (121 MHz, CDCl3) G: -7.41. MS (ESI, pos): m/z 234.1/235.2 (M + H+, 100/11) IR (cm-1) 
νmax: 1258 (P-O), 1660 (C=O), 2210 (C≡C), 3275 (NH) Rf: 0.27 (9/1 EtOAc/MeOH) Yield: 50%, 
yellowish oil.  
 
4.7.4. Preparation of Boc-protected hydroxamic acids 
tert-butyl (benzyloxy)carbamate 426 
Tert-butyl (benzyloxy)carbamate 426 was prepared according to a literature procedure. 
Spectral data are in accordance with literature values.378 
1H NMR (400 MHz, CDCl3) G: 1.48 (9H, s, Cq(CH3)3), 4.86 (2H, s, CH2), 
7.01-7.13 (1H, br. s, NH), 7.28-7.47 (5H, m, CHar) Yield: 69%, yellow 
oil.  
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tert-butyl (benzyloxy)(prop-2-yn-1-yl)carbamate 427 
Tert-butyl (benzyloxy)(prop-2-yn-1-yl)carbamate was prepared according to a literature 
procedure. Spectral data were in accordance with literature values.379 
1H NMR (400 MHz, CDCl3) G: 1.50 (9H, s, Cq(CH3)3), 2.24 (1H, t, J = 2.4 
Hz, CqCH), 4.13 (2H, d, J = 2.4 Hz, NCH2), 4.90-4.98 (2H, br. s, 
CH2Cq,ar), 7.28-7.48 (5H, m, CHar) Rf: 0.26 (95/5 PE/EtOAc) Yield: 78%, 
yellow oil. 
 
4.8. Synthetic entry into chiral spirocyclic oxaphospholenes 
4.8.1.  Procedure for the synthesis of (+)-menthone 
A three-necked flask, equipped with a dropping funnel was charged with 2.970 g (7.0 mmol) 
Dess-Martin periodinane, dissolved in 30 mL dry dichloromethane.380 Next, a solution of (+)-
menthol (0.780 g, 5.0 mmol) in 20 mL dry dichloromethane was added dropwise over fifteen 
minutes at room temperature. After one hour the reaction was completed as indicated by GC-
MS analysis and was poured into 80 mL of a 1M NaOH(aq.) solution. 100 mL diethylether was 
added and the organic phase separated. The aqueous phase was extracted with 100 mL 
diethylether. After combination of both organic phases, they were washed twice with 50 mL 
water, dried over MgSO4, filtered and concentrated in vacuo to give 770 mg (5.0 mmol) (+)-
menthone as a yellowish oil. No purification was needed and the (+)-menthone could be used 
as such in the next step. Spectral properties were in accordance with literature values.381  
 1H NMR (400 MHz, CDCl3) G: 0.85 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 0.91 (3H, 
d, J = 6.8 Hz, CH(CH3)(CH3)), 1.00 (3H, d, J = 6.3 Hz, CHCH3), 1.30-1.46 (2H, 
m, CHdHe, CHfHg), 1.77-2.21 (6H, m, CHaHb, CHc, CHdHe, CHfHg, CHh, 
CH(CH3)2), 2.35 (1H, ddd, J = 12.9 Hz, J = 4.0 Hz, J = 2.3 Hz, CHaHb) Yield: 
100% (770 mg), yellowish oil.  
 
4.8.2.  Procedure for the preparation of propargylic alcohols  
Method A: representative example 257a 
30 mL commercially available ethynylmagnesium bromide solution (0.26 M in THF, 7.8 mmol) 
was added to 1 mL THF in a 50 mL round-bottom flask, before the addition of 1.04 mL L-
menthone (6.0 mmol). The reaction was allowed to proceed at room temperature. After 
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complete consumption of the starting material, as indicated by GC-MS analysis, the reaction 
was quenched with water after which the reaction mixture was extracted three times with 
dichloromethane. The combined organic layers were dried over MgSO4, filtered and eventually 
the solvent was removed under reduced pressure. The two diastereoisomers could be 
chromatographically separated. 
Method B: representative example 257e 
A round-bottom flask was charged with 20 mL THF and cooled to -84 °C, before 1.72 mL 1-
hexyne (15.0 mmol) was introduced. Next, 11.2 ml of n-BuLi (16 mmol, 1.43 M in hexanes) 
was added dropwise. The mixture was allowed to warm to room temperature while stirring for 
15 minutes. After the addition of L-menthone at - 84 °C, the mixture was allowed warm to room 
temperature again and reaction progress was monitored by GC-MS analysis. After completion 
of the reaction, the reaction was quenched with water after which the mixture was extracted 
three times with dichloromethane. The combined organic layers were dried over MgSO4, 
filtered and eventually the solvent was removed under reduced pressure. The two 
diastereoisomers could be chromatographically separated. 
(1S,2S,5R)-1-ethynyl-2-isopropyl-5-methylcyclohexan-1-ol 257a 
 1H NMR (400 MHz, CDCl3) G: 0.84-0.97 (1H, m, CHdHe), 0.88 (3H, d, J = 6.3 
Hz, CHCH3), 0.94 (3H, d, J = 7.1 Hz, CH(CH3)(CH3)), 0.97 (3H, d, J = 7.1 Hz, 
CH(CH3)(CH3)), 1.26-1.55 (4H, m, CHaHb, CHfHg, CHh), 1.59 (1H, br. s, OH), 
1.66-1.83 (2H, m, CHc, CHdHe), 1.93-2.02 (1H, m, CHaHb), 2.34-2.49 (1H, m, 
CH(CH3)2), 2.46 (1H, s, CH) 13C NMR (100 MHz, CDCl3) G: 18.6 (CH(CH3)2), 
20.3 (CHfHg), 21.9 (CHCH3), 23.9 (CH(CH3)2), 27.2 (CHc), 28.3 (CH(CH3)2), 34.7 (CHdHe), 50.1 
(CHaHb), 50.3 (CHh), 71.5 (CH), 71.8 (OCq), 88.7 (OCqCq) HRMS: m/z calcd for C12H19 (M - 
H2O + H) 163.1487, found 163.1486. [D]23D = +8.85 (c 2.26, CH2Cl2) Rf: 0.17 (95/5 
cyclohexane/EtOAc). Yield: 66% (717 mg), yellow liquid.  
 
(1R,2S,5R)-1-ethynyl-2-isopropyl-5-methylcyclohexan-1-ol 258a 
 1H NMR (400 MHz, CDCl3) G: 0.74-0.86 (1H, m, CHdHe), 0.92 (3H, d, J = 6.2 
Hz, CHCH3), 0.98 (3H, d, J = 6.7 Hz, CH(CH3)(CH3)), 1.00 (3H, d, J = 6.6 Hz, 
CH(CH3)(CH3)), 1.17-1.39 (3H, m, CHaHb, CHfHg, CHh), 1.58 (1H, br. s, OH), 
1.66-1.83 (3H, m, CHc, CHdHe, CHfHg), 1.94-2.01 (1H, m, CHaHb), 2.12-2.24 
(1H, m, CH(CH3)2), 2.49 (1H, s, CH) 13C NMR (100 MHz, CDCl3) G: 18.3 
(CH(CH3)2), 21.8 (CHCH3), 24.0 (CH(CH3)2), 24.3 (CHfHg), 26.5 (CH(CH3)2), 30.6 (CHc), 34.7 
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(CHdHe), 51.3 (CHaHb), 52.7 (CHh), 71.8 (OCq), 74.5 (CH), 86.5 (OCqCq) HRMS: m/z calcd for 
C12H21O (M + H) 181.1592, found 181.1593. [D]23D = -26.67 (c 0.30, CH2Cl2) Rf: 0.10 (95/5 
cyclohexane/EtOAc). Yield: 21% (223 mg), yellow liquid.  
One proton not correctly assigned in literature data.217 CHd was reported to resonate at 1.41-
1.58 ppm, but HSQC shows it resonates at 0.83-0.96 ppm.  
(1S,2S,5R)-2-isopropyl-5-methyl-1-(phenylethynyl)cyclohexan-1-ol 257b 
 1H NMR (400 MHz, CDCl3) G: 0.83-0.96 (1H, m, CHdHe), 0.90 (3H, d, J = 
6.3 Hz, CHCH3), 0.97 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.01 (3H, d, J = 
6.6 Hz, CH(CH3)(CH3)), 1.35-1.59 (4H, m, CHaHb, CHfHg, CHh), 1.61 (1H, 
br. s, OH), 1.72-1.88 (2H, m, CHc, CHdHe), 2.00-2.14 (1H, m, CHaHb), 2.40-
2.56 (1H, m, CH(CH3)2), 7.28-7.33 (3H, m, CHar), 7.38-7.45 (2H, m, CHar) 
13C NMR (100 MHz, CDCl3) G: 18.9 (CH(CH3)2), 20.8 (CHfHg), 22.0 (CHCH3), 24.0 (CH(CH3)2), 
27.4 (CHc), 28.6 (CH(CH3)2), 34.9 (CHdHe), 50.1 (CHaHb), 50.7 (CHh), 72.3 (OCq), 83.5 
(CqCq,ar), 94.0 (OCqCq), 123.0 (CqCq,ar), 128.1 (CHar), 128.3 (2 x CHar), 131.7 (2 x CHar) HRMS: 
m/z calcd for C18H23 (M - H2O + H) 239.1800, found 239.1802. [D]23D = +4.88 (c 0.82, CH2Cl2) 
Rf: 0.11 (95/5 cyclohexane/EtOAc). Yield: 54% (821 mg), transparent liquid.  
 
(1R,2S,5R)-2-isopropyl-5-methyl-1-(phenylethynyl)cyclohexan-1-ol 258b 
 1H NMR (400 MHz, CDCl3) G: 0.74-0.85 (1H, m, CHdHe), 0.94 (3H, d, J = 
6.5 Hz, CHCH3), 1.02 (3H, d, J = 7.1 Hz, CH(CH3)(CH3)), 1.04 (3H, d, J = 
7.1 Hz, CH(CH3)(CH3)), 1.22-1.46 (3H, m, CHaHb, CHfHg, CHh), 1.55 (1H, 
br. s, OH), 1.66-1.91 (3H, m, CHc, CHdHe, CHfHg), 2.02-2.12 (1H, m, 
CHaHb), 2.21-2.33 (1H, m, CH(CH3)2), 7.28-7.34 (3H, m, CHar), 7.38-7.46 
(2H, m, CHar) 13C NMR (100 MHz, CDCl3) G: 18.3 (CH(CH3)2), 22.0 (CHCH3), 24.0 (CH(CH3)2), 
24.2 (CHfHg), 26.4 (CH(CH3)2), 30.8 (CHc), 34.8 (CHdHe), 51.4 (CHaHb), 53.8 (CHh), 72.2 (OCq), 
86.4 (CqCq,ar), 92.0 (OCqCq), 123.1 (CqCq,ar), 128.2 (CHar), 128.3 (2 x CHar), 131.2 (2 x CHar) 
HRMS: m/z calcd for C18H23 (M - H2O + H) 239.1800, found 239.1803. [D]23D = -14.29 (c 0.84, 
CH2Cl2) Rf: 0.05 (95/5 cyclohexane/EtOAc). Yield: 25% (387 mg), yellow needles.  
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(1S,2S,5R)-2-isopropyl-5-methyl-1-(p-tolylethynyl)cyclohexan-1-ol 257c 
 1H NMR (400 MHz, CDCl3) G: 0.90 (3H, d, J = 6.3 Hz, CHCH3), 0.93-
1.00 (1H, m, CHdHe), 0.97 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.00 
(3H, d, J = 7.1 Hz, CH(CH3)(CH3)), 1.36-1.57 (5H, m, CHaHb, CHfHg, 
CHh, OH), 1.73-1.85 (2H, m, CHc, CHdHe), 2.00-2.10 (1H, m, CHaHb), 
2.34 (1H, s, CH3Cq,ar), 2.47 (1H, quintd, J = 6.9 Hz, J = 2.0 Hz, CH(CH3)2), 7.10 (2H, d, J = 7.8 
Hz, CH3CqCHar), 7.31 (2H, d, J = 8.1 Hz, CqCq,arCHar) 13C NMR (100 MHz, CDCl3) G: 18.9 
(CH(CH3)2), 20.8 (CHfHg), 21.5 (CH3Cq,ar), 22.1 (CHCH3), 24.0 (CH(CH3)2), 27.4 (CHc), 28.5 
(CH(CH3)2), 34.9 (CHdHe), 50.2 (CHaHb), 50.7 (CHh), 72.3 (OCq), 83.6 (CqCq,ar), 93.4 (OCqCq), 
120.0 (CqCq,ar), 129.0 (CH3Cq,arCHar), 131.6 (CqCq,arCHar), 138.2 (CH3Cq,ar) HRMS: m/z calcd 
for C19H25 (M - H2O + H) 253.1956, found 253.1958. [D]23D = +3.28 (c 1.22, CH2Cl2) Rf: 0.17 
(95/5 cyclohexane/EtOAc). Yield: 58% (473 mg), yellow liquid.  
 
(1R,2S,5R)-2-isopropyl-5-methyl-1-(p-tolylethynyl)cyclohexan-1-ol 258c 
 1H NMR (400 MHz, CDCl3) G: 0.85-0.97 (1H, m, CHdHe), 0.93 (3H, 
d, J = 6.6 Hz, CHCH3), 1.01 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.03 
(3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.22-1.46 (3H, m, CHaHb, CHfHg, 
CHh), 1.64-1.89 (3H, m, CHc, CHdHe, CHfHg), 2.02-2.09 (1H, m, 
CHaHb), 2.18 (1H, br. s, OH), 2.21-2.26 (1H, quintd, J = 7.0 Hz, J = 2.5 Hz, CH(CH3)2), 2.34 
((1H, s, CH3Cq,ar), 7.08-7.14 (2H, m, CH3Cq,arCHar), 7.28-7.34 (2H, m, CqCq,arCHar) 13C NMR 
(100 MHz, CDCl3) G: 18.2 (CH(CH3)2), 21.5 (CH3Cq,ar), 22.0 (CHCH3), 24.0 (CH(CH3)2), 24.2 
(CHfHg), 26.4 (CH(CH3)2), 30.8 (CHc), 34.8 (CHdHe), 51.4 (CHaHb), 53.8 (CHh), 72.2 (OCq), 86.6 
(CqCq,ar), 91.1 (OCqCq), 120.0 (CqCq,ar), 129.1 (CH3Cq,arCHar), 131.4 (CqCq,arCHar), 138.3 
(CH3Cq,ar) HRMS: m/z calcd for C19H25 (M - H2O + H) 253.1956, found 253.1956. [D]23D = -
12.50 (c 0.32, CH2Cl2) Rf: 0.07 (95/5 cyclohexane/EtOAc). Yield: 33% (271 mg), yellow liquid. 
 
 (1S,2S,5R)-2-isopropyl-5-methyl-1-(o-tolylethynyl)cyclohexan-1-ol 257d 
 1H NMR (400 MHz, CDCl3) G: 0.87-1.05 (1H, m, CHdHe), 0.91 (3H, d, J 
= 6.3 Hz, CHCH3), 0.98 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.00 (3H, 
d, J = 7.1 Hz, CH(CH3)(CH3)), 1.36-1.56 (4H, m, CHaHb, CHfHg, CHh), 
1.67 (1H, br. s, OH), 1.75-1.87 (2H, m, CHc, CHdHe), 2.03-2.13 (1H, m, 
CHaHb), 2.42 (1H, s, CH3Cq,ar), 2.54 (1H, quintd, J = 6.9 Hz, J = 1.8 Hz, 
CH(CH3)2), 7.08-7.22 (3H, m, CHar), 7.36-7.41 (1H, m, CHar) 13C NMR (100 MHz, CDCl3) G: 
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18.8 (CH(CH3)2), 20.7 (CHfHg), 20.8 (CH3Cq,ar), 22.0 (CHCH3), 24.0 (CH(CH3)2), 27.4 (CHc), 
28.6 (CH(CH3)2), 34.9 (CHdHe), 50.3 (CHaHb), 50.8 (CHh), 72.6 (OCq), 82.4 (CqCq,ar), 98.2 
(OCqCq), 122.8 (CqCq,ar), 125.6 (CHar), 128.2 (CHar), 129.4 (CHar), 132.0 (CHar), 140.1 
(CH3Cq,ar) HRMS: m/z calcd C19H25 (M - H2O + H) 253.1956, found 253.1957. [D]23D = -3.08 (c 
1.30, CH2Cl2) Rf: 0.20 (95/5 cyclohexane/EtOAc). Yield: 75% (405 mg), transparent liquid.  
 
(1R,2S,5R)-2-isopropyl-5-methyl-1-(o-tolylethynyl)cyclohexan-1-ol 258d 
 1H NMR (400 MHz, CDCl3) G: 0.84-0.99 (1H, m, CHdHe), 0.95 (3H, d, J 
= 6.6 Hz, CHCH3), 1.04 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.04 (3H, 
d, J = 7.0 Hz, CH(CH3)(CH3)), 1.23-1.49 (3H, m, CHaHb, CHfHg, CHh), 
2.33 (1H, br. s, OH), 1.67-1.91 (3H, m, CHc, CHdHe, CHfHg), 2.04-2.12 
(1H, m, CHaHb), 2.25 (1H, quintd, J = 6.9 Hz, J = 2.8 Hz, CH(CH3)2), 
2.43 (1H, s, CH3Cq,ar), 7.09-7.22 (3H, m, CHar), 7.36-7.41 (1H, m, CHar) 13C NMR (100 MHz, 
CDCl3) G: 18.5 (CH(CH3)2), 20.9 (CH3Cq,ar), 22.0 (CHCH3), 24.0 (CH(CH3)2), 24.5 (CHfHg), 26.8 
(CH(CH3)2), 30.9 (CHc), 34.8 (CHdHe), 51.6 (CHaHb), 53.1 (CHh), 72.6 (OCq), 85.4 (CqCq,ar), 
95.9 (OCqCq), 122.8 (CqCq,ar), 125.6 (CHar), 128.2 (CHar), 129.4 (CHar), 132.0 (CHar), 140.0 
(CH3Cq,ar) HRMS: m/z calcd for C19H25 (M - H2O + H) 253.1956, found 253.1960. [D]23D = -
20.00 (c 0.20, CH2Cl2) Rf: 0.10 (95/5 cyclohexane/EtOAc). Yield: 14% (74 mg), transparent 
liquid.  
 
(1S,2S,5R)-1-(hex-1-yn-1-yl)-2-isopropyl-5-methylcyclohexan-1-ol 257e 
 1H NMR (400 MHz, CDCl3) G: 0.84-1.01 (1H, m, CHdHe), 0.86 (3H, d, 
J = 6.6 Hz, CHCH3), 0.91 (3H, t, J = 7.2 Hz, CH3CH2), 0.92 (3H, d, J = 
6.8 Hz, CH(CH3)(CH3)), 0.95 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 1.22-
1.58 (9H, m, CHaHb, CHfHg, CHh, CH3CH2, CH3CH2CH2, OH), 1.65-
1.79 (2H, m, CHc, CHdHe), 1.87-1.97 (1H, m, CHaHb), 2.20 (2H, t, J = 
6.9 Hz, CH2CqCq), 2.32-2.47 (1H, m, CH(CH3)2) 13C NMR (100 MHz, CDCl3) G: 13.6 (CH3CH2), 
18.4 (CH2CqCq), 18.7 (CH(CH3)2), 20.6 (CHfHg), 21.9 (CH3CH2), 22.0 (CHCH3), 23.9 
(CH(CH3)2), 27.3 (CHc), 28.2 (CH(CH3)2), 30.9 (CH3CH2CH2), 34.9 (CHdHe), 50.5 (CHaHb), 50.7 
(CHh), 71.9 (OCq), 83.8 (OCqCqCq or OCqCqCq), 85.0 (OCqCqCq or OCqCqCq) HRMS: m/z calcd 
for C16H27 (M - H2O + H) 219.2113, found 219.2111. [D]23D = +6.12 (c 1.96, CH2Cl2) Rf: 0.12 
(99/1 pentane/EtOAc). Yield: 76% (537 mg), transparent liquid.  
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(1R,2S,5R)-1-(hex-1-yn-1-yl)-2-isopropyl-5-methylcyclohexan-1-ol 258e 
 1H NMR (400 MHz, CDCl3) G: 0.75-0.89 (1H, m, CHdHe), 0.87 (3H, d, 
J = 6.0 Hz, CHCH3), 0.88 (3H, t, J = 7.1 Hz, CH3CH2), 0.93 (3H, d, J 
= 6.8 Hz, CH(CH3)(CH3)), 0.94 (3H, d, J = 6.9 Hz, CH(CH3)(CH3)), 
1.07-1.53 (7H, m, CHaHb, CHfHg, CHh, CH3CH2, CH3CH2CH2), 1.53-
1.77 (3H, m, CHfHg, CHc, CHdHe), 1.84-1.92 (1H, m, CHaHb), 2.17 (2H, 
t, J = 6.9 Hz, CH2CqCq), 2.07-2.23 (2H, m, CH(CH3)2, OH) 13C NMR (100 MHz, CDCl3) G: 13.6 
(CH3CH2), 18.2 (CH(CH3)2), 18.5 (CH2CqCq), 21.9 (CHCH3), 22.0 (CH3CH2), 24.0 (CH(CH3)2), 
24.3 (CHfHg), 26.4 (CH(CH3)2), 30.7 (CHc), 30.8 (CH3CH2CH2), 34.8 (CHdHe), 51.6 (CHaHb), 
52.9 (CHh), 71.9 (OCq), 82.5 (OCqCqCq or OCqCqCq), 86.7 (OCqCqCq or OCqCqCq) HRMS: m/z 
calcd for C16H27 (M - H2O + H) 2119.2113, found 219.2112. [D]23D = -13.33 (c 0.30, CH2Cl2) Rf: 
0.03 (99/1 pentane/EtOAc). Yield: 19% (133 mg), transparent liquid.  
 
(1R,2R,5S)-1-ethynyl-2-isopropyl-5-methylcyclohexan-1-ol 257f 
 1H NMR (400 MHz, CDCl3) G: 0.85-0.94 (1H, m, CHdHe), 0.87 (3H, d, J = 6.6 
Hz, CHCH3), 0.93 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 0.96 (3H, d, J = 6.8 Hz, 
CH(CH3)(CH3)), 1.27-1.55 (4H, m, CHaHb, CHfHg, CHh), 1.62 (1H, br. s, OH), 
1.65-1.81 (2H, m, CHc, CHdHe), 1.92-2.02 (1H, m, CHaHb), 2.33-2.48 (1H, m, 
CH(CH3)2), 2.46 (1H, s, CH) 13C NMR (100 MHz, CDCl3) G: 18.6 (CH(CH3)2), 
20.3 (CHfHg), 21.9 (CHCH3), 23.9 (CH(CH3)2), 27.3 (CHc), 28.3 (CH(CH3)2), 34.8 (CHdHe), 50.1 
(CHaHb), 50.3 (CHh), 71.5 (CH), 71.9 (OCq), 88.7 (OCqCq) HRMS: m/z calcd for C12H19 (M - 
H2O + H)+ 163.1487, found 163.1485. [D]23D = -10.53 (c 0.38, CH2Cl2) Rf: 0.18 (95/5 
hexane/EtOAc). Yield: 55% (443 mg), transparent liquid.  
 
(1S,2R,5S)-1-ethynyl-2-isopropyl-5-methylcyclohexan-1-ol 258f 
 1H NMR (400 MHz, CDCl3) G: 0.76-0.88 (1H, m, CHdHe), 0.89 (3H, d, J = 6.6 
Hz, CHCH3), 0.95 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 0.96 (3H, d, J = 7.0 Hz, 
CH(CH3)(CH3)), 1.14-1.37 (3H, m, CHaHb, CHfHg, CHh), 1.59-1.81 (3H, m, CHc, 
CHdHe, CHfHg), 1.92-2.00 (1H, m, CHaHb), 2.17 (1H, septd, J = 6.9 Hz, J = 2.8 
Hz, CH(CH3)2), 2.32 (1H, br. s, OH), 2.47 (1H, s, CH) 13C NMR (100 MHz, 
CDCl3) G: 18.3 (CH(CH3)2), 21.8 (CHCH3), 24.0 (CH(CH3)2), 24.2 (CHfHg), 26.5 (CHc), 30.5 
(CH(CH3)2), 34.7 (CHdHe), 51.3 (CHaHb), 52.7 (CHh), 71.8 (OCq), 74.5 (CH), 86.5 (OCqCq) 
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HRMS: m/z calcd for C12H19 (M - H2O + H)+ 163.1487, found 163.1486. [D]23D = +18.18 (c 0.22, 
CH2Cl2) Rf: 0.19 (95/5 hexane/EtOAc). Yield: 17% (138 mg), transparent liquid.  
(1R,2R,4S)-2-ethynyl-1,3,3-trimethylbicyclo[2.2.1]heptan-2-ol 257g 
A literature protocol was followed. The two diastereomers were present in a 98/2 ratio and the 
mixture was used as such in the next step. Spectral properties were in accordance with 
literature data.382 
 1H NMR (400 MHz, CDCl3) G: 0.96 (3H, s, C(CH3)(CH3)), 1.08-1.17 (2H, m, 
CHdHe, CHfHg), 1.15 (3H, s, C(CH3)(CH3)), 1.20 (3H, s, CH2CCH3), 1.35-1.47 
(1H, m, CHbHc), 1.65-1.78 (3H, m, CHa, CHfHg, CHbHc), 1.85-1.95 (1H, m, 
CHdHe), 2.56 (1H, s, CH) Yield: 72% (168 mg), transparent liquid.  
 
(1R,2S,4R)-2-ethynyl-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol 257h 
Standard protocol B afforded a mixture of two diastereomers, which were present in a 98/2 
ratio. These were recovered in the same ratio after column chromatography (Rf: 0.30 (97.5/2.5 
hexane/EA)) in 55% yield. Next, the alkyne (546 mg, 2.18 mmol) was dissolved in 15 mL MeOH 
and refluxed with K2CO3 (177 mg, 0.33 m%). After 90 minutes, the reaction was quenched with 
water and the solvent was evaporated under reduced pressure before 20 mL of diethylether 
and 5 mL of brine were added. The aqueous phase was extracted twice with 10 mL of 
diethylether. The combined organic layers were dried over MgSO4 and the solvent removed in 
vacuo. The two diastereomers were present in a 98/2 ratio and the mixture was used as such 
in the next step. Spectral properties were in accordance with literature data.383  
 1H NMR (400 MHz, CDCl3) G: 0.88 (3H, s, C(CH3)(CH3)), 0.96 (3H, s, 
C(CH3)(CH2)), 1.06 (3H, s, C(CH3)(CH3)), 1.10-1.18 (1H, m, CHbHc), 1.42-1.52 
(1H, m, CHfHg), 1.53-1.64 (1H, br. s, OH), 1.65-1.75 (1H, m, CHbHc), 1.77 (1H, 
t, J = 4.4 Hz, CHa), 1.84-1.95 (1H, m, CHfHg), 1.88 (1H, d, J = 13.6 Hz, CHdHe), 
2.23 (1H, dt, J = 13.4 Hz, J = 3.8 Hz, CHdHe), 2.46 (1H, s, CH) Yield: 58% (278 mg, two steps), 
white needles.  
 
4.8.3. Synthesis of chiral allenylphosphonates 
Diethylchlorophosphite (0.58 mL, 4.0 mmol) was added to a solution of propargylic alcohol 
257b (512 mg, 2.0 mmol) in 20 mL THF at room temperature. After the addition of triethylamine 
(0.32 mL, 2.2 mmol), the mixture was refluxed for 24 hours. The reaction was quenched with 
20 mL of water and brine. Next, the mixture was extracted three times with 20 mL diethylether, 
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the organic layers were combined and dried over MgSO4. After concentration of the mixture in 
vacuo and purification via flash chromatography, enantiomerically pure allenylphosphonate 
259b (481 mg, 1.28 mmol) was obtained.  
(S)-diethyl (2-((2S,5R)-2-isopropyl-5-methylcyclohexylidene)-vinyl)phosphonate 259a 
 1H NMR (400 MHz, CDCl3) G: 0.90 (3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 0.93 
(3H, d, J = 6.3 Hz, CHCH3), 0.94 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 0.94-
1.06 (1H, m, CHdHe), 1.17-1.30 (1H, m, CHfHg), 1.33 (6H, t, J = 7.2 Hz, 
P(OCH2CH3)2), 1.53-1.94 (6H, m, CHc, CHaHb, CH(CH3)2, CHh, CHdHe, 
CHfHg), 2.30-2.36 (1H, m, CHaHb), 4.02-4.18 (4H, m, P(OCH2CH3)2), 5.25 
(1H, td, 2JPH = 7.5 Hz, 5JHH = 3.8 Hz, PCH) 13C NMR (100 MHz, CDCl3) G: 16.4 (d, 3JPC = 2 Hz, 
P(OCH2CH3)), 16.4 (d, 3JPC = 2 Hz, P(OCH2CH3)), 18.9 (CH(CH3)2), 22.0 (CH(CH3)2), 22.0 
(CHCH3), 28.1 (d, 5JPC = 5 Hz, CHfHg), 29.4 (CH(CH3)2), 33.6 (d, 5JPC = 4 Hz, CHc), 34.5 
(CHdHe), 39.6 (d, 4JPC = 7 Hz, CHaHb), 46.3 (d, 4JPC = 5 Hz, CHh), 61.9 (d, 2JPC = 6 Hz, 
P(OCH2CH3)), 62.1 (d, 2JPC = 6 Hz, P(OCH2CH3)), 79.5 (d, 1JPC = 201 Hz, PCH), 107.3 (d, 3JPC 
= 18 Hz, PCHCqCq), 207.7 (PCHCqCq) 31P NMR (161 MHz, CDCl3) G: 16.62. HRMS: m/z calcd 
for C16H30O3P (M + H) 301.1933, found 301.1935. [D]23D = -2.90 (c 1.38, CH2Cl2) Rf: 0.19 (3/7 
cyclohexane/EtOAc). Yield: 75% (441 mg), yellow liquid.  
 
(S)-diethyl (2-((2S,5R)-2-isopropyl-5-methylcyclohexylidene)-1-phenyl-
vinyl)phosphonate 259b 
 1H NMR (400 MHz, CDCl3) G: 0.88 (3H, d, J = 6.7 Hz, CH(CH3)(CH3)), 0.92 
(3H, d, J = 6.8 Hz, CH(CH3)(CH3)), 0.96 (3H, d, J = 6.3 Hz, CHCH3), 0.99-
1.13 (1H, m, CHdHe), 1.24-1.38 (1H, m, CHfHg), 1.29 (6H, t, J = 7.0 Hz, 
P(OCH2CH3)2), 1.52-1.94 (6H, m, CHc, CHaHb, CH(CH3)2, CHh, CHdHe, 
CHfHg), 2.40-2.50 (1H, m, CHaHb), 4.01-4.21 (4H, m, P(OCH2CH3)2), 7.19-
7.24 (1H, m, CHar), 7.28-7.36 (2H, m, CHar), 7.52-759 (2H, m, CHar) 13C NMR (100 MHz, CDCl3) 
G: 16.3 (d, 3JPC = 2 Hz, P(OCH2CH3)), 16.4 (d, 3JPC = 2 Hz, P(OCH2CH3)), 19.0 (CH(CH3)2), 
22.0 (CH(CH3)2), 22.1 (CHCH3), 28.0 (d, 5JPC = 4 Hz, CHfHg), 29.9 (CH(CH3)2), 33.5 (d, 5JPC = 
4 Hz, CHc), 34.5 (CHdHe), 39.9 (d, 4JPC = 6 Hz, CHaHb), 47.1 (d, 4JPC = 5 Hz, CHh), 62.1 (d, 2JPC 
= 6 Hz, P(OCH2CH3)), 62.3 (d, 2JPC = 6 Hz, P(OCH2CH3)), 96.6 (d, 1JPC = 193 Hz, PCqCqCq), 
109.7 (d, 3JPC = 15 Hz, PCqCqCq), 127.0 (CarH), 127.4 (CarH), 127.5 (CarH), 128.4 (2 x CarH), 
133.3 (d, 2JPC = 6 Hz, Cq,ar), 207.2 (d, 2JPC = 5 Hz, PCqCqCq) 31P NMR (161 MHz, CDCl3) δ: 
16.58. HRMS: m/z calcd for C22H34O3P (M + H) 377.2246, found 377.2244. [D]23D = -23.81 (c 
0.84, CH2Cl2) Rf: 0.19 (7/3 cyclohexane/EtOAc). Yield: 64% (481 mg), transparent liquid.  
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(S)-diethyl (2-((2S,5R)-2-isopropyl-5-methylcyclohexylidene)-1-(p-tolyl)-
vinyl)phosphonate 259c 
 1H NMR (400 MHz, CDCl3) G: 0.86 (3H, d, J = 6.5 Hz, CH(CH3)(CH3)), 
0.90 (3H, d, J = 6.5 Hz, CHCH3), 0.94 (3H, d, J = 6.5 Hz, 
CH(CH3)(CH3)), 0.99-1.08 (1H, m, CHdHe), 1.24-1.29 (7H, m, 
P(OCH2CH3)2, CHfHg), 1.62-1.90 (6H, m, CHc, CHaCHb, CH(CH3)2, 
CHh, CHdCHe, CHfCHg), 2.30 (3H, s, CH3Cq,ar), 2.41-2.46 (1H, m, 
CHaCHb), 4.00-4.18 (4H, m, P(OCH2CH3)2), 7.10 (2H, d, J = 8.3 Hz, CHar), 7.43 (2H, d, J = 8.3 
Hz, CHar) 13C NMR (100MHz, CDCl3) G: 16.3 (P(OCH2CH3)) 16.4 (P(OCH2CH3)), 19.0 
(CH(CH3)2), 21.1 (CH3Cq,ar), 21.9 (CH(CH3)), 22.0 (CHCH3), 28.0 (d, 5JPC = 4 Hz, CHfHg), 29.8 
(CH(CH3)2), 33.5 (d, 5JPC = 5 Hz ,CHc), 34.5 (CHdHe), 39.9 (d, 4JPC = 6 Hz, CHaHb), 47.1 (d, 4JPC 
= 6 Hz ,CHh), 61.9 (d, 2JPC = 6 Hz, P(OCH2CH3)), 62.1 (d, 2JPC = 6 Hz, P(OCH2CH3)), 96.3 (d, 
1JPC = 193 Hz, PCqCqCq), 109.5 (d, 3JPC = 15 Hz, PCqCqCq), 127.3 (d, 3JPC = 6 Hz, CarH), 129.1 
(CarH), 130.2 (d, 2JPC = 10 Hz, Cq,ar), 136.4 (Cq,ar), 206.2 (d, 2JPC = 4 Hz, PCqCqCq). 31P NMR G: 
16.70. HRMS: m/z calcd for C23H36O3P (M+H)+ 391.2402, found 391.2396. [α]D20 = -18.39 (c 
2.04, CH2Cl2) Rf: 0.20 (4/6 EtOAc/n-hexane). Yield: 72% (280 mg), yellow oil. 
 
(S)-diethyl (2-((2S,5R)-2-isopropyl-5-methylcyclohexylidene)-1-(o-tolyl)-
vinyl)phosphonate 259d 
 1H NMR (400 MHz, CDCl3) G: 0.84 (3H, d, J = 6.6 Hz, CH(CH3)(CH3)), 
0.94 (3H, d, J = 6.7 Hz, CH(CH3)(CH3)), 0.92-1.04 (1H, m, CHdHe), 0.96 
(3H, d, J = 5.6 Hz, CHCH3), 1.19-1.32 (7H, m, CHfHg, P(OCH2CH3)2), 
1.57-1.91 (6H, m, CHc, CHaHb, CH(CH3)2, CHh, CHdHe, CHfHg), 2.37 (3H, 
br. s, CH3Cq,ar), 2.43-2.51 (1H, m, CHaHb), 3.94-4.15 (4H, m, 
P(OCH2CH3)2), 7.11-7.22 (3H, m, CHar), 7.30-7.37 (1H, m, CHar) 13C NMR (100 MHz, CDCl3) 
G: 16.37 (d, 3JPC = 4 Hz, P(OCH2CH3)), 16.44 (d, 3JPC = 4 Hz, P(OCH2CH3)), 18.9 (CH(CH3)2), 
20.5 (CH3Cq,ar), 22.1 (CH(CH3)2), 22.2 (CHCH3), 28.1 (d, 5JPC = 4 Hz, CHfHg), 29.7 (CH(CH3)2), 
33.8 (d, 5JPC = 4 Hz, CHc), 34.7 (CHdHe), 39.6 (d, 4JPC = 7 Hz, CHaHb), 46.8 (d, 4JPC = 5 Hz, 
CHh), 62.2 (d, 2JPC = 7 Hz, P(OCH2CH3)), 62.3 (d, 2JPC = 7 Hz, P(OCH2CH3)), 95.3 (d, 1JPC = 
196 Hz, PCqCqCq), 107.3 (d, 3JPC = 16 Hz, PCqCqCq), 125.6 (d, JPC = 2 Hz, CarH), 127.6 (d, JPC 
= 2 Hz, CarH), 130.0 (d, JPC = 4 Hz, CarH), 130.3 (CarH), 132.9 (d, JPC = 8 Hz, Cq,ar), 133.3 (d, 
JPC = 6 Hz, Cq,ar), 205.0 (d, 2JPC = 6 Hz, PCqCqCq) 31P NMR (161 MHz, CDCl3) G: 15.91 HRMS: 
m/z calcd for C23H36O3P (M + H) 391.2402, found 391.2401. [D]23D = +17.05 (c 2.33, CH2Cl2) 
Rf: 0.20 (7/3 pentane/EtOAc). Yield: 66% (514 mg), yellow liquid.  
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(S)-diethyl (1-((2S,5R)-2-isopropyl-5-methylcyclohexylidene)-hex-1-en-2-
yl)phosphonate 259e 
 1H NMR (400 MHz, CDCl3) G: 0.86-1.07 (13H, m, CH(CH3)2, CHCH3, 
CHdHe, CH3CH2), 1.17-1.29 (1H, m, CHfHg), 1.31 (6H, t, J = 7.1 Hz, 
P(OCH2CH3)2), 1.31-1.39 (2H, m, CH3CH2CH2), 1.41-1.50 (2H, m, 
CH3CH2CH2), 1.60-1.65 (CHc), 1.67-1.73 (2H, m, CHaHb, CHh) 1.73-1.78 
(CH(CH3)2), 1.78-1.88 (2H, CHdHe, CHfHg), 2.08-2.18 (2H, m, 
CH2CqCqCq), 2.23-2.37 (1H, m, CHaHb), 3.98-4.19 (4H, m, P(OCH2CH3)2) 13C NMR (100 MHz, 
CDCl3) G: 14.0 (CH3CH2), 16.4 (d, 3JPC = 2 Hz, P(OCH2CH3)), 16.5 (d, 3JPC = 2 Hz, 
P(OCH2CH3)), 19.0 (CH(CH3)(CH3)), 21.96 (CH(CH3)(CH3) + CHCH3), 22.3 (CH3CH2CH2), 
27.9 (d, 5JPC = 5 Hz, CHfHg), 28.6 (d, 2JPC = 9 Hz, CH2CqCqCq), 29.5 (CH(CH3)2), 30.7 (d, 3JPC 
= 7 Hz, CH3CH2CH2), 33.5 (d, 5JPC = 4 Hz, CHc), 34.5 (CHdHe), 40.2 (d, 4JPC = 7 Hz, CHaHb), 
46.6 (d, 4JPC = 5 Hz, CHh), 61.6 (d, 2JPC = 6 Hz, P(OCH2CH3)), 61.9 (d, 2JPC = 7 Hz, 
P(OCH2CH3)), 93.1 (d, 1JPC = 197 Hz, PCq), 108.1 (d, 3JPC = 17 Hz, PCqCqCq), 204.1 (d, 2JPC = 
6 Hz, PCqCqCq) 31P NMR (161 MHz, CDCl3) G: 19.61. HRMS: m/z calcd for C20H38O3P (M + H) 
357.2559, found 357.2561. [D]23D = -15.44 (c 2.05, CH2Cl2) Rf: 0.18 (7/3 pentane/EtOAc). 
Yield: 78% (555 mg), transparent liquid.  
 
(R)-diethyl (2-((2R,5S)-2-isopropyl-5-methylcyclohexylidene)-vinyl)phosphonate 259f 
 1H NMR (400 MHz, CDCl3) G: 0.87 (3H, d, J = 6.7 Hz, CH(CH3)(CH3)), 0.91 
(3H, d, J = 6.0 Hz, CHCH3), 0.92 (3H, d, J = 6.7 Hz, CH(CH3)(CH3)), 0.96-
1.01 (1H, m, CHdHe), 1.17-1.30 (1H, m, CHfHg), 1.30 (6H, t, J = 7.2 Hz, 
P(OCH2CH3)2), 1.52-1.85 (6H, m, CHc, CHaHb, CH(CH3)2, CHh, CHdHe, 
CHfHg), 2.29-2.32 (1H, m, CHaHb), 4.01-4.14 (4H, m, P(OCH2CH3)2), 5.22 
(1H, dt, 2JPH = 7.4 Hz , 5JHH = 3.7 Hz, PCH). 13C NMR (100MHz, CDCl3) G: 16.3 (d, 3JPC = 1 Hz, 
P(OCH2CH3)), 16.3 (d, 3JPC = 1 Hz, P(OCH2CH3)), 18.9 (CH(CH3)2), 21.8 (CH(CH3)2), 21.8 
(CHCH3), 28.1 (d, 5JPC = 5 Hz, CHfHg), 29.3 (CH(CH3)2), 33.6 (d, 5JPC = 4 Hz, CHc), 34.4 
(CHdHe), 39.5 (d, 5JPC = 7 Hz, CHaHb), 46.3 (d, 4JPC = 6 Hz, CHh), 61.8 (d, 2JPC = 6 Hz, 
P(OCH2CH3)), 61.9 (d, 2JPC = 6 Hz, P(OCH2CH3)), 79.5 (d, 1JPC = 201 Hz, PCH), 107.2 (d, 3JPC 
= 17 Hz, PCHCqCq), 207 (PCHCqCq). 31P NMR (161 MHz, CDCl3) G: 16.54 HRMS: m/z calcd 
for C16H30O3P (M+H)+ 301.1933, found 301.1913. [α]D20 = +2.27 (c 2.07, CH2Cl2), Rf: 0.17 (4:6 
EtOAc/n-hexane). Yield: 56% (336 mg), yellow oil. 
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(S)-diethyl (2-((1R,4S)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-ylidene)-vinyl)phosphonate 
259g 
 1H NMR (400 MHz, CDCl3) G: 1.01 (3H, s, C(CH3)(CH3)), 1.16 (3H, s, 
C(CH3)(CH3)), 1.20 (3H, s, CH3CqCHaHb), 1.30-1.35 (1H, m, CHaHb), 1.33 
(6H, t, J = 7.1 Hz, P(OCH2CH3)2), 1.46-1.58 (3H, m, CHcHd, CHfHg), 1.69-
1.75 (1H, m, CHaHb), 1.77-1.84 (1H, m, CHcHd), 1.87-1.92 (1H, m, CHe), 
3.99-4.20 (4H, m, P(OCH2CH3)2), 5.42 (1H, d, J = 8.6 Hz, CHP) 13C NMR 
(100 MHz, CDCl3) G: 15.3 (P(OCH2CH3)), 15.4 (P(OCH2CH3)), 17.9 (CH3CqCHaHb), 24.31 
((CH3)(CH3)Cq), 24.34 (CHcHd), 27.7 (d, 5JPC = 6 Hz, (CH3)(CH3)Cq), 34.1 (d, 5JPC = 7 Hz, 
CHfHg), 43.3 (d, 4JPC = 6 Hz, CqCHe), 44.0 (d, 5JPC = 1 Hz, CHaHb), 46.8 (CHe), 49.1 (d, 4JPC = 
5 Hz, CqCHaHb), 60.8 (d, 2JPC = 3 Hz, P(OCH2CH3)), 60.9 (d, 2JPC = 3 Hz, P(OCH2CH3)), 83.0 
(d, 1JPC = 200 Hz, PCH), 121.7 (d, 3JPC = 18 Hz, PCHCqCq), 203.6 (PCHCqCq) 31P NMR (161 
MHz, CDCl3) G: 16.70 HRMS: m/z calcd for C16H28O3P (M + H) 299.1776, found 299.1779. 
[D]23D = -65.77 (c 2.12, CH2Cl2) Rf: 0.17 (5/5 EtOAc/n-hexane). Yield: 67% (598 mg), 
transparent liquid.  
 
(R)-diethyl (2-((1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ylidene)-vinyl)phosphonate 
259h 
 1H NMR (400 MHz, CDCl3) G: 0.89 (3H, s, C(CH3)(CH3)), 0.91 (3H, s, 
C(CH3)(CH3)), 0.94 (3H, s, CH3CqCHdHe), 1.19-1.26 (1H, m, CHbHc), 1.31 
(3H, t, 3JHH = 7.0 Hz, P(OCH2CH3)), 1.32 (3H, t, 3JHH = 7.1 Hz, 
P(OCH2CH3)), 1.44-1.50 (1H, m, CHgHf), 1.62-1.71 (1H, m, CHeHd), 1.75-
1.85 (2H, m, CHbHc, CHa), 2.05-2.12 (1H, m, CHfHg), 2.56-2.66 (1H, m, 
CHeHd), 3.99-4.12 (4H, m, P(OCH2CH3)2), 5.26-5.30 (1H, m, PCH). 13C NMR (100MHz, CDCl3) 
G: 13.0 (CH3CqCHdHe), 16.3 (P(OCH2CH3)), 16.4 (P(OCH2CH3)), 18.6 (C(CH3)(CH3)), 19.7 
(C(CH3)(CH3)), 27.7 (CHbHc), 34.5 (d, 4JPC = 6 Hz, CHfHg), 34.9 (d, 5JPC = 6 Hz, CHdHe), 44.9 
(CHa), 48.6 (d, 5JPC = 2 Hz, C(CH3)(CH3)), 52.5 (d, 4JPC = 5 Hz, CH2CCH3), 61.8 (d, 2JPC = 6 Hz, 
P(OCH2CH3)), 61.9 (d, 2JPC = 6 Hz, P(OCH2CH3)), 81.9 (d, 1JPC = 198 Hz, PCH), 112.8 (d, 3JPC 
= 17 Hz, PCHCqCq), 205.9 (PCHCqCq). 31P NMR (161 MHz, CDCl3) G: 16.50. HRMS: m/z calcd 
for C16H28O3P (M+H)+, 299.1776, found 299.1771. [D]23D = -99.80 (c 9.98, CH2Cl2) Rf: 0.19 
(5:5 EtOAc/n-hexane). Yield: 59% (351 mg), yellow oil. 
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4.8.4. Synthesis of chiral spirocyclic oxaphospholenes 
Iodine (84 mg, 0.3 mmol) was added to a Schlenk tube, charged with a solution of 
allenylphosphonate 259b (100 mg, 0.3 mmol) in cyclohexane. The reaction was stirred for 30 
minutes at 80 °C, after which 10 mL dichloromethane, Na2S2O5 and few drops of water were 
added and stirred until completely decolorization. The organic layer was eventually dried over 
MgSO4 and the solvent evaporated under reduced pressure to immediately give the desired 
spirocyclic oxaphospholenes 263b (121 mg, 0.31 mmol) as a mixture of diastereomers at the 
phosphorus atom.  
(5S,6S,9R)-2-ethoxy-4-iodo-6-isopropyl-9-methyl-1-oxa-2-phosphaspiro[4.5]dec-3-ene 
2-oxide 263a  
dr: 61/39  
1H NMR (400 MHz, CDCl3) G: 0.75-1.02 (10 H, m, CH(CH3)2, CHCH3, CHdHe), 
1.32 (3H, t, J = 7.1 Hz, POCH2CH3), 1.43-1.94 (8H, m, CHc, CHaHb, CH(CH3)2, 
CHh, CHdHe, CHfHg), 3.95-4.37 (2H, m, POCH2CH3), 6.56 (1H, d, 2JPH = 26.3 
Hz, PCH) 13C NMR (100 MHz, CDCl3) G: 16.7 (d, 3JPC = 5 Hz, POCH2CH3), 
17.5 (CH(CH3)2), 21.1 (CHfHg), 22.0 (CHCH3), 23.8 (d, 5JPC = 4 Hz, CH(CH3)2), 
26.5 (CHc), 28.5 (d, 4JPC = 4 Hz, CH(CH3)2), 34.3 (CHdHe), 45.3 (CHaHb), 46.9 (d, 3JPC = 4 Hz, 
CHh), 63.1 (d, 2JPC = 7 Hz, POCH2CH3), 94.6 (d, 2JPC = 4 Hz, OCq), 127.5 (d, 1JPC = 156 Hz, 
PCH), 127.7 (d, 2JPC = 27 Hz, ICq) 31P NMR (161 MHz, CDCl3) G: 33.47 HRMS: m/z calcd for 
C14H25IO3P (M + H) 399.0586, found 399.0587. Yield: 91% (108 mg), yellow liquid. 
 
(5S,6S,9R)-2-ethoxy-4-iodo-6-isopropyl-9-methyl-3-phenyl-1-oxa-2-
phosphaspiro[4.5]dec-3-ene 2-oxide 263b 
dr: 61/39 
 1H NMR (400 MHz, CDCl3) G: 0.81-1.05 (10 H, m, CH(CH3)2, CHCH3, 
CHdHe), 1.16 (3H, t, J = 6.6 Hz, POCH2CH3), 1.51-1.97 (8H, m, CHc, CHaHb, 
CH(CH3)2, CHh, CHdHe, CHfHg), 3.95-4.30 (2H, m, POCH2CH3), 7.33-7.45 
(3H, m, CHar), 7.50-7.60 (2H, m, CHar) 13C NMR (100 MHz, CDCl3) G: 16.6 
(d, 3JPC = 5 Hz, POCH2CH3), 17.7 (CH(CH3)2), 21.2 (CHfHg), 22.1 (CHCH3), 
23.9 (d, 5JPC = 4 Hz, CH(CH3)2), 26.6 (CHc), 28.5 (CH(CH3)2), 34.3 (CHdHe), 46.0 (s, CHaHb), 
46.7 (d, 3JPC = 4 Hz, CHh), 63.4 (d, 2JPC = 7 Hz, POCH2CH3), 92.6 (d, 2JPC = 4 Hz, OCq), 125.2 
(d, 2JCP = 39 Hz, ICq), 128.3 (d, 4JCP = 6 Hz, CHar,o), 128.6 (2x CHar,m), 129.0 (d, 6JCP = 1 Hz, 
CHar,p), 132.6 (d, 2JCP = 11 Hz, Cq, ar), 136.6 (d, 1JPC = 151 Hz, PCq) 31P NMR (161 MHz, CDCl3) 
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G: 33.47 HRMS: m/z calcd for C20H29IO3P (M + H) 475.0899, found 475.0898. Yield: 94 % 
(133 mg), yellow liquid. 
 
(5S,6S,9R)-2-ethoxy-4-iodo-6-isopropyl-9-methyl-3-(p-tolyl)-1-oxa-2-
phosphaspiro[4.5]dec-3-ene 2-oxide 263c 
dr: 62/48 
 1H NMR (400 MHz, CDCl3) G: 0.85-0.98 (10H, m, CH(CH3)2, CHCH3, 
CHdHe), 1.18 (3H, t, J = 7.1 Hz, POCH2CH3), 1.53-2.06 (8H, m, CHc, 
CHaHb, CH(CH3)2, CHh, CHfHg, CHdHe), 2.37 (3H, s, CH3Cq,ar), 3.98-
4.22 (2H, m, P(OCH2CH3)), 7.22 (2H, J = 7.9 Hz, CHar), 7.45-7.51 (2H, 
m, CHar). 13C NMR (100MHz, CDCl3) G: 16.5 (d, 3JPC = 5 Hz, 
P(OCH2CH3)), 17.7 (CH(CH3)(CH3)), 21.1 (CHfHg), 21.4 (CH3Cq,ar), 22.0 (CH(CH3)(CH3)), 23.8 
(CHCH3), 26.5(CHc), 28.5 (CHh), 34.4 (CHdHe), 46.0(CHaHb), 46.6(CH(CH3)2), 63.3 (d, 2JPC = 7 
Hz, P(OCH2CH3)), 92.4 (d, 2JPC = 4 Hz, OCq), 124.2 (d, 2JPC = 40 Hz, PCqCqI), 127.9 (d, 3JPC = 
6 Hz, CarH), 129.2 (CarH), 129.5 (d, 2JPC = 10 Hz, PCqCq,ar), 136.0 (d, 1JPC = 150 Hz, PCq), 139.0 
(d, 5JPC = 1 Hz, Cq,arCH3). 31P NMR (161 MHz, CDCl3) G: 28.87 HRMS: m/z calcd for C21H31IO3P 
(M+H)+ 489.1056, found 489.1043. Yield: 87% (127 mg), yellow oil. 
 
(5S,6S,9R)-2-ethoxy-4-iodo-6-isopropyl-9-methyl-3-(o-tolyl)-1-oxa-2-
phosphaspiro[4.5]dec-3-ene 2-oxide 263d 
For each epimer, a pair of rotamers is observed at room temperature, due to hindered rotation 
around the Coxaphospholene - Co-tolyl bond. When recording the 1H NMR spectrum at 60 °C, the 
signals for the benzylic protons of each epimer merge together, appearing as one, almost 
entirely superimposed broad singlet. At 75 °C, carbon signals sufficiently sharpened to reduce 
hindered rotation and one epimer could be described as was the case for the previous 
derivatives. In 31P NMR, a hump of broadened signals was observed. An accurate 
measurement of the diastereomeric ratio could not be obtained. 
1H NMR (400 MHz, DMSO-d6, 60 °C) G: 0.88-0.99 (10H, m, CH(CH3)2, 
CHCH3, CHdHe), 1.00-1.14 (3H, m, P(OCH2CH3)), 1.46-1.91 (8H, m, 
CHc, CHaHb, CH(CH3)2, CHh, CHfHg, CHdHe), 2.26 (3H, s, CH3Cq,ar, 
major), 2.27 (3H, s, CH3Cq,ar, minor), 3.92-4.08 (2H, m, P(OCH2CH3)), 
6.90-7.10 (1H, m, CHar), 7.22-7.35 (3H, m, CHar). 13C NMR (100MHz, 
DMSO-d6, 75 °C) G: 16.7 (d, 3JCP = 4 Hz, P(OCH2CH3)), 17.8 (CH(CH3)(CH3)), 19. (d, 3JCP = 1 
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Hz, CH3Cq,ar), 21.4 (CHfHg), 22.1 (CH(CH3)(CH3)), 24.1 (CHCH3), 26.7 (CHc), 28.5 (CHh), 34.4 
(CHdHe), 46.0 (CHaHb), 47.2 (CH(CH3)2), 63.2 (d, 2JPC = 7 Hz, P(OCH2CH3)), 92.8 (d, 2JPC = 4 
Hz, OCq), 126 (CarH), 128.6 (CarH), 129.1 (CarH), 129.7 (d, 2JPC = 37 Hz, PCqCqI), 130.0 (d, 1JPC 
= 170 Hz, PCq), 130.8 (CarH), 138.0 (PCqCq,ar), 139.5 (PCqCqCq,ar). 31P NMR (161 MHz, DMSO-
d6, 60 °C) G: 28.0-30.7 (broadened peaks). HRMS: m/z calcd for C21H31IO3P (M+H)+ 489.1056, 
found 489.1035. Yield: 91% (133 mg), yellow oil. 
 
(5S,6S,9R)-3-butyl-2-ethoxy-4-iodo-6-isopropyl-9-methyl-1-oxa-2-
phosphaspiro[4.5]dec-3-ene 2-oxide 263e 
dr = 57/43 
 1H NMR (400 MHz, CDCl3) G: 0.87 (3H, d, J = 6.7 Hz, CH(CH3)(CH3) or 
CH3CHc), 0.89-1.02 (1H, m, CHdHe), 0.898 (3H, d, J = 6.7 Hz, 
CH(CH3)(CH3) or CH3CHc), 0.904 (3H, d, J = 7.1 Hz, CH(CH3)(CH3) or 
CH3CHc), 0.94 (3H, t, J = 7.3 Hz, CH3CH2), 1.32 (3H, t, J = 7.1 Hz, 
POCH2CH3), 1.21-1.99 (12H, m, CH3CH2, CH3CH2CH2, CHc, CH(CH3)2, 
CHgCHf, CHdHe, CHaHb, CHh), 2.21-2.48 (2H, m, CH2CqP), 4.08-4.33 (2H, m, POCH2CH3) 13C 
NMR (100 MHz, CDCl3) G: 12.8 (CH3CH2), 15.7 (d, 3JPC = 5 Hz, POCH2CH3), 16.6 ((CH3)2CH) 
or CH3CHc), 20.0 (CH3CH2 or CH3CH2CH2 or CHgCHf), 21.0 ((CH3)2CH) or CH3CHc), 21.50 
(CH3CH2 or CH3CH2CH2 or CHgCHf), 22.8 ((CH3)2CH) or CH3CHc), 25.4 (CHc or CH(CH3)2), 
27.5 (CHc or CH(CH3)2), 28.6 (CH3CH2 or CH3CH2CH2 or CHgCHf), 30.5 (d, 2JPC = 12 Hz, 
CH2CqP), 33.4 (CHdHe), 44.7 (CHaHb), 45.9 (d, 3JPC = 4 Hz, CHh), 61.7 (d, 2JPC = 7 Hz, 
POCH2CH3), 91.1 (d, 2JPC = 4 Hz, OCq), 124.8 (d, 2JCP = 40 Hz, ICq), 135.4 (d, 1JPC = 148 Hz, 
PCq) 31P NMR (161 MHz, CDCl3) G: 30.98 HRMS: m/z calcd for C18H33IO3P (M + H) 455.1212, 
found 455.1211. Yield: 95 % (129 mg), transparent liquid. 
 
(5R,6R,9S)-2-ethoxy-4-iodo-6-isopropyl-9-methyl-1-oxa-2-phosphaspiro[4.5]dec-3-ene 
2-oxide 263f 
dr: 64/36  
1H NMR (400 MHz, CDCl3) G: 0.81-0.97 (10H, m, CH(CH3)2, CHCH3, CHdHe), 
1.33 (3H, t, 3J = 7.1 Hz, P(OCH2CH3)), 1.49-1.68 (6H, m, CHc, CHaHb, 
CH(CH3)2, CHh, CHfHg), 1.81-1.85 (2H, m, CHdHe, CHaHb), 4.14-4.23 (2H, m, 
P(OCH2CH3)), 6.57 (1H, 2JPH = 26.5 Hz, CHP). 13C NMR (100MHz, CDCl3) G: 
16.5 (d 3JPC = 5 Hz, POCH2CH3), 17.5 (CH(CH3)(CH3)), 21.0 (CHCH3), 21.9 
V. Experimental procedures 
 
182 
(CHfHg), 23.7 (CH(CH3)(CH3)), 26.3 (CHc), 28.3 (CH(CH3)2), 34.3 (CHdHe), 45.4 (CHaHb), 46.8 
(d, 3JPC = 4 Hz, CHh), 63.0 (P(OCH2CH3)), 94.5 (POC), 127.4 (d, 2JPC = 30 Hz, CqI), 127.5 (d, 
1JPC = 155 Hz, PCH). 31P NMR G: 33.4 HRMS: m/z calcd for C14H25IO3P (M+H)+ 399.0586, 
found 399.0596. Yield: 92% (109 mg), yellow oil. 
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In order to explore the potential of novel reactive intermediates bearing a phosphonate moiety, 
a synthetic transformation of allenylphosphonates iv towards chiral, spirocyclic 
oxaphospholenes v was designed. Upon deprotection, these chiral spirocyclic 
oxaphospholenes could make up for interesting chiral inducers. Like BINOL phosphate 
catalysts, which are configurationally restricted because of hindered rotation around the 
binaphthyl bond, the spirocyclic connection locks the configuration in the case of the spirocyclic 
oxaphospholenes. The chirality in the products was introduced from chiral pool ketoterpenes. 
So first, a series of acetylides was added to (+)-menthone in excellent yields and good 
diastereoselectivities (Scheme 92) 
 
Scheme 92: Addition of acetylides to ketoterpenes, yielding the corresponding propargyl alcohols. 
Propargylic alcohols are known to spontaneously rearrange to the corresponding 
allenylphosphonates upon treatment with diethyl chlorophosphite. Thus, using this 
[2,3]-sigmatropic rearrangement, an array of menthone-based allenylphosphonates iva-e were 
easily obtained (Scheme 93). Next, cyclization of the allenylphosphonates with a Lewis acid 
was found to be very effective. While a copper-catalysed procedure gave a mixture of the 
desired oxaphospholenes together with some other compounds, simple addition of an 
equimolar amount of iodine smoothly afforded the target compounds va-e as a mixture of 
epimers at the phosphorus atom in a 40/60 ratio in almost quantitative yields. Solvent 
screening revealed that Brønsted acid-catalysed cyclization could be avoided when the 
reaction was run in cyclohexane. No purification was needed at this stage. Different 
substituents on the allene were well tolerated, as even an ortho-methyl group did not prevent 
the iodine from being attacked by the distal double bond of the allene. 
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Scheme 93: Treatment of propargyl alcohols with diethyl chlorophosphite followed by cyclization of the 
resulting allenylphosphonates to yield chiral spirocyclic oxaphospholenes. 
In a second series of derivatives, an ethynyl moiety was introduced to different ketoterpenic 
substrates. The (-)-menthone derived propargylic alcohol was isolated in excellent yield once 
again, while addition of the acetylide to (+)-fenchone and (-)-camphor occurred with almost 
perfect diastereoselectivity because of the increased steric hindrance. Under the optimized 
conditions the corresponding allenes were all obtained in decent yields. Although the 
(-)-menthone derivative reacted with similar ease as the first series of allenylphosphonates, 
(+)-fenchone and (-)-camphor based allenylphosphonates only reacted reluctantly. Increased 
steric hindrance around the double bond in the case of (+)-fenchone was thought to hamper 
the electrophilic addition, while rearrangements immediately occurred in the case of 
(-)-camphor. The created carbocation was found to be very prone to rearrangement, before 
the internal phosphonate nucleophile could intercept the carbocation. 
In a second part of this work, a one-pot procedure for the synthesis of 5-bisphosphonomethyl 
oxazol-2-ones was discovered (Scheme 94). The bisphosphonomethyl motif is present in 
important antiosteoporotic drugs, while the saturated counterparts of oxazol-2-ones, 
oxazolidin-2-ones, are pharmacophores in numerous other marketed drugs. Treatment of 
N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate vi with an excess of LDA and diethyl 
chlorophosphate afforded the 5-bisphosphonomethyl oxazol-2-one vii as the major product. 
Difficult purification resulted in a low 17% isolated yield and hence a stepwise approach was 
evaluated. 
 
Scheme 94: One-pot synthesis of 5-bisphosphonomethyl oxazol-2-ones. 
Treatment of N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate vi with a slight excess of 
organolithium base and diethyl chlorophosphate did afford the desired phosphonylated 
alkyne viii, but not very selectively (Scheme 95). Moreover, the phosphonylated alkyne could 
not be entirely separated from the other reaction products during purification. However, a 
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copper-catalyzed oxidative cross coupling of N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonate 
with diethyl phosphite did yield the phosphonylated alkyne viii. With an excess of diethyl 
phosphite and a sufficient supply of oxygen, this literature procedure could be improved to 
produce phosphonylated alkynes on a 10 mmol scale in good yields. With 2 mol% Au(I)Cl, this 
intermediate was very efficiently cyclized to 5-phosphonomethylidene oxazol-2-ones ix in 
quantitative yield. Unfortunately, a second phosphonate group could not be introduced on the 
5-phosphonomethylidene oxazol-2-one ix, nor on the alkynylphosphonate viii. 
 
Scheme 95: Attempted stepwise preparation of 5-bisphosphonomethyl oxazol-2-ones. 
While an aminoallenylbisphosphonate x was thought to be an intermediate in the one-pot 
synthesis of 5-bisphosphonomethyl oxazol-2-one vii, this could not be confirmed 
experimentally. It was next investigated in the third chapter if aminoallenylphosphonates, which 
had never been reported at the start of this research, could be prepared and isolated. A 
Skattebøl rearrangement, converting dihalocyclopropanes to the corresponding allenes, was 
the key step in the first approach. Phosphonylated alkyne xii was easily accessible from the 
earlier improved literature procedure and was readily hydroaminated in good yield (Scheme 
96). Unfortunately, the obtained enaminophosphonate xiii did not afford the dihalocyclopropyl 
aminophosphonate xiv upon treatment with various dihalocarbene sources. 
 
Scheme 96: Attempted preparation of dihalocyclopropyl aminophosphonates. 
In a second approach, the isomerization of phosphonylated propargylamine xvi was evaluated 
(Scheme 97). None of the investigated bases was able to produce the 
3-aminoallenylphosphonate xvii. Introduction of a phenyl group could favour the alkyne-allene 
isomerization step, but the preparation of the corresponding precursor via an A³ coupling was 
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not straightforward and efforts were cancelled even before the isomerization could be 
investigated. 
 
Scheme 97: Attempted synthesis of 3-aminoallenylphosphonates via 3-aminoprop-1-yn-1-
ylphosphonates. 
Alternatively, it was observed that the acetylide of prop-2-yn-1-yl phosphonate rearranged to 
the internal alkyne upon removal of the TMS group at the terminal alkyne. This spontaneous 
rearrangement would, however, be interesting to produce 1-aminoallenylphosphonates xviii if 
the TMS-protected alkyne xix could be aptly substituted (Scheme 98). To that end, a 
Kabachnik-Fields reaction between an ynaldehyde, a secondary amine and a dialkyl phosphite 
was evaluated. Irrespective of the order of the addition of the reagents, the three component 
reaction failed to produce the aminophosphonate xix. 
Scheme 98: Retrosynthetic approach towards 1-aminoallenylphosphonates. 
As it was reasoned that N,N-dialkylaminoallenylphosphonates might be too electron rich to be 
formed, it was decided to study the isomerization of phthaloyl protected alkyne xxiii. A series 
of bases was evaluated and the 3-imidoallenylphosphonate xxiv was almost immediately 
detected in important amounts. With KOt-Bu, addition of tert-butoxide to the 
imidoallenylphosphonate xxiv was noticed. When focussing on this one-pot isomerization and 
E-alkoxylation, it was found that O-nucleophiles could add extremely easily under very mild 
conditions, in short reaction times and high yields (Scheme 99). More complex nucleophiles 
such as amino acids, monoglycerides and nucleobases could be coupled in similar fashion. 
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Scheme 99: Preparation of 3-imidoallenylphosphonates and in situ E-alkoxylation. 
Next, it was investigated if substituted tetrahydrofurans xxvi could be obtained when treating 
the same precursor with haloalcohols (Scheme 100). Haloalcohols efficiently participated in 
the one-pot alkoxylation, although ring-closure did not occur. Ring-closure could be realized, 
on the other hand, when salicylaldehyde was used as a nucleophile. Three phosphonylated 
chromene isomers xxviia-c were produced, along a dephosphonylated chromene xxviid, 
originating from a Horner-Wadsworth-Emmons reaction. However, no conditions could be 
found that brought about a sufficient selectivity towards one of the reaction products. 
N-nucleophiles could be introduced as well, although not in each case with the same ease as 
O-nucleophiles. Diethylamine selectively yielded one regioisomer, while pyrrolidine and 
dibenzylamine gave a mixture of regioisomers. Diisopropylamine and N-methylphenylamine 
gave complex mixtures. Addition of diethylphosphite afforded novel imido-substituted vicinal 
bisphosphonates xxvxa-c and one product in which two equivalents of diethyl phosphite had 
been incorporated. Unfortunately, no conditions could be found that allowed the selective 
synthesis of one of these compounds. Carbon nucleophiles reacted as well, but only limited 
conversion was observed for the introduction of the cyanide anion. Diethyl malonate did 
efficiently add to the 3-imidoallenylphosphonate xxiii, but no selective conversion to one of the 
three regioisomers xxxia-c could be obtained. 
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Scheme 100: Overview of the nucleophiles reacted with 3-imidoallenylphosphonates. 
In a fifth chapter, it was investigated whether 3-imidoallenylphosphonates could be applied for 
the synthesis of new nucleoside phosphonates (Scheme 101). These nucleosides would be 
tested in a broad-spectrum antiviral test and should preferably have a deprotected ribose and 
phosphonic acid unit. Because dibenzyl phosphonates can give the corresponding phosphonic 
acid upon hydrogenation, addition of uridine acetonide to dibenzyl alkynylphosphonate xxxii 
was first evaluated. This was successful but the addition product could not be separated from 
the impurities. Purification at the stage of the deprotected ribose phosphonate or at the stage 
of the fully deprotected nucleoside phosphonic acid xxxv, both failed as well.  
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Scheme 101: Preparation of diethyl nucleoside phosphonate prodrugs. 
Except in the case of inosine addition, the diethyl nucleoside phosphonates xxxvia-b and 
xxxvid were successfully prepared, purified and accordingly treated with pTsOH. Eventually, 
four new diethyl nucleoside phosphonate prodrugs were obtained and screened for their 
biological properties. No antiviral activity of the nucleoside phosphonates was detected in cell 
cultures against any of the selected viruses – including HSV-1, HSV-2, para-influenza-3-virus, 
HIV-1, HIV-2 and yellow fever virus – at the highest concentrations tested. Influenza PA-Nter 
endonuclease was not inhibited by any of the four compounds either. On the other hand, the 
compounds were not found to be cytotoxic. 
In the last chapter, a strategy towards new E-substituted fosmidomycin derivatives was 
explored, in which an aminoallenylphosphonate would be the key intermediate. Hydroxamic 
acid xxxix was obtained from O-benzyl hydroxylamine hydrochloride after acylation with acetyl 
chloride and alkylation with propargyl bromide (Scheme 102). The earlier developed cross 
coupling procedure with dialkyl phosphites could be applied once more, yielding the 
phosphonylated alkynes xla-b.  
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Scheme 102: Preparation of aminoallenylphosphonate precursors through acylation and alkylation of 
O-benzylhydroxylamine hydrochloride, followed by oxidative cross coupling with dialkyl phosphites. 
When the introduction of ethanol was attempted, the addition product xli could be detected but 
not isolated (Scheme 103). Moreover, a cyclization reaction occurred, producing oxazoles 
xlii-xliv. A mechanism was proposed which explains the formation of these products and 
presumably starts with the elimination of the benzyloxy moiety. A few intermediates of this 
pathway could be obtained.  
Scheme 103: Attempted preparation of E-substituted fosmidomycin derivatives.  
Downregulating the acidity of the propargylic protons by replacing the N-acetyl group with a 
N-Boc group was not successful either, as loss of the benzyloxy group was observed again. 
In a final attempt to obtain E-substituted fosmidomycin derivatives, substrate xla was evaluated 
in the copper-catalyzed hydroamination reaction with diethylamine. Minor amounts of the 
desired product were detected in a complex mixture, but a double Michael addition seemed to 
have taken place. This route was finally abandoned as well. 
In retrospect, it was illustrated that chiral allenylphosphonates with a ketoterpenic skeleton 
bring about an elegant entry into chiral spirocyclic oxaphospholenes. Further efforts should be 
made to produce the corresponding phosphonic acids in order to gauge their chiral inducing 
properties in asymmetric transformations. A second pinnacle was the first ever synthesis of 
3-imidoallenylphosphonates. These hynod functionalized small molecules were prepared 
under extremely mild conditions from simple precursors and were swiftly functionalized at the 
central carbon atom with a variety of nucleophiles. Several transformations were characterized 
by a mediocre selectivity and their potential has to be elaborated in further research. In the 
search for novel antiviral lead compounds, these 3-imidoallenylphosphonates have 
engendered novel nucleoside phosphonates, while they were also evaluated in the design of 
novel fosmidomycin analogues.  
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Om het potentieel van nieuwe reactieve intermediairen met een fosfonaatgroep te 
onderzoeken, werd een synthetische transformatie van allenylfosfonaten iv naar chirale, 
spirocyclische oxafosfolenen v ontworpen. Na ontscherming kunnen deze verbindingen 
dienen als interessante chirale inducers. Zoals BINOL-fosfaatkatalysatoren, die 
configurationeel beperkt zijn vanwege de gehinderde rotatie rond de binaftylbinding, legt ook 
de spirocyclische connectie in deze chirale molecule de configuratie vast. De chiraliteit in deze 
verbindingen werd geïntroduceerd gebruikmakende van ketoterpenen uit de chiral pool. 
Zodoende werd in eerste instantie een reeks acetyliden geaddeerd aan (+)-menthon met 
uitstekende rendementen en een goede diastereoselectiviteit (Schema 104). 
 
Schema 104: Addtie van acetyliden aan ketoterpenen om de overeenkomstige propargylalcoholen te 
bekomen.  
Propargylische alcoholen ondergaan spontaan een omlegging tot de overeenkomstige 
allenylfosfonaten wanneer ze behandeld worden met diëthylchloorfosfiet. Gebruikmakende 
van deze [2,3]-sigmatrope omlegging, werd op eenvoudige wijze een verzameling menthon-
gebaseerde allenylfosfonaten iva-e bekomen (Schema 105). Een Lewiszuurgemedieerde 
ringsluiting bleek zeer doeltreffend te zijn. Hoewel een CuBr2-gemedieerde procedure een 
mengsel van de gewenste oxafosfolenen gaf samen met enkele onzuiverheden, leverde het 
toevoegen van een equimolaire hoeveelheid dijood de doelstructuren va-e bijna kwantitatief 
als een mengsel van epimeren aan het fosforatoom. Brønstedzuurgekatalyseerde ringsluiting 
kon worden vermeden als de reactie uitgevoerd werd in cyclohexaan. Opzuivering was 
overbodig na deze reactiestap. Een verscheidenheid aan substituenten op het alleen werd 
goed getolereerd, aangezien zelfs een ortho-methylgroep de elektrofiele additie van jood aan 
de dubbele binding niet verhinderde.  
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Schema 105: Behandeling van propargylalcoholen met diëthylchloorfosfiet, gevolgd door cyclisatie van 
de bekomen allenylfosfonaten om chirale spirocyclische oxafosfolenen te bekomen. 
In een tweede reeks derivaten werd een ethynylgroep geïntroduceerd op een aantal 
verschillende ketoterpeensubstraten. Het propargylisch alcohol, afgeleid van (-)-menthon, kon 
opnieuw geïsoleerd worden met een uitstekend rendement, terwijl de additie van het acetylide 
aan (+)-fenchon en (-)-kamfer dankzij de grote sterische hinder met een bijna perfecte 
diastereoselectiviteit verliep. Onder de eerder geoptimaliseerde omstandigheden konden de 
overeenkomstige allenylfosfonaten opnieuw geïsoleerd worden met degelijke rendementen. 
Het (-)-menthonderivaat leverde, volledig analoog aan de vorige gevallen, het oxafosfoleen, 
maar de op (+)-fenchon- en (-)-kamfergebaseerde allenylfosfonaten reageerden slechts 
moeizaam in de cyclisatiestap. In het geval van (+)-fenchon verhinderde de grote sterische 
hinder rond de distale dubbele binding vermoedelijk de elektrofiele additie, terwijl er meteen 
allerhande omleggingen optraden in het geval van (-)-kamfer. Deze omleggingen vonden 
plaats voordat het gecreëerde carbokation door het interne nucleofiel onderschept kon 
worden.  
In een tweede hoofdstuk werd de one-pot-procedure voor de synthese van 5-bisfosfonomethyl 
oxazol-2-onen vii onderzocht (Schema 106). Het bisfosfonomethylmotief vindt men terug in 
geneesmiddelen, gebruikt voor de behandeling van osteoporose, terwijl de verzadigde 
tegenhangers van de oxazol-2-onen, oxazolidin-2-onen, de farmacofore eenheid vormen van 
verschillende andere geneesmiddelen. Behandeling van N,N-di-tert-butylprop-2-yn-
1-ylimidodicarbonaat vi met een overmaat aan LDA en diëthylchloorfosfaat leverde het 
5-bisfosfonomethyloxazol-2-on vii als het voornaamste reactieproduct. Een moeilijke 
opzuivering resulteerde echter in een laag rendement van 17% en bijgevolg werd een 
stapsgewijze benadering overwogen. 
 
Schema 106: One-pot synthese van 5-bisfosfonomethyl oxazol-2-onen. 
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Via behandeling van N,N-di-tert-butylprop-2-yn-1-ylimidodicarbonaat vi met een lichte 
overmaat aan organolithiumbase en diëthylchloorfosfaat werd het gefosfonyleerd alkyn viii 
bekomen, maar niet op een selectieve manier (Schema 107). Bovendien kon het gewenste 
product tijdens opzuivering niet volledig gescheiden worden van andere onzuiverheden. Een 
koper-gekatalyseerde oxidatieve cross-koppelingsreactie van N,N-di-tert-butylprop-2-yn-1-
ylimidodicarbonaat vi met diëthylfosfiet leverde echter wel het gefosfonyleerde alkyn viii. Met 
behulp van een overmaat diëthylfosfiet en voldoende zuurstofgas kon deze literatuurprocedure 
geoptimaliseerd worden zodat gefosfonyleerde alkynen eenvoudig op een 10 mmol-schaal 
bereid konden worden. Dit intermediair kon vervolgens eenvoudig en kwantitatief ringsluiting 
ondergaan tot het 5-fosfonomethinoxazol-2-on ix door middel van 2 mol% Au(I)Cl. Helaas kon 
een tweede fosfonaatgroep niet ingevoerd worden, niet op het niveau van het 
5-fosfonomethinoxazol-2-on ix, noch in de reactie met alkynylfosfonaat viii. 
 
Schema 107: Poging tot stapsgewijze bereiding van 5-bisfosfonomethyl oxazol-2-onen. 
Hoewel vermoed werd dat aminoallenylbisfosfonaat x een intermediair was in de one-pot-
synthese van 5-bisfosfonomethyloxazol-2-on vii, kon dit niet experimenteel bewezen worden. 
In het derde luik van dit werk werd onderzocht of aminoallenylfosfonaten, waarvan bij het begin 
van dit onderzoek nog nooit een synthese gerapporteerd was, bereid en geïsoleerd konden 
worden. Een Skattebøl omlegging, een reactie die dihalocyclopropanen omzet in de 
overeenkomstige allenen, was de cruciale stap in deze eerste benadering. Gefosfonyleerde 
alkynen konden nu eenvoudig bereid worden dankzij de eerder ontwikkelde koppelingsreactie 
met dialkylfosfieten (Schema 108). Alkyn xii kon vlot gehydroamineerd worden. Helaas gaven 
de bekomen enaminofosfonaten xiii geen aanleiding tot de vorming van 
dihalocyclopropylaminofosfonaten xiv, wanneer deze eerste behandeld werden met 
verschillende dihalocarbeenprecursoren.  
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Schema 108: Poging tot bereiding van dihalocyclopropyl aminofosfonaten. 
In een tweede strategie werd de isomerisatie van gefosfonyleerde propargylamines xvi 
geëvalueerd (Schema 109). Geen enkele van de onderzochte basen was in staat om het 
3-aminoallenylfosfonaat xvii te genereren. Het invoeren van een extra fenylgroep zou de 
daaropvolgende isomerisatie gunstig kunnen beïnvloeden, maar de bereiding van precursor 
via een A³ koppelingsreactie bleek niet voordehandliggend te zijn. Uiteindelijk werd deze 
strategie verlaten voordat de isomerisatiereactie onderzocht kon worden.  
 
Schema 109: Poging tot synthese van 3-aminoallenylfosfonaten via 3-aminoprop-1-yn-1-ylfosfonaten. 
Anderzijds werd vastgesteld dat het acetylide van prop-2-yn-1-ylfosfonaat zich spontaan 
omlegde tot het intern alkyn wanneer de TMS-groep op het eindstandig alkyn ontschermd 
werd. Deze spontane omlegging zou echter op een elegante manier aanleiding kunnen geven 
tot 1-aminoallenylfosfonaten als het TMS-beschermd alkyn xix met de gepaste substituenten 
uitgerust zou kunnen worden (Schema 110). Daarom werd de Kabachnik-Fieldsreactie tussen 
een ynaldehyde, een secundair amine en een dialkylfosfiet onderzocht. Onafhankelijk van de 
volgorde waarin de reagentia toegevoegd worden, kon het aminofosfonaat xix niet bereid 
worden. 
 
Schema 110: Retrosynthetische benadering tot 1-aminoallenylfosfonaten. 
Vermoedelijk zijn de N,N-dialkylaminoallenylfosfonaten te elektronenrijk om gevormd te 
worden. Daarom werd beslist om de isomerisatiereactie van het ftaloylbeschermd alkyn xxiii 
te bestuderen. Het gebruik van een aantal verschillende basen werd geëvalueerd en bijna 
onmiddellijk kon het 3-imidoallenylfosfonaat xxiv gedetecteerd worden in belangrijke 
hoeveelheden. Wanneer KOt-Bu gebruikt werd, trad additie van tert-butoxide op aan het 
imidoallenylfosfonaat xxiv. Wanneer de focus op deze one-pot isomerisatie en E-alkoxylering 
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gelegd werd, bleken O-nucleofielen zeer snel, onder zeer milde omstandigheden, en met 
uitstekende rendementen te adderen (Schema 111). Complexere nucleofielen zoals 
aminozuren, monoglyceriden en nucleosiden konden op dezelfde manier gekoppeld worden. 
 
Schema 111: Bereiding van 3-imidoallenylfosfonaten en in situ E-alkoxylering. 
Vervolgens werd onderzocht of gesubstitueerde tetrahydrofuranen xxvi bereid konden worden 
bij behandeling van dezelfde precursoren met haloalcoholen (Schema 112). Deze 
haloalcoholen reageren weldegelijk in deze one-pot-alkoxylering, hoewel er geen ringsluiting 
optrad. Ringsluiting was wel mogelijk wanneer salicylaldehyde gebruikt werd als nucleofiel. 
Drie gefosfonyleerde chromeenisomeren xxviia-c werden gevormd, in combinatie met een 
gedefosfonyleerd chromeen xxviid als resultaat van een Horner-Wadsworth-Emmonsreactie. 
Er konden geen reactieomstandigheden gevonden worden die leidden tot de selectieve 
vorming van één van deze producten. N-nucleofielen konden ook geïntroduceerd worden, 
hoewel deze niet allemaal even vlot reageerden als O-nucleofielen. Diëthylamine gaf selectief 
één regioisomeer, terwijl pyrrolidine en dibenzylamine een mengsel van regioisomeren 
leverden. Di-isopropylamine en N-methylfenylamine leidden tot complexe mengsels. Additie 
van diëthylfosfiet leverde nieuwe imido-gesubstitueerde vicinale bisfosfonaten xxxa-c en een 
product waarbij twee equivalenten diëthylfosfiet ingebouwd werden. Helaas werden geen 
reactieomstandigheden gevonden die de selectieve synthese van één van deze producten 
mogelijk maakte. Koolstofnucleofielen konden ook ingezet worden, hoewel er slechts een 
beperkte conversie waargenomen werd in het geval van het cyanide-anion. Diëthylmalonaat 
reageerde vlot met 3-imidoallenylfosfonaat xxiii, maar de reactie kon niet selectief naar één 
van de drie bekomen regioisomeren xxxia-c gestuurd worden.  
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Schema 112: Overzicht van de nucleofielen die reageren met 3-imidoallenylfosfonaten. 
In een vijfde hoofdstuk werd onderzocht of 3-imidoallenylfosfonaten ingezet konden worden 
voor de synthese van nieuwe nucleosidefosfonaten. Omdat deze nucleosidefosfonaten later 
getest zouden worden op hun activiteit in een breed-spectrum antivirale test, dienen deze bij 
voorkeur te beschikken over ontschermde ribose- en fosfonaateenheden. Aangezien 
dibenzylfosfonaten de vrije fosfonzuren kunnen geven via hydrogenatie, werd eerst de additie 
van uridineacetonide geëvalueerd aan dibenzylalkynylfosfonaat xxxii (Schema 113). Dit trad 
op met goed gevolg, maar het additieproduct kon niet gescheiden worden van enkele 
onzuiverheden, gevormd in deze reactie. Opzuivering na ontschermen van enkel de ribose-
eenheid of na ontschermen van zowel de ribose-eenheid als het fosfonaat, slaagde evenmin.  
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Schema 113: Bereiding van diethyl nucleosidefosfonaat prodrugs. 
Diëthylnucleosidefosfonaten xxxvia-b en xxxvia-d konden wel met succes opgezuiverd 
worden en werden nadien behandeld met pTsOH. Uiteindelijk werden vier nieuwe 
diëthylnucleosidefosfonaat prodrugs bekomen en vervolgens gescreend op hun biologische 
activiteit. Helaas werd in celcultuur voor geen enkele van deze verbindingen antivirale activiteit 
tegen de geselecteerde virussen gedetecteerd. HSV-1, HSV-2, para-influenza-3-virus, HIV-1, 
HIV-2 en gelekoortsvirus behoorden onder andere tot het panel van de breed-spectrum 
antivirale test. In een enzymassay werd ook influenza PA-Nter endonuclease niet geïnhibeerd 
door één van de vier nucleosidefosfonaten. De verbindingen bleken wel niet cytotoxisch te 
zijn.  
In het laatste hoofdstuk werd een strategie voor de toetreding tot E-gesubstitueerde 
fosmidomycinederivaten onderzocht, waarin het aminoallenylfosfonaatintermediair centraal 
stond. Hydroxamaat xxxix werd bekomen na acylering van O-benzylhydroxylamine 
hydrochloride met acetylchloride en alkylering met propargylbromide (Schema 114). De eerder 
ontwikkelde cross-koppelingsreactie met dialkylfosfieten kon opnieuw toegepast worden, 
zodat de gefosfonyleerde alkynen xla-b met succes bekomen werden.  
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Schema 114: Bereiding van aminoallenylfosfonaatprecursoren door acylering en alkylering van O-benzyl 
hydroxylamine hydrochloride, gevolgd door oxidatieve cross koppeling met dialkylfosfieten. 
Wanneer gepoogd werd ethanol te introduceren, kon het additieproduct xli wel gedetecteerd 
maar niet geïsoleerd worden (Schema 115). Bovendien trad een ringsluitingsreactie op tot 
oxazolen xlii-xliv. Een reactiemechanisme werd voorgesteld dat de vorming van deze 
producten kan verklaren en vermoedelijk startte met de eliminatie van een benzyloxygroep. 
Enkele intermediairen konden gesynthetiseerd worden die deze hypothese ondersteunen.  
Schema 115: Poging tot bereiding van E-gesubstitueerde fosmidomycine derivaten. 
Het verlagen van de zuurtegraad van de protonen in de propargylische positie, door 
vervanging van de N-acetylgroep door een N-Boc-groep, was niet succesvol en verlies van de 
benzyloxygroep werd opnieuw geobserveerd. In een ultieme poging om E-gesubstitueerde 
fosmidomycinederivaten te bekomen, werd substraat xl bestudeerd in de koper-
gekatalyseerde hydroamineringsreactie met diëthylamine. In het bekomen complex mengsel 
werden kleine hoeveelheden van product xli gedecteerd, naast een product dat een dubbele 
Michael-additie ondergaan leek te hebben. Uiteindelijk werd ook deze strategie verlaten.  
Samenvattend werd aangetoond dat chirale allenylfosfonaten met een ketoterpeenskelet op 
elegante wijze toetreding verlenen tot chirale spirocyclische oxafosfolenen. Verdere 
inspanningen moeten gevoerd worden om de corresponderende fosfonzuren vrij te stellen 
zodat hun chiraliteitsinducerende eigenschappen in asymmetrische transformaties beoordeeld 
kunnen worden. Centraal stond ook de bereiding van de nooit eerder gerapporteerde 
3-imidoallenylfosfonaten. Deze sterk gefunctionaliseerde kleine moleculen konden bereid 
worden onder zeer milde omstandigheden uit eenvoudige precursoren en reageerden zeer 
vlot met een verscheidenheid aan nucleofielen. Een aantal transformaties vertoonden slechts 
een matige selectiviteit en hun potentieel moet in verder onderzoek bestudeerd worden. 
Zoekende naar nieuwe antivirale lead compounds, hebben deze sleutelbouwsteen een aantal 
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nieuwe nucleosidefosfonaten voortgebracht terwijl ze ook onderzocht werden voor het 
ontwerpen van nieuwe fosmidomycine analoga. 
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